| Drug Name |
Drug Class |
Is Cardiotoxic |
Cardiomyocyte Line |
Up/Down |
Pathway |
Enrichment p-value |
Enrichment rank |
Pathway F1 score AUC rank |
Cardiotoxicity of pathway |
Pathway Genes |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Z-disc organization |
5.96E-05 |
1 |
NaN |
|
CSRP3;DES;MYPN;PDLIM3;TCAP |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Z-disc organization |
1.75E-07 |
1 |
NaN |
|
ACTN2;CSRP3;DES;DYSF;NEXN;PDLIM3;TCAP |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Z-disc organization |
7.73E-08 |
1 |
NaN |
|
ACTN2;CSRP3;DES;DYSF;MYPN;PDLIM3;TCAP |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Z-disc organization |
9.62E-05 |
3 |
NaN |
|
ACTN2;CSRP3;DES;PDLIM3;TCAP |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Z-disc organization |
2.10E-07 |
2 |
NaN |
|
ACTN2;CSRP3;DES;DYSF;MYOZ1;PDLIM3;TCAP |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Mitotic spindle disassembly |
0.028316867 |
14 |
NaN |
|
CDK1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Myofibril formation |
0.030954254 |
18 |
NaN |
|
DES;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Myofibril formation |
0.033865605 |
20.5 |
NaN |
|
DES;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Myofibril formation |
0.027130428 |
17 |
NaN |
|
DES;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Myofibril formation |
0.037267993 |
20 |
NaN |
|
DES;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Myofibril formation |
0.002883263 |
6.5 |
NaN |
|
DES;MYOZ1;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.011119254 |
8 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.012210551 |
9.5 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.009695754 |
10 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.013493828 |
10.5 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.012844883 |
12 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Nodal growth differentiation factor receptor signaling |
0.019919132 |
13 |
NaN |
|
LEFTY2;TCEA3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Non-vesicular phospholipid transport |
0.015277597 |
11.5 |
NaN |
|
PITPNM1;PLTP |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Notch receptor signaling |
0.033700302 |
15.5 |
NaN |
|
DLK1;NOTCH3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Osteopontin receptor signaling |
0.015790402 |
9.5 |
NaN |
|
SPP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Osteopontin receptor signaling |
0.014643613 |
12 |
NaN |
|
SPP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.000466725 |
5 |
NaN |
|
PDGFD;PDGFRA;PDGFRB |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.037136486 |
20.5 |
NaN |
|
FOSL1;TNK2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Potassium transmembrane transport |
0.033202869 |
18 |
NaN |
|
ATP1A2;ATP1A3;FXYD1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Potassium transmembrane transport |
0.024408174 |
13 |
NaN |
|
ATP1A2;ATP1A3;FXYD1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Potassium transmembrane transport |
0.037880307 |
22 |
NaN |
|
ATP1A2;ATP1A3;FXYD1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Progesterone receptor signaling |
0.016231475 |
3.5 |
NaN |
|
PGR |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Progesterone receptor signaling |
0.029728299 |
17 |
NaN |
|
PGR |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Progesterone receptor signaling |
0.026376147 |
14.5 |
NaN |
|
PGR |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Prostaglandin E2 receptor signaling |
0.0030397 |
4 |
NaN |
|
PTGER3;RAPGEF4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Recycling endosome dynamics |
0.008937543 |
7 |
NaN |
|
RAB11FIP5;RAB15;S100A10;SNAP23 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Recycling endosome dynamics |
0.036588123 |
19 |
NaN |
|
EHD1;RAB11FIP5;RAB15 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Restriction point |
0.033865605 |
20.5 |
NaN |
|
CCND2;CDKN1A |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Restriction point |
0.035550215 |
16.5 |
NaN |
|
CDKN1A;PFKFB3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Retinol metabolism |
0.000985446 |
2 |
NaN |
|
ALDH1A2;DHRS3;RDH10 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Roundabout signaling |
0.004214967 |
5 |
NaN |
|
ROBO1;ROBO2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Semaphorin signaling |
0.017405753 |
6 |
NaN |
|
PLXNC1;RND1;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Semaphorin signaling |
0.00142787 |
3 |
NaN |
|
NRP2;PLXNC1;SEMA6A;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Semaphorin signaling |
0.000178161 |
1 |
NaN |
|
NRP2;PLXNC1;PLXND1;SEMA6A;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Semaphorin signaling |
0.00142787 |
1 |
NaN |
|
NRP2;PLXNC1;SEMA6A;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Semaphorin signaling |
0.001460037 |
6 |
NaN |
|
NRP2;PLXNC1;SEMA6A;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Serine and glycine metabolism |
0.00359729 |
4 |
NaN |
|
PHGDH;SHMT2;SLC1A5 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Serine and glycine metabolism |
0.004166579 |
6 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Serotonin inactivation |
0.031332839 |
14.5 |
NaN |
|
MAOA |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Serotonin inactivation |
0.029074064 |
18 |
NaN |
|
MAOA |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.029074064 |
18 |
NaN |
|
NUF2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Sister chromatid segregation |
0.003076041 |
8 |
NaN |
|
PTTG1;TOP2A |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Sister chromatid segregation |
0.011119254 |
8 |
NaN |
|
PTTG1;TOP2A |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Sodium transmembrane transport |
0.001530203 |
3 |
NaN |
|
SCN1A;SCN2A;SCN3A;SCN9A |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Syndecan receptor signaling |
0.007553576 |
4.5 |
NaN |
|
SDC1;SDC3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Syndecan receptor signaling |
0.006578004 |
7.5 |
NaN |
|
SDC3;SDC4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Syndecan receptor signaling |
0.009185114 |
8 |
NaN |
|
SDC3;SDC4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Syndecan receptor signaling |
0.008738735 |
10 |
NaN |
|
SDC3;SDC4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Thin myofilament organization |
0.015277597 |
11.5 |
NaN |
|
ACTA1;TNNI3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Thin myofilament organization |
0.016761242 |
12.5 |
NaN |
|
ACTA1;TNNI3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Thin myofilament organization |
1.56E-05 |
3 |
NaN |
|
ACTA1;LMOD3;TNNI3;TPM2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Thin myofilament organization |
0.018503192 |
13.5 |
NaN |
|
ACTA1;TNNI3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.000900451 |
3 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.005081293 |
5 |
NaN |
|
THBS2;THBS4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Thrombospondin receptor signaling |
0.004016669 |
6 |
NaN |
|
THBS2;THBS4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Tight junction organization |
0.017618286 |
14 |
NaN |
|
CLDN6;CRB2;MPP5;MYLK |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.015790402 |
9.5 |
NaN |
|
ELN |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Tropoelastin synthesis |
0.014643613 |
12 |
NaN |
|
ELN |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.031316161 |
16.5 |
NaN |
|
ELN |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Versican receptor signaling |
0.028900203 |
13.5 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Versican receptor signaling |
0.031332839 |
14.5 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Versican receptor signaling |
0.028900203 |
8.5 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Versican synthesis |
0.014555399 |
9 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Versican synthesis |
0.015790402 |
9.5 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Versican synthesis |
0.014555399 |
4.5 |
NaN |
|
VCAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Water transmembrane transport |
0.02302747 |
15 |
NaN |
|
AQP10;AQP3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Actin filament bundling and crosslinking |
0.040847464 |
23 |
NaN |
|
ACTN2;SYNPO;TAGLN |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Actin filament bundling and crosslinking |
0.007494453 |
8 |
NaN |
|
ACTN2;FLNB;SYNPO;TAGLN |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Actin polymerization |
0.030357852 |
16 |
NaN |
|
ABRA;ACTA1;ENAH;HSPB1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Actin polymerization |
0.041593261 |
23 |
NaN |
|
ABRA;ACTA1;MAL2;VAV3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Actin polymerization |
0.038416284 |
19 |
NaN |
|
ABRA;ACTA1;ENAH;HSPB1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Adenylyl cyclase signaling pathway |
0.03380839 |
10 |
NaN |
|
PDE3A;PDE4D |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Adenylyl cyclase signaling pathway |
0.027655274 |
12 |
NaN |
|
PDE3A;RAPGEF4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Aggrecan synthesis |
0.031316161 |
16.5 |
NaN |
|
ACAN |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.014555399 |
9 |
NaN |
|
ALB |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.031316161 |
16.5 |
NaN |
|
ALB |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Alternative complement pathway |
0.002046016 |
2 |
NaN |
|
C1S;C3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Alternative complement pathway |
0.002070599 |
7 |
NaN |
|
C1S;C3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Amyloid plaque organization |
0.037136486 |
20.5 |
NaN |
|
APOE;HSPB6 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.027130428 |
17 |
NaN |
|
HLA-A;HLA-C |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.035550215 |
16.5 |
NaN |
|
HLA-A;HLA-C |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Aspartate and arginine metabolism |
0.033865605 |
20.5 |
NaN |
|
DDAH1;SLC7A1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Aspartate and arginine metabolism |
0.037267993 |
20 |
NaN |
|
ARG2;SLC7A1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Basement membrane attachment to cell surface |
0.013493828 |
10.5 |
NaN |
|
CD151;ITGA5 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Biglycan synthesis |
0.016231475 |
3.5 |
NaN |
|
BGN |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Biglycan synthesis |
0.014555399 |
4.5 |
NaN |
|
BGN |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Cardiomyocyte depolarization during action potential |
0.026376147 |
14.5 |
NaN |
|
SCN5A |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Cardiomyocyte pacemaker current generation |
0.005566383 |
6 |
NaN |
|
CACNA1D;CACNA1G |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Cardiomyocyte pacemaker current generation |
0.006521753 |
6 |
NaN |
|
CACNA1D;CACNA1G |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.020976831 |
7 |
NaN |
|
KCNIP2;KCNJ2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.017084419 |
7 |
NaN |
|
KCNIP2;KCNJ2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.017280609 |
15.5 |
NaN |
|
KCNIP2;KCNJ2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.007553576 |
4.5 |
NaN |
|
CTGF;CYR61 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Cellular cholesterol uptake and efflux |
0.014783725 |
11 |
NaN |
|
ABCA1;ABCG1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.017250642 |
12 |
NaN |
|
ABCA1;ABCG1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Cellular cholesterol uptake and efflux |
0.014783725 |
6 |
NaN |
|
ABCA1;ABCG1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Cellular cholesterol uptake and efflux |
0.014954359 |
14 |
NaN |
|
ABCA1;ABCG1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Centrosome maturation |
0.043745388 |
22.5 |
NaN |
|
PLK1;TPX2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Centrosome separation |
0.00034312 |
4 |
NaN |
|
CCNB1;KIF11;NEK2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Centrosome separation |
0.030954254 |
18 |
NaN |
|
CCNB1;CDK1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Cholesterol synthesis |
1.07E-06 |
2 |
NaN |
|
CYP51A1;DHCR24;DHCR7;HMGCR;MSMO1;NSDHL;SQLE |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Cholesterol synthesis |
0.021860488 |
14 |
NaN |
|
DHCR7;MSMO1;MVD |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.003567273 |
4.5 |
NaN |
|
INSIG1;SREBF1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Citric acid cycle |
0.044651224 |
20 |
NaN |
|
ACO2;IDH2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Classical complement pathway |
0.004214967 |
3 |
NaN |
|
C1R;C1S |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Classical complement pathway |
0.004265108 |
9 |
NaN |
|
C1R;C1S |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Collagen fiber crosslinking |
0.007553576 |
4.5 |
NaN |
|
LOXL1;PXDN |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.003567273 |
4.5 |
NaN |
|
COL14A1;COL9A3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.012210551 |
9.5 |
NaN |
|
COL12A1;COL9A2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.013493828 |
10.5 |
NaN |
|
COL12A1;COL9A2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.033865605 |
20.5 |
NaN |
|
DES;SYNM |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.027130428 |
17 |
NaN |
|
DES;SYNM |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.037267993 |
20 |
NaN |
|
DES;SYNM |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.002883263 |
6.5 |
NaN |
|
DES;ILK;SYNM |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Decorin synthesis |
0.016231475 |
3.5 |
NaN |
|
DCN |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Decorin synthesis |
0.014555399 |
9 |
NaN |
|
DCN |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.015790402 |
9.5 |
NaN |
|
DCN |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Decorin synthesis |
0.031316161 |
16.5 |
NaN |
|
DCN |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Desaturation of fatty acids |
0.016761242 |
12.5 |
NaN |
|
FADS3;SCD |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Discoidin domain receptor signaling |
0.047912477 |
13.5 |
NaN |
|
DDR2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Discoidin domain receptor signaling |
0.043037442 |
11.5 |
NaN |
|
DDR2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Elastin cross-linking and assembly |
0.043037442 |
11.5 |
NaN |
|
LOX |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.019992392 |
13 |
NaN |
|
KRT19;KRT8 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.02191339 |
15 |
NaN |
|
KRT7;KRT8 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.017477983 |
12 |
NaN |
|
KRT7;KRT8 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
5.99E-05 |
2 |
NaN |
|
KRT19;KRT7;KRT8;TCHH |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.001408213 |
5 |
NaN |
|
KRT19;KRT7;KRT8 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
1.10E-06 |
1 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;NDC80;NUF2;TTK |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000366348 |
2 |
NaN |
|
ADAMTS1;ADAMTS10;ADAMTS14;ADAMTS6 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.047145108 |
14 |
NaN |
|
ADAM12;ADAMTS1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.004978893 |
10 |
NaN |
|
ADAM33;ADAMTS14;ADAMTS5 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.000464199 |
1 |
NaN |
|
COL11A1;COL1A2;COL5A2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.030954254 |
18 |
NaN |
|
COL2A1;COL3A1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Fibrillin synthesis |
0.047912477 |
13.5 |
NaN |
|
FBN1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Fibroblast growth factor receptor signaling |
0.012628988 |
7 |
NaN |
|
ANOS1;FGF10 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Fibroblast growth factor receptor signaling |
0.014748304 |
7 |
NaN |
|
ANOS1;FGF18 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Fibronectin synthesis and extracellular assembly |
0.008302765 |
6 |
NaN |
|
FN1;ITGB3 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Fibulin receptor signaling |
0.028900203 |
8.5 |
NaN |
|
FBLN1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Fibulin receptor signaling |
0.029074064 |
18 |
NaN |
|
FBLN1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Filopodium organization |
0.029320646 |
15 |
NaN |
|
ENAH;MYL9;TNK2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Focal adhesion organization |
0.035582818 |
18 |
NaN |
|
CSRP1;ILK;RND3;ZYX |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
G2 M transition checkpoint |
0.043745388 |
22.5 |
NaN |
|
CCNB1;CDK1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Gap junction organization |
0.017280609 |
15.5 |
NaN |
|
GJA1;GJA5 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
0.003649528 |
2 |
NaN |
|
ENO1;HK2;LDHA;TPI1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.029688885 |
16 |
NaN |
|
ENO1;HK2;LDHA |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
1.41E-06 |
2 |
NaN |
|
ALDOA;ENO1;HK2;LDHA;PGAM1;PGK1;TPI1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Glycolysis and Gluconeogenesis |
4.43E-06 |
1 |
NaN |
|
ALDOA;ENO1;GPI;LDHA;PCK2;PGK1;TPI1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
5.41E-13 |
1 |
NaN |
|
ALDOA;ENO1;GPI;HK2;LDHA;PFKFB3;PFKFB4;PFKL;PFKP;PGAM1;PGK1;TPI1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
G-protein coupled receptor signaling pathway |
0.041109436 |
11 |
NaN |
|
PDE4D;RGS4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
G-protein coupled receptor signaling pathway |
0.033700302 |
15.5 |
NaN |
|
GRK5;RGS6 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000881227 |
3 |
NaN |
|
JAK2;JUND |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000693436 |
4 |
NaN |
|
JAK2;JUND |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000978026 |
4 |
NaN |
|
JAK2;JUND |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000928996 |
4 |
NaN |
|
JAK2;JUND |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Growth differentiation factor receptor signaling |
0.001516721 |
5 |
NaN |
|
GDF11;GDF2;GDF6 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Hemidesmosome organization |
0.018503192 |
13.5 |
NaN |
|
CD151;ITGB4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Hemoglobin and myoglobin synthesis |
0.047912477 |
13.5 |
NaN |
|
MB |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Hemoglobin and myoglobin synthesis |
0.043037442 |
17 |
NaN |
|
MB |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Hemoglobin and myoglobin synthesis |
0.043037442 |
11.5 |
NaN |
|
MB |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Hemoglobin and myoglobin synthesis |
0.043294437 |
20 |
NaN |
|
MB |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Hepatocyte growth factor receptor signaling |
0.032200898 |
8.5 |
NaN |
|
HGF |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.014643613 |
12 |
NaN |
|
HMMR |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.047912477 |
13.5 |
NaN |
|
A2M |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
3.03E-06 |
1 |
NaN |
|
A2M;MME;PLAT |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Inhibition of apoptosis |
0.003348691 |
5 |
NaN |
|
IFI6;PEA15;XAF1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
JAK-STAT signaling pathway |
0.008572798 |
7 |
NaN |
|
SOCS2;SOCS3;STAT4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.007987951 |
9 |
NaN |
|
SOCS2;SOCS3;STAT4 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Lectin complement pathway |
0.007553576 |
4.5 |
NaN |
|
COLEC11;MASP1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Lipid droplet fusion |
0.016231475 |
3.5 |
NaN |
|
CIDEC |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Lysine metabolism |
0.043037442 |
11.5 |
NaN |
|
LOX |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Macrophage migration inhibitory factor signaling |
0.006578004 |
7.5 |
NaN |
|
ACKR3;JUND |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
8.62E-06 |
2 |
NaN |
|
BUB1;CCNB2;CENPE;MAD2L1;PTTG1;TTK |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
0.014985954 |
10 |
NaN |
|
BUB1;CDC20;LZTS1;PTTG1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Microfibril scaffold organization |
0.032200898 |
8.5 |
NaN |
|
FBN1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Microfibril scaffold organization |
0.028900203 |
13.5 |
NaN |
|
MFAP2 |
| verapamil |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Microtubule crosslinking and bundling |
0.011119254 |
8 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Microtubule crosslinking and bundling |
0.012210551 |
9.5 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Microtubule crosslinking and bundling |
0.009695754 |
10 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Microtubule crosslinking and bundling |
0.013493828 |
10.5 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Microtubule crosslinking and bundling |
0.012844883 |
12 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Microtubule polymerization |
0.012210551 |
9.5 |
NaN |
|
MAP4;TUBA1A |
| verapamil |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Microtubule polymerization |
0.009695754 |
10 |
NaN |
|
MAP4;TUBA1A |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Microtubule polymerization |
0.012844883 |
12 |
NaN |
|
MAP4;TUBA1A |
| verapamil |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Mitotic spindle assembly |
2.86E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001561493 |
2 |
NaN |
|
ADAM19;ADAMTS5;ADAMTS6;ADAMTS7 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.018503677 |
13 |
NaN |
|
ADAMTS14;ADAMTS15;ADAMTS8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001682921 |
6 |
NaN |
|
ADAMTS14;ADAMTS15;ADAMTS2;ADAMTS8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000287499 |
2 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS15;ADAMTS8;ADAMTS9 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
1.59E-05 |
2 |
NaN |
|
ADAMTS14;ADAMTS15;ADAMTS17;ADAMTS5;ADAMTS8;ADAMTS9 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001446344 |
5 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS15;ADAMTS8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.01809121 |
12 |
NaN |
|
MMP1;MMP3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.015505928 |
10 |
NaN |
|
MMP1;MMP3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Extracellular matrix breakdown by serine proteases |
0.009455468 |
4.5 |
NaN |
|
KLK5;PRSS8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
7.16E-07 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL5A1;COL5A2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
1.00E-06 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL5A1;COL5A2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
2.89E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL5A2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.01910546 |
7 |
NaN |
|
COL1A1;COL1A2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
4.37E-05 |
2 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL5A2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.001401225 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.025134697 |
14.5 |
NaN |
|
COL11A1;COL2A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.001401225 |
5 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.00098321 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fibroblast growth factor receptor signaling |
0.031652619 |
16.5 |
NaN |
|
ANOS1;FGF18 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
GABA metabolism |
0.0055816 |
4 |
NaN |
|
ABAT;SLC6A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Gap junction organization |
0.035147755 |
11 |
NaN |
|
GJA5;GJA8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Gap junction organization |
0.002388906 |
3 |
NaN |
|
GJA1;GJA5;GJA8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Gap junction organization |
0.03648388 |
13.5 |
NaN |
|
GJA1;GJA8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Gap junction organization |
0.037023918 |
12 |
NaN |
|
GJA5;GJA8 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Glutamate and glutamine metabolism |
0.036831666 |
19 |
NaN |
|
SLC1A5;SLC7A5 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
0.01647391 |
11 |
NaN |
|
ENO1;LDHA;PFKFB3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.020445489 |
12.5 |
NaN |
|
SOCS3;STAT3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Heparin and heparan sulfate synthesis |
0.022263706 |
13.5 |
NaN |
|
GLCE;HS6ST1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Hepatocyte growth factor receptor signaling |
0.039650143 |
13 |
NaN |
|
MET |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Hepatocyte growth factor receptor signaling |
0.042414608 |
13.5 |
NaN |
|
MET |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Hepatocyte growth factor receptor signaling |
0.043622809 |
14 |
NaN |
|
MET |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.046898366 |
17 |
NaN |
|
HGF |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.043277686 |
12.5 |
NaN |
|
HGF |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.046898366 |
21 |
NaN |
|
HGF |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.041551141 |
15 |
NaN |
|
HGF |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
HIF-1 receptor signaling pathway |
0.020445489 |
12.5 |
NaN |
|
CITED2;EGLN3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hyaluronan synthesis |
0.001409479 |
4.5 |
NaN |
|
HAS2;HAS3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Hyaluronan synthesis |
0.001298656 |
4 |
NaN |
|
HAS2;HAS3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Inhibin receptor signaling |
0.016169721 |
10.5 |
NaN |
|
INHA;INHBA |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Inhibin receptor signaling |
0.014292788 |
11.5 |
NaN |
|
INHA;INHBA |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001656732 |
4 |
NaN |
|
A2M;MME |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001409479 |
4.5 |
NaN |
|
A2M;MME |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001884281 |
4.5 |
NaN |
|
A2M;MME |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001656732 |
6 |
NaN |
|
A2M;MME |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of apoptosis |
0.031652619 |
15 |
NaN |
|
BIRC5;IFI6 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Inhibition of apoptosis |
0.031652619 |
16.5 |
NaN |
|
BIRC3;IFI6 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Inositol metabolism and transport |
0.043277686 |
16 |
NaN |
|
INPP5D |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.031008959 |
10 |
NaN |
|
SOCS2;STAT4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
JAK-STAT signaling pathway |
0.004751696 |
7 |
NaN |
|
SOCS3;STAT3;STAT4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Leptin receptor signaling |
0.003705518 |
6 |
NaN |
|
SOCS3;STAT3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Lipogenesis |
0.046898366 |
17 |
NaN |
|
FASN |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Lipogenesis |
0.043277686 |
12.5 |
NaN |
|
FASN |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Lipogenesis |
0.049996342 |
20.5 |
NaN |
|
FASN |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Lipogenesis |
0.000561055 |
3.5 |
NaN |
|
ACLY;FASN |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Macrophage migration inhibitory factor signaling |
0.005350837 |
7.5 |
NaN |
|
ACKR3;CXCR4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
MAPK signaling pathway |
0.033465072 |
18 |
NaN |
|
DUSP1;RPS6KA2;TRIM45 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Methionine cycle |
0.042414608 |
13.5 |
NaN |
|
BHMT |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Methionine cycle |
0.043622809 |
14 |
NaN |
|
BHMT |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Methionine cycle |
0.041551141 |
15 |
NaN |
|
MAT1A |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Microtubule crosslinking and bundling |
0.007900936 |
9 |
NaN |
|
MAP2;MTCL1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.008957388 |
9 |
NaN |
|
NPPB;NPR3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.007900936 |
9 |
NaN |
|
NPPB;NPR3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Osteonectin receptor signaling |
0.00229214 |
2 |
NaN |
|
SMOC2;SPOCK1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Osteonectin receptor signaling |
4.07E-05 |
1.5 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.0200247 |
6.5 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.021436133 |
7.5 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.019848271 |
8 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.021877205 |
9.5 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.022053634 |
9.5 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.021308064 |
11 |
NaN |
|
PDGFD;TNK2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Progesterone receptor signaling |
0.021877205 |
9.5 |
NaN |
|
PGR |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Prostaglandin E2 receptor signaling |
0.006227501 |
8.5 |
NaN |
|
PTGER3;RAPGEF4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Regulation of coagulation cascade by protein C |
0.00277824 |
4 |
NaN |
|
PROS1;THBD |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Restriction point |
0.019397192 |
7 |
NaN |
|
CCND2;E2F1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Restriction point |
0.022263706 |
14 |
NaN |
|
CDKN1A;PFKFB3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Retinol metabolism |
0.003167864 |
5 |
NaN |
|
ALDH1A3;RDH10;TTR |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Retinol metabolism |
5.37E-06 |
1 |
NaN |
|
ALDH1A3;CYP26A1;RDH10;RPE65;TTR |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Retinol metabolism |
0.041452288 |
19 |
NaN |
|
RDH10;RPE65 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Retinol metabolism |
0.002236525 |
6 |
NaN |
|
RDH10;RPE65;TTR |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Semaphorin signaling |
0.04605371 |
20 |
NaN |
|
DPYSL3;NRP2;SEMA3C |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.023018072 |
12 |
NaN |
|
PHGDH;PSAT1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.02679052 |
15 |
NaN |
|
SHMT2;SLC1A5 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serotonin inactivation |
0.000561055 |
2 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serotonin inactivation |
0.000476724 |
3 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serotonin inactivation |
0.000638802 |
3 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Serotonin inactivation |
0.000561055 |
3.5 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Serotonin inactivation |
0.000438979 |
2 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid attachment to mitotic spindle |
0.042414608 |
13.5 |
NaN |
|
NUF2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid attachment to mitotic spindle |
0.039304304 |
13 |
NaN |
|
NUF2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Sister chromatid attachment to mitotic spindle |
0.043277686 |
16 |
NaN |
|
NUF2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.043622809 |
14 |
NaN |
|
NUF2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sodium transmembrane transport |
0.028965755 |
12 |
NaN |
|
FXYD5;SCN1A;SLC5A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Sphingolipid metabolism |
0.01523495 |
6 |
NaN |
|
CERS4;ST8SIA1;UGCG |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Thrombospondin receptor signaling |
0.002332606 |
2 |
NaN |
|
THBS2;THBS4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
4.07E-05 |
1.5 |
NaN |
|
CD47;THBS2;THBS4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Thrombospondin receptor signaling |
4.17E-05 |
1 |
NaN |
|
CD47;THBS2;THBS4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tight junction organization |
0.033900141 |
13 |
NaN |
|
CLDN11;CLDN6;MYLK |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Transmembrane glucose transport |
0.003261527 |
6 |
NaN |
|
SLC2A1;SLC2A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Transsulfuration pathway |
0.02099506 |
10 |
NaN |
|
MAT1A |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Tropoelastin synthesis |
0.0200247 |
6.5 |
NaN |
|
ELN |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.021877205 |
11 |
NaN |
|
ELN |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.039650143 |
13 |
NaN |
|
VIPR2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.042414608 |
13.5 |
NaN |
|
VIPR2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.039304304 |
13 |
NaN |
|
VIPR2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.043277686 |
16 |
NaN |
|
VIPR2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.041551141 |
15 |
NaN |
|
VIPR1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Versican receptor signaling |
0.039304304 |
13 |
NaN |
|
VCAN |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Versican synthesis |
0.019848271 |
8 |
NaN |
|
VCAN |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Vimentin-like intermediate filament dynamics |
0.001884281 |
4.5 |
NaN |
|
DES;GFAP |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Water transmembrane transport |
0.010149397 |
6 |
NaN |
|
AQP10;AQP7 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.039120547 |
11 |
NaN |
|
FZD1;SFRP1;SFRP2;WNT3A |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.002420842 |
3 |
NaN |
|
FZD1;FZD2;PAX6;SFRP1;SFRP2;WNT3A |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Z-disc organization |
0.039837635 |
15 |
NaN |
|
CSRP3;DYSF |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Z-disc organization |
0.047440656 |
16 |
NaN |
|
CSRP3;DYSF |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Z-disc organization |
0.046759314 |
14 |
NaN |
|
DES;PDLIM3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Z-disc organization |
0.043409684 |
17 |
NaN |
|
DES;PDLIM3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Adrenergic receptor signaling |
0.02715843 |
18 |
NaN |
|
ADRB3;GRK5;PDE4D |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Aggrecan synthesis |
0.0200247 |
6.5 |
NaN |
|
ACAN |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Aggrecan synthesis |
0.021877205 |
9.5 |
NaN |
|
ACAN |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.0200247 |
6.5 |
NaN |
|
ALB |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.021436133 |
7.5 |
NaN |
|
ALB |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.022053634 |
9.5 |
NaN |
|
ALB |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.025317572 |
16.5 |
NaN |
|
ALB |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Aspartate and arginine metabolism |
0.025134697 |
14.5 |
NaN |
|
ASS1;SLC7A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Aspartate and arginine metabolism |
0.022263706 |
13.5 |
NaN |
|
ASS1;SLC7A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Axonal intermediate filament dynamics |
0.008950881 |
5 |
NaN |
|
NEFL;NES |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Axonal intermediate filament dynamics |
0.007712399 |
5 |
NaN |
|
NEFM;NES |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Axonal intermediate filament dynamics |
0.009309998 |
6 |
NaN |
|
NEFH;NES |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Axonal intermediate filament dynamics |
0.009455468 |
4.5 |
NaN |
|
NEFH;NEFM |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Biglycan synthesis |
0.0200247 |
6.5 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Biglycan synthesis |
0.021436133 |
7.5 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Biglycan synthesis |
0.019848271 |
8 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Biglycan synthesis |
0.021877205 |
9.5 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Biglycan synthesis |
0.022053634 |
9.5 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Calcitonin receptor signaling |
0.046898366 |
17 |
NaN |
|
RAMP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030506558 |
11 |
NaN |
|
KCNA1;KCNJ2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.03648388 |
13.5 |
NaN |
|
KCNA1;KCNJ2 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005350837 |
7.5 |
NaN |
|
CTGF;CYR61 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004563637 |
7 |
NaN |
|
CTGF;CYR61 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006072761 |
8 |
NaN |
|
CTGF;CYR61 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005350837 |
7 |
NaN |
|
CTGF;CYR61 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004209808 |
7 |
NaN |
|
CTGF;WISP1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.039650143 |
13 |
NaN |
|
CD44 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.049996342 |
20.5 |
NaN |
|
CD44 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cellular cholesterol uptake and efflux |
0.03055135 |
10 |
NaN |
|
ABCA1;ABCG1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.02648975 |
10 |
NaN |
|
ABCA1;ABCG1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cellular cholesterol uptake and efflux |
0.002514941 |
3 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Cholesterol synthesis |
4.95E-06 |
1 |
NaN |
|
FDPS;HMGCR;HMGCS1;MVD;MVK;SQLE |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Cholesterol synthesis |
5.70E-05 |
2 |
NaN |
|
DHCR7;FDPS;HMGCR;HMGCS1;MVD |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cholesterol synthesis |
5.81E-15 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;NSDHL;SQLE |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Cholesterol synthesis |
1.52E-13 |
1 |
NaN |
|
CYP51A1;DHCR7;FDFT1;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cholesterol synthesis |
4.69E-05 |
1 |
NaN |
|
CYP51A1;DHCR7;HMGCS1;MVD;MVK |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.007900936 |
9 |
NaN |
|
INSIG1;SREBF1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.007900936 |
9 |
NaN |
|
INSIG1;SREBF1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.006227501 |
8.5 |
NaN |
|
INSIG1;SREBF1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005678798 |
3 |
NaN |
|
COL12A1;COL9A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006484773 |
4 |
NaN |
|
COL12A1;COL9A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006746931 |
5 |
NaN |
|
COL12A1;COL9A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006853158 |
3 |
NaN |
|
COL12A1;COL9A3 |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006746931 |
8 |
NaN |
|
COL14A1;COL9A1 |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Decorin synthesis |
0.0200247 |
6.5 |
NaN |
|
DCN |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Decorin synthesis |
0.021436133 |
7.5 |
NaN |
|
DCN |
| vemurafenib |
Kinase inhibitor |
No |
MSN09 |
Up |
Decorin synthesis |
0.022053634 |
9.5 |
NaN |
|
DCN |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Decorin synthesis |
0.025317572 |
16.5 |
NaN |
|
DCN |
| vemurafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Desaturation of fatty acids |
0.01088894 |
10 |
NaN |
|
FADS2;SCD |
| vemurafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Desaturation of fatty acids |
0.009309998 |
9 |
NaN |
|
FADS2;SCD |
| vemurafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.016169721 |
10.5 |
NaN |
|
KRT19;KRT4 |
| vemurafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
0.014292788 |
11.5 |
NaN |
|
KRT19;KRT7 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Activin receptor signaling |
0.028464226 |
10 |
NaN |
|
ACVRL1;SMAD9 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.02099506 |
12 |
NaN |
|
ALB |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.02099506 |
10 |
NaN |
|
ALB |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.020906845 |
11.5 |
NaN |
|
ALB |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Alternative complement pathway |
0.004209808 |
5.5 |
NaN |
|
C1S;CFH |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Alternative complement pathway |
0.004209808 |
4.5 |
NaN |
|
C1S;CFH |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Alternative complement pathway |
0.004175176 |
4.5 |
NaN |
|
C1S;CFH |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.023200423 |
10 |
18 |
Down by cardiotoxic TKIs |
BGN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Biglycan synthesis |
0.022582922 |
4.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Biglycan synthesis |
0.022406493 |
7.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Cardiomyocyte pacemaker current generation |
0.013690263 |
6 |
NaN |
|
CACNA1G;KCNK2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.013002108 |
3 |
NaN |
|
CACNA1G;KCNK2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002802661 |
4 |
NaN |
|
KCNA5;KCNIP2;KCNJ2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002802661 |
3 |
NaN |
|
KCND2;KCNIP2;KCNJ2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002769359 |
3 |
NaN |
|
KCNA5;KCNIP2;KCNJ2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
CD44-Mediated leukocyte rolling |
0.041551141 |
18 |
NaN |
|
CD44 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
CD44-Mediated leukocyte rolling |
0.041551141 |
17 |
NaN |
|
CD44 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
CD44-Mediated leukocyte rolling |
0.041378401 |
17.5 |
NaN |
|
CD44 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Cellular cholesterol uptake and efflux |
0.035340255 |
15 |
23 |
Down by cardiotoxic TKIs |
ABCA1;SCARA3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.002752604 |
1 |
23 |
Down by cardiotoxic TKIs |
ABCA1;MYLIP;SCARA3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome separation |
0.021340058 |
7 |
NaN |
|
CDK1;NEK6 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Chloride transmembrane transport |
0.03363188 |
7.5 |
17 |
Down by cardiotoxic TKIs |
SLC12A7;SLC26A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cholesterol synthesis |
0.00070437 |
2 |
22 |
Up by cardiotoxic TKIs |
HMGCR;HMGCS1;MSMO1;MVD |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Classical complement pathway |
0.0085983 |
8 |
NaN |
|
C1R;C1S |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Classical complement pathway |
0.0085983 |
6.5 |
NaN |
|
C1R;C1S |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Classical complement pathway |
0.00852857 |
7 |
NaN |
|
C1R;C1S |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006227501 |
7 |
NaN |
|
COL14A1;COL9A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006176635 |
6 |
NaN |
|
COL14A1;COL9A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Decorin synthesis |
0.02099506 |
12 |
NaN |
|
DCN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Decorin synthesis |
0.02099506 |
10 |
NaN |
|
DCN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.020906845 |
11.5 |
NaN |
|
DCN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Eicosanoid metabolism |
0.046155652 |
19 |
NaN |
|
CYP2J2;PTGS2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Eicosanoid metabolism |
0.043339696 |
12 |
NaN |
|
CYP2J2;PTGS2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Endogenous control of complement activity |
0.004209808 |
5.5 |
NaN |
|
CFH;CFI |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Endogenous control of complement activity |
0.004209808 |
4.5 |
NaN |
|
CFH;CFI |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Endogenous control of complement activity |
0.004175176 |
4.5 |
NaN |
|
CFH;CFI |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic spindle disassembly |
0.023200423 |
10 |
NaN |
|
CDK1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.007067944 |
2.5 |
NaN |
|
NPR1;NPR3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Notch receptor signaling |
0.010508893 |
5 |
NaN |
|
DLK1;JAG1;LFNG |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Notch receptor signaling |
0.009558809 |
4 |
NaN |
|
DLK1;JAG1;LFNG |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Osteonectin receptor signaling |
0.002561319 |
3 |
NaN |
|
SMOC2;SPARC |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Osteonectin receptor signaling |
0.002561319 |
1.5 |
NaN |
|
SMOC2;SPOCK1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Osteonectin receptor signaling |
0.002540098 |
2 |
NaN |
|
SMOC2;SPARC |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Osteopontin receptor signaling |
0.02099506 |
12 |
NaN |
|
SPP1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Osteopontin receptor signaling |
0.02099506 |
10 |
NaN |
|
SPP1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Osteopontin receptor signaling |
0.020906845 |
11.5 |
NaN |
|
SPP1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Perlecan synthesis |
0.023200423 |
10 |
NaN |
|
HSPG2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.025687982 |
13 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRB |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.02407108 |
9 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRB |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Progesterone receptor signaling |
0.020906845 |
11.5 |
NaN |
|
PGR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Prostacycline receptor signaling |
0.045864587 |
17 |
NaN |
|
PTGIR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Prostacycline receptor signaling |
0.044657802 |
11.5 |
NaN |
|
PTGIR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Prostacycline receptor signaling |
0.044312867 |
14 |
NaN |
|
PTGIR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.045864587 |
17 |
NaN |
|
PTGFR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.044657802 |
11.5 |
NaN |
|
PTGFR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.044312867 |
14 |
NaN |
|
PTGFR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Regulation of coagulation cascade by protein C |
0.002561319 |
1.5 |
NaN |
|
PROS1;THBD |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Restriction point |
0.017535602 |
9 |
3 |
Up by cardiotoxic TKIs |
CDKN1A;E2F1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Retinol metabolism |
0.029399062 |
13.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.00297168 |
1 |
NaN |
|
DHRS3;RLBP1;STRA6 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Retinol metabolism |
0.03363188 |
7.5 |
NaN |
|
DHRS3;RLBP1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.033150099 |
11 |
NaN |
|
DHRS3;RLBP1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Roundabout signaling |
0.010426243 |
4 |
NaN |
|
ROBO1;ROBO2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serine and glycine metabolism |
0.021308064 |
14 |
19 |
Up by cardiotoxic TKIs |
PSAT1;SLC1A5 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serine and glycine metabolism |
0.021308064 |
12 |
19 |
Up by cardiotoxic TKIs |
PSAT1;SLC1A5 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serotonin inactivation |
0.041551141 |
18 |
NaN |
|
MAOA |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serotonin inactivation |
0.041551141 |
17 |
NaN |
|
MAOA |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Serotonin inactivation |
0.041378401 |
17.5 |
NaN |
|
MAOA |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Sodium transmembrane transport |
0.028654752 |
15 |
NaN |
|
ATP1A2;SLC38A2;SLC5A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Thin myofilament organization |
0.0085983 |
6.5 |
NaN |
|
ACTA1;LMOD3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.00311962 |
2 |
NaN |
|
THBS2;THBS4 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.002957925 |
2 |
NaN |
|
THBS2;THBS4 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.023200423 |
10 |
NaN |
|
ELN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.022582922 |
4.5 |
NaN |
|
ELN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.022406493 |
7.5 |
NaN |
|
ELN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041551141 |
18 |
NaN |
|
VIPR2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041551141 |
17 |
NaN |
|
VIPR2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041378401 |
17.5 |
NaN |
|
VIPR2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
ER unfolded protein response pathway |
0.012808436 |
5.5 |
NaN |
|
HERPUD1;PPP1R15A |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014337343 |
10 |
NaN |
|
MMP1;MMP2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014337343 |
8 |
NaN |
|
MMP1;MMP2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014222736 |
8 |
NaN |
|
MMP1;MMP2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
3.60E-05 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
8.86E-07 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fibronectin synthesis and extracellular assembly |
0.004782464 |
1 |
NaN |
|
FN1;ITGB3 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fibulin receptor signaling |
0.045864587 |
17 |
NaN |
|
FBLN1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fibulin receptor signaling |
0.044312867 |
14 |
NaN |
|
FBLN1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
G2 M transition checkpoint |
0.02522021 |
15 |
NaN |
|
CCNG1;WEE1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
G2 M transition checkpoint |
0.025022959 |
14 |
NaN |
|
CCNG1;WEE1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
GABA metabolism |
0.007562538 |
3 |
NaN |
|
ABAT;SLC6A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
GABA metabolism |
0.007067944 |
2.5 |
NaN |
|
ABAT;SLC6A1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Gap junction organization |
0.038662978 |
9 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJD2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.029399062 |
13.5 |
NaN |
|
SLC1A5;SLC7A5 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Growth differentiation factor receptor signaling |
0.012808436 |
5.5 |
NaN |
|
GDF10;GDF2 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.023200423 |
10 |
NaN |
|
HMMR |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Inhibin receptor signaling |
0.011306612 |
9 |
NaN |
|
INHA;INHBA |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Inhibition of apoptosis |
0.030360474 |
14 |
NaN |
|
BIRC5;BIRC7 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Inhibition of apoptosis |
0.028881222 |
6 |
NaN |
|
BIRC5;BIRC7 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.033831795 |
16 |
NaN |
|
STAT3;STAT4 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.033831795 |
15 |
NaN |
|
STAT3;STAT4 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Lipogenesis |
0.044657802 |
11.5 |
NaN |
|
FASN |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Methionine cycle |
0.041378401 |
17.5 |
NaN |
|
BHMT |
| vandetanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Microfibril scaffold organization |
0.044657802 |
11.5 |
NaN |
|
FBN1 |
| vandetanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Z-disc organization |
0.048814568 |
16 |
NaN |
|
DES;TCAP |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.009672366 |
12 |
NaN |
|
DACT1;FZD7;MSX2;SFRP2;WNT1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.038589958 |
19 |
NaN |
|
DACT1;FZD7;SFRP2;WNT1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Z-disc organization |
0.003569197 |
6 |
NaN |
|
CSRP3;DYSF;TCAP |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Z-disc organization |
0.048814568 |
20.5 |
NaN |
|
DES;TCAP |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Z-disc organization |
0.006383649 |
1 |
NaN |
|
CSRP3;DES;TCAP |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Mitotic spindle assembly |
0.000249918 |
5 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Mitotic spindle assembly |
0.032910271 |
23 |
NaN |
|
NUSAP1;TPX2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Mitotic spindle disassembly |
0.025582216 |
22 |
NaN |
|
CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Mitotic spindle disassembly |
0.022318278 |
18.5 |
NaN |
|
CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Mitotic spindle disassembly |
0.019936486 |
15 |
NaN |
|
CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Natriuretic peptide receptor signaling |
0.008362857 |
2.5 |
NaN |
|
NPPC;NPR1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Natriuretic peptide receptor signaling |
0.007013957 |
13 |
NaN |
|
NPPA;NPPB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.005875567 |
9.5 |
NaN |
|
NPPA;NPPB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.0056301 |
9.5 |
NaN |
|
NPPA;NPPB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Osteonectin receptor signaling |
0.003782172 |
14 |
NaN |
|
SPARC;SPOCK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Osteonectin receptor signaling |
0.002889904 |
8.5 |
NaN |
|
SPARC;SPOCK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Osteopontin receptor signaling |
0.019848271 |
15 |
NaN |
|
SPP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Osteopontin receptor signaling |
0.022406493 |
11.5 |
NaN |
|
SPP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Osteopontin receptor signaling |
0.024170783 |
8 |
NaN |
|
SPP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Osteopontin receptor signaling |
0.024435427 |
8 |
NaN |
|
SPP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.002347329 |
10.5 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRA;TNK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
7.07E-05 |
2 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFRA;PDGFRB;TNK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.001221097 |
5 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;PDGFRB;TNK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.001146233 |
3.5 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;PDGFRB;TNK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Potassium transmembrane transport |
0.011481125 |
10 |
7 |
Up by cardiotoxic TKIs |
ABCC9;ATP1A2;KCNE4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Potassium transmembrane transport |
0.015893011 |
6.5 |
7 |
Up by cardiotoxic TKIs |
ATP1A2;KCNE4;KCNQ1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Protein polyubiquitination |
0.048814568 |
20.5 |
NaN |
|
ISG15;UCHL1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Removal of caspase inhibition |
0.039304304 |
21 |
NaN |
|
XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Removal of caspase inhibition |
0.044312867 |
18 |
NaN |
|
XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Removal of caspase inhibition |
0.047759421 |
12 |
NaN |
|
XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Removal of caspase inhibition |
0.048275867 |
14 |
NaN |
|
XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Retinol metabolism |
0.033150099 |
15 |
NaN |
|
ALDH1A1;ALDH1A3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Retinol metabolism |
0.00020098 |
1 |
NaN |
|
ALDH1A2;ALDH1A3;DHRS3;RBP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Retinol metabolism |
0.038858469 |
11 |
NaN |
|
ALDH1A2;ALDH1A3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Semaphorin signaling |
0.039932176 |
16 |
NaN |
|
NRP2;PLXND1;RND1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Semaphorin signaling |
0.04819315 |
14 |
NaN |
|
PLXND1;RND1;SEMA6B |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Serine and glycine metabolism |
0.002347329 |
10.5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Serine and glycine metabolism |
0.001587334 |
7 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Serine and glycine metabolism |
0.020145007 |
14 |
NaN |
|
PHGDH;SHMT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Serine and glycine metabolism |
0.001146233 |
3.5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Serotonin inactivation |
0.000652251 |
7 |
NaN |
|
MAOA;MAOB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Sister chromatid segregation |
0.009139439 |
17.5 |
NaN |
|
PTTG1;TOP2A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Sister chromatid segregation |
0.007013957 |
13 |
NaN |
|
ESPL1;TOP2A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Sister chromatid segregation |
0.005875567 |
9.5 |
NaN |
|
ESPL1;TOP2A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Sister chromatid segregation |
0.0056301 |
9.5 |
NaN |
|
ESPL1;TOP2A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Thick myofilament organization |
0.001161278 |
3 |
NaN |
|
MYBPC3;TTN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Thick myofilament organization |
0.001478116 |
1 |
NaN |
|
MYBPC3;MYH7 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Thin myofilament organization |
0.000254603 |
2 |
NaN |
|
ACTA1;LMOD3;TNNI3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Thin myofilament organization |
0.000454886 |
2 |
NaN |
|
ACTA1;LMOD3;TNNI3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Thin myofilament organization |
0.011520133 |
4 |
NaN |
|
ACTA1;LMOD3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Thrombospondin receptor signaling |
0.003782172 |
14 |
NaN |
|
THBS1;THBS4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Thrombospondin receptor signaling |
0.002889904 |
8.5 |
NaN |
|
THBS1;THBS4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Thrombospondin receptor signaling |
3.29E-05 |
2 |
NaN |
|
THBS1;THBS2;THBS4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Thrombospondin receptor signaling |
0.00231233 |
6 |
NaN |
|
THBS1;THBS4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.025582216 |
22 |
NaN |
|
ELN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Tropoelastin synthesis |
0.022318278 |
18.5 |
NaN |
|
ELN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.020377558 |
16.5 |
NaN |
|
ELN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.019936486 |
15 |
NaN |
|
ELN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Versican receptor signaling |
0.044140376 |
26 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Versican receptor signaling |
0.040341633 |
21 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Versican receptor signaling |
0.039477231 |
21.5 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Versican synthesis |
0.022318278 |
18.5 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Versican synthesis |
0.020377558 |
16.5 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Versican synthesis |
0.019936486 |
15 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Water transmembrane transport |
0.015114208 |
5.5 |
NaN |
|
AQP1;AQP3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.03806357 |
20 |
NaN |
|
CTHRC1;SFRP4;SFRP5;WNT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
WNT-Beta-catenin signaling pathway |
0.014145821 |
5 |
NaN |
|
CTHRC1;FZD2;SFRP4;SFRP5;WNT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Aggrecan synthesis |
0.019848271 |
15 |
NaN |
|
ACAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Aggrecan synthesis |
0.022406493 |
11.5 |
NaN |
|
ACAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Aggrecan synthesis |
0.024435427 |
8 |
NaN |
|
ACAN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.022406493 |
11.5 |
NaN |
|
ALB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.024170783 |
8 |
NaN |
|
ALB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.024435427 |
8 |
NaN |
|
ALB |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Antigen presentation via MHC class I molecules |
0.015890842 |
12.5 |
NaN |
|
HLA-A;HLA-C |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Aspartate and arginine metabolism |
0.025627571 |
24 |
NaN |
|
ARG2;SLC7A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Aspartate and arginine metabolism |
0.019838394 |
15 |
NaN |
|
ARG2;SLC7A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Biglycan synthesis |
0.022318278 |
18.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.020377558 |
16.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Biglycan synthesis |
0.019936486 |
15 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Cardiomyocyte depolarization during action potential |
0.019848271 |
15 |
NaN |
|
SCN5A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Cardiomyocyte depolarization during action potential |
0.022406493 |
11.5 |
NaN |
|
SCN5A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Cardiomyocyte depolarization during action potential |
0.024170783 |
8 |
NaN |
|
SCN5A |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Cardiomyocyte pacemaker current generation |
0.010149397 |
8.5 |
NaN |
|
CACNA1G;HCN4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030506558 |
19 |
NaN |
|
KCNA1;KCNQ5 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004745654 |
10.5 |
NaN |
|
CTGF;CYR61 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003970259 |
6.5 |
NaN |
|
CTGF;CYR61 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003803269 |
7 |
NaN |
|
CTGF;CYR61 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.044140376 |
26 |
NaN |
|
CD44 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
CD44-Mediated leukocyte rolling |
0.039477231 |
21.5 |
NaN |
|
CD44 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Cellular cholesterol uptake and efflux |
0.02648975 |
18 |
NaN |
|
ABCA1;SCARA3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Centrosome separation |
7.80E-05 |
3 |
NaN |
|
CCNB1;CDK1;KIF11;SPAG5 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Centrosome separation |
0.001173699 |
5 |
NaN |
|
CCNB1;CDK1;ESPL1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Centrosome separation |
0.016025171 |
12 |
NaN |
|
CDK1;ESPL1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Chaperone-mediated autophagy |
0.048275867 |
14 |
NaN |
|
HSPA8 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Cholesterol synthesis |
3.48E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;HMGCR;HMGCS1;MSMO1;MVD;MVK;SC5D;SQLE |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Cholesterol synthesis |
0.000629594 |
3 |
NaN |
|
DHCR24;DHCR7;MSMO1;MVK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.009139439 |
17.5 |
NaN |
|
INSIG1;SREBF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.005875567 |
9.5 |
NaN |
|
INSIG1;SREBF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.0056301 |
9.5 |
NaN |
|
INSIG1;SREBF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Classical complement pathway |
0.00974952 |
3 |
NaN |
|
C1QB;C1R |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Collagen fiber crosslinking |
0.003770283 |
7 |
NaN |
|
LOX;PXDN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Collagen fiber crosslinking |
0.005547025 |
3 |
NaN |
|
LOX;PXDN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000147651 |
1 |
NaN |
|
COL12A1;COL14A1;COL9A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007067944 |
2 |
NaN |
|
COL14A1;COL9A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008362857 |
2.5 |
NaN |
|
COL14A1;COL9A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Connection of muscle sarcomere to plasma membrane |
0.023046241 |
5.5 |
NaN |
|
DES;TLN2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Contractile ring constriction |
0.000159506 |
4 |
NaN |
|
ANLN;ECT2;MYLK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Contractile ring constriction |
0.004745654 |
10.5 |
NaN |
|
ECT2;MYLK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.003970259 |
6.5 |
NaN |
|
ANLN;MYLK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Decorin synthesis |
0.025582216 |
22 |
NaN |
|
DCN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Decorin synthesis |
0.022318278 |
18.5 |
NaN |
|
DCN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Decorin synthesis |
0.020377558 |
16.5 |
NaN |
|
DCN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Decorin synthesis |
0.019936486 |
15 |
NaN |
|
DCN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Desaturation of fatty acids |
0.012580282 |
19 |
NaN |
|
FADS2;SCD |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Eicosanoid metabolism |
0.049688981 |
15 |
NaN |
|
CYP2J2;PTGS1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Epithelial intermediate filament dynamics |
0.012808436 |
4 |
NaN |
|
KRT7;TCHH |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Epithelial intermediate filament dynamics |
0.015114208 |
5.5 |
NaN |
|
KRT7;KRT8 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Equatorial RhoA activation |
0.003782172 |
14 |
NaN |
|
ECT2;KIF23 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
ER unfolded protein response pathway |
0.00084348 |
8 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
0.000368695 |
6 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;TTK;ZWINT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.015893011 |
6.5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS8 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.019424314 |
4 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS8 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Extracellular matrix breakdown by cathepsins |
0.019986419 |
8.5 |
NaN |
|
CTSH;CTSV |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
0.023046241 |
5.5 |
NaN |
|
CTSH;CTSV |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.000835321 |
4 |
NaN |
|
MMP12;MMP2;MMP3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.015890842 |
12.5 |
NaN |
|
COL11A1;COL2A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.019986419 |
8.5 |
NaN |
|
COL11A1;COL2A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
2.40E-06 |
2 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1;COL5A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Fibrillar collagen core structure organization |
4.58E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.000901583 |
4 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.000846027 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
G2 M transition checkpoint |
0.036346966 |
25.5 |
NaN |
|
CCNB1;CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
G2 M transition checkpoint |
0.028256676 |
22 |
NaN |
|
CCNB1;CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
GABA metabolism |
0.007013957 |
13 |
NaN |
|
ABAT;SLC6A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
GABA metabolism |
0.005875567 |
9.5 |
NaN |
|
ABAT;SLC6A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
GABA metabolism |
0.0056301 |
9.5 |
NaN |
|
ABAT;SLC6A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Gap junction organization |
0.044617901 |
12 |
NaN |
|
GJA5;GJB2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
0.002529748 |
12 |
NaN |
|
ENO1;HK2;LDHA;PCK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Glycolysis and Gluconeogenesis |
0.000128846 |
3 |
NaN |
|
ENO1;HK2;LDHA;PCK2;PFKFB3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.010947197 |
13 |
NaN |
|
ENO1;HK2;LDHA |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.001011093 |
2 |
NaN |
|
ENO1;HK2;LDHA;PFKFB4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.044312867 |
18 |
NaN |
|
JAK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.047759421 |
12 |
NaN |
|
JAK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048275867 |
14 |
NaN |
|
JAK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.012879711 |
11 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Growth differentiation factor receptor signaling |
0.010149397 |
8.5 |
NaN |
|
GDF11;GDF6 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Growth differentiation factor receptor signaling |
0.016492549 |
20 |
NaN |
|
GDF15;GDF2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.022318278 |
18.5 |
NaN |
|
HMMR |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001466565 |
6 |
NaN |
|
A2M;PLAT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
8.35E-06 |
1 |
NaN |
|
A2M;MME;PLAT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001171577 |
5 |
NaN |
|
A2M;PLAT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Inhibition of apoptosis |
0.022707438 |
17 |
NaN |
|
IFI6;XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Inhibition of apoptosis |
0.028464226 |
14 |
NaN |
|
IFI6;XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Inhibition of apoptosis |
0.032746265 |
10 |
NaN |
|
IFI6;XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Up |
Inhibition of apoptosis |
0.033409737 |
10 |
NaN |
|
IFI6;XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Inhibition of apoptosis |
0.036346966 |
25.5 |
NaN |
|
BIRC3;BIRC5 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Insulin receptor signaling |
0.043031062 |
24 |
NaN |
|
IRS1;IRS2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Insulin receptor signaling |
0.036462821 |
19 |
NaN |
|
IRS1;IRS2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Insulin receptor signaling |
0.035030785 |
18 |
NaN |
|
IRS1;IRS2 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.002388906 |
5 |
NaN |
|
SOCS3;STAT3;STAT4 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Up |
Leptin receptor signaling |
0.00229214 |
4 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Lipogenesis |
0.040341633 |
21 |
NaN |
|
FASN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Lipogenesis |
0.039477231 |
21.5 |
NaN |
|
FASN |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
0.0016025 |
9 |
NaN |
|
BUB1;CCNB2;CENPE;PTTG1;TTK |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Up |
Methionine cycle |
0.044312867 |
18 |
NaN |
|
BHMT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Up |
Methionine cycle |
0.047759421 |
12 |
NaN |
|
BHMT |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN02 |
Down |
Microfibril scaffold organization |
0.044140376 |
26 |
NaN |
|
FBN1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN05 |
Down |
Microfibril scaffold organization |
0.040341633 |
21 |
NaN |
|
FBN1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN09 |
Down |
Microfibril scaffold organization |
0.039477231 |
21.5 |
NaN |
|
FBN1 |
| trastuzumab |
Monoclonal antibody |
Yes |
MSN01 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.006197282 |
16 |
NaN |
|
AURKB;CCNA2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
3.42E-07 |
2 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;NDC80;NUF2;SPC24;TTK;ZWINT |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
2.29E-08 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
1.70E-12 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPI;CENPU;KIF15;KNSTRN;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
1.30E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;NDC80;NUF2;SPC24;TTK;ZWINT |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.041630095 |
8.5 |
NaN |
|
ADAM33;ADAMTS5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.007238399 |
2.5 |
NaN |
|
ADAMTS1;ADAMTS5;ADAMTS6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.022338334 |
22 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.006199885 |
15.5 |
NaN |
|
SULF1;SULF2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.005110927 |
18.5 |
NaN |
|
SULF1;SULF2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.005140644 |
15.5 |
NaN |
|
SULF1;SULF2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
4.71E-05 |
5 |
NaN |
|
MMP1;MMP12;MMP2;MMP3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.027648786 |
29 |
NaN |
|
BRIP1;FANCD2;FANCI |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.009718089 |
19 |
NaN |
|
FANCA;FANCD2;FANCI;UBE2T |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.000897935 |
13 |
NaN |
|
BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.006979217 |
17 |
NaN |
|
FANCA;FANCD2;FANCI;UBE2T |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.000912967 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.007681705 |
1 |
NaN |
|
COL1A2;COL3A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.000471631 |
1 |
NaN |
|
COL11A1;COL1A1;COL5A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
1.48E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.025462828 |
23 |
NaN |
|
COL2A1;COL5A2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
G2 M transition checkpoint |
0.003040976 |
11.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
G2 M transition checkpoint |
0.006230507 |
17.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
G2 M transition checkpoint |
0.004730779 |
16.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
G2 M transition checkpoint |
0.004770148 |
13.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
GABA metabolism |
0.009078567 |
18.5 |
NaN |
|
ABAT;SLC6A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.028040621 |
9 |
NaN |
|
SLC1A5;SLC7A5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Glycolysis and Gluconeogenesis |
0.011076009 |
7 |
NaN |
|
HK2;LDHA;PCK2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040514466 |
10.5 |
NaN |
|
JAK2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Heme degradation to bilirubin |
0.049448514 |
13 |
NaN |
|
HMOX1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Hemoglobin and myoglobin synthesis |
0.040207462 |
6.5 |
NaN |
|
MB |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Hemoglobin and myoglobin synthesis |
0.048168598 |
12.5 |
NaN |
|
MB |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hemoglobin and myoglobin synthesis |
0.049448514 |
13 |
NaN |
|
MB |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Heparin-binding EGF-like growth factor receptor signaling |
0.048168598 |
12.5 |
NaN |
|
HBEGF |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hepatocyte growth factor receptor signaling |
0.033242055 |
9 |
NaN |
|
MET |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
HIF-1 receptor signaling pathway |
0.008843799 |
5 |
NaN |
|
CITED2;EGLN3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hyaluronan receptor CD44 signaling |
0.049448514 |
13 |
NaN |
|
CD44 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.025494001 |
26 |
NaN |
|
HMMR |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.029904728 |
27.5 |
NaN |
|
HMMR |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.049448514 |
13 |
NaN |
|
A2M |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Integrin-mediated leukocyte rolling |
0.012497227 |
20.5 |
NaN |
|
MAPK14;VCAM1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Interferon alpha receptor signaling |
0.010765432 |
5.5 |
NaN |
|
IRF9;STAT1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Intracellular bridge assembly |
0.001910452 |
10 |
NaN |
|
INCENP;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Intracellular bridge assembly |
0.003168907 |
14 |
NaN |
|
INCENP;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Intracellular bridge assembly |
0.002606858 |
14 |
NaN |
|
INCENP;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Intracellular bridge assembly |
0.002622171 |
12 |
NaN |
|
INCENP;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Lysine metabolism |
0.048168598 |
12.5 |
NaN |
|
LOX |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
1.65E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
1.09E-05 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
5.30E-06 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Metaphase to anaphase checkpoint |
5.39E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mitotic chromosome condensation |
0.012497227 |
20.5 |
NaN |
|
INCENP;SMC4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic chromosome condensation |
0.001120646 |
13 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mitotic chromosome condensation |
0.000841063 |
10 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000157878 |
7 |
NaN |
|
AURKB;CCNA2;INCENP |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000336392 |
8 |
NaN |
|
AURKB;CCNA2;INCENP |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000251283 |
7.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000253492 |
6 |
NaN |
|
AURKB;CCNA2;INCENP |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mitotic spindle assembly |
1.13E-05 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic spindle assembly |
3.89E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mitotic spindle assembly |
2.42E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mitotic spindle assembly |
2.45E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mitotic spindle disassembly |
0.025494001 |
26 |
NaN |
|
CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mitotic spindle disassembly |
0.029904728 |
27.5 |
NaN |
|
CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.014835138 |
22 |
NaN |
|
NPPA;NPPB |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.012280307 |
23 |
NaN |
|
NPPA;NPPB |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.012350245 |
20.5 |
NaN |
|
NPPA;NPPB |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Nuclear intermediate filaments |
0.014835138 |
22 |
NaN |
|
LMNB1;LMNB2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Nuclear intermediate filaments |
0.012280307 |
23 |
NaN |
|
LMNB1;LMNB2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Osteopontin receptor signaling |
0.029904728 |
27.5 |
NaN |
|
SPP1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.030604726 |
30 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;TNK2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.003627561 |
15 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;PDGFRB;TNK2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Potassium transmembrane transport |
0.041630095 |
8.5 |
7 |
Up by cardiotoxic TKIs |
ABCC9;SLC12A6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Potassium transmembrane transport |
0.000565038 |
2 |
7 |
Up by cardiotoxic TKIs |
ABCC9;ATP1A2;FXYD1;SLC12A6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Potassium transmembrane transport |
0.007238399 |
2.5 |
7 |
Up by cardiotoxic TKIs |
ABCC9;ATP1A2;SLC12A6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Pyrimidine synthesis and salvage |
0.026511442 |
27.5 |
NaN |
|
TK1;TYMS |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Pyrimidine synthesis and salvage |
0.022035993 |
27 |
NaN |
|
TK1;TYMS |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Pyrimidine synthesis and salvage |
0.022158893 |
24 |
NaN |
|
TK1;TYMS |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.000651322 |
10 |
NaN |
|
ALDH1A1;ALDH1A3;DHRS3;RDH10 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.000453515 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;DHRS3;RDH10 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Semaphorin signaling |
0.010810161 |
2 |
NaN |
|
NRP2;SEMA6A;SEMA6D |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Semaphorin signaling |
0.017656862 |
7 |
NaN |
|
NRP2;SEMA6A;SEMA6D |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Semaphorin signaling |
0.018943017 |
6 |
NaN |
|
NRP2;SEMA6A;SEMA6D |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serine and glycine metabolism |
0.001236434 |
4 |
19 |
Up by cardiotoxic TKIs |
PHGDH;SHMT2;SLC1A5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serotonin and melatonin synthesis |
0.048168598 |
12.5 |
NaN |
|
SLC6A4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000647752 |
9 |
NaN |
|
NUF2;TACC3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.001079867 |
12 |
NaN |
|
NUF2;TACC3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000886472 |
11 |
NaN |
|
NUF2;TACC3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000891733 |
10 |
NaN |
|
NUF2;TACC3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Sister chromatid segregation |
0.000309793 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Sister chromatid segregation |
0.000656363 |
11 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Sister chromatid segregation |
0.000491456 |
9 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Sister chromatid segregation |
0.000495743 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Thin myofilament organization |
0.000278703 |
2 |
NaN |
|
ACTA1;LMOD3;TNNI3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Thin myofilament organization |
0.005270942 |
3 |
NaN |
|
ACTA1;LMOD3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.016951006 |
22 |
21 |
Down by cardiotoxic TKIs |
ACTA1;TNNI3 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Thrombospondin receptor signaling |
6.44E-05 |
6 |
NaN |
|
THBS1;THBS2;THBS4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.000137929 |
6 |
NaN |
|
THBS1;THBS2;THBS4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.000102789 |
6 |
NaN |
|
THBS1;THBS2;THBS4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thrombospondin receptor signaling |
0.005140644 |
15.5 |
NaN |
|
THBS1;THBS4 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tight junction organization |
0.017966495 |
23 |
NaN |
|
CLDN1;CLDN6;CRB2;MYLK |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Tropoelastin synthesis |
0.020465773 |
8 |
NaN |
|
ELN |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.029904728 |
27.5 |
NaN |
|
ELN |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.040514466 |
10.5 |
NaN |
|
VIPR2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Versican synthesis |
0.025494001 |
26 |
NaN |
|
VCAN |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Versican synthesis |
0.029904728 |
27.5 |
NaN |
|
VCAN |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Water transmembrane transport |
0.010765432 |
5.5 |
NaN |
|
AQP3;AQP7 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.041836543 |
12 |
NaN |
|
AMER1;FZD1;FZD2;SFRP2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.020407614 |
8 |
NaN |
|
AMER1;FZD1;FZD2;SFRP1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Z-disc organization |
0.000256358 |
1 |
NaN |
|
CSRP3;DES;PDLIM3;TCAP |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Aggrecan synthesis |
0.016319689 |
6 |
NaN |
|
ACAN |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Aggrecan synthesis |
0.016760762 |
4.5 |
NaN |
|
ACAN |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.025494001 |
26 |
NaN |
|
ALB |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Alternative complement pathway |
0.006155642 |
15 |
NaN |
|
C3;CFH |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Androgen receptor signaling |
0.026986707 |
5 |
NaN |
|
AR |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Androgen receptor signaling |
0.032374463 |
9 |
NaN |
|
AR |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Androgen receptor signaling |
0.033242055 |
9 |
NaN |
|
AR |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Axonal intermediate filament dynamics |
0.020320935 |
24.5 |
NaN |
|
NEFL;NES |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Biglycan synthesis |
0.025494001 |
26 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Biglycan synthesis |
0.029904728 |
27.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cardiomyocyte pacemaker current generation |
0.006952765 |
4 |
NaN |
|
CACNA1D;CACNA1G |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.014991487 |
4 |
NaN |
|
KCNIP2;KCNQ5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.022276912 |
7 |
NaN |
|
KCNIP2;KCNQ5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Caveolin-mediated endocytosis |
0.049448514 |
13 |
NaN |
|
CAV1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006155642 |
15 |
NaN |
|
CTGF;CYR61 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.01010888 |
20 |
NaN |
|
CTGF;CYR61 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
CD44-Mediated leukocyte rolling |
0.033242055 |
9 |
NaN |
|
CD44 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cellular iron storage |
0.040207462 |
6.5 |
NaN |
|
FTL |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cellular iron storage |
0.048168598 |
12.5 |
NaN |
|
FTL |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome duplication |
0.005983039 |
20 |
NaN |
|
CCNF;CEP152;PLK4;STIL |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Centrosome maturation |
0.003040976 |
11.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome maturation |
0.006230507 |
17.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome maturation |
0.004730779 |
16.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Centrosome maturation |
0.004770148 |
13.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Centrosome organization |
0.007595905 |
17 |
NaN |
|
ASPM;CEP152;NEK2;POC1A;TACC3;WDR62 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome organization |
0.024067422 |
26 |
NaN |
|
ASPM;NEK2;POC1A;TACC3;TUBG1;WDR62 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome organization |
0.00089418 |
12 |
NaN |
|
ASPM;CEP152;NEK2;PLK4;POC1A;STIL;TACC3;WDR62 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Centrosome separation |
6.98E-12 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome separation |
5.42E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome separation |
2.46E-11 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Centrosome separation |
2.52E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cholesterol synthesis |
0.020558376 |
26 |
NaN |
|
DHCR24;DHCR7;MVK |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009078567 |
18.5 |
NaN |
|
COL14A1;COL9A1 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.014835138 |
22 |
NaN |
|
COL9A1;COL9A2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.012280307 |
23 |
NaN |
|
COL9A1;COL9A2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.012350245 |
20.5 |
NaN |
|
COL9A1;COL9A2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Contractile ring constriction |
0.006155642 |
15 |
NaN |
|
ANLN;ECT2 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.000336392 |
8 |
NaN |
|
ANLN;ECT2;MYLK |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Contractile ring constriction |
0.000251283 |
7.5 |
NaN |
|
ANLN;ECT2;MYLK |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Contractile ring constriction |
0.008398745 |
18.5 |
NaN |
|
ANLN;MYLK |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Decorin synthesis |
0.013585039 |
3 |
NaN |
|
DCN |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.016760762 |
4.5 |
NaN |
|
DCN |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Desaturation of fatty acids |
0.020320935 |
24.5 |
NaN |
|
FADS2;SCD |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Desaturation of fatty acids |
0.016856005 |
25 |
NaN |
|
FADS2;SCD |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Desaturation of fatty acids |
0.000848344 |
9 |
NaN |
|
FADS2;FADS3;SCD |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
DNA replication elongation |
0.000336392 |
8 |
NaN |
|
MCM5;MCM7;PCNA |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
DNA replication elongation |
0.00835069 |
21 |
NaN |
|
MCM4;MCM5 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
DNA replication elongation |
0.008398745 |
18.5 |
NaN |
|
MCM5;MCM7 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
DNA replication initiation |
1.14E-05 |
4 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM5;MCM7 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
DNA replication initiation |
3.99E-07 |
3 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM4;MCM5;MCM6 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
DNA replication initiation |
7.49E-05 |
5 |
NaN |
|
CDC45;CDC6;GINS2;MCM10;MCM5;MCM7 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Elastin cross-linking and assembly |
0.048168598 |
12.5 |
NaN |
|
LOX |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.026511442 |
27.5 |
NaN |
|
KRT7;KRT8 |
| trametinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.001327345 |
11 |
NaN |
|
KRT19;KRT7;KRT8 |
| trametinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Equatorial RhoA activation |
0.003756536 |
13 |
NaN |
|
ECT2;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Equatorial RhoA activation |
0.006199885 |
15.5 |
NaN |
|
ECT2;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Equatorial RhoA activation |
0.005110927 |
18.5 |
NaN |
|
ECT2;KIF23 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Actin filament bundling and crosslinking |
0.032545775 |
15 |
NaN |
|
PLS3;SYNPO;TAGLN |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Adrenergic receptor signaling |
0.026672865 |
13 |
NaN |
|
RAPGEF4;RGS16;RGS4 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Adrenergic receptor signaling |
0.02789576 |
15 |
NaN |
|
RAPGEF4;RASD1;RGS4 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.026287932 |
12.5 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.025141143 |
11 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Aggrecan synthesis |
0.026287932 |
13.5 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.025582216 |
12.5 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.027170078 |
12.5 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.018348624 |
7 |
NaN |
|
ALB |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.019671842 |
9.5 |
NaN |
|
ALB |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.018260409 |
7 |
NaN |
|
ALB |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.018436838 |
8 |
NaN |
|
ALB |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Androgen receptor signaling |
0.036362165 |
11 |
NaN |
|
AR |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Androgen receptor signaling |
0.038958404 |
14.5 |
NaN |
|
AR |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Androgen receptor signaling |
0.036188958 |
13 |
NaN |
|
AR |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.026961659 |
15 |
NaN |
|
HLA-B;HLA-C |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.025627571 |
14 |
NaN |
|
HLA-B;HLA-C |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.028669216 |
14 |
NaN |
|
HLA-B;HLA-C |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Biglycan synthesis |
0.018348624 |
7 |
NaN |
|
BGN |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Biglycan synthesis |
0.019671842 |
9.5 |
NaN |
|
BGN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Biglycan synthesis |
0.019230769 |
9 |
NaN |
|
BGN |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Biglycan synthesis |
0.018436838 |
8 |
NaN |
|
BGN |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
CCN intercellular signaling protein family receptor signaling |
5.93E-05 |
2 |
NaN |
|
CTGF;CYR61;WISP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.003704726 |
4 |
NaN |
|
CTGF;CYR61 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.003543247 |
4.5 |
NaN |
|
CTGF;WISP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
CCN intercellular signaling protein family receptor signaling |
5.84E-05 |
2 |
NaN |
|
CTGF;CYR61;WISP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cellular fatty acid uptake |
0.036362165 |
11 |
NaN |
|
CD36 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cellular fatty acid uptake |
0.038958404 |
14.5 |
NaN |
|
CD36 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cellular fatty acid uptake |
0.036535356 |
11.5 |
NaN |
|
CD36 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome separation |
0.014964605 |
7 |
NaN |
|
CCNB1;SPAG5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Chaperone-mediated autophagy |
0.036362165 |
11 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Chaperone-mediated autophagy |
0.038958404 |
14.5 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Chaperone-mediated autophagy |
0.03809338 |
14 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Chaperone-mediated autophagy |
0.036188958 |
13 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Chaperone-mediated autophagy |
0.036535356 |
11.5 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Chloride transmembrane transport |
0.047110708 |
17.5 |
NaN |
|
ANO1;BEST1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Cholesterol synthesis |
6.93E-10 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;HMGCR;HMGCS1;MSMO1;MVD;SC5D;SQLE |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cholesterol synthesis |
9.13E-15 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SC5D;SQLE |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cholesterol synthesis |
0.016074254 |
9 |
NaN |
|
DHCR7;MSMO1;SC5D |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.009633191 |
6.5 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.008836966 |
6 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.009633191 |
7.5 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.009139439 |
7.5 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.010267232 |
6.5 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Classical complement pathway |
0.013253688 |
8.5 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Classical complement pathway |
0.012167509 |
7 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Classical complement pathway |
0.013253688 |
10 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Classical complement pathway |
0.012580282 |
9 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Classical complement pathway |
0.014117723 |
8 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Coagulation cascade |
0.022330855 |
11 |
NaN |
|
F2RL1;TFPI |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Coagulation cascade |
0.019416232 |
8 |
NaN |
|
F2RL1;TFPI |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000116919 |
3 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005485195 |
5.5 |
NaN |
|
COL12A1;COL14A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005247657 |
6 |
NaN |
|
COL14A1;COL9A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000115256 |
3 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009633191 |
6.5 |
NaN |
|
COL9A2;COL9A3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009633191 |
7.5 |
NaN |
|
COL9A2;COL9A3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010267232 |
6.5 |
NaN |
|
COL9A2;COL9A3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Contractile ring constriction |
0.003543247 |
4.5 |
NaN |
|
ANLN;MYLK |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Contractile ring constriction |
0.003200174 |
5 |
NaN |
|
ANLN;MYLK |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Decorin synthesis |
0.018348624 |
7 |
NaN |
|
DCN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Decorin synthesis |
0.019230769 |
9 |
NaN |
|
DCN |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Decorin synthesis |
0.018436838 |
8 |
NaN |
|
DCN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Desaturation of fatty acids |
0.013253688 |
10 |
NaN |
|
FADS2;SCD |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
DNA replication elongation |
6.82E-05 |
3 |
NaN |
|
MCM4;MCM5;PCNA |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
DNA replication elongation |
5.53E-07 |
2 |
NaN |
|
MCM2;MCM4;MCM7;PCNA |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
DNA replication initiation |
3.16E-07 |
1 |
NaN |
|
CDC45;CDC6;MCM10;MCM3;MCM4;MCM5;MCM6 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
DNA replication initiation |
0.010265284 |
6 |
NaN |
|
CDC6;MCM5;MCM6 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
DNA replication initiation |
2.37E-07 |
1 |
NaN |
|
CDC45;CDC6;MCM2;MCM3;MCM4;MCM6;MCM7 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.017367241 |
10 |
NaN |
|
KRT19;KRT8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.00091303 |
3 |
NaN |
|
KRT19;KRT8;TCHH |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
0.016492549 |
10 |
NaN |
|
KRT19;TCHH |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.018488625 |
10 |
NaN |
|
KRT19;KRT8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Muscarinic receptor signaling |
0.009139439 |
7.5 |
NaN |
|
CHRM4;RGS4 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Myofibril formation |
0.013810218 |
4.5 |
NaN |
|
KLHL41;XIRP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.005485195 |
5.5 |
NaN |
|
NPPA;NPPB |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Oncostatin-M receptor signaling |
0.006535173 |
4 |
NaN |
|
OSMR;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Oncostatin-M receptor signaling |
0.005990412 |
5 |
NaN |
|
OSMR;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Oncostatin-M receptor signaling |
0.006197282 |
6 |
NaN |
|
OSMR;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Oncostatin-M receptor signaling |
0.006969423 |
5 |
NaN |
|
OSMR;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Osteonectin receptor signaling |
0.001962106 |
4 |
NaN |
|
SPARC;SPOCK1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Osteonectin receptor signaling |
0.002252017 |
3 |
NaN |
|
SPARC;SPOCK1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.019230769 |
9 |
NaN |
|
SPP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.025141143 |
11 |
NaN |
|
SPP1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.016676089 |
6 |
NaN |
|
PDGFRA;PDGFRB |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.03809338 |
14 |
NaN |
|
PTGFR |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Removal of caspase inhibition |
0.049652372 |
19 |
NaN |
|
XAF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Retinol metabolism |
0.024976036 |
11 |
NaN |
|
ALDH1A1;TTR |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Retinol metabolism |
0.022673855 |
9 |
NaN |
|
ALDH1A2;TTR |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Retinol metabolism |
0.044381109 |
15 |
NaN |
|
DHRS3;RDH10 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Retinol metabolism |
0.040928231 |
15 |
NaN |
|
ALDH1A1;RDH10 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Retinol metabolism |
0.044381109 |
16.5 |
NaN |
|
DHRS3;RDH10 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.001102755 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.000133471 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.000151646 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Serotonin inactivation |
0.036362165 |
11 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Serotonin inactivation |
0.038958404 |
14.5 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Serotonin inactivation |
0.03809338 |
14 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Serotonin inactivation |
0.036188958 |
13 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serotonin inactivation |
0.036535356 |
11.5 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serotonin inactivation |
0.049652372 |
19 |
NaN |
|
MAOB |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sodium transmembrane transport |
0.047614878 |
16 |
NaN |
|
SCN1A;SLC5A1;SLC5A5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Thin myofilament organization |
0.013253688 |
8.5 |
NaN |
|
ACTA1;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thin myofilament organization |
0.000510607 |
1 |
NaN |
|
ACTA1;NEBL;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Thin myofilament organization |
0.013253688 |
10 |
NaN |
|
ACTA1;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thin myofilament organization |
0.000537331 |
3 |
NaN |
|
ACTA1;NEBL;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Thin myofilament organization |
0.000641005 |
2 |
NaN |
|
ACTA1;NEBL;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.003782172 |
4.5 |
NaN |
|
THBS1;THBS2 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.026287932 |
12.5 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.025141143 |
11 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.026287932 |
13.5 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.025582216 |
12.5 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.027170078 |
12.5 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.03449629 |
12 |
NaN |
|
DACT1;DKK2;FRZB;FZD7 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.029303797 |
10 |
NaN |
|
DKK2;FZD7;SFRP2;SFRP5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
0.014752831 |
8 |
NaN |
|
CENPE;SKA2;SPC24;TTK |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.011207265 |
7 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000861504 |
4 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS5;ADAMTS8 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Extracellular matrix breakdown by cathepsins |
0.01368451 |
5 |
NaN |
|
CTSF;CTSV |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
0.015623688 |
8 |
NaN |
|
CTSF;CTSV |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
0.013810218 |
4.5 |
NaN |
|
CTSF;CTSV |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
2.12E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
2.79E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
5.85E-07 |
2 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
2.08E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
2.16E-05 |
3 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibulin receptor signaling |
0.038958404 |
14.5 |
NaN |
|
FBLN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.036188958 |
13 |
NaN |
|
FBLN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.044381109 |
16.5 |
NaN |
|
SLC1A5;SLC7A5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Glutamate and glutamine metabolism |
0.047110708 |
17.5 |
NaN |
|
SLC1A5;SLC7A5 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.021945601 |
11 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.020177706 |
9 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.021945601 |
12 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.020850038 |
11 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.023349005 |
11 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.049652372 |
19 |
NaN |
|
HGF |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002030414 |
2 |
NaN |
|
A2M;MME |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001858288 |
3 |
NaN |
|
A2M;MME |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002030414 |
4 |
NaN |
|
A2M;MME |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.66E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of apoptosis |
0.038203861 |
14 |
NaN |
|
BIRC5;XAF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Inhibition of apoptosis |
0.035205397 |
14 |
NaN |
|
BIRC5;XAF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Inhibition of apoptosis |
0.040576702 |
16 |
NaN |
|
IFI6;XAF1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Interleukin 6 receptor signaling |
0.049652372 |
19 |
NaN |
|
JAK3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Interleukin 7 receptor signaling |
0.049652372 |
19 |
NaN |
|
JAK3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
JAK-STAT signaling pathway |
0.046973016 |
16 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
JAK-STAT signaling pathway |
0.048468491 |
17 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Leptin receptor signaling |
0.003990278 |
3 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Leptin receptor signaling |
0.003654836 |
4 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Leptin receptor signaling |
0.003990278 |
5 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Leptin receptor signaling |
0.003782172 |
4.5 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Leptin receptor signaling |
0.00425795 |
4 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.036362165 |
11 |
NaN |
|
FBN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.038958404 |
14.5 |
NaN |
|
FBN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.036188958 |
13 |
NaN |
|
FBN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.036535356 |
11.5 |
NaN |
|
FBN1 |
| tofacitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Z-disc organization |
0.007811597 |
5 |
NaN |
|
CSRP3;DES;PDLIM3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Z-disc organization |
0.000560649 |
2 |
NaN |
|
CSRP3;DES;NEBL;PDLIM3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Z-disc organization |
0.007811597 |
6 |
NaN |
|
CSRP3;DES;PDLIM3 |
| tofacitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Z-disc organization |
3.67E-05 |
2 |
NaN |
|
CSRP3;DES;NEBL;PDLIM3;TCAP |
| tofacitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Z-disc organization |
0.000751011 |
3 |
NaN |
|
CSRP3;DES;NEBL;PDLIM3 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.028954927 |
20 |
NaN |
|
APCDD1;FZD10;FZD2;PAX6;SFRP5 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Z-disc organization |
0.006642272 |
11 |
NaN |
|
CSRP3;DYSF;TCAP |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Mitotic spindle assembly |
0.00351239 |
4 |
NaN |
|
NUSAP1;TACC3;TPX2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Mitotic spindle assembly |
2.52E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Mitotic spindle assembly |
0.000306964 |
4.5 |
NaN |
|
DLGAP5;TACC3;TPX2;TTK |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Mitotic spindle assembly |
2.32E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Mitotic spindle disassembly |
0.030081157 |
18 |
NaN |
|
CDK1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Mitotic spindle disassembly |
0.02955187 |
22 |
NaN |
|
CDK1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.008598393 |
12 |
NaN |
|
NPPA;NPR3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Natriuretic peptide receptor signaling |
0.012490666 |
14.5 |
NaN |
|
NPPA;NPPB |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.010138932 |
14 |
NaN |
|
NPPA;NPPB |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.012071583 |
15.5 |
NaN |
|
NPPA;NPPB |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Neuregulin receptor signaling |
0.02030943 |
9 |
NaN |
|
ERBB3;SH3TC2 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Neuregulin receptor signaling |
0.019010322 |
6.5 |
NaN |
|
ERBB3;SH3TC2 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Osteopontin receptor signaling |
0.020465773 |
12 |
NaN |
|
SPP1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Osteopontin receptor signaling |
0.024788285 |
19 |
NaN |
|
SPP1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Osteopontin receptor signaling |
0.024347212 |
14.5 |
NaN |
|
SPP1 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Osteopontin receptor signaling |
0.026993649 |
18 |
NaN |
|
SPP1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Osteopontin receptor signaling |
0.02955187 |
22 |
NaN |
|
SPP1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Phosphoglyceride biosynthesis |
0.019655219 |
7 |
NaN |
|
PCYT1B;PCYT2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.04147483 |
23 |
NaN |
|
PDGFB;TNK2 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.02047443 |
11 |
NaN |
|
PDGFB;TNK2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Potassium transmembrane transport |
0.04817565 |
15 |
NaN |
|
ABCC9;SLC12A6 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Procollagen cleavage into collagen |
0.043551386 |
12 |
NaN |
|
PCOLCE |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Procollagen cleavage into collagen |
0.047400097 |
11.5 |
NaN |
|
PCOLCE |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Progesterone receptor signaling |
0.020465773 |
12 |
NaN |
|
PGR |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Progesterone receptor signaling |
0.024788285 |
19 |
NaN |
|
PGR |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Progesterone receptor signaling |
0.024347212 |
14.5 |
NaN |
|
PGR |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Protein polyubiquitination |
0.011292395 |
13 |
NaN |
|
ISG15;UBE2S;UCHL1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Protein polyubiquitination |
0.040157393 |
16 |
NaN |
|
ISG15;UCHL1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Protein polyubiquitination |
0.041771182 |
17 |
NaN |
|
ISG15;UCHL1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Protein polyubiquitination |
0.010760649 |
14 |
NaN |
|
ISG15;UBE2S;UCHL1 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Pyrimidine synthesis and salvage |
0.018261874 |
16 |
NaN |
|
TK1;TYMS |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Pyrimidine synthesis and salvage |
0.021669075 |
18 |
NaN |
|
TK1;TYMS |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Removal of caspase inhibition |
0.029247909 |
8.5 |
NaN |
|
XAF1 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Removal of caspase inhibition |
0.039131362 |
13.5 |
NaN |
|
XAF1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Removal of caspase inhibition |
0.031853721 |
9 |
NaN |
|
XAF1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Removal of caspase inhibition |
0.039823039 |
13.5 |
NaN |
|
XAF1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Retinoic acid receptor signaling |
0.027149894 |
9 |
NaN |
|
NR4A1;RARG |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Retinol metabolism |
0.003583963 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;CYP26A1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Retinol metabolism |
0.038602752 |
18.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Retinol metabolism |
0.039371914 |
14 |
NaN |
|
ALDH1A2;RDH10 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Retinol metabolism |
0.006165206 |
11 |
NaN |
|
DHRS3;RBP1;RDH10 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Retinol metabolism |
0.000306964 |
4.5 |
NaN |
|
ALDH1A1;ALDH1A3;RBP1;RDH10 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Retinol metabolism |
0.000433512 |
5 |
NaN |
|
ALDH1A3;DHRS3;RBP1;RDH10 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Semaphorin signaling |
0.003246644 |
8.5 |
NaN |
|
CRMP1;DPYSL4;FARP1;PLXNA2;SEMA6B |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Semaphorin signaling |
0.003007696 |
9 |
NaN |
|
CRMP1;DPYSL4;FARP1;PLXNA2;SEMA6B |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Serine and glycine metabolism |
0.001117129 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Serine and glycine metabolism |
0.028671146 |
12 |
NaN |
|
PHGDH;PSAT1 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Serine and glycine metabolism |
0.000224525 |
4 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Serine and glycine metabolism |
4.71E-05 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Serine and glycine metabolism |
5.12E-05 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Serotonin inactivation |
0.040687284 |
15 |
NaN |
|
MAOA |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.048620086 |
17 |
NaN |
|
TACC3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Sister chromatid segregation |
0.012490666 |
14.5 |
NaN |
|
PTTG1;TOP2A |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Sister chromatid segregation |
0.010138932 |
14 |
NaN |
|
PTTG1;TOP2A |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Sister chromatid segregation |
0.012071583 |
15.5 |
NaN |
|
PTTG1;TOP2A |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Thick myofilament organization |
0.043551386 |
12 |
NaN |
|
TTN |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Thick myofilament organization |
0.047400097 |
11.5 |
NaN |
|
TTN |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Thin myofilament organization |
0.000863028 |
6.5 |
NaN |
|
ACTA1;TNNI3;TPM4 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Thin myofilament organization |
0.008252285 |
5 |
NaN |
|
ACTA1;TPM2 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Thin myofilament organization |
0.016572431 |
17 |
NaN |
|
ACTA1;TNNI3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Thrombospondin receptor signaling |
0.003554482 |
5.5 |
NaN |
|
THBS2;THBS4 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Thrombospondin receptor signaling |
0.003430939 |
6.5 |
NaN |
|
THBS2;THBS4 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Thrombospondin receptor signaling |
0.003504812 |
3 |
NaN |
|
THBS1;THBS4 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Tight junction organization |
0.032121671 |
13 |
NaN |
|
CLDN11;CRB2;MYLK |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Tropoelastin synthesis |
0.024347212 |
14.5 |
NaN |
|
ELN |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Tropoelastin synthesis |
0.024611856 |
11 |
NaN |
|
ELN |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Tropoelastin synthesis |
0.026993649 |
18 |
NaN |
|
ELN |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Tropoelastin synthesis |
0.02955187 |
22 |
NaN |
|
ELN |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Urea cycle |
0.008480245 |
6.5 |
NaN |
|
ARG2;ASS1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Urea cycle |
0.005727694 |
4.5 |
NaN |
|
ARG2;ASS1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Vascular endothelial growth factor receptor signaling |
0.008252285 |
5 |
NaN |
|
FLT1;KDR |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.039823039 |
13.5 |
NaN |
|
VIPR1 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Actin polymerization |
0.036714622 |
22 |
NaN |
|
ACTA1;HSPB1;PFN1;TMSB10 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Albumin mediated blood protein transport |
0.020465773 |
12 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Albumin mediated blood protein transport |
0.014731828 |
5.5 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Albumin mediated blood protein transport |
0.024788285 |
19 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Albumin mediated blood protein transport |
0.024347212 |
14.5 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Albumin mediated blood protein transport |
0.019760056 |
8.5 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Albumin mediated blood protein transport |
0.016055046 |
6.5 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Alternative complement pathway |
0.005827311 |
9.5 |
NaN |
|
C3;CFH |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Alternative complement pathway |
0.005626438 |
9.5 |
NaN |
|
C3;CFH |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Amyloid plaque organization |
0.019010322 |
6.5 |
NaN |
|
APOE;COL25A1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Antigen presentation via MHC class I molecules |
0.000912967 |
2 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Antigen presentation via MHC class I molecules |
0.00158905 |
3.5 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.001508963 |
4 |
NaN |
|
B2M;HLA-B;HLA-C |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Aspartate and arginine metabolism |
0.001556699 |
2 |
NaN |
|
ARG2;ASS1;SLC7A1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Aspartate and arginine metabolism |
0.016295327 |
6 |
NaN |
|
ARG2;ASS1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Biglycan synthesis |
0.024788285 |
19 |
NaN |
|
BGN |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Biglycan synthesis |
0.030081157 |
18 |
NaN |
|
BGN |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Biglycan synthesis |
0.026993649 |
18 |
NaN |
|
BGN |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Biglycan synthesis |
0.02955187 |
22 |
NaN |
|
BGN |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Cardiomyocyte depolarization during action potential |
0.020465773 |
12 |
NaN |
|
SCN5A |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Cardiomyocyte depolarization during action potential |
0.024347212 |
14.5 |
NaN |
|
SCN5A |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Cardiomyocyte pacemaker current generation |
0.010854789 |
7 |
NaN |
|
HCN4;KCNJ5 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.032279631 |
16.5 |
NaN |
|
KCNA1;KCNQ5 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.017477776 |
7 |
NaN |
|
KCNIP2;KCNQ5 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.044326811 |
20 |
NaN |
|
KCNA1;KCNQ5 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030256623 |
11 |
NaN |
|
KCNIP2;KCNQ5 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.02055093 |
8 |
NaN |
|
KCNIP2;KCNQ5 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.045202293 |
15 |
NaN |
|
KCNIP2;KCNJ2 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002480731 |
3 |
NaN |
|
KCNIP2;KCNJ2;KCNQ1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005827311 |
9.5 |
NaN |
|
CTGF;CYR61 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.038602752 |
18.5 |
NaN |
|
ABCA12;SCARA3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Cellular cholesterol uptake and efflux |
0.027149894 |
9 |
NaN |
|
ABCA1;ABCG1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Cellular fatty acid uptake |
0.048103734 |
22.5 |
NaN |
|
CD36 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Cellular fatty acid uptake |
0.039131362 |
13.5 |
NaN |
|
CD36 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Centrosome maturation |
0.048799898 |
24.5 |
NaN |
|
PLK1;TPX2 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Centrosome maturation |
0.04009759 |
21 |
NaN |
|
PLK1;TPX2 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Centrosome maturation |
0.047261143 |
26.5 |
NaN |
|
PLK1;TPX2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Centrosome separation |
5.32E-06 |
1 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Centrosome separation |
0.002029907 |
7 |
NaN |
|
CCNB1;KIF11;SPAG5 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Centrosome separation |
4.88E-06 |
1 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Cholesterol synthesis |
2.28E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MSMO1;MVD;MVK;SC5D;SQLE |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Cholesterol synthesis |
1.92E-05 |
2 |
NaN |
|
DHCR7;MSMO1;MVD;MVK;NSDHL;SQLE |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Cholesterol synthesis |
1.90E-06 |
1 |
NaN |
|
DHCR7;HMGCR;HMGCS1;MSMO1;MVD;MVK |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Cholesterol synthesis |
8.74E-08 |
1 |
NaN |
|
DHCR7;HMGCR;HMGCS1;MSMO1;MVD;MVK;SQLE |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Cholesterol synthesis |
0.000154045 |
2 |
NaN |
|
CYP51A1;DHCR7;MSMO1;MVD;SQLE |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Cholesterol synthesis |
1.74E-05 |
2 |
NaN |
|
DHCR7;MSMO1;MVD;MVK;NSDHL;SQLE |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.005727694 |
4.5 |
NaN |
|
INSIG1;SREBF1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.005975135 |
3 |
NaN |
|
INSIG1;SREBF1 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Collagen fiber crosslinking |
0.006881519 |
11 |
NaN |
|
LOX;LOXL1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000161702 |
1 |
NaN |
|
COL14A1;COL9A2;COL9A3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Collagen fibril organization by fibril-associated bridges |
6.08E-05 |
1 |
NaN |
|
COL14A1;COL19A1;COL9A3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000285148 |
1 |
NaN |
|
COL12A1;COL9A1;COL9A2 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
4.86E-08 |
1 |
NaN |
|
COL12A1;COL19A1;COL9A1;COL9A2;COL9A3 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005533298 |
3 |
NaN |
|
COL14A1;COL9A3 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
7.86E-05 |
1 |
NaN |
|
COL14A1;COL19A1;COL9A3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.034610193 |
21 |
NaN |
|
DES;LIMS2 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.016979423 |
9.5 |
NaN |
|
DES;LIMS2 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Contractile ring constriction |
0.005746561 |
5 |
NaN |
|
ANLN;MYLK |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Contractile ring constriction |
0.000257949 |
5 |
NaN |
|
ANLN;MYH14;MYLK |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Contractile ring constriction |
0.006881519 |
11 |
NaN |
|
ANLN;MYLK |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Contractile ring constriction |
0.008207301 |
12 |
NaN |
|
ANLN;MYLK |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Decorin synthesis |
0.020465773 |
12 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Decorin synthesis |
0.014731828 |
5.5 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Decorin synthesis |
0.024788285 |
19 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Decorin synthesis |
0.024347212 |
14.5 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Decorin synthesis |
0.019760056 |
8.5 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Decorin synthesis |
0.016055046 |
6.5 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Desaturation of fatty acids |
0.011680465 |
8 |
NaN |
|
FADS2;SCD |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Desaturation of fatty acids |
0.000863028 |
6.5 |
NaN |
|
FADS2;FADS3;SCD |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Desaturation of fatty acids |
0.008252285 |
5 |
NaN |
|
FADS2;SCD |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Desaturation of fatty acids |
0.000819463 |
7 |
NaN |
|
FADS2;FADS3;SCD |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
DNA replication elongation |
0.008207301 |
12 |
NaN |
|
MCM5;PCNA |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Drug and toxin export via membrane transport proteins |
0.049880636 |
18 |
NaN |
|
ABCA1;ABCB6 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Elastin cross-linking and assembly |
0.002140056 |
8 |
NaN |
|
LOX;LOXL1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Endogenous control of complement activity |
0.005626438 |
9.5 |
NaN |
|
CFH;CFI |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Epithelial intermediate filament dynamics |
0.010765432 |
4 |
NaN |
|
KRT19;KRT4 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Epithelial intermediate filament dynamics |
0.0155326 |
14 |
NaN |
|
KRT19;KRT7 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Epithelial intermediate filament dynamics |
0.022405582 |
16 |
NaN |
|
KRT7;KRT8 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Epithelial intermediate filament dynamics |
0.000986163 |
6 |
NaN |
|
KRT19;KRT7;KRT8 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.001282499 |
8 |
NaN |
|
KRT19;KRT7;KRT8 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
ER unfolded protein response pathway |
0.010062749 |
4.5 |
NaN |
|
DDIT3;HERPUD1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
0.013737565 |
9 |
NaN |
|
BUB1;CENPF;CENPU;ZWINT |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Eukaryotic kinetochore dynamics |
0.005310417 |
10 |
NaN |
|
BUB1;CENPF;NDC80;SPC24;TTK |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
5.99E-05 |
1 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;SPC24;TTK;ZWINT |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
0.000790538 |
6 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;SPC24;TTK |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012470268 |
5 |
NaN |
|
ADAMTS1;ADAMTS5;ADAMTS6 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000383518 |
3 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS5;ADAMTS6 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.020755752 |
16 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002487369 |
5 |
NaN |
|
ADAMTS1;ADAMTS5;ADAMTS6;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000531234 |
2 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS5;ADAMTS6 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.034214016 |
20 |
NaN |
|
ADAMTS12;ADAMTS15;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012615481 |
8 |
NaN |
|
ADAM33;ADAMTS14;ADAMTS2 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.00360961 |
9 |
NaN |
|
ADAM19;ADAMTS12;ADAMTS7;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.004984789 |
10 |
NaN |
|
ADAM19;ADAMTS12;ADAMTS15;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016979423 |
9.5 |
NaN |
|
CTSF;CTSZ |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Extracellular matrix breakdown by cathepsins |
0.033495803 |
25 |
NaN |
|
CTSV;CTSZ |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Extrinsic apoptosis pathway |
0.011841806 |
13 |
NaN |
|
FAS;TNFRSF10A |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.016841612 |
8 |
NaN |
|
COL2A1;COL3A1 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.000349234 |
2 |
NaN |
|
COL11A1;COL11A2;COL3A1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.00158905 |
3.5 |
NaN |
|
COL11A1;COL1A2;COL2A1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.023362497 |
11 |
NaN |
|
COL1A2;COL3A1 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.000824437 |
1 |
NaN |
|
COL11A2;COL1A1;COL3A1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.010599032 |
4 |
NaN |
|
COL11A2;COL3A1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Fibroblast growth factor receptor signaling |
0.024046558 |
15 |
NaN |
|
ANOS1;FGF18 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
G2 M transition checkpoint |
0.048799898 |
24.5 |
NaN |
|
CCNB1;CDK1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
G2 M transition checkpoint |
0.047261143 |
26.5 |
NaN |
|
CCNB1;CDK1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.027149894 |
9 |
NaN |
|
SLC1A5;SLC7A5 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.028265172 |
12 |
NaN |
|
SLC1A5;SLC7A5 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Gluthatione conjugation |
0.030081157 |
18 |
NaN |
|
GSTP1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Gluthatione conjugation |
0.02955187 |
22 |
NaN |
|
GSTP1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Glycogen synthesis and glycogenolysis |
0.041446435 |
20 |
NaN |
|
PPP1R3A;PPP1R3B |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Glycogen synthesis and glycogenolysis |
0.038884414 |
12 |
NaN |
|
PPP1R3B;PYGM |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
0.018147346 |
10 |
NaN |
|
ALDOA;ENO1;LDHA |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.029238552 |
19 |
NaN |
|
ENO1;LDHA;TPI1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040514466 |
18.5 |
NaN |
|
JAK2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.029247909 |
8.5 |
NaN |
|
JAK2 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048964244 |
23 |
NaN |
|
JAK2 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048103734 |
22.5 |
NaN |
|
JAK2 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.013655883 |
6.5 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.019646762 |
15 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.001075569 |
2.5 |
NaN |
|
INPP5D;SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Hemoglobin and myoglobin synthesis |
0.043551386 |
12 |
NaN |
|
MB |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Hemoglobin and myoglobin synthesis |
0.047400097 |
11.5 |
NaN |
|
MB |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.048620086 |
17 |
NaN |
|
HGF |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.039823039 |
13.5 |
NaN |
|
HGF |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Hepatocyte growth factor receptor signaling |
0.040687284 |
15 |
NaN |
|
HGF |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
HIF-1 receptor signaling pathway |
0.013655883 |
6.5 |
NaN |
|
CITED2;EGLN1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
HIF-1 receptor signaling pathway |
0.001133031 |
2 |
NaN |
|
CITED2;EGLN1;EGLN3 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
HIF-1 receptor signaling pathway |
0.001075569 |
2.5 |
NaN |
|
CITED2;EGLN1;EGLN3 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Inhibin receptor signaling |
0.010062749 |
4.5 |
NaN |
|
INHBE;TGFBR3 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.000640957 |
4 |
NaN |
|
A2M;MME |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.000760969 |
3 |
NaN |
|
A2M;MME |
| tnf-alpha |
Cytokine |
|
MSN08 |
Up |
Inhibition of apoptosis |
0.02251881 |
10 |
NaN |
|
IFI6;XAF1 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Inhibition of apoptosis |
0.015221369 |
5 |
NaN |
|
CFLAR;XAF1 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Inositol metabolism and transport |
0.048103734 |
22.5 |
NaN |
|
INPP5D |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Insulin receptor signaling |
0.035600836 |
11 |
NaN |
|
IRS1;IRS2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Intracellular bridge assembly |
0.043551386 |
12 |
NaN |
|
NEK7 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
JAK-STAT signaling pathway |
0.032279631 |
16.5 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
JAK-STAT signaling pathway |
0.0044785 |
8 |
NaN |
|
SOCS3;STAT3;STAT4 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
JAK-STAT signaling pathway |
0.004258398 |
8 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Leptin receptor signaling |
0.002435279 |
3 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Leptin receptor signaling |
0.003554482 |
5.5 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Leptin receptor signaling |
0.003430939 |
6.5 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Lipogenesis |
0.048620086 |
17 |
NaN |
|
FASN |
| tnf-alpha |
Cytokine |
|
MSN06 |
Down |
Lipogenesis |
0.040687284 |
15 |
NaN |
|
FASN |
| tnf-alpha |
Cytokine |
|
MSN02 |
Up |
Lysine metabolism |
0.043551386 |
12 |
NaN |
|
AASS |
| tnf-alpha |
Cytokine |
|
MSN09 |
Up |
Lysine metabolism |
0.047400097 |
11.5 |
NaN |
|
AASS |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Mammalian target of rapamycin signaling pathway |
0.044920687 |
17 |
NaN |
|
DDIT4;FLCN |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
MAPK signaling pathway |
0.036701282 |
13 |
NaN |
|
FOXM1;MAP2K3;MAP2K6 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Metaphase to anaphase checkpoint |
0.003246644 |
8.5 |
NaN |
|
BUB1;CCNB2;CDC20;PTTG1;TTK |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Metaphase to anaphase checkpoint |
0.000261746 |
3 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;PTTG1;TTK |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Metaphase to anaphase checkpoint |
0.000425339 |
4 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;PTTG1;TTK |
| tnf-alpha |
Cytokine |
|
MSN01 |
Up |
Methionine cycle |
0.040514466 |
18.5 |
NaN |
|
BHMT |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Methionine cycle |
0.048964244 |
23 |
NaN |
|
BHMT |
| tnf-alpha |
Cytokine |
|
MSN06 |
Up |
Methionine cycle |
0.048103734 |
22.5 |
NaN |
|
BHMT |
| tnf-alpha |
Cytokine |
|
MSN05 |
Up |
Microfibril scaffold organization |
0.048964244 |
23 |
NaN |
|
FBN1 |
| tnf-alpha |
Cytokine |
|
MSN01 |
Down |
Microtubule crosslinking and bundling |
0.008480245 |
6.5 |
NaN |
|
DCX;MAP2 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Microtubule crosslinking and bundling |
0.010138932 |
14 |
NaN |
|
MAP2;MTCL1 |
| tnf-alpha |
Cytokine |
|
MSN05 |
Down |
Mineralocorticoid receptor signaling |
0.039823039 |
13.5 |
NaN |
|
NR3C2 |
| tnf-alpha |
Cytokine |
|
MSN02 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.008495241 |
12 |
NaN |
|
AURKB;CCNA2 |
| tnf-alpha |
Cytokine |
|
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.006881519 |
11 |
NaN |
|
AURKB;CCNA2 |
| tnf-alpha |
Cytokine |
|
MSN09 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.008207301 |
12 |
NaN |
|
AURKB;CCNA2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000102089 |
1 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS6;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.013057005 |
8 |
NaN |
|
ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001117947 |
4 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001234155 |
4 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001009684 |
5 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001234155 |
5 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
0.015490863 |
7 |
NaN |
|
CTSF;CTSV |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by cathepsins |
0.01470451 |
7.5 |
NaN |
|
CTSF;CTSV |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
0.016295327 |
9 |
NaN |
|
CTSF;CTSV |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000632653 |
4 |
NaN |
|
MMP1;MMP12;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000682052 |
2 |
NaN |
|
MMP1;MMP12;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000570464 |
2 |
NaN |
|
MMP12;MMP2;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000616715 |
3 |
NaN |
|
MMP12;MMP2;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000526515 |
3 |
NaN |
|
MMP12;MMP2;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000616715 |
4 |
NaN |
|
MMP12;MMP2;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.00089029 |
5.5 |
NaN |
|
COL1A1;COL1A2;COL2A1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.000959425 |
3 |
NaN |
|
COL11A2;COL1A2;COL2A1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
6.41E-07 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Fibrillar collagen core structure organization |
7.31E-07 |
2 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Fibrillar collagen core structure organization |
2.46E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
7.31E-07 |
1.5 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1;COL5A2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fibulin receptor signaling |
0.045175089 |
16 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Fibulin receptor signaling |
0.044830247 |
16.5 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fibulin receptor signaling |
0.046036922 |
15 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Fibulin receptor signaling |
0.045002676 |
11.5 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fibulin receptor signaling |
0.046209242 |
13.5 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fibulin receptor signaling |
0.047070608 |
17 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Glycolysis and Gluconeogenesis |
0.010566066 |
9 |
NaN |
|
ENO1;LDHA;PFKFB4 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040168784 |
13.5 |
NaN |
|
JUND |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.03878543 |
13 |
NaN |
|
JUND |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039823039 |
14 |
NaN |
|
JUND |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Growth differentiation factor receptor signaling |
0.013889809 |
9 |
NaN |
|
GDF15;GDF2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Growth differentiation factor receptor signaling |
0.01439434 |
9 |
NaN |
|
GDF2;GDF6 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Heme degradation to bilirubin |
0.001536541 |
6 |
NaN |
|
BLVRB;HMOX1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.000520042 |
5 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Hepatocyte growth factor receptor signaling |
0.000512026 |
5 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.000540354 |
5 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Hepatocyte growth factor receptor signaling |
0.000516026 |
4 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.000544463 |
1 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Inhibin receptor signaling |
0.013789873 |
8 |
NaN |
|
INHBA;INHBE |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Inhibin receptor signaling |
0.01439434 |
9 |
NaN |
|
INHBA;INHBE |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.18E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.15E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.25E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.17E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001608121 |
2 |
NaN |
|
MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.34E-05 |
2 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Inhibition of apoptosis |
0.023660622 |
12 |
NaN |
|
BIRC3;IFI6 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.002480731 |
8 |
NaN |
|
SOCS2;STAT1;STAT4 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.00212632 |
6 |
NaN |
|
SOCS2;STAT1;STAT4 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Lipogenesis |
0.041205645 |
15.5 |
NaN |
|
FASN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
0.041922907 |
14 |
NaN |
|
CDC20;PLK3;PTTG1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Metaphase to anaphase checkpoint |
0.041120613 |
13 |
NaN |
|
CDC20;PLK3;PTTG1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Methionine cycle |
0.045175089 |
16 |
NaN |
|
BHMT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Methionine cycle |
0.046036922 |
15 |
NaN |
|
BHMT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Methionine cycle |
0.046209242 |
13.5 |
NaN |
|
BHMT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Methionine cycle |
0.047070608 |
17 |
NaN |
|
BHMT |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Microfibril scaffold organization |
0.000409904 |
2 |
NaN |
|
FBN1;MFAP2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Microfibril scaffold organization |
0.041205645 |
15.5 |
NaN |
|
FBN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Microfibril scaffold organization |
0.03878543 |
13 |
NaN |
|
FBN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Microfibril scaffold organization |
0.039823039 |
16 |
NaN |
|
FBN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Microfibril scaffold organization |
0.037747261 |
15 |
NaN |
|
FBN1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Microfibril scaffold organization |
0.000402791 |
3 |
NaN |
|
FBN1;MFAP2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mineralocorticoid receptor signaling |
0.046036922 |
15 |
NaN |
|
GPER1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Mineralocorticoid receptor signaling |
0.045002676 |
11.5 |
NaN |
|
GPER1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.007340787 |
9.5 |
NaN |
|
NPPA;NPPB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Natriuretic peptide receptor signaling |
0.00723107 |
7 |
NaN |
|
NPPA;NPPB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.007285832 |
7.5 |
NaN |
|
NPPA;NPPB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Nuclear mRNA export |
0.04780063 |
20 |
NaN |
|
NXF1;THOC6 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Nuclear mRNA export |
0.044920687 |
18 |
NaN |
|
NAB2;THOC6 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Osteonectin receptor signaling |
0.002393952 |
7.5 |
NaN |
|
SPARC;SPOCK1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Osteonectin receptor signaling |
0.002518963 |
4 |
NaN |
|
SPARC;SPOCK1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Osteonectin receptor signaling |
0.002232086 |
5 |
NaN |
|
SMOC2;SPARC |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Osteonectin receptor signaling |
0.002352969 |
6 |
NaN |
|
SPARC;SPOCK1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Osteonectin receptor signaling |
0.002352969 |
6 |
NaN |
|
SPARC;SPOCK1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Osteopontin receptor signaling |
0.01905434 |
10 |
NaN |
|
SPP1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Osteopontin receptor signaling |
0.022847565 |
12.5 |
NaN |
|
SPP1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Osteopontin receptor signaling |
0.022671136 |
9 |
NaN |
|
SPP1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Progesterone receptor signaling |
0.022671136 |
9 |
NaN |
|
PGR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Progesterone receptor signaling |
0.023288638 |
10.5 |
NaN |
|
PGR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Progesterone receptor signaling |
0.023376853 |
10.5 |
NaN |
|
PGR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Progesterone receptor signaling |
0.023817925 |
13 |
NaN |
|
PGR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.041205645 |
15.5 |
NaN |
|
PTGFR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.039823039 |
16 |
NaN |
|
PTGFR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.037747261 |
15 |
NaN |
|
PTGFR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Proteasomal regulatory particle organization |
0.008459104 |
5.5 |
NaN |
|
PSMC4;PSMD14 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Protein polyubiquitination |
0.042751342 |
18 |
NaN |
|
ISG15;UCHL1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Protein polyubiquitination |
0.038254008 |
11 |
NaN |
|
ISG15;UCHL1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Protein polyubiquitination |
0.036387431 |
13 |
NaN |
|
ISG15;UCHL1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Protein polyubiquitination |
0.040157393 |
16 |
NaN |
|
ISG15;UCHL1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Regulation of coagulation cascade by protein C |
0.002352969 |
6 |
NaN |
|
PROCR;THBD |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Restriction point |
0.00089029 |
5.5 |
3 |
Up by cardiotoxic TKIs |
CCND2;CDKN1A;PFKFB3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Restriction point |
0.000803203 |
3 |
3 |
Up by cardiotoxic TKIs |
CCND2;CDK6;CDKN1A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Restriction point |
0.016295327 |
10.5 |
3 |
Up by cardiotoxic TKIs |
CCND2;CDKN1A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Restriction point |
0.000741619 |
4 |
3 |
Up by cardiotoxic TKIs |
CCND2;E2F1;PFKFB3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Restriction point |
7.31E-07 |
1.5 |
3 |
Up by cardiotoxic TKIs |
CCND1;CCND2;CDK6;CDKN1A;PFKFB3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Retinol metabolism |
0.024550455 |
12 |
NaN |
|
ALDH1A1;RDH10 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Retinol metabolism |
0.03387383 |
11.5 |
NaN |
|
ALDH1A3;DHRS3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Retinol metabolism |
0.034116484 |
9 |
NaN |
|
ALDH1A3;DHRS3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Semaphorin signaling |
0.046477669 |
15 |
NaN |
|
PLXNA4;PLXNC1;RND1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Serine and glycine metabolism |
0.020972888 |
12 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Serine and glycine metabolism |
0.026053323 |
12 |
NaN |
|
PSAT1;SHMT2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serotonin inactivation |
0.040168784 |
13.5 |
NaN |
|
MAOA |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Serotonin inactivation |
0.041205645 |
15.5 |
NaN |
|
MAOA |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Serotonin inactivation |
0.039823039 |
16 |
NaN |
|
MAOA |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Serotonin inactivation |
0.044830247 |
16.5 |
NaN |
|
MAOB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Serotonin inactivation |
0.046036922 |
15 |
NaN |
|
MAOB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Serotonin inactivation |
0.045002676 |
11.5 |
NaN |
|
MAOB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Serotonin inactivation |
0.047070608 |
17 |
NaN |
|
MAOB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Sister chromatid segregation |
0.007340787 |
9.5 |
NaN |
|
ESPL1;PTTG1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Sister chromatid segregation |
0.000237111 |
3 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Sister chromatid segregation |
0.007285832 |
7.5 |
NaN |
|
PTTG1;TOP2A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Sister chromatid segregation |
0.007958007 |
6 |
NaN |
|
ESPL1;PTTG1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Thin myofilament organization |
0.000385498 |
2.5 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Thin myofilament organization |
0.000376804 |
4 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Thin myofilament organization |
0.01050272 |
7 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Thin myofilament organization |
0.000381135 |
2.5 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Thin myofilament organization |
0.010579453 |
7 |
21 |
Down by cardiotoxic TKIs |
ACTA1;TNNI3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.01096695 |
7 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Thrombospondin receptor signaling |
0.002393952 |
7.5 |
NaN |
|
THBS1;THBS2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Thrombospondin receptor signaling |
0.002352969 |
6 |
NaN |
|
THBS1;THBS4 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Thrombospondin receptor signaling |
0.002980769 |
6 |
NaN |
|
THBS2;THBS4 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Tight junction organization |
0.033182637 |
13 |
NaN |
|
CLDN11;CLDN6;MYLK |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Tropoelastin synthesis |
0.020289344 |
10 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Tropoelastin synthesis |
0.020818631 |
10 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Tropoelastin synthesis |
0.019583627 |
9 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.020112915 |
13 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Tropoelastin synthesis |
0.01905434 |
10 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Tropoelastin synthesis |
0.020112915 |
11 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.037747261 |
15 |
NaN |
|
VIPR2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.039823039 |
14 |
NaN |
|
VIPR2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.044830247 |
16.5 |
NaN |
|
VIPR1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.040737529 |
15 |
NaN |
|
AXIN2;FZD2;LEF1;WNT5A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
WNT-Beta-catenin signaling pathway |
0.044085052 |
19 |
NaN |
|
FZD2;FZD8;SFRP5;WNT5A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.008226445 |
6 |
NaN |
|
AXIN2;FZD2;FZD8;PAX6;WNT5A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.000204525 |
2 |
NaN |
|
AXIN2;DACT1;FZD2;FZD8;PAX6;SFRP5;WNT5A |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Z-disc organization |
0.000390166 |
4 |
NaN |
|
CSRP3;DYSF;PDLIM3;TCAP |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Z-disc organization |
2.05E-05 |
2 |
NaN |
|
CSRP3;DES;DYSF;PDLIM3;TCAP |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Z-disc organization |
0.005585744 |
6 |
NaN |
|
DYSF;PDLIM3;TCAP |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Z-disc organization |
0.00523916 |
6 |
NaN |
|
DES;PDLIM3;TCAP |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.008459104 |
5.5 |
NaN |
|
AGRN;CHRNA1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Aggrecan synthesis |
0.022847565 |
12.5 |
NaN |
|
ACAN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Aggrecan synthesis |
0.022671136 |
9 |
NaN |
|
ACAN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Aggrecan synthesis |
0.023288638 |
10.5 |
NaN |
|
ACAN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Aggrecan synthesis |
0.023817925 |
13 |
NaN |
|
ACAN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.020289344 |
10 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.020818631 |
10 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.019583627 |
9 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.020112915 |
13 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.01905434 |
10 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.020112915 |
11 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Alternative complement pathway |
0.004968548 |
8 |
NaN |
|
C3;CFH |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Alternative complement pathway |
0.005389806 |
4.5 |
NaN |
|
C1S;CFH |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Androgen receptor signaling |
0.03878543 |
13 |
NaN |
|
AR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Androgen receptor signaling |
0.039823039 |
14 |
NaN |
|
AR |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.016295327 |
10.5 |
NaN |
|
HLA-B;HLA-C |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Antigen presentation via MHC class I molecules |
0.01470451 |
7.5 |
NaN |
|
HLA-B;HLA-C |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Axonal intermediate filament dynamics |
0.010579453 |
7 |
NaN |
|
NEFH;NEFM |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Biglycan synthesis |
0.020289344 |
10 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Biglycan synthesis |
0.020818631 |
10 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Biglycan synthesis |
0.019583627 |
9 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Biglycan synthesis |
0.020112915 |
13 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Biglycan synthesis |
0.020112915 |
11 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Cardiomyocyte pacemaker current generation |
0.01439434 |
9 |
NaN |
|
CACNA1G;KCNK2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.003798018 |
4 |
NaN |
|
KCNA1;KCNIP2;KCNQ1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000111361 |
3 |
NaN |
|
CTGF;CYR61;NOV |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000120634 |
2 |
NaN |
|
CTGF;CYR61;WISP1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00493106 |
5 |
NaN |
|
CTGF;CYR61 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005196305 |
5 |
NaN |
|
CTGF;CYR61 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005389806 |
4.5 |
NaN |
|
CYR61;WISP1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
CD44-Mediated leukocyte rolling |
0.045175089 |
16 |
NaN |
|
CD44 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.044830247 |
16.5 |
NaN |
|
CD44 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.046036922 |
15 |
NaN |
|
CD44 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.045002676 |
11.5 |
NaN |
|
CD44 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.002845211 |
7 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ABCG1;ARL4C |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.003036207 |
3 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ARL4C;SCARA3 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Cellular cholesterol uptake and efflux |
0.003201324 |
3 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ABCG1;ARL4C |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Centrosome separation |
0.020733699 |
11 |
NaN |
|
ESPL1;SPAG5 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome separation |
0.021492826 |
9 |
NaN |
|
ESPL1;SPAG5 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Centrosome separation |
0.022419283 |
11 |
NaN |
|
ESPL1;SPAG5 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Chloride transmembrane transport |
0.03387383 |
11.5 |
17 |
Down by cardiotoxic TKIs |
ANO1;SLC12A7 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Chloride transmembrane transport |
0.035587098 |
12 |
17 |
Down by cardiotoxic TKIs |
ANO1;BEST1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol synthesis |
0.000619396 |
3 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;HMGCS1;MSMO1;SC5D |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Cholesterol synthesis |
4.50E-05 |
1 |
22 |
Up by cardiotoxic TKIs |
HMGCR;HMGCS1;MSMO1;SC5D;SQLE |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cholesterol synthesis |
7.53E-08 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;HMGCR;HMGCS1;MSMO1;SC5D;SQLE |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol synthesis |
0.007108895 |
8 |
22 |
Up by cardiotoxic TKIs |
MSMO1;SC5D;SQLE |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005727694 |
7 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Classical complement pathway |
0.000385498 |
2.5 |
NaN |
|
C1QB;C1QC;C1R |
| sunitinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Classical complement pathway |
0.0004078 |
4 |
NaN |
|
C1QB;C1QC;C1R |
| sunitinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Classical complement pathway |
0.000381135 |
2.5 |
NaN |
|
C1QB;C1QC;C1R |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Classical complement pathway |
0.010579453 |
7 |
NaN |
|
C1QB;C1QC |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Classical complement pathway |
1.04E-05 |
1 |
NaN |
|
C1QB;C1QC;C1R;C1S |
| sunitinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Decorin synthesis |
0.023376853 |
10.5 |
NaN |
|
DCN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Decorin synthesis |
0.023817925 |
13 |
NaN |
|
DCN |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Eicosanoid metabolism |
0.044270729 |
14 |
NaN |
|
CYP2J2;PTGS2 |
| sunitinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Epithelial intermediate filament dynamics |
0.011124876 |
7 |
NaN |
|
KRT4;KRT7 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Actin polymerization |
0.044957827 |
20 |
NaN |
|
ABRA;ACTA1;ENAH |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.018966126 |
9 |
NaN |
|
ALB |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.020201129 |
12.5 |
NaN |
|
ALB |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.017907551 |
8 |
NaN |
|
ALB |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.02099506 |
12.5 |
NaN |
|
ALB |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.000731661 |
2 |
NaN |
|
B2M;HLA-B;HLA-C |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.017675877 |
9.5 |
NaN |
|
B2M;HLA-C |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Biglycan synthesis |
0.017907551 |
8 |
18 |
Down by cardiotoxic TKIs |
BGN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Cardiomyocyte pacemaker current generation |
0.010499387 |
4 |
NaN |
|
CACNA1D;CACNA1G |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.008322328 |
3 |
NaN |
|
CACNA1D;CACNA1G |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Cardiomyocyte pacemaker current generation |
0.011306612 |
6 |
NaN |
|
CACNA1D;CACNA1G |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
CD44-Mediated leukocyte rolling |
0.049652372 |
28.5 |
NaN |
|
CD44 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
CD44-Mediated leukocyte rolling |
0.047931585 |
25.5 |
NaN |
|
CD44 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cell cycle arrest in response to DNA damage |
0.021538908 |
15 |
NaN |
|
CDKN1A;H2AFX;MDM2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Centrosome maturation |
0.003131352 |
12 |
NaN |
|
AURKA;PLK1;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Centrosome maturation |
0.002923036 |
10 |
NaN |
|
AURKA;PLK1;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome maturation |
0.003317085 |
10 |
NaN |
|
AURKA;PLK1;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Centrosome maturation |
0.002640821 |
9 |
NaN |
|
AURKA;PLK1;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Centrosome organization |
0.02793459 |
19 |
NaN |
|
ASPM;ATF5;NEK2;TACC3;WDR62 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome organization |
0.008770243 |
11 |
NaN |
|
ASPM;ATF5;NEK2;PLK3;TACC3;WDR62 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Centrosome organization |
0.006002146 |
12 |
NaN |
|
ASPM;ATF5;NEK2;PLK3;TACC3;WDR62 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Centrosome separation |
7.87E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Centrosome separation |
6.64E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome separation |
9.07E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Centrosome separation |
5.17E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol synthesis |
0.000123613 |
2 |
22 |
Up by cardiotoxic TKIs |
DHCR24;DHCR7;MVD;MVK;SQLE |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cholesterol synthesis |
6.90E-06 |
4 |
22 |
Up by cardiotoxic TKIs |
DHCR24;DHCR7;HMGCR;HMGCS1;MVD;MVK |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.009261749 |
13.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Coagulation cascade |
0.035205397 |
23 |
NaN |
|
F5;TFPI |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Coagulation cascade |
0.032966818 |
21 |
NaN |
|
F5;TFPI |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Collagen fiber crosslinking |
0.005586664 |
11 |
NaN |
|
LOXL1;PXDN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005107525 |
3 |
NaN |
|
COL12A1;COL9A2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000108759 |
1 |
NaN |
|
COL12A1;COL9A2;COL9A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006227501 |
3 |
NaN |
|
COL9A2;COL9A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Contractile ring constriction |
0.005990412 |
12 |
NaN |
|
ANLN;ECT2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Decorin synthesis |
0.018966126 |
9 |
NaN |
|
DCN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Decorin synthesis |
0.020201129 |
12.5 |
NaN |
|
DCN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Decorin synthesis |
0.017907551 |
8 |
NaN |
|
DCN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Decorin synthesis |
0.02099506 |
12.5 |
NaN |
|
DCN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Desaturation of fatty acids |
0.000548269 |
8 |
11 |
Up by cardiotoxic TKIs |
FADS2;FADS3;SCD |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Desaturation of fatty acids |
0.012167509 |
13.5 |
11 |
Up by cardiotoxic TKIs |
FADS2;SCD |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Desaturation of fatty acids |
0.000581947 |
7 |
11 |
Up by cardiotoxic TKIs |
FADS2;FADS3;SCD |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Desaturation of fatty acids |
0.011360812 |
14 |
11 |
Up by cardiotoxic TKIs |
FADS2;SCD |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Eicosanoid metabolism |
0.038506003 |
17 |
NaN |
|
CYP2J2;PTGES |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.000351179 |
1 |
NaN |
|
KRT19;KRT7;TCHH |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.010499387 |
4 |
NaN |
|
KRT19;KRT7 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.011306612 |
6 |
NaN |
|
KRT19;KRT7 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Equatorial RhoA activation |
0.003654836 |
11 |
NaN |
|
ECT2;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
ER unfolded protein response pathway |
0.017367241 |
12 |
NaN |
|
ATF4;HERPUD1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic spindle disassembly |
0.025758645 |
15 |
NaN |
|
CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mitotic spindle disassembly |
0.025141143 |
17 |
NaN |
|
CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic spindle disassembly |
0.026287932 |
13 |
NaN |
|
CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic spindle disassembly |
0.024258998 |
16 |
NaN |
|
CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Myofibril formation |
0.016431153 |
8 |
6 |
Down by cardiotoxic TKIs |
DES;KLHL41 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Nuclear intermediate filaments |
0.009261749 |
13.5 |
NaN |
|
LMNB1;LMNB2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Osteopontin receptor signaling |
0.018966126 |
9 |
NaN |
|
SPP1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.020201129 |
12.5 |
NaN |
|
SPP1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Osteopontin receptor signaling |
0.017907551 |
8 |
NaN |
|
SPP1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Osteopontin receptor signaling |
0.02099506 |
12.5 |
NaN |
|
SPP1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.031194976 |
17 |
NaN |
|
FOSL1;TNK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.029825004 |
20.5 |
NaN |
|
FOSL1;TNK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.032389398 |
14 |
NaN |
|
FOSL1;TNK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.027912485 |
18.5 |
NaN |
|
FOSL1;TNK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.017593716 |
6 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;RGS5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.019817901 |
10 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.015780154 |
5 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;RGS5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.021308064 |
15 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Progesterone receptor signaling |
0.018966126 |
9 |
NaN |
|
PGR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.041551141 |
19.5 |
NaN |
|
PTGFR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Removal of caspase inhibition |
0.049652372 |
28.5 |
NaN |
|
XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Removal of caspase inhibition |
0.047931585 |
25.5 |
NaN |
|
XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Retinoic acid receptor signaling |
0.024338824 |
12.5 |
NaN |
|
NR4A1;TBL1XR1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Retinol metabolism |
0.024338824 |
12.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.02737145 |
15.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Retinol metabolism |
0.021860273 |
11 |
NaN |
|
ALDH1A1;ALDH1A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.029399062 |
16 |
NaN |
|
ALDH1A1;ALDH1A3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Semaphorin signaling |
0.048626917 |
29 |
NaN |
|
PLXNA2;PLXNA4;RND1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serine and glycine metabolism |
0.002393839 |
11 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serine and glycine metabolism |
0.029825004 |
20.5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serine and glycine metabolism |
0.000133471 |
2 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Serine and glycine metabolism |
0.027912485 |
18.5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Serotonin inactivation |
0.037574179 |
17 |
NaN |
|
MAOA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Serotonin inactivation |
0.039995919 |
19.5 |
NaN |
|
MAOA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Serotonin inactivation |
0.035495973 |
13.5 |
NaN |
|
MAOA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Serotonin inactivation |
0.041551141 |
19.5 |
NaN |
|
MAOA |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000661294 |
9 |
NaN |
|
NUF2;TACC3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000629915 |
8 |
NaN |
|
NUF2;TACC3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000586411 |
7 |
NaN |
|
NUF2;TACC3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Sister chromatid segregation |
0.000319382 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Sister chromatid segregation |
0.000297304 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Sister chromatid segregation |
0.000339137 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Sister chromatid segregation |
0.00026753 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.018966126 |
9 |
NaN |
|
ELN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.020201129 |
12.5 |
NaN |
|
ELN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.017907551 |
8 |
NaN |
|
ELN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.02099506 |
12.5 |
NaN |
|
ELN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Versican receptor signaling |
0.049652372 |
28.5 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Versican receptor signaling |
0.047931585 |
25.5 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Versican synthesis |
0.025141143 |
17 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Versican synthesis |
0.024258998 |
16 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
0.000382484 |
7 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Eukaryotic kinetochore dynamics |
3.67E-06 |
3 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
0.002991751 |
9 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;SPC24 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
2.82E-06 |
3 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown by cathepsins |
0.014575224 |
4.5 |
NaN |
|
CTSF;CTSV |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016431153 |
8 |
NaN |
|
CTSF;CTSV |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by cathepsins |
0.013063701 |
4 |
NaN |
|
CTSF;CTSV |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.014575224 |
4.5 |
NaN |
|
COL11A1;COL3A1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.016431153 |
8 |
NaN |
|
COL1A2;COL3A1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.000618808 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.017675877 |
9.5 |
NaN |
|
COL1A2;COL3A1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Fibulin receptor signaling |
0.049652372 |
28.5 |
NaN |
|
FBLN1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Fibulin receptor signaling |
0.047931585 |
25.5 |
NaN |
|
FBLN1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
G2 M transition checkpoint |
0.036807701 |
18 |
NaN |
|
CCNB1;CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
G2 M transition checkpoint |
0.035205397 |
23 |
NaN |
|
CCNB1;CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
G2 M transition checkpoint |
0.038203861 |
15.5 |
NaN |
|
CCNB1;CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
G2 M transition checkpoint |
0.032966818 |
21 |
NaN |
|
CCNB1;CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Gap junction organization |
0.04907168 |
19 |
NaN |
|
GJA5;GJB2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Gap junction organization |
0.046973016 |
25 |
NaN |
|
GJA1;GJA5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Gap junction organization |
0.004215197 |
10 |
NaN |
|
GJA1;GJA5;GJB2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.044381109 |
17 |
NaN |
|
SLC1A5;SLC7A5 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.02737145 |
15.5 |
NaN |
|
SLC1A5;SLC38A2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.010692227 |
6 |
NaN |
|
HK2;LDHA;PCK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.01186753 |
8 |
NaN |
|
HK2;LDHA;PGK1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.037574179 |
17 |
NaN |
|
JAK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039995919 |
19.5 |
NaN |
|
JAK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.035495973 |
13.5 |
NaN |
|
JAK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.041551141 |
19.5 |
NaN |
|
JAK2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Hepatocyte growth factor receptor signaling |
0.049652372 |
28.5 |
NaN |
|
HGF |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hepatocyte growth factor receptor signaling |
0.047931585 |
25.5 |
NaN |
|
HGF |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.025141143 |
17 |
NaN |
|
HMMR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.024258998 |
16 |
NaN |
|
HMMR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Inhibition of apoptosis |
0.035205397 |
23 |
NaN |
|
BIRC5;XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Inhibition of apoptosis |
0.038203861 |
15.5 |
NaN |
|
BIRC5;XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Inhibition of apoptosis |
0.032966818 |
21 |
NaN |
|
BIRC5;XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Interferon alpha receptor signaling |
0.010499387 |
4 |
NaN |
|
IRF9;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Interferon alpha receptor signaling |
0.011306612 |
6 |
NaN |
|
IRF9;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Interferon beta receptor signaling |
0.0085983 |
4 |
NaN |
|
IFIT2;IRF9 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Intracellular bridge assembly |
0.001950041 |
10 |
NaN |
|
INCENP;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Intracellular bridge assembly |
0.001858288 |
9 |
NaN |
|
INCENP;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Intracellular bridge assembly |
0.002030414 |
8 |
NaN |
|
INCENP;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Intracellular bridge assembly |
0.001730983 |
8 |
NaN |
|
INCENP;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.028045575 |
14 |
NaN |
|
SOCS2;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
JAK-STAT signaling pathway |
0.031514722 |
17 |
NaN |
|
SOCS2;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.002802661 |
2 |
NaN |
|
SOCS2;SOCS3;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Lipogenesis |
0.049652372 |
28.5 |
NaN |
|
FASN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Lipogenesis |
0.047931585 |
25.5 |
NaN |
|
FASN |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mammalian target of rapamycin signaling pathway |
0.040389424 |
19 |
NaN |
|
PIK3R1;RICTOR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mammalian target of rapamycin signaling pathway |
0.045276928 |
22 |
NaN |
|
PIK3R1;RICTOR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mammalian target of rapamycin signaling pathway |
0.036376129 |
16 |
NaN |
|
PIK3R1;RICTOR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mammalian target of rapamycin signaling pathway |
0.048531229 |
23 |
NaN |
|
PIK3R1;RICTOR |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
0.000203151 |
4 |
NaN |
|
BUB1;BUB1B;CDC20;CENPE;MXD3;PTTG1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Metaphase to anaphase checkpoint |
1.49E-06 |
2 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MXD3;PTTG1;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
0.00022683 |
4 |
NaN |
|
BUB1;BUB1B;CDC20;CENPE;PLK3;PTTG1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
1.14E-06 |
2 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PLK3;PTTG1;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Methionine cycle |
0.037574179 |
17 |
NaN |
|
BHMT |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Methionine cycle |
0.039995919 |
19.5 |
NaN |
|
BHMT |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Methionine cycle |
0.035495973 |
13.5 |
NaN |
|
BHMT |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Microfibril scaffold organization |
0.039995919 |
19.5 |
NaN |
|
FBN1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Microfibril scaffold organization |
0.035495973 |
13.5 |
NaN |
|
FBN1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Microfibril scaffold organization |
0.041551141 |
19.5 |
NaN |
|
FBN1 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Microtubule crosslinking and bundling |
0.008246232 |
13 |
NaN |
|
MAP1B;MAP2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitochondrial transport |
0.025958406 |
16 |
NaN |
|
KIF1A;RHOT2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mitotic chromosome condensation |
0.012167509 |
13.5 |
NaN |
|
INCENP;SMC4 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000162797 |
3 |
NaN |
|
AURKB;CCNA2;INCENP |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000151472 |
6 |
NaN |
|
AURKB;CCNA2;INCENP |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000172936 |
3 |
NaN |
|
AURKB;CCNA2;INCENP |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000136211 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic spindle assembly |
0.00025659 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mitotic spindle assembly |
1.06E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic spindle assembly |
0.00027738 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic spindle assembly |
8.89E-06 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.009336933 |
2 |
NaN |
|
FZD1;PAX6;SFRP2;WNT5A;WNT9A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.000369348 |
1 |
NaN |
|
DKK2;FRZB;FZD7;PAX6;SFRP2;WNT5A;WNT9A |
| sorafenib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Z-disc organization |
0.036079961 |
15 |
NaN |
|
CSRP3;PDLIM3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Z-disc organization |
0.003750874 |
1 |
NaN |
|
CSRP3;DES;PDLIM3 |
| sorafenib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Z-disc organization |
0.043409684 |
22 |
NaN |
|
CSRP3;PDLIM3 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
WNT-Beta-catenin signaling pathway |
0.013495554 |
8 |
NaN |
|
DACT1;DKK2;FRZB;WNT2;WNT9A |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.003718285 |
8 |
NaN |
|
APCDD1;DACT1;DKK2;FRZB;WNT2;WNT9A |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.002626412 |
4 |
NaN |
|
DKK2;FRZB;SFRP2;SFRP4;WNT2;WNT9A |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Mitotic spindle assembly |
0.002602492 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Mitotic spindle assembly |
0.002602492 |
5.5 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Mitotic spindle assembly |
0.003036207 |
6.5 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Mitotic spindle assembly |
0.031486283 |
19 |
NaN |
|
DLGAP5;NUSAP1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Mitotic spindle disassembly |
0.022141849 |
14.5 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Mitotic spindle disassembly |
0.022141849 |
12 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Mitotic spindle disassembly |
0.023376853 |
14 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Mitotic spindle disassembly |
0.021788991 |
10.5 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Mitotic spindle disassembly |
0.021788991 |
15 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.007395936 |
5 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Natriuretic peptide receptor signaling |
0.006960163 |
8 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.006381277 |
7 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.007562538 |
9.5 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Natriuretic peptide receptor signaling |
0.007176501 |
5 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Neuregulin receptor signaling |
0.026053323 |
17 |
NaN |
|
ERBB3;NRG1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Osteopontin receptor signaling |
0.022141849 |
14.5 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Osteopontin receptor signaling |
0.022141849 |
12 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.023376853 |
14 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.021788991 |
10.5 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Osteopontin receptor signaling |
0.021788991 |
15 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Potassium transmembrane transport |
0.015397967 |
9 |
NaN |
|
ABCC9;ATP1A2;ATP1A3 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Potassium transmembrane transport |
0.001758867 |
4 |
NaN |
|
ABCC9;ATP1A2;ATP1A3;KCNE4 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Potassium transmembrane transport |
0.001658125 |
7 |
NaN |
|
ABCC9;ATP1A2;ATP1A3;KCNE4 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Progesterone receptor signaling |
0.022141849 |
14.5 |
NaN |
|
PGR |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.046209242 |
20 |
NaN |
|
PTGFR |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Protein polyubiquitination |
0.048125749 |
15 |
NaN |
|
ISG15;UCHL1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Protein polyubiquitination |
0.044404489 |
18 |
NaN |
|
ISG15;UCHL1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Protein polyubiquitination |
0.049507089 |
14 |
NaN |
|
ISG15;UCHL1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Regulation of coagulation cascade by protein C |
0.002756163 |
8.5 |
NaN |
|
PROS1;THBD |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Retinoic acid receptor signaling |
0.035340255 |
14.5 |
NaN |
|
NR4A1;TBL1XR1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Retinol metabolism |
0.03008824 |
14.5 |
NaN |
|
DHRS3;RLBP1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Retinol metabolism |
0.00297168 |
5 |
NaN |
|
ALDH1A2;RLBP1;RPE65 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Semaphorin signaling |
0.038761798 |
20 |
NaN |
|
CRMP1;SEMA3E;SEMA6B |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Serine and glycine metabolism |
0.025144066 |
11 |
NaN |
|
GLDC;PSAT1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Serine and glycine metabolism |
0.00156935 |
5 |
NaN |
|
GLDC;PSAT1;SLC1A5 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.001380012 |
3 |
NaN |
|
GLDC;PSAT1;SLC1A5 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.025687982 |
13 |
NaN |
|
SHMT2;SLC1A5 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Serine and glycine metabolism |
0.024426533 |
9 |
NaN |
|
GLDC;PSAT1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.022844529 |
13 |
NaN |
|
PHGDH;PSAT1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Serotonin inactivation |
0.042069268 |
16.5 |
NaN |
|
MAOA |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Serotonin inactivation |
0.045864587 |
18.5 |
NaN |
|
MAOA |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.043795347 |
21.5 |
NaN |
|
NUF2 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.043105102 |
15.5 |
NaN |
|
NUF2 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.00311962 |
7 |
NaN |
|
THBS1;THBS4 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Tight junction organization |
0.000985853 |
2 |
NaN |
|
CGN;CLDN11;CLDN19;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Tight junction organization |
0.006548178 |
7 |
NaN |
|
CGN;CLDN19;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Tight junction organization |
0.005599924 |
6 |
NaN |
|
CGN;CLDN19;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Tight junction organization |
0.043551421 |
17 |
NaN |
|
CLDN11;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Tight junction organization |
0.006917983 |
4 |
NaN |
|
CGN;CLDN19;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.022141849 |
14.5 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Tropoelastin synthesis |
0.022141849 |
12 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.023376853 |
14 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.021788991 |
10.5 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.021788991 |
15 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Actin filament bundling and crosslinking |
0.019151001 |
11 |
NaN |
|
SYNPO;SYNPO2;USH1C |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Actin filament bundling and crosslinking |
0.019151001 |
8 |
NaN |
|
SYNPO;SYNPO2;USH1C |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Actin filament bundling and crosslinking |
0.022080775 |
11 |
NaN |
|
SYNPO;SYNPO2;USH1C |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Actin filament bundling and crosslinking |
0.018356825 |
12 |
NaN |
|
SYNPO;SYNPO2;USH1C |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Actin filament severing and depolymerization |
0.034603897 |
13 |
NaN |
|
SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Actin filament severing and depolymerization |
0.032671153 |
12 |
NaN |
|
SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Actin filament severing and depolymerization |
0.03008824 |
14.5 |
NaN |
|
SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Actin filament severing and depolymerization |
0.00297168 |
5 |
NaN |
|
LIMA1;SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Actin filament severing and depolymerization |
0.03363188 |
11 |
NaN |
|
SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Aggrecan synthesis |
0.02293578 |
9.5 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Aggrecan synthesis |
0.022230064 |
10.5 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Aggrecan synthesis |
0.021259704 |
12.5 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Aggrecan synthesis |
0.023200423 |
12 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Aggrecan synthesis |
0.022582922 |
7.5 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.022141849 |
14.5 |
NaN |
|
ALB |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Albumin mediated blood protein transport |
0.022141849 |
12 |
NaN |
|
ALB |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.023376853 |
14 |
NaN |
|
ALB |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.021788991 |
15 |
NaN |
|
ALB |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Androgen receptor signaling |
0.043967869 |
13.5 |
NaN |
|
AR |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Androgen receptor signaling |
0.042069268 |
16.5 |
NaN |
|
AR |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Antigen presentation via MHC class I molecules |
0.018099639 |
11 |
NaN |
|
HLA-A;HLA-C |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Biglycan synthesis |
0.022141849 |
14.5 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Biglycan synthesis |
0.022141849 |
12 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Biglycan synthesis |
0.023376853 |
14 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Biglycan synthesis |
0.021788991 |
10.5 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Biglycan synthesis |
0.021788991 |
15 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.00500617 |
4 |
NaN |
|
CYR61;WISP1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.046209242 |
20 |
NaN |
|
CD44 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.000143348 |
2 |
NaN |
|
ABCA1;ABCA12;ABCG1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Cellular cholesterol uptake and efflux |
0.002602492 |
5.5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Cellular cholesterol uptake and efflux |
0.003036207 |
6.5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.031486283 |
14 |
NaN |
|
ABCA1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Cellular cholesterol uptake and efflux |
0.000134719 |
2 |
NaN |
|
ABCA1;ABCA12;ABCG1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Centrosome separation |
0.001147047 |
4.5 |
NaN |
|
CCNB1;CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Centrosome separation |
0.001147047 |
3 |
NaN |
|
CCNB1;CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Centrosome separation |
0.001341925 |
4.5 |
NaN |
|
CCNB1;CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Centrosome separation |
0.018960318 |
8 |
NaN |
|
CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Centrosome separation |
0.001094912 |
4.5 |
NaN |
|
CCNB1;CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Chloride transmembrane transport |
0.034603897 |
13 |
NaN |
|
ANO1;SLC12A6 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Chloride transmembrane transport |
0.035340255 |
14.5 |
NaN |
|
ANO1;SLC12A6 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Chloride transmembrane transport |
0.03363188 |
11 |
NaN |
|
ANO1;SLC12A6 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Cholesterol synthesis |
0.001052619 |
3 |
NaN |
|
DHCR24;HMGCR;HMGCS1;MSMO1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Classical complement pathway |
0.000389893 |
1 |
NaN |
|
C1QA;C1QB;C1QC |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Classical complement pathway |
0.000355631 |
3 |
NaN |
|
C1QB;C1QC;C1R |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Classical complement pathway |
0.008809063 |
8 |
NaN |
|
C1QB;C1QC |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Classical complement pathway |
0.000403274 |
2 |
NaN |
|
C1QA;C1QB;C1QC |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Classical complement pathway |
0.000372505 |
1 |
NaN |
|
C1QB;C1QC;C1R |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Collagen fiber crosslinking |
0.005119846 |
8 |
NaN |
|
LOXL1;TGM2 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000204193 |
3 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000204193 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000239777 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000194704 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000194704 |
3 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Decorin synthesis |
0.02293578 |
9.5 |
NaN |
|
DCN |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Decorin synthesis |
0.022230064 |
10.5 |
NaN |
|
DCN |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Decorin synthesis |
0.021259704 |
12.5 |
NaN |
|
DCN |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Decorin synthesis |
0.022582922 |
7.5 |
NaN |
|
DCN |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
DNA replication elongation |
0.000105033 |
2 |
NaN |
|
MCM4;MCM5;MCM7 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
DNA replication elongation |
9.20E-05 |
1 |
NaN |
|
MCM4;MCM5;PCNA |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
DNA replication initiation |
0.002339767 |
3 |
NaN |
|
CDC6;MCM10;MCM5;MCM6 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
DNA replication initiation |
1.41E-05 |
1 |
NaN |
|
CDC6;MCM10;MCM4;MCM5;MCM6;MCM7 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
DNA replication initiation |
0.001773432 |
4 |
NaN |
|
CDC6;MCM4;MCM5;MCM6 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
DNA replication initiation |
0.002211379 |
3 |
NaN |
|
CDC6;MCM10;MCM5;MCM6 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.013889809 |
9 |
NaN |
|
KRT19;KRT8 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01691013 |
7 |
NaN |
|
ADAMTS2;ADAMTS5;ADAMTS9 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.013812565 |
10 |
NaN |
|
ADAMTS2;ADAMTS5;ADAMTS9 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017432245 |
11 |
NaN |
|
ADAMTS2;ADAMTS5;ADAMTS9 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017785355 |
10 |
NaN |
|
ADAM12;ADAMTS12;ADAMTS14 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Extracellular matrix breakdown by serine proteases |
0.009528592 |
7 |
NaN |
|
KLK5;PRSS12 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown by serine proteases |
0.009237654 |
7 |
NaN |
|
KLK5;PRSS12 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by serine proteases |
0.009237654 |
10 |
NaN |
|
KLK5;PRSS12 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Fatty acid transfer between membranes |
0.001398195 |
6 |
NaN |
|
FABP3;FABP5 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.02088458 |
8 |
NaN |
|
COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.001160324 |
4 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.001019591 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.001312886 |
3 |
NaN |
|
COL11A2;COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.001214412 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.001147047 |
4.5 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Fibrillar collagen core structure organization |
0.019543779 |
9 |
NaN |
|
COL2A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.001341925 |
4.5 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
4.17E-05 |
1 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.001094912 |
4.5 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Fibronectin synthesis and extracellular assembly |
0.000103796 |
1 |
NaN |
|
FN1;ITGA5;ITGB3 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Fibronectin synthesis and extracellular assembly |
0.000103796 |
1 |
NaN |
|
FN1;ITGA5;ITGB3 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Fibronectin synthesis and extracellular assembly |
0.000121999 |
1 |
NaN |
|
FN1;ITGA5;ITGB3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Fibronectin synthesis and extracellular assembly |
9.89E-05 |
1 |
NaN |
|
FN1;ITGA5;ITGB3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Fibulin receptor signaling |
0.043105102 |
15.5 |
NaN |
|
FBLN1 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
G2 M transition checkpoint |
0.027843478 |
18 |
NaN |
|
CCNB1;CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
G2 M transition checkpoint |
0.027843478 |
15 |
NaN |
|
CCNB1;CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
G2 M transition checkpoint |
0.030788722 |
18 |
NaN |
|
CCNB1;CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
G2 M transition checkpoint |
0.027024728 |
18 |
NaN |
|
CCNB1;CDK1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Gap junction organization |
0.040610666 |
16 |
NaN |
|
GJA5;GJA8 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.034603897 |
13 |
NaN |
|
GLS;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Glutamate and glutamine metabolism |
0.002632093 |
6 |
NaN |
|
GLS;SLC1A5;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.002317901 |
5 |
NaN |
|
GLS;SLC1A5;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.00297168 |
5 |
NaN |
|
GLS;SLC1A5;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.03363188 |
11 |
NaN |
|
GLS;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.015864433 |
10 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.000778938 |
3 |
NaN |
|
CSF3R;SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.015387237 |
11 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Hepatocyte growth factor receptor signaling |
0.045347487 |
15 |
NaN |
|
HGF |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Hepatocyte growth factor receptor signaling |
0.045864587 |
18.5 |
NaN |
|
HGF |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Up |
Inhibin receptor signaling |
0.013393382 |
6 |
NaN |
|
INHBB;INHBE |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Inhibin receptor signaling |
0.012616077 |
9 |
NaN |
|
INHBB;INHBE |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.011581726 |
9 |
NaN |
|
INHBB;INHBE |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Inhibin receptor signaling |
1.84E-05 |
1 |
NaN |
|
INHBA;INHBB;INHBE;TGFBR3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Inhibin receptor signaling |
0.013002108 |
6 |
NaN |
|
INHBB;INHBE |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.037295126 |
19 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
JAK-STAT signaling pathway |
0.00311366 |
6 |
NaN |
|
SOCS3;STAT3;STAT4 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.036215054 |
20 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Leptin receptor signaling |
0.002844982 |
7 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Down |
Leptin receptor signaling |
0.002756163 |
5 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Leptin receptor signaling |
0.002756163 |
8.5 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Up |
Lipogenesis |
0.043967869 |
13.5 |
NaN |
|
FASN |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Up |
Lipogenesis |
0.044657802 |
13 |
NaN |
|
FASN |
| saxagliptin |
Antidiabetic |
No |
MSN01 |
Down |
Microfibril scaffold organization |
0.043795347 |
21.5 |
NaN |
|
FBN1 |
| saxagliptin |
Antidiabetic |
No |
MSN02 |
Down |
Microfibril scaffold organization |
0.043795347 |
16 |
NaN |
|
FBN1 |
| saxagliptin |
Antidiabetic |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.046209242 |
20 |
NaN |
|
FBN1 |
| saxagliptin |
Antidiabetic |
No |
MSN09 |
Down |
Microfibril scaffold organization |
0.043105102 |
21 |
NaN |
|
FBN1 |
| saxagliptin |
Antidiabetic |
No |
MSN08 |
Up |
Microtubule crosslinking and bundling |
0.007562538 |
9.5 |
NaN |
|
DCX;MAP2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
ER unfolded protein response pathway |
0.014496215 |
8 |
NaN |
|
ATF4;DDIT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
ER unfolded protein response pathway |
0.017036884 |
11.5 |
NaN |
|
ATF4;DDIT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
ER unfolded protein response pathway |
0.017700401 |
11 |
NaN |
|
ATF4;DDIT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
5.24E-05 |
4 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;NDC80;ZWINT |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Eukaryotic kinetochore dynamics |
8.45E-09 |
2 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
0.006779643 |
11 |
NaN |
|
BUB1;CENPE;CENPF;NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.011207265 |
7 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.006331148 |
8 |
NaN |
|
ADAM12;ADAMTS5;ADAMTS8 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000438946 |
6 |
NaN |
|
MMP12;MMP2;MMP3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000298278 |
3 |
NaN |
|
MMP12;MMP2;MMP3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.012661705 |
8 |
NaN |
|
MMP12;MMP3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000313327 |
3 |
NaN |
|
MMP12;MMP2;MMP3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Fanconi anemia interstrand cross-link repair pathway |
0.020586647 |
20 |
NaN |
|
BRIP1;FAAP20;UBE2T |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
6.06E-09 |
2 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Fibrillar collagen core structure organization |
1.35E-06 |
4 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
2.75E-09 |
2 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
1.07E-08 |
2 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
2.32E-07 |
2 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
1.34E-10 |
1 |
NaN |
|
COL11A1;COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibrillin synthesis |
0.046374785 |
16 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillin synthesis |
0.047143838 |
22 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Fibulin receptor signaling |
0.045002676 |
29.5 |
NaN |
|
FBLN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibulin receptor signaling |
0.038958404 |
22.5 |
NaN |
|
FBLN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.031680109 |
17 |
NaN |
|
FBLN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Fibulin receptor signaling |
0.039650143 |
22.5 |
NaN |
|
FBLN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
G2 M transition checkpoint |
0.018715218 |
17 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
G2 M transition checkpoint |
0.029300737 |
27 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
G2 M transition checkpoint |
0.022330855 |
16.5 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
G2 M transition checkpoint |
0.023086706 |
18 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
GABA metabolism |
0.004565005 |
10 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
GABA metabolism |
0.003528251 |
4.5 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
GABA metabolism |
0.005485195 |
4 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
GABA metabolism |
0.003645933 |
5.5 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
GABA metabolism |
0.005678798 |
8.5 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Gap junction organization |
0.025206934 |
19 |
NaN |
|
GJA1;GJA5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.005074033 |
6 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.037334294 |
16.5 |
NaN |
|
SLC1A5;SLC7A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.006165206 |
7 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Glutamate and glutamine metabolism |
0.045193362 |
17.5 |
NaN |
|
SLC1A5;SLC7A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.024789627 |
16 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.018346559 |
9 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.028241393 |
15 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.021531918 |
13 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.026868005 |
12 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.022362683 |
12 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.001681304 |
5 |
NaN |
|
ADAM9;HBEGF |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.002071198 |
4 |
NaN |
|
ADAM9;HBEGF |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.000784522 |
3 |
NaN |
|
HGF;MET |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Hepatocyte growth factor receptor signaling |
0.047242835 |
21 |
NaN |
|
HGF |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.000902302 |
3 |
NaN |
|
HGF;MET |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.000855234 |
4 |
NaN |
|
HGF;MET |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.022759351 |
23 |
NaN |
|
HMMR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.047143838 |
22 |
NaN |
|
PLAT |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Inhibition of apoptosis |
0.022330855 |
16.5 |
NaN |
|
BIRC5;IFI6 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Inhibition of apoptosis |
0.015062947 |
9 |
NaN |
|
BIRC5;IFI6 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Integrin-mediated leukocyte rolling |
0.007580082 |
6 |
NaN |
|
ICAM1;SELPLG |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Interleukin 6 receptor signaling |
0.047242835 |
21 |
NaN |
|
JAK3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Interleukin 7 receptor signaling |
0.047242835 |
21 |
NaN |
|
JAK3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Intracellular bridge assembly |
0.001524767 |
9 |
NaN |
|
INCENP;KIF23 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
JAK-STAT signaling pathway |
0.042882493 |
18 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
JAK-STAT signaling pathway |
0.005131546 |
5 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.005428272 |
6 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Leptin receptor signaling |
0.004533971 |
5 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Leptin receptor signaling |
0.003309507 |
6 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Leptin receptor signaling |
0.005200324 |
6 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Leptin receptor signaling |
0.003911609 |
3.5 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Leptin receptor signaling |
0.004934362 |
6 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Leptin receptor signaling |
0.004069701 |
5 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Lipogenesis |
0.045002676 |
29.5 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Lipogenesis |
0.03115918 |
12.5 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Lipogenesis |
0.038958404 |
22.5 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Lipogenesis |
0.031680109 |
17 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Lipogenesis |
0.039650143 |
22.5 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Lysine metabolism |
0.046374785 |
16 |
NaN |
|
LOX |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Lysine metabolism |
0.047143838 |
22 |
NaN |
|
LOX |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
1.90E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Metaphase to anaphase checkpoint |
7.02E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
0.000533686 |
4 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;PTTG1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Methionine cycle |
0.047242835 |
21 |
NaN |
|
BHMT |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.035495973 |
20.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Microfibril scaffold organization |
0.045002676 |
29.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.03115918 |
12.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Microfibril scaffold organization |
0.038958404 |
22.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.031680109 |
17 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.039650143 |
22.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Microtubule crosslinking and bundling |
0.010919862 |
11.5 |
NaN |
|
MAP2;MTCL1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Microtubule destabilization |
0.007285832 |
14 |
NaN |
|
KIF2C;STMN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Microtubule destabilization |
0.005678798 |
8.5 |
NaN |
|
KIF2C;STMN1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.003079589 |
8 |
NaN |
|
AURKB;CCNA2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000112656 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle assembly |
6.29E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Mitotic spindle assembly |
0.000159406 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic spindle assembly |
0.001953592 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.017907551 |
15 |
NaN |
|
CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Mitotic spindle disassembly |
0.022759351 |
23 |
NaN |
|
CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle disassembly |
0.019671842 |
13.5 |
NaN |
|
CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic spindle disassembly |
0.0200247 |
15 |
NaN |
|
CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.010919862 |
11.5 |
NaN |
|
NPPB;NPR3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Neuregulin receptor signaling |
0.018850561 |
10.5 |
NaN |
|
ERBB3;SH3TC2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Notch receptor signaling |
0.021041398 |
14 |
NaN |
|
JAG2;LFNG;NOTCH3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Notch receptor signaling |
0.014324969 |
10 |
NaN |
|
DLK1;LFNG;NOTCH3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Notch receptor signaling |
0.002413942 |
5 |
NaN |
|
DLK1;JAG2;LFNG;NOTCH3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Notch receptor signaling |
0.015117884 |
10 |
NaN |
|
DLK1;LFNG;NOTCH3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Nuclear intermediate filaments |
0.007285832 |
14 |
NaN |
|
LMNB1;LMNB2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Nucleosome assembly |
0.001387858 |
8 |
NaN |
|
ASF1B;H2AFZ;HIST1H1C;TSPYL2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Oncostatin-M receptor signaling |
0.00741681 |
8.5 |
NaN |
|
OSMR;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Oncostatin-M receptor signaling |
0.008495241 |
9 |
NaN |
|
OSMR;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Osteonectin receptor signaling |
0.003911609 |
3.5 |
NaN |
|
SMOC2;SPOCK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.015702188 |
7.5 |
NaN |
|
SPP1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.015966831 |
11.5 |
NaN |
|
SPP1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.0200247 |
15 |
NaN |
|
SPP1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Potassium transmembrane transport |
0.023568011 |
14 |
NaN |
|
ATP1A3;KCNE4;KCNQ1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Potassium transmembrane transport |
0.03196174 |
16 |
NaN |
|
ATP1A3;KCNE4;KCNQ1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Progesterone receptor signaling |
0.02390614 |
13 |
NaN |
|
PGR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Progesterone receptor signaling |
0.026023289 |
15.5 |
NaN |
|
PGR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Progesterone receptor signaling |
0.029287227 |
14 |
NaN |
|
PGR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Progesterone receptor signaling |
0.026552576 |
14 |
NaN |
|
PGR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Prostaglandin E2 receptor signaling |
0.012490666 |
11.5 |
NaN |
|
PTGER3;RAPGEF4 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Protein polyubiquitination |
0.039837635 |
25 |
NaN |
|
ISG15;UBE2S |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Recycling endosome dynamics |
0.028486074 |
15 |
NaN |
|
RAB15;S100A10;SNAP23 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Recycling endosome dynamics |
0.035364453 |
19 |
NaN |
|
EHD3;RAB15;S100A10 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Retinoic acid receptor signaling |
0.049902543 |
20.5 |
NaN |
|
NR4A1;TBL1XR1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Retinoic acid receptor signaling |
0.037334294 |
16.5 |
NaN |
|
NR4A1;TBL1XR1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Retinoic acid receptor signaling |
0.043574597 |
20 |
NaN |
|
NR4A1;TBL1XR1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Retinoic acid receptor signaling |
0.045193362 |
17.5 |
NaN |
|
NR4A1;TBL1XR1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Retinol metabolism |
0.021860273 |
18 |
NaN |
|
ALDH1A1;ALDH1A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Retinol metabolism |
0.017068908 |
10 |
NaN |
|
ALDH1A1;RDH10 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Retinol metabolism |
0.026053443 |
18 |
NaN |
|
ALDH1A2;RDH10 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Retinol metabolism |
0.001017685 |
4 |
NaN |
|
ALDH1A1;RDH10;TTR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Retinol metabolism |
0.026929091 |
19 |
NaN |
|
ALDH1A1;RDH10 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Sarcoplasmic reticulum organization |
0.019640794 |
15 |
NaN |
|
PLN;TRDN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Sarcoplasmic reticulum organization |
0.017036884 |
11.5 |
NaN |
|
PLN;TRDN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sarcoplasmic reticulum organization |
0.021304837 |
11 |
NaN |
|
PLN;TRDN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Selectin-mediated Leukocyte rolling |
0.005485195 |
4 |
NaN |
|
ICAM1;SELPLG |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Semaphorin signaling |
0.016664642 |
14 |
NaN |
|
DPYSL4;NRP2;SEMA6D |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.000171562 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Serine and glycine metabolism |
9.23E-05 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.000224525 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.002464684 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.000202562 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.000138746 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Serotonin inactivation |
0.047242835 |
21 |
NaN |
|
MAOA |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.035495973 |
20.5 |
NaN |
|
TACC3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Sister chromatid attachment to mitotic spindle |
0.045002676 |
29.5 |
NaN |
|
NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid attachment to mitotic spindle |
0.038958404 |
22.5 |
NaN |
|
NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.039650143 |
22.5 |
NaN |
|
NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid segregation |
0.004565005 |
10 |
NaN |
|
ESPL1;PTTG1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Sister chromatid segregation |
0.000221517 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Thin myofilament organization |
0.015006283 |
14 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Thin myofilament organization |
0.000440408 |
3 |
NaN |
|
ACTA1;NEBL;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thin myofilament organization |
0.017141721 |
13 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Thin myofilament organization |
0.012999296 |
9 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thin myofilament organization |
0.016291005 |
9.5 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Thin myofilament organization |
0.013510309 |
9 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.028052223 |
17.5 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Tropoelastin synthesis |
0.02390614 |
13 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.030081157 |
16.5 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.029287227 |
14 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.026552576 |
14 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Urea cycle |
0.012490666 |
11.5 |
NaN |
|
ARG2;ASS1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Urea cycle |
0.009446625 |
8 |
NaN |
|
ARG2;ASS1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Urea cycle |
0.011864496 |
8 |
NaN |
|
ARG2;ASS1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Urea cycle |
0.009821443 |
7.5 |
NaN |
|
ARG2;ASS1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Vascular endothelial growth factor receptor signaling |
0.006315881 |
13 |
NaN |
|
FLT1;KDR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.005681554 |
12 |
NaN |
|
APCDD1;DACT1;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
WNT-Beta-catenin signaling pathway |
0.015045373 |
18 |
NaN |
|
APCDD1;DKK2;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.017982282 |
11 |
NaN |
|
APCDD1;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.037023388 |
20 |
NaN |
|
APCDD1;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.039120547 |
20 |
NaN |
|
APCDD1;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Z-disc organization |
5.70E-05 |
1 |
NaN |
|
CSRP3;DES;LDB3;PDLIM3;TCAP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Z-disc organization |
1.16E-06 |
1 |
NaN |
|
CSRP3;DES;LDB3;NEBL;PDLIM3;TCAP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Z-disc organization |
0.001098997 |
4 |
NaN |
|
CSRP3;DES;PDLIM3;TCAP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Z-disc organization |
0.00759691 |
7 |
NaN |
|
CSRP3;DES;LDB3 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Z-disc organization |
7.00E-05 |
1 |
NaN |
|
CSRP3;DES;LDB3;PDLIM3;TCAP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Z-disc organization |
4.38E-05 |
1 |
NaN |
|
CSRP3;DES;LDB3;PDLIM3;TCAP |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.007845779 |
12 |
NaN |
|
AGRN;CHRNA1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Actin polymerization |
0.006114931 |
7 |
NaN |
|
ABRA;ACTA1;ENAH;FMNL2;GAS7 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Acute-phase response |
0.047143838 |
22 |
NaN |
|
TTR |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.028052223 |
17.5 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Aggrecan synthesis |
0.02390614 |
13 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.030081157 |
16.5 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Aggrecan synthesis |
0.026023289 |
15.5 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.029287227 |
14 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.026552576 |
14 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.017907551 |
15 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.022759351 |
23 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.015702188 |
7.5 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.019671842 |
13.5 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.015966831 |
11.5 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.0200247 |
15 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Alternative complement pathway |
0.008495241 |
9 |
NaN |
|
C3;CFH |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Amyloid plaque organization |
0.018850561 |
10.5 |
NaN |
|
SLC30A3;SNCA |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.030420468 |
19 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Antigen presentation via MHC class I molecules |
0.022575326 |
10.5 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.034610193 |
18 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.026458023 |
17.5 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.032944232 |
17 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.027469295 |
16 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Aspartate and arginine metabolism |
0.002266266 |
4 |
NaN |
|
ARG2;SLC7A1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Aspartate and arginine metabolism |
0.00143149 |
4 |
NaN |
|
ARG2;SLC7A1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Aspartate and arginine metabolism |
0.002766197 |
5 |
NaN |
|
ARG2;ASS1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Aspartate and arginine metabolism |
0.0018275 |
1 |
NaN |
|
ARG2;ASS1;SLC7A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Aspartate and arginine metabolism |
0.000131941 |
2 |
NaN |
|
ARG2;ASS1;SLC7A1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Aspartate and arginine metabolism |
9.02E-05 |
2 |
NaN |
|
ARG2;ASS1;SLC7A1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Axonal intermediate filament dynamics |
0.010047711 |
17 |
NaN |
|
NEFH;NEFM |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Biglycan synthesis |
0.022759351 |
23 |
NaN |
|
BGN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Biglycan synthesis |
0.019671842 |
13.5 |
NaN |
|
BGN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Biglycan synthesis |
0.015966831 |
11.5 |
NaN |
|
BGN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Biglycan synthesis |
0.0200247 |
15 |
NaN |
|
BGN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cardiomyocyte depolarization during action potential |
0.015702188 |
7.5 |
NaN |
|
SCN5A |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030007535 |
19 |
NaN |
|
KCNIP2;KCNQ5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.049981772 |
21 |
NaN |
|
KCNJ12;KCNQ1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00741681 |
8.5 |
NaN |
|
CYR61;NOV |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006407471 |
6 |
NaN |
|
CTGF;NOV |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Cell cycle arrest in response to DNA damage |
0.016567078 |
19 |
NaN |
|
H2AFX;MDM2;UHRF1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cellular iron storage |
0.046374785 |
16 |
NaN |
|
FTL |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cellular iron storage |
0.047143838 |
22 |
NaN |
|
FTL |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cellular iron uptake and export |
0.017616631 |
15 |
NaN |
|
CD163;RASD1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome maturation |
0.001104833 |
7 |
NaN |
|
AURKA;PLK1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Centrosome maturation |
0.002201501 |
10 |
NaN |
|
AURKA;PLK1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Centrosome maturation |
0.001525179 |
5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome separation |
6.11E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Centrosome separation |
3.30E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome separation |
0.015623688 |
9 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Centrosome separation |
7.16E-07 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;NEK2;SPAG5 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Chloride transmembrane transport |
0.049902543 |
20.5 |
NaN |
|
ANO1;BEST1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Cholesterol synthesis |
0.009974492 |
16 |
NaN |
|
DHCR24;FDPS;HMGCS1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol synthesis |
3.39E-10 |
1 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVK |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cholesterol synthesis |
2.03E-09 |
1 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVD |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cholesterol synthesis |
1.53E-08 |
1 |
NaN |
|
DHCR7;FDFT1;FDPS;HMGCS1;MSMO1;MVD;MVK |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cholesterol synthesis |
2.34E-09 |
2 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MVD;MVK |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.010919862 |
11.5 |
NaN |
|
INSIG1;SREBF1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Classical complement pathway |
0.005050837 |
7 |
NaN |
|
C1QB;C1QC |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Classical complement pathway |
0.000863028 |
2 |
NaN |
|
C1QA;C1R;C4A |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Classical complement pathway |
0.016291005 |
9.5 |
NaN |
|
C1QA;C1R |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.004565005 |
10 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007285832 |
14 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.003528251 |
4.5 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005485195 |
4 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.003645933 |
5.5 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005678798 |
8.5 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010919862 |
11.5 |
NaN |
|
COL12A1;COL9A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.00801527 |
7 |
NaN |
|
COL12A1;COL9A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009821443 |
7.5 |
NaN |
|
COL12A1;COL9A2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Connection of muscle sarcomere to extracellular matrix |
0.005678798 |
8.5 |
NaN |
|
AGRN;SGCD |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.022575326 |
10.5 |
NaN |
|
DES;SYNM |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.026458023 |
17.5 |
NaN |
|
DES;SYNM |
| ruxolitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Decorin synthesis |
0.017907551 |
15 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
Decorin synthesis |
0.022759351 |
23 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Decorin synthesis |
0.015702188 |
7.5 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Decorin synthesis |
0.019671842 |
13.5 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Decorin synthesis |
0.015966831 |
11.5 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Decorin synthesis |
0.0200247 |
15 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
DNA cleavage |
0.024784198 |
26 |
NaN |
|
FEN1;HMGB2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
DNA replication elongation |
0.00493106 |
12 |
NaN |
|
MCM2;PCNA |
| ruxolitinib |
Kinase inhibitor |
No |
MSN02 |
Up |
DNA replication initiation |
0.002274944 |
11 |
NaN |
|
CDC45;CDC6;GINS2;MCM2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Elastin cross-linking and assembly |
0.046374785 |
16 |
NaN |
|
LOX |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Elastin cross-linking and assembly |
0.047143838 |
22 |
NaN |
|
LOX |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Endogenous control of complement activity |
0.008495241 |
9 |
NaN |
|
CFH;CFI |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Endogenous control of complement activity |
0.008065076 |
7 |
NaN |
|
CFH;CFI |
| ruxolitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Ephrin receptor signaling |
0.046374785 |
16 |
NaN |
|
EPHA2 |
| ruxolitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Ephrin receptor signaling |
0.047143838 |
22 |
NaN |
|
EPHA2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Actin filament severing and depolymerization |
0.024127969 |
17.5 |
NaN |
|
LIMA1;TAGLN2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Adherens junction organization |
0.041831268 |
23 |
NaN |
|
CDH1;CGNL1;MYO1D |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Adherens junction organization |
0.010590543 |
8 |
NaN |
|
CDH1;CDH3;CGNL1;MYO1D |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Adherens junction organization |
0.007599392 |
6 |
NaN |
|
CDH1;CDH3;CGNL1;MYO1D |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.016055046 |
11 |
NaN |
|
ACAN |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.020377558 |
14 |
NaN |
|
ACAN |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.018877911 |
14.5 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Albumin mediated blood protein transport |
0.021083275 |
12.5 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.016055046 |
11 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.019142555 |
11.5 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.020377558 |
14 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Alternative complement pathway |
0.006365168 |
8.5 |
NaN |
|
C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Alternative complement pathway |
0.005666345 |
5.5 |
NaN |
|
C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Alternative complement pathway |
0.000240425 |
4 |
NaN |
|
C1S;C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Alternative complement pathway |
0.006072761 |
9.5 |
NaN |
|
C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Alternative complement pathway |
0.005350837 |
5 |
NaN |
|
C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Amyloid plaque organization |
0.039716535 |
20 |
NaN |
|
APOE;SLC30A3 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Amyloid plaque organization |
0.000978687 |
2 |
NaN |
|
APOE;COL25A1;HSPB6 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Amyloid plaque organization |
0.02147651 |
15.5 |
NaN |
|
APOE;COL25A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Amyloid plaque organization |
0.020145007 |
11 |
NaN |
|
COL25A1;HSPB6 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Androgen receptor signaling |
0.048275867 |
19.5 |
NaN |
|
AR |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Androgen receptor signaling |
0.049996342 |
28.5 |
NaN |
|
AR |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Antigen presentation via MHC class I molecules |
0.00152477 |
2.5 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Aspartate and arginine metabolism |
0.001809764 |
4.5 |
NaN |
|
ASS1;DDAH1;SLC7A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Aspartate and arginine metabolism |
0.033127671 |
19 |
NaN |
|
ARG2;ASS1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Aspartate and arginine metabolism |
0.022263706 |
11 |
NaN |
|
ARG2;SLC7A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Axonal intermediate filament dynamics |
0.012914996 |
11.5 |
NaN |
|
NEFH;NEFM |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Axonal intermediate filament dynamics |
0.01088894 |
8 |
NaN |
|
NEFH;NEFM |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Biglycan synthesis |
0.023729711 |
13 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Biglycan synthesis |
0.018877911 |
14.5 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Biglycan synthesis |
0.021083275 |
12.5 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Biglycan synthesis |
0.016055046 |
11 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Biglycan synthesis |
0.019142555 |
11.5 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Cardiomyocyte pacemaker current generation |
0.01692739 |
14 |
NaN |
|
CACNA1G;KCNK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.049677703 |
23.5 |
NaN |
|
KCNIP2;KCNJ2 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.042309999 |
18.5 |
NaN |
|
KCNA1;KCNIP2 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Carnitine shuttle |
0.005105448 |
4.5 |
NaN |
|
CPT1A;SLC25A20 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005350837 |
5 |
NaN |
|
CTGF;CYR61 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004244577 |
4 |
NaN |
|
NOV;WISP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.041723865 |
19 |
NaN |
|
CD44 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.024127969 |
17.5 |
NaN |
|
ABCA1;ABCG1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Cellular cholesterol uptake and efflux |
0.029628054 |
17 |
NaN |
|
ABCA1;SCARA3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.02476286 |
14 |
NaN |
|
ABCA1;ABCG1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Cellular cholesterol uptake and efflux |
0.027816815 |
18 |
NaN |
|
ABCA1;SCARA3 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Cellular fatty acid uptake |
0.046898366 |
21.5 |
NaN |
|
CD36 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Cellular iron uptake and export |
0.041452288 |
24 |
NaN |
|
CP;TFRC |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Cellular iron uptake and export |
0.036831666 |
16 |
NaN |
|
CP;TFRC |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Cholesterol synthesis |
6.20E-16 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;NSDHL;SC5D;SQLE |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Cholesterol synthesis |
0.000715545 |
1 |
NaN |
|
HMGCS1;MSMO1;MVD;MVK |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.011933343 |
13 |
NaN |
|
INSIG1;SREBF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Classical complement pathway |
0.016384575 |
15 |
NaN |
|
C1R;C1S |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Classical complement pathway |
0.006997877 |
7 |
NaN |
|
C1QB;C1QC |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Classical complement pathway |
0.005105448 |
4.5 |
NaN |
|
C1QA;C1QC |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Collagen fiber crosslinking |
0.006365168 |
8.5 |
NaN |
|
LOXL1;PXDN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Collagen fiber crosslinking |
0.008112355 |
9.5 |
NaN |
|
LOXL1;PXDN |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Collagen fiber crosslinking |
0.005350837 |
5 |
NaN |
|
LOXL1;PXDN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.011933343 |
13 |
NaN |
|
COL14A1;COL9A3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008957388 |
11.5 |
NaN |
|
COL9A2;COL9A3 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005061213 |
4.5 |
NaN |
|
COL12A1;COL14A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006278564 |
5 |
NaN |
|
COL12A1;COL14A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005200747 |
3.5 |
NaN |
|
COL12A1;COL14A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005875567 |
5 |
NaN |
|
COL14A1;COL9A2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Contractile ring constriction |
0.006365168 |
8.5 |
NaN |
|
MYH14;MYLK |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Contractile ring constriction |
0.008112355 |
9.5 |
NaN |
|
MYH14;MYLK |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Decorin synthesis |
0.024435427 |
13.5 |
NaN |
|
DCN |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Decorin synthesis |
0.025317572 |
20.5 |
NaN |
|
DCN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Decorin synthesis |
0.016055046 |
11 |
NaN |
|
DCN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Desaturation of fatty acids |
2.39E-05 |
2 |
NaN |
|
FADS1;FADS2;SCD;SCD5 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
DNA replication initiation |
0.02604878 |
19 |
NaN |
|
CDC45;GINS2;MCM7 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
DNA replication initiation |
0.022313229 |
11 |
NaN |
|
CDC45;CDC6;MCM5 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
DNA replication initiation |
0.003344472 |
5 |
NaN |
|
CDC45;CDC6;MCM5;MCM6 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Elastin cross-linking and assembly |
0.047400097 |
21 |
NaN |
|
LOX |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Endogenous control of complement activity |
0.006365168 |
8.5 |
NaN |
|
CFH;CFI |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Endogenous control of complement activity |
0.005666345 |
5.5 |
NaN |
|
CFH;CFI |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Endogenous control of complement activity |
0.008112355 |
9.5 |
NaN |
|
CFH;CFI |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Endogenous control of complement activity |
0.006072761 |
9.5 |
NaN |
|
CFH;CFI |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Endothelin receptor signaling |
0.006997877 |
7 |
NaN |
|
ECE1;EDN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Endothelin receptor signaling |
0.008668292 |
6.5 |
NaN |
|
ECE1;EDN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Epithelial intermediate filament dynamics |
0.021425951 |
16.5 |
NaN |
|
KRT19;KRT7 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.000346395 |
1 |
NaN |
|
KRT19;KRT4;KRT7 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Epithelial intermediate filament dynamics |
0.011397983 |
9 |
NaN |
|
KRT19;KRT7 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.010676413 |
7.5 |
NaN |
|
KRT19;KRT7 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.000325881 |
1 |
NaN |
|
NPPA;NPPB;NPR1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.008957388 |
11.5 |
NaN |
|
NPPA;NPPB |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Natriuretic peptide receptor signaling |
0.007900936 |
7 |
NaN |
|
NPPA;NPPB |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Notch receptor signaling |
0.001546422 |
3 |
NaN |
|
DLK1;JAG1;LFNG;NOTCH3 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Notch receptor signaling |
0.012093552 |
7 |
NaN |
|
DLK1;JAG1;LFNG |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Notch receptor signaling |
0.013306061 |
14 |
NaN |
|
DLK1;JAG1;LFNG |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Notch receptor signaling |
0.01117202 |
9 |
NaN |
|
DLK1;LFNG;NOTCH3 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Osteonectin receptor signaling |
0.002414572 |
3 |
NaN |
|
SMOC2;SPOCK1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Osteopontin receptor signaling |
0.018877911 |
14.5 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Osteopontin receptor signaling |
0.021083275 |
12.5 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.016055046 |
11 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.019142555 |
11.5 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Osteopontin receptor signaling |
0.020377558 |
14 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.030213822 |
22 |
NaN |
|
FOSL1;PDGFRB |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.017439282 |
12 |
NaN |
|
PDGFRA;TNK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.02147651 |
15.5 |
NaN |
|
PDGFRA;TNK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.017904373 |
9 |
NaN |
|
PDGFRA;TNK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Potassium transmembrane transport |
0.019988845 |
10 |
NaN |
|
KCNE4;KCNK2;KCNK5 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.037401081 |
20.5 |
NaN |
|
PTGFR |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.031853721 |
16.5 |
NaN |
|
PTGFR |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.037920328 |
17 |
NaN |
|
PTGFR |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.040341633 |
22 |
NaN |
|
PTGFR |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Regulation of coagulation cascade by protein C |
0.002414572 |
3 |
NaN |
|
PROCR;THBD |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Removal of caspase inhibition |
0.037401081 |
20.5 |
NaN |
|
XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Removal of caspase inhibition |
0.031853721 |
16.5 |
NaN |
|
XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.037920328 |
17 |
NaN |
|
XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.040341633 |
22 |
NaN |
|
XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Restriction point |
0.023521317 |
12 |
NaN |
|
CCND2;E2F1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Retinol metabolism |
0.043307043 |
21.5 |
NaN |
|
DHRS3;RLBP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Retinol metabolism |
0.003441711 |
4 |
NaN |
|
ALDH1A1;DHRS3;RLBP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Retinol metabolism |
0.041452288 |
24 |
NaN |
|
DHRS3;RLBP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Retinol metabolism |
0.036831666 |
16 |
NaN |
|
DHRS3;RLBP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
RIG-I-like receptor signaling |
0.003705518 |
7 |
NaN |
|
DDX58;DHX58 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Roundabout signaling |
0.012331868 |
13 |
NaN |
|
ROBO2;ROBO3 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Serine and glycine metabolism |
0.031591061 |
20 |
NaN |
|
SHMT2;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Serine and glycine metabolism |
0.028290753 |
15 |
NaN |
|
GLDC;PSAT1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.000204921 |
3 |
NaN |
|
GLDC;PHGDH;SHMT2;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.002278637 |
3 |
NaN |
|
GLDC;PSAT1;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Serine and glycine metabolism |
0.001893039 |
3 |
NaN |
|
PHGDH;SHMT2;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Serotonin inactivation |
0.048275867 |
19.5 |
NaN |
|
MAOA |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Serotonin inactivation |
0.049996342 |
28.5 |
NaN |
|
MAOA |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Serotonin inactivation |
0.040341633 |
22 |
NaN |
|
MAOA |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Syndecan ectodomain shedding |
0.003705518 |
7 |
NaN |
|
ADAMTS1;MMP7 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Thrombospondin receptor signaling |
0.002075737 |
3 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Thrombospondin receptor signaling |
0.002582626 |
3 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.001505846 |
2 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.00213372 |
2 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Thrombospondin receptor signaling |
0.002414572 |
3 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Tight junction organization |
0.04605371 |
20 |
NaN |
|
CRB2;CRB3;MYLK |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Tight junction organization |
0.03142457 |
19 |
NaN |
|
CGNL1;CLDN4;CLDN6 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Tropoelastin synthesis |
0.025935074 |
18 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Tropoelastin synthesis |
0.024435427 |
13.5 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Tropoelastin synthesis |
0.029375441 |
18 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.025317572 |
20.5 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.020377558 |
14 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Urea cycle |
0.011933343 |
13 |
NaN |
|
ARG2;ASS1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Versican receptor signaling |
0.037401081 |
20.5 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Versican receptor signaling |
0.041723865 |
19 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Versican receptor signaling |
0.037920328 |
17 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Versican receptor signaling |
0.040341633 |
22 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Versican synthesis |
0.018877911 |
14.5 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Versican synthesis |
0.021083275 |
12.5 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Versican synthesis |
0.019142555 |
11.5 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Versican synthesis |
0.020377558 |
14 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
ER unfolded protein response pathway |
0.006735652 |
6.5 |
NaN |
|
DDIT3;PPP1R15A |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.023360518 |
17 |
NaN |
|
ADAMTS10;ADAMTS2;ADAMTS6 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
1.17E-06 |
1 |
NaN |
|
ADAM19;ADAM33;ADAMTS1;ADAMTS12;ADAMTS2;ADAMTS5;ADAMTS9 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.0005693 |
5 |
NaN |
|
ADAM33;ADAMTS1;ADAMTS14;ADAMTS2;ADAMTS5 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
2.29E-05 |
2 |
NaN |
|
ADAM19;ADAM33;ADAMTS1;ADAMTS2;ADAMTS5;ADAMTS9 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
1.59E-05 |
1 |
NaN |
|
ADAM19;ADAMTS1;ADAMTS12;ADAMTS2;ADAMTS5;ADAMTS9 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.010408866 |
7 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS8 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Extracellular matrix breakdown by cathepsins |
0.014446446 |
10.5 |
NaN |
|
CTSF;CTSZ |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Extracellular matrix breakdown by cathepsins |
0.017816642 |
10 |
NaN |
|
CTSF;CTSZ |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown by cathepsins |
0.014834304 |
8 |
NaN |
|
CTSB;CTSZ |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016704296 |
10 |
NaN |
|
CTSF;CTSZ |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.020445489 |
17.5 |
NaN |
|
MMP1;MMP7 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.013543754 |
9 |
NaN |
|
MMP14;MMP2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Extracellular matrix breakdown by serine proteases |
0.006997877 |
7 |
NaN |
|
KLK5;PRSS12 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Extracellular matrix breakdown by serine proteases |
0.008668292 |
6.5 |
NaN |
|
KLK5;PRSS12 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown by serine proteases |
0.007189535 |
5 |
NaN |
|
KLK5;PRSS12 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by serine proteases |
0.008115724 |
6 |
NaN |
|
KLK5;PRSS12 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Fatty acid transfer between membranes |
0.047400097 |
21 |
NaN |
|
FABP3 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.001809764 |
4.5 |
NaN |
|
COL11A2;COL1A2;COL3A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.00152477 |
2.5 |
NaN |
|
COL11A2;COL1A2;COL3A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.002585183 |
7 |
NaN |
|
COL11A2;COL1A2;COL5A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.025134697 |
19 |
NaN |
|
COL1A2;COL3A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.001401225 |
2 |
NaN |
|
COL11A2;COL1A2;COL2A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.014446446 |
10.5 |
NaN |
|
COL11A1;COL1A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Fibrillar collagen core structure organization |
0.000995243 |
2 |
NaN |
|
COL1A1;COL2A1;COL5A2 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.000751664 |
1 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Fibulin receptor signaling |
0.048275867 |
19.5 |
NaN |
|
FBLN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.049996342 |
28.5 |
NaN |
|
FBLN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Fibulin receptor signaling |
0.046898366 |
21.5 |
NaN |
|
FBLN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Filopodium organization |
0.000104201 |
1 |
NaN |
|
DAAM2;FMNL2;GAP43;RHOU;TNK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
GABA metabolism |
0.005061213 |
4.5 |
NaN |
|
ABAT;SLC6A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
GABA metabolism |
0.003685571 |
3 |
NaN |
|
ABAT;SLC6A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
GABA metabolism |
0.005200747 |
3.5 |
NaN |
|
ABAT;SLC6A1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Gap junction organization |
0.049677703 |
23.5 |
NaN |
|
GJA5;GJA8 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Gap junction organization |
0.044617901 |
16.5 |
NaN |
|
GJA5;GJA8 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Gap junction organization |
0.047569054 |
26 |
NaN |
|
GJA1;GJA8 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Gap junction organization |
0.042309999 |
18.5 |
NaN |
|
GJA5;GJA8 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.043307043 |
21.5 |
NaN |
|
SLC1A5;SLC7A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.041452288 |
24 |
NaN |
|
SLC1A5;SLC7A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.036831666 |
16 |
NaN |
|
SLC1A3;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Glutamate-mediated control of postsynaptic potential |
0.025388614 |
14 |
NaN |
|
GRID2;GRIN2D;GRIN3A |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Glycolysis and Gluconeogenesis |
0.01780527 |
9 |
NaN |
|
ENO1;HK2;LDHA |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Glycolysis and Gluconeogenesis |
0.00243598 |
4 |
NaN |
|
ENO1;HK2;LDHA;PCK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049996342 |
28.5 |
NaN |
|
JAK2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.021394782 |
16 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.020445489 |
17.5 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Growth differentiation factor receptor signaling |
0.009215038 |
9 |
NaN |
|
GDF2;GDF6 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Growth differentiation factor receptor signaling |
0.006735652 |
6.5 |
NaN |
|
GDF2;GDF6 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Growth differentiation factor receptor signaling |
0.010676413 |
7.5 |
NaN |
|
GDF2;GDF6 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Hepatocyte growth factor receptor signaling |
0.048275867 |
19.5 |
NaN |
|
HGF |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.031853721 |
16.5 |
NaN |
|
HGF |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.040341633 |
22 |
NaN |
|
HGF |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Hippo signaling |
0.022960869 |
12 |
NaN |
|
AMOTL1;CRB2;CRB3 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Hyaluronan synthesis |
0.047400097 |
21 |
NaN |
|
HAS2 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Inhibin receptor signaling |
0.01692739 |
14 |
NaN |
|
INHBE;TGFBR3 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Inhibin receptor signaling |
0.015114208 |
8 |
NaN |
|
INHBB;INHBE |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.021425951 |
16.5 |
NaN |
|
INHBE;TGFBR3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Inhibin receptor signaling |
0.016169721 |
15.5 |
NaN |
|
INHBB;INHBE |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Inhibin receptor signaling |
0.014292788 |
10 |
NaN |
|
INHBA;TGFBR3 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.000760969 |
1 |
NaN |
|
MME;PLAT |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Inhibition of apoptosis |
0.015221369 |
8 |
NaN |
|
BIRC3;XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Inhibition of apoptosis |
0.023853258 |
17 |
NaN |
|
BIRC3;XAF1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Inhibition of matrix metalloproteinase and adamalysin activity |
0.047400097 |
21 |
NaN |
|
TIMP1 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Insulin receptor signaling |
0.023465436 |
14 |
NaN |
|
IRS2;PIK3CD |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Interferon alpha receptor signaling |
0.01692739 |
14 |
NaN |
|
IRF9;STAT1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Interferon alpha receptor signaling |
0.016169721 |
15.5 |
NaN |
|
IRF9;STAT1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.000361252 |
2 |
NaN |
|
SOCS2;SOCS3;STAT1;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Up |
JAK-STAT signaling pathway |
0.044617901 |
16.5 |
NaN |
|
SOCS2;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
1.67E-05 |
1 |
NaN |
|
SOCS2;SOCS3;STAT1;STAT3;STAT4 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Leptin receptor signaling |
0.003885554 |
6 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Leptin receptor signaling |
0.003705518 |
7 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Lipogenesis |
0.000860401 |
6 |
NaN |
|
ACLY;FASN |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Lysine metabolism |
0.047400097 |
21 |
NaN |
|
LOX |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Macrophage migration inhibitory factor signaling |
0.008112355 |
9.5 |
NaN |
|
ACKR3;JUND |
| rosiglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Methionine cycle |
0.031853721 |
16.5 |
NaN |
|
BHMT |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Methionine cycle |
0.037920328 |
17 |
NaN |
|
BHMT |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Microfibril scaffold organization |
0.037401081 |
20.5 |
NaN |
|
FBN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Microfibril scaffold organization |
0.041723865 |
19 |
NaN |
|
FBN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Microfibril scaffold organization |
0.037920328 |
17 |
NaN |
|
FBN1 |
| rosiglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Mitotic chromosome condensation |
0.012914996 |
11.5 |
NaN |
|
INCENP;NCAPG2 |
| rosiglitazone |
Antidiabetic |
No |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.041284933 |
25 |
NaN |
|
AMER1;DKK2;PAX6;SFRP2 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.034993337 |
10 |
NaN |
|
DKK2;FZD7;SFRP2;WNT9A |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Z-disc organization |
0.049854732 |
14 |
NaN |
|
CSRP3;TCAP |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.005294767 |
1 |
NaN |
|
NPPA;NPPB |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Non-vesicular phospholipid transport |
0.011123733 |
9.5 |
NaN |
|
PITPNM1;PLTP |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Osteonectin receptor signaling |
0.003333624 |
5 |
NaN |
|
SPARC;SPOCK1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Osteonectin receptor signaling |
0.003480103 |
7.5 |
NaN |
|
SMOC2;SPOCK1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.019936486 |
8.5 |
NaN |
|
SPP1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Perlecan synthesis |
0.024523641 |
15 |
NaN |
|
HSPG2 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Perlecan synthesis |
0.022141849 |
12 |
NaN |
|
HSPG2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.027349088 |
17 |
NaN |
|
PDGFRB;TNK2 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.028480684 |
17 |
NaN |
|
FOSL1;TNK2 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.023542064 |
14 |
NaN |
|
FOSL1;TNK2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.020972888 |
11 |
NaN |
|
PDGFD;PDGFRA |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Potassium transmembrane transport |
0.018868897 |
8 |
NaN |
|
ATP1A2;ATP1A3;KCNQ1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Progesterone receptor signaling |
0.024523641 |
15 |
NaN |
|
PGR |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Progesterone receptor signaling |
0.02390614 |
11 |
NaN |
|
PGR |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Prostaglandin E2 receptor signaling |
0.00801527 |
6.5 |
NaN |
|
PTGER3;RAPGEF4 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Prostaglandin E2 receptor signaling |
0.006125965 |
5.5 |
NaN |
|
PTGER3;RAPGEF4 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.039477231 |
15.5 |
NaN |
|
PTGFR |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Protein polyubiquitination |
0.039518883 |
17 |
NaN |
|
ISG15;UCHL1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Removal of caspase inhibition |
0.047242835 |
15.5 |
NaN |
|
XAF1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Removal of caspase inhibition |
0.041205645 |
14.5 |
NaN |
|
XAF1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.038266416 |
11.5 |
NaN |
|
XAF1 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.044830247 |
12 |
NaN |
|
XAF1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Retinol metabolism |
0.026709042 |
11.5 |
NaN |
|
ALDH1A2;STRA6 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Retinol metabolism |
0.03758663 |
18 |
NaN |
|
ALDH1A3;STRA6 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Retinol metabolism |
0.003476939 |
6 |
NaN |
|
ALDH1A2;RLBP1;STRA6 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Selectin-mediated Leukocyte rolling |
0.006906563 |
5 |
NaN |
|
SELPLG;VCAM1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Semaphorin signaling |
0.008536055 |
8 |
NaN |
|
CRMP1;PLXNA2;PLXNA4;PLXND1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Semaphorin signaling |
0.049939927 |
22 |
NaN |
|
CRMP1;PLXNA4;PLXND1 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Semaphorin signaling |
0.038761798 |
16.5 |
NaN |
|
CRMP1;PLXNA4;PLXND1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.001299007 |
2 |
NaN |
|
PHGDH;SHMT2;SLC1A4 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.001660577 |
2 |
NaN |
|
PHGDH;SHMT2;SLC1A4 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Serotonin inactivation |
0.041205645 |
14.5 |
NaN |
|
MAOA |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Sulfonation |
0.005706386 |
9 |
NaN |
|
SULT1A1;SULT1E1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.003309507 |
4 |
NaN |
|
THBS2;THBS4 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Thrombospondin receptor signaling |
0.002980769 |
3 |
NaN |
|
THBS2;THBS4 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Tight junction organization |
0.029717612 |
13 |
NaN |
|
CGN;CLDN1;CLDN6 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Tight junction organization |
0.047331485 |
21 |
NaN |
|
CGN;CLDN6;CRB2 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Tight junction organization |
0.009201964 |
10 |
NaN |
|
CLDN11;CLDN19;CLDN6;CRB2 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Tight junction organization |
0.038761798 |
16.5 |
NaN |
|
CLDN19;CLDN6;CRB2 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Tropoelastin synthesis |
0.019936486 |
8.5 |
NaN |
|
ELN |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.023994354 |
16 |
NaN |
|
ELN |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.024523641 |
15 |
NaN |
|
ELN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.022141849 |
12 |
NaN |
|
ELN |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.041205645 |
14.5 |
NaN |
|
VIPR2 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Versican receptor signaling |
0.039477231 |
15.5 |
NaN |
|
VCAN |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Versican synthesis |
0.019936486 |
8.5 |
NaN |
|
VCAN |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Actin filament bundling and crosslinking |
0.014497956 |
5 |
NaN |
|
FSCN2;TAGLN;USH1C |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Adenylyl cyclase signaling pathway |
0.046398674 |
13 |
NaN |
|
ADCY1;RAPGEF4 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Adrenergic receptor signaling |
0.020377978 |
7 |
NaN |
|
ADCY2;RAPGEF4;RGS4 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.02390614 |
11 |
NaN |
|
ACAN |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Aggrecan synthesis |
0.020818631 |
8.5 |
NaN |
|
ACAN |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.019318984 |
6.5 |
NaN |
|
ACAN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.022671136 |
8.5 |
NaN |
|
ACAN |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.02390614 |
11 |
NaN |
|
ALB |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.020818631 |
8.5 |
NaN |
|
ALB |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.019318984 |
6.5 |
NaN |
|
ALB |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Androgen synthesis |
0.012230733 |
3 |
NaN |
|
AKR1C3;HSD17B2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.022731834 |
14 |
NaN |
|
HLA-B;HLA-C |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Antigen presentation via MHC class I molecules |
0.023680597 |
12.5 |
NaN |
|
HLA-B;HLA-C |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Antigen presentation via MHC class I molecules |
0.019543779 |
9 |
NaN |
|
HLA-B;HLA-C |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Axonal intermediate filament dynamics |
0.000440408 |
3 |
NaN |
|
NEFH;NEFL;NES |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Basement membrane assembly and organization |
0.001540682 |
5 |
NaN |
|
COL4A4;COL8A2;HSPG2 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Basement membrane assembly and organization |
0.019543779 |
9 |
NaN |
|
COL4A4;HSPG2 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Biglycan synthesis |
0.019936486 |
8.5 |
NaN |
|
BGN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Biglycan synthesis |
0.022141849 |
12 |
NaN |
|
BGN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Calcitonin receptor signaling |
0.044830247 |
12 |
NaN |
|
RAMP1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030757337 |
14 |
NaN |
|
KCNIP2;KCNJ2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.043169865 |
19.5 |
NaN |
|
KCNIP2;KCNJ2 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.044909729 |
19.5 |
NaN |
|
KCNIP2;KCNJ2 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.038938896 |
10 |
NaN |
|
KCNA1;KCNQ1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Carnitine shuttle |
0.011123733 |
9.5 |
NaN |
|
CPT1A;CPT1B |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00542891 |
5 |
NaN |
|
NOV;WISP1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004140681 |
4 |
NaN |
|
NOV;WISP1 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004893708 |
4 |
NaN |
|
NOV;WISP1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Cellular cholesterol uptake and efflux |
0.002183285 |
3 |
NaN |
|
ABCA1;ABCG1;MYLIP |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.025189984 |
9 |
NaN |
|
ABCA1;ABCG1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Centrosome duplication |
0.011956352 |
2 |
NaN |
|
CDKN1A;GADD45A;PLK2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Centrosome separation |
0.022731834 |
14 |
NaN |
|
CCNB1;NEK6 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Cholesterol synthesis |
8.84E-05 |
2 |
NaN |
|
DHCR24;DHCR7;HMGCR;MSMO1;MVD |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Cholesterol synthesis |
5.98E-06 |
2 |
NaN |
|
DHCR24;DHCR7;HMGCR;HMGCS1;MSMO1;MVD |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.00801527 |
6.5 |
NaN |
|
INSIG1;SREBF1 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.0056301 |
3 |
NaN |
|
COL9A1;COL9A3 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008072724 |
7 |
NaN |
|
COL9A2;COL9A3 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000276247 |
4 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000204193 |
4 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Contractile ring constriction |
0.005468147 |
6 |
NaN |
|
ANLN;MYH14 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Decorin synthesis |
0.02390614 |
11 |
NaN |
|
DCN |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Decorin synthesis |
0.020818631 |
8.5 |
NaN |
|
DCN |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Decorin synthesis |
0.019318984 |
6.5 |
NaN |
|
DCN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Decorin synthesis |
0.022671136 |
8.5 |
NaN |
|
DCN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Electron transport chain |
0.000110683 |
1 |
NaN |
|
COX7A1;NDUFA4;NDUFS4;NDUFV2 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Epithelial intermediate filament dynamics |
0.010236386 |
4 |
NaN |
|
KRT19;KRT4 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Epithelial intermediate filament dynamics |
0.012520391 |
7 |
NaN |
|
KRT19;KRT4 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001194517 |
2 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS8 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.019053024 |
12 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS9 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
1.07E-05 |
1 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS17;ADAMTS9 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
0.016025171 |
6 |
NaN |
|
CTSD;CTSV |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Extracellular matrix breakdown by cathepsins |
0.022731834 |
14 |
NaN |
|
CTSD;CTSV |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Extracellular matrix breakdown by cathepsins |
0.023680597 |
12.5 |
NaN |
|
CTSD;CTSV |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
0.019543779 |
9 |
NaN |
|
CTSD;CTSV |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
1.79E-05 |
1 |
NaN |
|
MMP12;MMP14;MMP2;MMP3 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.00103097 |
4 |
NaN |
|
MMP12;MMP14;MMP3 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
9.95E-07 |
1 |
NaN |
|
MMP1;MMP12;MMP14;MMP2;MMP3 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
2.71E-05 |
2 |
NaN |
|
MMP12;MMP14;MMP2;MMP3 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
3.50E-08 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
6.62E-05 |
3 |
NaN |
|
COL11A2;COL1A1;COL2A1;COL5A1 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
4.44E-05 |
3 |
NaN |
|
COL11A2;COL2A1;COL3A1;COL5A2 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
1.72E-06 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL5A1;COL5A3 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.015095412 |
4 |
NaN |
|
COL11A1;COL1A2 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Gap junction organization |
0.043169865 |
19.5 |
NaN |
|
GJA1;GJA5 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Glucuronidation |
0.02390614 |
11 |
NaN |
|
UGT2B4 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Glucuronidation |
0.020818631 |
8.5 |
NaN |
|
UGT2B4 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Glucuronidation |
0.019318984 |
6.5 |
NaN |
|
UGT2B4 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.026709042 |
11.5 |
NaN |
|
SLC1A5;SLC7A5 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Glutamate and glutamine metabolism |
0.000195395 |
3 |
NaN |
|
FOLH1;SLC1A3;SLC1A5;SLC7A5 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.039114857 |
18 |
NaN |
|
SLC1A5;SLC7A5 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.032432748 |
15 |
NaN |
|
SLC1A3;SLC1A5 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.000177835 |
2 |
NaN |
|
ALDOA;LDHA;PCK2;PGK1;TPI1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
0.001187546 |
1 |
NaN |
|
HK2;LDHA;PGK1;TPI1 |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.014587162 |
6 |
NaN |
|
LDHA;PGK1;TPI1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.018474823 |
11 |
NaN |
|
INPP5D;STAT3 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.019252614 |
11 |
NaN |
|
SOCS3;STAT3 |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.047242835 |
15.5 |
NaN |
|
MET |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.044830247 |
12 |
NaN |
|
MET |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Inhibition of apoptosis |
0.024826363 |
12 |
NaN |
|
IFI6;XAF1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Inositol metabolism and transport |
0.047415046 |
22.5 |
NaN |
|
INPP5D |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Integrin-mediated leukocyte rolling |
0.009528592 |
6 |
NaN |
|
SELPLG;VCAM1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.044909729 |
19.5 |
NaN |
|
SOCS3;STAT3 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Leptin receptor signaling |
0.003480103 |
7.5 |
NaN |
|
SOCS3;STAT3 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Up |
Lipogenesis |
0.047415046 |
22.5 |
NaN |
|
FASN |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Up |
Lipogenesis |
0.048447984 |
21 |
NaN |
|
FASN |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Up |
Lipogenesis |
0.043795347 |
18 |
NaN |
|
FASN |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Methionine cycle |
0.047242835 |
15.5 |
NaN |
|
BHMT |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Methionine cycle |
0.041205645 |
14.5 |
NaN |
|
BHMT |
| rituximab |
Monoclonal antibody |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.047242835 |
15.5 |
NaN |
|
FBN1 |
| rituximab |
Monoclonal antibody |
No |
MSN08 |
Down |
Microfibril scaffold organization |
0.038266416 |
11.5 |
NaN |
|
FBN1 |
| rituximab |
Monoclonal antibody |
No |
MSN06 |
Down |
Microtubule polymerization |
0.006125965 |
5.5 |
NaN |
|
DCLK1;TUBA1A |
| rituximab |
Monoclonal antibody |
No |
MSN09 |
Down |
Microtubule polymerization |
0.00723107 |
5 |
NaN |
|
DCLK1;TUBA1A |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
ER unfolded protein response pathway |
0.010676413 |
5.5 |
NaN |
|
ATF4;HERPUD1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
ER unfolded protein response pathway |
0.011766804 |
7.5 |
NaN |
|
ATF4;HERPUD1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
1.66E-09 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;KNSTRN;MTUS2;NDC80;NUF2;SPC24;TTK;ZWINT |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Eukaryotic kinetochore dynamics |
3.18E-05 |
4 |
NaN |
|
BUB1;CENPE;CENPF;MTUS2;NDC80;NUF2;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
0.015101604 |
15 |
NaN |
|
BUB1;CENPE;CENPF;MTUS2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
2.70E-07 |
3 |
NaN |
|
BUB1;CENPE;CENPF;MTUS2;NDC80;NUF2;SPC24;TTK;ZWINT |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.022540734 |
23 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS2 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.021936586 |
16 |
NaN |
|
ADAMTS12;ADAMTS15;ADAMTS2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.020755752 |
22 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS2 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.014567791 |
8 |
NaN |
|
MMP1;MMP14 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown by serine proteases |
0.012331868 |
13 |
NaN |
|
PRSS12;ST14 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fanconi anemia interstrand cross-link repair pathway |
0.02789576 |
30 |
NaN |
|
BRIP1;FANCI;UBE2T |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.001739908 |
12 |
NaN |
|
COL11A1;COL2A1;COL5A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
6.52E-05 |
5 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
7.49E-05 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
6.90E-05 |
6 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.000901583 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
3.72E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
2.89E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.001044316 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fibroblast growth factor receptor signaling |
0.025616672 |
13 |
NaN |
|
FGF10;FGF18 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
G2 M transition checkpoint |
0.003070918 |
14 |
NaN |
|
CCNB1;CDC25B;CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
G2 M transition checkpoint |
0.033409737 |
22 |
NaN |
|
CCNB1;CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
G2 M transition checkpoint |
0.03430279 |
28 |
NaN |
|
CCNB1;CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Gap junction organization |
0.034355742 |
15.5 |
NaN |
|
GJA3;GJA5 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Gap junction organization |
0.002388906 |
6 |
NaN |
|
GJA3;GJA5;GJA8 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.027816815 |
11 |
NaN |
|
SLC1A5;SLC7A5 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.029857781 |
14 |
NaN |
|
SLC38A2;SLC7A5 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.02648975 |
14 |
NaN |
|
SLC38A2;SLC7A5 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039304304 |
17 |
NaN |
|
JUND |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.042414608 |
15 |
NaN |
|
JUND |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.025582216 |
26.5 |
NaN |
|
HMMR |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.024788285 |
25 |
NaN |
|
HMMR |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibin receptor signaling |
0.010676413 |
5.5 |
NaN |
|
INHBE;TGFBR3 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Inhibin receptor signaling |
0.010149397 |
10 |
NaN |
|
INHBB;TGFBR3 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Inhibin receptor signaling |
0.011766804 |
7.5 |
NaN |
|
INHBB;TGFBR3 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.032023829 |
12 |
NaN |
|
SOCS2;STAT1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
JAK-STAT signaling pathway |
0.034355742 |
15.5 |
NaN |
|
SOCS2;SOCS3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Lipogenesis |
0.048275867 |
24 |
NaN |
|
FASN |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Lipogenesis |
0.049996342 |
22.5 |
NaN |
|
FASN |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Macrophage migration inhibitory factor signaling |
0.003770283 |
7.5 |
NaN |
|
CXCR4;JUND |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Macrophage migration inhibitory factor signaling |
0.004385018 |
5 |
NaN |
|
CXCR4;JUND |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
MAPK signaling pathway |
0.006805386 |
19 |
NaN |
|
FOXM1;MAP2K3;MAP2K6;PEBP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
MAPK signaling pathway |
0.037367454 |
29 |
NaN |
|
FOXM1;MAP2K3;MAP2K6 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
1.98E-05 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Metaphase to anaphase checkpoint |
1.47E-05 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Metaphase to anaphase checkpoint |
0.000184953 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
1.62E-05 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Methionine cycle |
0.040341633 |
14 |
NaN |
|
BHMT |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Methionine cycle |
0.041896574 |
19 |
NaN |
|
BHMT |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Methionine cycle |
0.039304304 |
17 |
NaN |
|
BHMT |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Methionine cycle |
0.042414608 |
15 |
NaN |
|
BHMT |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Microfibril scaffold organization |
0.039304304 |
17 |
NaN |
|
FBN1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Microtubule destabilization |
0.009139439 |
20 |
NaN |
|
KIF2C;STMN1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Microtubule destabilization |
0.008598393 |
18 |
NaN |
|
KIF2C;STMN1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.006197282 |
17 |
NaN |
|
AURKB;CCNA2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.005827311 |
15.5 |
NaN |
|
AURKB;CCNA2 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle assembly |
1.15E-05 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle assembly |
0.000209572 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle assembly |
0.00380409 |
8 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic spindle assembly |
9.88E-06 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.025582216 |
26.5 |
NaN |
|
CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle disassembly |
0.024435427 |
19 |
NaN |
|
CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic spindle disassembly |
0.024788285 |
25 |
NaN |
|
CDK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Muscarinic receptor signaling |
0.008957388 |
10.5 |
NaN |
|
CHRM4;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Muscarinic receptor signaling |
0.008598393 |
18 |
NaN |
|
CHRM4;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Myofibril formation |
0.016704296 |
8 |
NaN |
|
DES;MYOZ1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Myofibril formation |
0.017957896 |
9.5 |
NaN |
|
DES;MYOZ1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Myofibril formation |
0.018384589 |
9.5 |
NaN |
|
DES;MYOZ1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.005875567 |
4 |
NaN |
|
NPPA;NPPB |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.006329822 |
6 |
NaN |
|
NPPA;NPPB |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.0055816 |
9 |
NaN |
|
NPPA;NPPB |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.006484773 |
6 |
NaN |
|
NPPA;NPPB |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Non-vesicular phospholipid transport |
0.008738546 |
7 |
NaN |
|
PITPNM1;PLTP |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Notch receptor signaling |
0.012093552 |
15 |
NaN |
|
DLK1;JAG1;NOTCH3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Osteonectin receptor signaling |
0.002604019 |
3.5 |
NaN |
|
SPARC;SPOCK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Osteonectin receptor signaling |
0.00229214 |
4.5 |
NaN |
|
SPARC;SPOCK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Osteonectin receptor signaling |
0.00266871 |
4 |
NaN |
|
SPARC;SPOCK1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.025582216 |
26.5 |
NaN |
|
SPP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.024435427 |
19 |
NaN |
|
SPP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.025317572 |
18 |
NaN |
|
SPP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.024788285 |
25 |
NaN |
|
SPP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.030213822 |
20 |
NaN |
|
PDGFRA;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.002145083 |
11 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Polyol pathway |
0.003455479 |
9 |
NaN |
|
AKR1A1;SORD |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Polyol pathway |
0.003705518 |
7 |
NaN |
|
AKR1A1;SORD |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Polyol pathway |
0.003554482 |
13.5 |
NaN |
|
AKR1A1;SORD |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Progesterone receptor signaling |
0.019848271 |
12.5 |
NaN |
|
PGR |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.041896574 |
19 |
NaN |
|
PTGFR |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.039304304 |
17 |
NaN |
|
PTGFR |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.042414608 |
15 |
NaN |
|
PTGFR |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Proteasomal regulatory particle organization |
0.012580282 |
21.5 |
NaN |
|
PSMC4;PSMD14 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Proteasomal regulatory particle organization |
0.011520133 |
13.5 |
NaN |
|
PSMC4;PSMD14 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Proteasomal regulatory particle organization |
0.012331868 |
13 |
NaN |
|
PSMC4;PSMD14 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Proteasomal regulatory particle organization |
0.011841806 |
20.5 |
NaN |
|
PSMC4;PSMD14 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Protein folding in mitochondria |
0.001923604 |
13 |
NaN |
|
HSPD1;PPIF |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Retinol metabolism |
0.001904718 |
3 |
NaN |
|
RDH10;RPE65;STRA6 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Retinol metabolism |
0.03055135 |
12 |
NaN |
|
RDH10;STRA6 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serine and glycine metabolism |
4.95E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.001363561 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.019170669 |
11 |
NaN |
|
PHGDH;SHMT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.001413291 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serotonin inactivation |
0.040341633 |
14 |
NaN |
|
MAOA |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serotonin inactivation |
0.041896574 |
19 |
NaN |
|
MAOA |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serotonin inactivation |
0.039304304 |
17 |
NaN |
|
MAOA |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Serotonin inactivation |
0.042414608 |
15 |
NaN |
|
MAOA |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000652251 |
10.5 |
NaN |
|
NUF2;TACC3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid attachment to mitotic spindle |
0.048275867 |
24 |
NaN |
|
NUF2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000612326 |
9 |
NaN |
|
NUF2;TACC3 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid segregation |
0.000312969 |
8.5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid segregation |
0.000273321 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid segregation |
0.000303507 |
5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Sister chromatid segregation |
0.000285148 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.002604019 |
3.5 |
NaN |
|
THBS1;THBS4 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Thrombospondin receptor signaling |
0.00229214 |
4.5 |
NaN |
|
THBS1;THBS4 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.020377558 |
10 |
NaN |
|
ELN |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.021171489 |
11.5 |
NaN |
|
ELN |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.019848271 |
12.5 |
NaN |
|
ELN |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.021436133 |
11 |
NaN |
|
ELN |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.040341633 |
14 |
NaN |
|
VIPR1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.041896574 |
19 |
NaN |
|
VIPR1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.042414608 |
15 |
NaN |
|
VIPR1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Versican receptor signaling |
0.041896574 |
19 |
NaN |
|
VCAN |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Versican synthesis |
0.021171489 |
11.5 |
NaN |
|
VCAN |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.019844862 |
16 |
NaN |
|
CTHRC1;DKK2;FRZB;SFRP5;WNT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.001120405 |
6 |
NaN |
|
APCDD1;CTHRC1;FRZB;PAX6;SFRP4;SFRP5;WNT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.000990707 |
10 |
NaN |
|
APCDD1;CTHRC1;DACT1;DKK2;FRZB;SFRP5;WNT2 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Z-disc organization |
0.000252154 |
2 |
NaN |
|
CSRP3;DES;MYOZ1;PDLIM3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Z-disc organization |
0.004279574 |
5 |
NaN |
|
DES;MYOZ1;PDLIM3 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Z-disc organization |
0.00030602 |
1 |
NaN |
|
CSRP3;DES;MYOZ1;PDLIM3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Aggrecan synthesis |
0.024435427 |
19 |
NaN |
|
ACAN |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Aggrecan synthesis |
0.025317572 |
18 |
NaN |
|
ACAN |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Aggrecan synthesis |
0.024788285 |
25 |
NaN |
|
ACAN |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.025582216 |
26.5 |
NaN |
|
ALB |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.016704296 |
8 |
NaN |
|
HLA-B;HLA-C |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.017957896 |
9.5 |
NaN |
|
HLA-B;HLA-C |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.000835187 |
2 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.018384589 |
9.5 |
NaN |
|
HLA-B;HLA-C |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Apoptosome assembly |
0.006197282 |
17 |
NaN |
|
BAG3;CDC6 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Down |
Aspartate and arginine metabolism |
0.016704296 |
8 |
NaN |
|
ARG2;SLC7A1 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Down |
Betaglycan signaling |
0.003770283 |
7.5 |
NaN |
|
SMAD6;TGFBR3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Biglycan synthesis |
0.024435427 |
19 |
NaN |
|
BGN |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome maturation |
0.000176562 |
7 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome maturation |
0.002695833 |
8 |
NaN |
|
AURKA;PLK1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome maturation |
0.035660258 |
21 |
NaN |
|
PLK1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome maturation |
0.002807996 |
12 |
NaN |
|
AURKA;PLK1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome separation |
7.50E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome separation |
5.44E-10 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome separation |
2.28E-06 |
2 |
NaN |
|
CCNB1;ESPL1;KIF11;NEK2;SPAG5 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome separation |
6.01E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Chaperone-mediated autophagy |
0.000652251 |
10.5 |
NaN |
|
HSP90AA1;HSPA8 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Chaperone-mediated autophagy |
0.048275867 |
24 |
NaN |
|
HSPA8 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Chaperone-mediated autophagy |
0.049996342 |
22.5 |
NaN |
|
HSPA8 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cholesterol synthesis |
3.89E-07 |
3 |
NaN |
|
DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MVD;NSDHL |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol synthesis |
3.79E-15 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;NSDHL;SQLE |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cholesterol synthesis |
5.81E-15 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;NSDHL;SQLE |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cholesterol synthesis |
1.26E-08 |
2 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MVD;NSDHL |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000312969 |
8.5 |
NaN |
|
COL14A1;COL9A2;COL9A3 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008362857 |
12 |
NaN |
|
COL9A2;COL9A3 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008957388 |
10.5 |
NaN |
|
COL9A2;COL9A3 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008598393 |
18 |
NaN |
|
COL9A2;COL9A3 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Contractile ring constriction |
0.000159506 |
6 |
NaN |
|
ANLN;ECT2;MYH14 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring constriction |
0.005666345 |
10.5 |
NaN |
|
ANLN;MYH14 |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Contractile ring constriction |
0.006072761 |
9 |
NaN |
|
ANLN;MYH14 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Contractile ring constriction |
0.00014524 |
7 |
NaN |
|
ANLN;ECT2;MYH14 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Contractile ring formation |
0.006197282 |
17 |
NaN |
|
MYH14;RACGAP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring formation |
0.005666345 |
10.5 |
NaN |
|
MYH14;RACGAP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Contractile ring formation |
0.005827311 |
15.5 |
NaN |
|
MYH14;RACGAP1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cytosolic protein folding |
0.025582216 |
26.5 |
NaN |
|
HSP90AA1 |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Decorin synthesis |
0.025582216 |
26.5 |
NaN |
|
DCN |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Decorin synthesis |
0.024435427 |
19 |
NaN |
|
DCN |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Decorin synthesis |
0.025317572 |
18 |
NaN |
|
DCN |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Decorin synthesis |
0.024788285 |
25 |
NaN |
|
DCN |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Desaturation of fatty acids |
0.012580282 |
21.5 |
NaN |
|
FADS2;SCD |
| regorafenib |
Kinase inhibitor |
No |
MSN05 |
Up |
Desaturation of fatty acids |
0.011520133 |
13.5 |
NaN |
|
FADS2;SCD |
| regorafenib |
Kinase inhibitor |
No |
MSN06 |
Up |
Desaturation of fatty acids |
0.012331868 |
13 |
NaN |
|
FADS2;SCD |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Desaturation of fatty acids |
0.011841806 |
20.5 |
NaN |
|
FADS2;SCD |
| regorafenib |
Kinase inhibitor |
No |
MSN01 |
Up |
Equatorial RhoA activation |
0.003782172 |
15 |
NaN |
|
ECT2;KIF23 |
| regorafenib |
Kinase inhibitor |
No |
MSN08 |
Up |
Equatorial RhoA activation |
0.003554482 |
13.5 |
NaN |
|
ECT2;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.002291272 |
1 |
NaN |
|
CHRNA1;UTRN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Actin filament bundling and crosslinking |
0.002124398 |
2 |
NaN |
|
FHOD1;FLNB;SYNPO;SYNPO2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Actin filament bundling and crosslinking |
0.002187303 |
9 |
NaN |
|
ACTN1;ACTN4;PLS3;SYNPO;TAGLN |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.010673959 |
3.5 |
NaN |
|
ALB |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Alternative complement pathway |
0.012307779 |
18.5 |
NaN |
|
C1S;CFH |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Androgen receptor signaling |
0.043622809 |
18.5 |
NaN |
|
AR |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Base excision repair |
0.000932089 |
14 |
NaN |
|
EME1;FEN1;NEIL3;PCNA;POLQ |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Biglycan synthesis |
0.022494707 |
9 |
NaN |
|
BGN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Biglycan synthesis |
0.023641496 |
19 |
NaN |
|
BGN |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Biglycan synthesis |
0.036432604 |
27.5 |
NaN |
|
BGN |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.022230064 |
18 |
NaN |
|
BGN |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Biglycan synthesis |
0.020465773 |
23.5 |
NaN |
|
BGN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Calcitonin receptor signaling |
0.042414608 |
10.5 |
NaN |
|
RAMP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Cardiomyocyte depolarization during action potential |
0.010673959 |
3.5 |
NaN |
|
SCN5A |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.010765432 |
18.5 |
NaN |
|
CACNA1G;HCN4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.022717669 |
7 |
NaN |
|
KCNJ12;KCNJ2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Caveolin-mediated endocytosis |
0.04996016 |
16 |
NaN |
|
CAV1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00045452 |
4 |
NaN |
|
CTGF;CYR61;WISP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.043967869 |
26 |
NaN |
|
CD44 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Cell cycle arrest in response to DNA damage |
0.021145298 |
11 |
NaN |
|
CDKN1A;GADD45A;MDM2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Cell cycle arrest in response to DNA damage |
0.004004263 |
20 |
NaN |
|
CHEK2;FBXO5;H2AFX;UHRF1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Cellular cholesterol uptake and efflux |
0.032195057 |
15 |
NaN |
|
SCARA3;VLDLR |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Cellular iron uptake and export |
0.03055135 |
9 |
NaN |
|
RASD1;SLC39A14 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Cellular iron uptake and export |
0.033150099 |
12 |
NaN |
|
RASD1;SLC39A14 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Cellular iron uptake and export |
0.003656435 |
6 |
NaN |
|
RASD1;SLC39A14;TFRC |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Cellular iron uptake and export |
0.019689026 |
6 |
NaN |
|
RASD1;SLC39A14 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Centrosome duplication |
0.031104825 |
30 |
NaN |
|
CCNF;PLK4;STIL |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Centrosome maturation |
0.031435723 |
23.5 |
NaN |
|
PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Centrosome maturation |
0.02804976 |
22.5 |
NaN |
|
PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Centrosome maturation |
0.027637833 |
13 |
NaN |
|
PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Centrosome maturation |
7.44E-05 |
7.5 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Centrosome maturation |
0.000242684 |
9.5 |
NaN |
|
AURKA;BORA;PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Centrosome organization |
0.002716449 |
18 |
NaN |
|
ASPM;NEK2;PLK4;POC1A;STIL;TACC3;WDR62 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Centrosome separation |
5.73E-05 |
4 |
NaN |
|
CCNB1;CDK1;KIF11;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Centrosome separation |
1.20E-06 |
3 |
NaN |
|
CCNB1;CDK1;ESPL1;KIF11;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Centrosome separation |
1.15E-06 |
2 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Centrosome separation |
1.35E-08 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Centrosome separation |
1.34E-09 |
4 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Chaperone mediated protein folding in ER |
0.044399281 |
13 |
NaN |
|
ERO1A;ERO1B |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Chaperone-mediated autophagy |
0.049308339 |
14.5 |
NaN |
|
HSPA8 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Cholesterol synthesis |
0.000106652 |
2 |
NaN |
|
CYP51A1;HMGCR;HMGCS1;MSMO1;SQLE |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Cholesterol synthesis |
0.004409512 |
3 |
NaN |
|
DHCR24;HMGCS1;MSMO1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Chondroitin sulfate and dermatan sulfate synthesis |
0.00982368 |
4 |
NaN |
|
SERPIND1;SOX9 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Citric acid cycle |
0.033150099 |
12 |
NaN |
|
IDH2;PDHA1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Class switch recombination |
0.040400304 |
12 |
NaN |
|
BCL6;IRF8 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Classical complement pathway |
0.024624794 |
23.5 |
NaN |
|
C1R;C1S |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Collagen fiber crosslinking |
0.012307779 |
18.5 |
NaN |
|
LOX;PXDN |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.0087173 |
8 |
NaN |
|
COL12A1;COL9A2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007844056 |
11 |
NaN |
|
COL14A1;COL19A1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000884463 |
6 |
NaN |
|
COL12A1;COL14A1;COL9A3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005925252 |
16.5 |
NaN |
|
COL14A1;COL9A1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Contractile ring constriction |
0.005312003 |
7.5 |
NaN |
|
ANLN;ECT2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Contractile ring constriction |
0.012307779 |
18.5 |
NaN |
|
ANLN;MYLK |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.004708979 |
11.5 |
NaN |
|
ANLN;ECT2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Contractile ring constriction |
0.007281219 |
22 |
NaN |
|
ANLN;ECT2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.022494707 |
9 |
NaN |
|
DCN |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Decorin synthesis |
0.036432604 |
27.5 |
NaN |
|
DCN |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Decorin synthesis |
0.022230064 |
18 |
NaN |
|
DCN |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
DNA cleavage |
0.023717846 |
21 |
NaN |
|
FEN1;HMGB2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
DNA cleavage |
0.02030943 |
20.5 |
NaN |
|
FEN1;HMGB2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
DNA replication elongation |
3.44E-09 |
2 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
DNA replication elongation |
1.61E-08 |
5 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
DNA replication initiation |
7.22E-13 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM2;MCM3;MCM4;MCM5;MCM6;MCM7 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
DNA replication initiation |
4.16E-16 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM4;MCM5;MCM6;MCM7;ORC1;ORC6;TICRR |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Endogenous control of complement activity |
0.00481941 |
3 |
NaN |
|
CFH;CFI |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Endogenous control of complement activity |
0.012307779 |
18.5 |
NaN |
|
CFH;CFI |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Epidermal growth factor receptor signaling |
0.014285498 |
5 |
NaN |
|
AREG;ERRFI1;LRIG2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Equatorial RhoA activation |
0.003237663 |
6 |
NaN |
|
ECT2;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Equatorial RhoA activation |
0.002867401 |
10 |
NaN |
|
ECT2;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Equatorial RhoA activation |
0.00445029 |
21 |
NaN |
|
ECT2;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Mitotic spindle assembly |
2.47E-07 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Mitotic spindle assembly |
0.010454835 |
15.5 |
NaN |
|
NUSAP1;TACC3;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Mitotic spindle assembly |
1.71E-07 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Mitotic spindle assembly |
5.58E-06 |
3 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TPX2;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Mitotic spindle assembly |
0.000105704 |
10 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Mitotic spindle assembly |
6.39E-07 |
7 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Mitotic spindle disassembly |
0.023641496 |
19 |
NaN |
|
CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Mitotic spindle disassembly |
0.022230064 |
18 |
NaN |
|
CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Mitotic spindle disassembly |
0.022053634 |
9.5 |
NaN |
|
CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Mitotic spindle disassembly |
0.020465773 |
23.5 |
NaN |
|
CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Mitotic spindle disassembly |
0.027787579 |
28 |
NaN |
|
CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.006484773 |
4 |
NaN |
|
NPPA;NPPB |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.007067944 |
3 |
NaN |
|
NPPA;NPPB |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.000291184 |
3 |
NaN |
|
NPPA;NPPB;NPR3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Natriuretic peptide receptor signaling |
0.004093177 |
2 |
NaN |
|
NPPA;NPPB |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Natriuretic peptide receptor signaling |
0.018019436 |
21.5 |
NaN |
|
NPPA;NPPB |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Neuregulin receptor signaling |
0.023366841 |
11 |
NaN |
|
ERBB4;SH3TC2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Notch receptor signaling |
0.005289729 |
12 |
NaN |
|
DLK1;JAG1;LFNG;NOTCH3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Nuclear envelope maintenance |
0.007844056 |
11 |
NaN |
|
LMNB1;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Nuclear envelope maintenance |
0.006960163 |
13.5 |
NaN |
|
LMNB1;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Nuclear intermediate filaments |
0.007844056 |
11 |
NaN |
|
LMNB1;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Nuclear intermediate filaments |
0.006960163 |
13.5 |
NaN |
|
LMNB1;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Nuclear intermediate filaments |
0.005925252 |
16.5 |
NaN |
|
LMNB1;LMNB2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Nuclear intermediate filaments |
0.01072213 |
24 |
NaN |
|
LMNB1;LMNB2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Nucleosome assembly |
0.000935608 |
13 |
NaN |
|
ASF1B;CHAF1A;CHAF1B;H2AFZ |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Nucleosome assembly |
0.002879543 |
19 |
NaN |
|
ASF1B;CHAF1A;CHAF1B;H2AFZ |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Osteonectin receptor signaling |
0.002935166 |
2 |
NaN |
|
SMOC2;SPARC |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Osteonectin receptor signaling |
0.000186869 |
2.5 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.022230064 |
18 |
NaN |
|
SPP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Osteopontin receptor signaling |
0.020465773 |
23.5 |
NaN |
|
SPP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Osteopontin receptor signaling |
0.027787579 |
28 |
NaN |
|
SPP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Perlecan synthesis |
0.021436133 |
8 |
NaN |
|
HSPG2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Perlecan synthesis |
0.022406493 |
8 |
NaN |
|
HSPG2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Phosphoglyceride biosynthesis |
0.02407108 |
10 |
NaN |
|
PCYT2;PTDSS1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.024248529 |
11 |
NaN |
|
PDGFRA;PDGFRB |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.026605409 |
22 |
NaN |
|
PDGFD;RGS5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.000467333 |
5 |
NaN |
|
PDGFB;PDGFRA;PDGFRB;TNK2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Procollagen processing in the ER |
0.003876672 |
10.5 |
NaN |
|
P3H1;SERPINH1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Progesterone receptor signaling |
0.036432604 |
27.5 |
NaN |
|
PGR |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Progesterone receptor signaling |
0.022230064 |
18 |
NaN |
|
PGR |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Progesterone receptor signaling |
0.022053634 |
9.5 |
NaN |
|
PGR |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Purinergic P1 receptor signaling |
0.04996016 |
16 |
NaN |
|
ADORA1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Pyrimidine synthesis and salvage |
0.032051473 |
25 |
NaN |
|
TK1;TYMS |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Pyrimidine synthesis and salvage |
0.012425035 |
7 |
NaN |
|
TK1;TYMS |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Pyrimidine synthesis and salvage |
0.010765432 |
18.5 |
NaN |
|
TK1;TYMS |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Pyrimidine synthesis and salvage |
0.019291933 |
25 |
NaN |
|
TK1;TYMS |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Restriction point |
0.022108594 |
15 |
NaN |
|
CDK6;E2F1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Retinol metabolism |
0.033150099 |
12 |
NaN |
|
DHRS3;TTR |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Retinol metabolism |
1.02E-05 |
1 |
NaN |
|
ALDH1A1;ALDH1A3;CYP26A1;DHRS3;RLBP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Ribonucleotide reduction |
0.00123431 |
14 |
NaN |
|
RRM1;RRM2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
RIG-I-like receptor signaling |
0.042022559 |
12 |
NaN |
|
MAVS |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Semaphorin signaling |
0.006368335 |
6 |
NaN |
|
CRMP1;DPYSL4;SEMA3D;SEMA6A |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Serine and glycine metabolism |
0.02030943 |
20.5 |
NaN |
|
AMT;PHGDH |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Serotonin inactivation |
0.042414608 |
10.5 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Serotonin inactivation |
0.021234916 |
6 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Serotonin inactivation |
0.044312867 |
14.5 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Serotonin inactivation |
0.044485342 |
13 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Serotonin inactivation |
0.049308339 |
14.5 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Serotonin inactivation |
0.033588983 |
10.5 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000556884 |
5 |
NaN |
|
NUF2;TACC3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000492258 |
8 |
NaN |
|
NUF2;TACC3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.040514466 |
28.5 |
NaN |
|
TACC3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000769766 |
13 |
NaN |
|
NUF2;TACC3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Sister chromatid segregation |
0.007844056 |
11 |
NaN |
|
PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Sister chromatid segregation |
0.018019436 |
21.5 |
NaN |
|
PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Sister chromatid segregation |
0.000206611 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Sister chromatid segregation |
0.000161702 |
11 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Sister chromatid segregation |
0.000399396 |
11 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Telomere replication and maintenance |
0.009096755 |
23 |
NaN |
|
EXO1;PIF1;RECQL4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Thick myofilament organization |
0.031684058 |
9 |
NaN |
|
TTN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Thin myofilament organization |
0.008950881 |
5 |
NaN |
|
ACTA1;TNNI3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Thin myofilament organization |
0.024624794 |
23.5 |
NaN |
|
ACTA1;TPM4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Thrombospondin receptor signaling |
0.000186869 |
2.5 |
NaN |
|
THBS1;THBS2;THBS4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Thrombospondin receptor signaling |
4.27E-05 |
5 |
NaN |
|
CD47;THBS1;THBS2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Transcription termination |
0.001832472 |
5 |
NaN |
|
PCF11;SETX |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Transmembrane glucose transport |
0.042022559 |
12 |
NaN |
|
SLC2A1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Transmembrane glucose transport |
0.002912493 |
1 |
NaN |
|
SLC2A1;SLC2A4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Tropoelastin synthesis |
0.022406493 |
8 |
NaN |
|
ELN |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.022494707 |
9 |
NaN |
|
ELN |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Tropoelastin synthesis |
0.024964714 |
13 |
NaN |
|
ELN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.023641496 |
19 |
NaN |
|
ELN |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Tropoelastin synthesis |
0.036432604 |
27.5 |
NaN |
|
ELN |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.033588983 |
10.5 |
NaN |
|
VIPR2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.043967869 |
26 |
NaN |
|
VIPR1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.043622809 |
18.5 |
NaN |
|
VIPR1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Versican receptor signaling |
0.046726108 |
26.5 |
NaN |
|
VCAN |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Versican receptor signaling |
0.040514466 |
28.5 |
NaN |
|
VCAN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Versican synthesis |
0.023641496 |
19 |
NaN |
|
VCAN |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Versican synthesis |
0.020465773 |
23.5 |
NaN |
|
VCAN |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Water transmembrane transport |
0.011766804 |
6 |
NaN |
|
AQP1;AQP10 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Water transmembrane transport |
0.012808436 |
4 |
NaN |
|
AQP1;AQP10 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.014145821 |
5 |
NaN |
|
AXIN2;DKK3;KREMEN1;SFRP5;WNT9A |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.023026228 |
8 |
NaN |
|
AXIN2;DKK3;SFRP5;WNT9A |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
1.72E-12 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPU;MAD2L1;MIS18BP1;NDC80;NUF2;SKA2;SKA3;TTK;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
3.73E-10 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPU;MAD2L1;MIS18BP1;NDC80;NUF2;TTK;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Eukaryotic kinetochore dynamics |
9.97E-08 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPU;NDC80;SPC24;TTK;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
1.01E-05 |
4 |
NaN |
|
BUB1;CENPF;CENPU;MAD2L1;NDC80;SPC24;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
6.51E-13 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPI;CENPU;KIF15;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.014121703 |
7 |
NaN |
|
ADAMTS14;ADAMTS5;ADAMTS8 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.026758713 |
7 |
NaN |
|
ADAMTS14;ADAMTS5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001500564 |
8 |
NaN |
|
ADAM12;ADAM19;ADAMTS12;ADAMTS2;ADAMTS7 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.007566475 |
13 |
NaN |
|
SULF1;SULF2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.04023116 |
30 |
NaN |
|
MMP14;MMP2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.024353565 |
26 |
NaN |
|
MMP1;MMP2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.022739051 |
16 |
NaN |
|
BRCA2;BRIP1;FANCI |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.019352519 |
15 |
NaN |
|
BRCA2;FANCI;USP1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.018950674 |
8 |
NaN |
|
BRCA2;FANCD2;UBE2T |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
1.13E-05 |
5 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCG;FANCI |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
3.28E-07 |
6 |
NaN |
|
BRCA2;BRIP1;EME1;FANCA;FANCD2;FANCG;FANCI;UBE2T |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Fatty acid elongation |
0.001156554 |
4 |
NaN |
|
ELOVL6;ELOVL7;HACD1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Fatty acid omega-hydroxylation |
0.022406493 |
8 |
NaN |
|
CYP2E1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Fatty acid transfer between membranes |
0.04996016 |
16 |
NaN |
|
FABP3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Fibrillar collagen core structure organization |
1.27E-06 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Fibrillar collagen core structure organization |
8.85E-09 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.000912967 |
12 |
NaN |
|
COL1A2;COL2A1;COL3A1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.002205632 |
16 |
NaN |
|
COL1A1;COL1A2;COL2A1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Fibroblast growth factor receptor signaling |
0.027637833 |
13 |
NaN |
|
FGF1;FGF7 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Fibulin receptor signaling |
0.046726108 |
26.5 |
NaN |
|
FBLN1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Fibulin receptor signaling |
0.040514466 |
28.5 |
NaN |
|
FBLN1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
G2 M transition checkpoint |
0.031435723 |
23.5 |
NaN |
|
CCNB1;CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
G2 M transition checkpoint |
0.02804976 |
22.5 |
NaN |
|
CCNB1;CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
G2 M transition checkpoint |
0.027637833 |
13 |
NaN |
|
CCNB1;CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
G2 M transition checkpoint |
7.44E-05 |
7.5 |
NaN |
|
CCNB1;CDC25B;CDC25C;CDK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
G2 M transition checkpoint |
0.000242684 |
9.5 |
NaN |
|
CCNB1;CDC25C;CDK1;CHEK2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Galactose metabolism |
0.042022559 |
12 |
NaN |
|
GALK1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Gap junction organization |
0.037023918 |
16 |
NaN |
|
GJA3;PANX2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Gap junction organization |
0.032279631 |
26 |
NaN |
|
GJA5;GJD2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.036581377 |
25 |
NaN |
|
GLS;SLC38A2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.010454835 |
15.5 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Glycogen synthesis and glycogenolysis |
0.004431277 |
3 |
NaN |
|
GYS1;PPP1R3B;PYGM |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Glycogen synthesis and glycogenolysis |
0.012296662 |
5 |
NaN |
|
AGL;PPP1R3B |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Glycogen synthesis and glycogenolysis |
0.005015598 |
2 |
NaN |
|
AGL;GYG2;PPP1R3B |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Glycogen synthesis and glycogenolysis |
0.02930283 |
9 |
NaN |
|
AGL;PPP1R3B |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Glyoxylate metabolism |
0.044312867 |
14.5 |
NaN |
|
GRHPR |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Hepatocyte growth factor receptor signaling |
0.044485342 |
13 |
NaN |
|
HGF |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
HIF-1 receptor signaling pathway |
0.016348087 |
6 |
NaN |
|
EGLN3;HIF1A |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
HIF-1 receptor signaling pathway |
0.019911463 |
10 |
NaN |
|
EGLN1;HIF1A |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
HIF-1 receptor signaling pathway |
0.009500113 |
4 |
NaN |
|
EGLN1;HIF1A |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Histamine metabolism |
0.043967869 |
26 |
NaN |
|
HNMT |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Homologous recombination DSB repair |
0.00237953 |
15 |
NaN |
|
BRCA2;PIF1;RAD51AP1;RECQL4;RMI2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Homologous recombination DSB repair |
0.001611497 |
15 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RECQL4;XRCC2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.023641496 |
19 |
NaN |
|
HMMR |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.027787579 |
28 |
NaN |
|
HMMR |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.003876672 |
10.5 |
NaN |
|
MME;PLAT |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Inhibition of apoptosis |
0.016845643 |
5 |
NaN |
|
CFLAR;PEA15 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Inositol metabolism and transport |
0.043967869 |
26 |
NaN |
|
SLC5A3 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Insulin receptor signaling |
0.042110321 |
17 |
NaN |
|
IRS1;PIK3C2B |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Intracellular bridge assembly |
0.04996016 |
16 |
NaN |
|
NEK7 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Intracellular bridge assembly |
0.001455058 |
9 |
NaN |
|
INCENP;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Intracellular bridge assembly |
0.002266783 |
17 |
NaN |
|
INCENP;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Lipid droplet biogenesis |
3.91E-05 |
1 |
NaN |
|
FITM2;PLIN2;PLIN4;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Lipid droplet biogenesis |
0.004807987 |
2 |
NaN |
|
PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Up |
Lipid droplet biogenesis |
0.019986419 |
6 |
NaN |
|
PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Lipid droplet biogenesis |
0.020134923 |
7 |
NaN |
|
PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Lipid droplet biogenesis |
0.024483872 |
12 |
NaN |
|
PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Lipid droplet biogenesis |
0.000525812 |
1 |
NaN |
|
FITM2;PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Lipid droplet mitochondria interaction |
0.031684058 |
9 |
NaN |
|
PLIN2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Up |
Lipid droplet mitochondria interaction |
0.04996016 |
16 |
NaN |
|
PLIN2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Up |
Lysine metabolism |
0.031684058 |
9 |
NaN |
|
AASS |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
9.36E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
7.95E-06 |
4 |
NaN |
|
BUB1;BUB1B;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Metaphase to anaphase checkpoint |
7.54E-06 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MXD3;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
5.73E-05 |
6 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;MAD2L1;PTTG1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Metaphase to anaphase checkpoint |
1.04E-09 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;FBXO5;MAD2L1;MASTL;MXD3;PTTG1;TTK |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Microfibril scaffold organization |
0.044485342 |
13 |
NaN |
|
FBN1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
Microfibril scaffold organization |
0.001324238 |
7 |
NaN |
|
FBN1;MFAP2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Microfibril scaffold organization |
0.040514466 |
28.5 |
NaN |
|
MFAP2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Microtubule destabilization |
0.007844056 |
11 |
NaN |
|
KIF2C;STMN1 |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Microtubule stabilization |
0.015743705 |
9 |
NaN |
|
MAP1B;MAPRE2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Mineralocorticoid receptor signaling |
0.043967869 |
26 |
NaN |
|
NR3C2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Mitotic chromosome condensation |
0.010811186 |
14 |
NaN |
|
SMC2;SMC4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Mitotic chromosome condensation |
0.000355631 |
7 |
NaN |
|
INCENP;SMC2;SMC4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Mitotic chromosome condensation |
0.000684569 |
12 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.005312003 |
7.5 |
NaN |
|
AURKB;CCNA2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.004708979 |
11.5 |
NaN |
|
CCNA2;INCENP |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.004636036 |
5 |
NaN |
|
CCNA2;INCENP |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
8.21E-05 |
9 |
NaN |
|
AURKB;CCNA2;INCENP |
| prednisolone |
Glucocorticoid |
Yes |
MSN09 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000203897 |
8 |
NaN |
|
AURKB;CCNA2;INCENP |
| prednisolone |
Glucocorticoid |
Yes |
MSN02 |
Down |
WNT-Beta-catenin signaling pathway |
0.008408768 |
14 |
NaN |
|
CTHRC1;DACT1;DKK2;FRZB;FZD7;SFRP1;SFRP2 |
| prednisolone |
Glucocorticoid |
Yes |
MSN01 |
Up |
Z-disc organization |
0.04507252 |
12 |
NaN |
|
CSRP3;TCAP |
| prednisolone |
Glucocorticoid |
Yes |
MSN06 |
Up |
Z-disc organization |
0.049160367 |
15 |
NaN |
|
NEXN;TCAP |
| prednisolone |
Glucocorticoid |
Yes |
MSN08 |
Up |
Z-disc organization |
0.006773923 |
7 |
NaN |
|
DNAJB6;NEXN;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Z-disc organization |
4.05E-05 |
2 |
NaN |
|
CSRP3;DES;MYPN;PDLIM3;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Z-disc organization |
0.000575652 |
2 |
NaN |
|
CSRP3;MYPN;PDLIM3;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Z-disc organization |
0.000778844 |
2 |
NaN |
|
CSRP3;DES;PDLIM3;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Z-disc organization |
0.000630429 |
2 |
NaN |
|
CSRP3;MYPN;PDLIM3;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Z-disc organization |
0.000463359 |
2 |
NaN |
|
CSRP3;MYPN;PDLIM3;TCAP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic spindle disassembly |
0.020906845 |
20.5 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Mitotic spindle disassembly |
0.020377558 |
15 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Mitotic spindle disassembly |
0.018966126 |
17.5 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic spindle disassembly |
0.0200247 |
21.5 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic spindle disassembly |
0.022230064 |
16 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Muscarinic receptor signaling |
0.008957388 |
8 |
NaN |
|
CHRM4;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Myofibril formation |
0.001845347 |
3 |
6 |
Down by cardiotoxic TKIs |
DES;KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Myofibril formation |
0.025134697 |
12 |
6 |
Down by cardiotoxic TKIs |
KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Myofibril formation |
0.002126394 |
4 |
6 |
Down by cardiotoxic TKIs |
DES;KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Myofibril formation |
0.026291036 |
11.5 |
6 |
Down by cardiotoxic TKIs |
KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Myofibril formation |
0.022575326 |
8 |
6 |
Down by cardiotoxic TKIs |
KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Neuregulin receptor signaling |
0.03798877 |
7 |
NaN |
|
ERBB4;NRG1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Osteonectin receptor signaling |
0.002540098 |
11.5 |
NaN |
|
SMOC2;SPOCK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Osteopontin receptor signaling |
0.025317572 |
14 |
NaN |
|
SPP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.016055046 |
8.5 |
NaN |
|
SPP1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.002488588 |
4 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFB;PDGFRA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.002278637 |
6 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFRA;PDGFRB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.012818624 |
6 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;PDGFRB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.002864754 |
6 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFB;PDGFRA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.031591061 |
13 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFRA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Potassium transmembrane transport |
0.021936586 |
11 |
NaN |
|
ATP1A2;ATP1A3;SLC12A6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Procollagen cleavage into collagen |
0.047400097 |
16 |
NaN |
|
PCOLCE |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Progesterone receptor signaling |
0.027434721 |
11 |
NaN |
|
PGR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Protein polyubiquitination |
0.036079961 |
23 |
NaN |
|
ISG15;UCHL1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Protein polyubiquitination |
0.048125749 |
23 |
NaN |
|
ISG15;UCHL1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Ribonucleotide reduction |
0.047400097 |
16 |
NaN |
|
RRM2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Semaphorin signaling |
0.015618719 |
3 |
NaN |
|
CRMP1;DPYSL3;NRP2;SEMA6B |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serine and glycine metabolism |
5.48E-05 |
5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Serine and glycine metabolism |
0.001221097 |
6 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Serine and glycine metabolism |
3.74E-05 |
5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serine and glycine metabolism |
4.63E-05 |
5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Serine and glycine metabolism |
0.00156935 |
5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Serine and glycine metabolism |
1.94E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serotonin inactivation |
0.041378401 |
26 |
NaN |
|
MAOA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Serotonin inactivation |
0.040341633 |
19.5 |
NaN |
|
MAOA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Serotonin inactivation |
0.037574179 |
24 |
NaN |
|
MAOA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serotonin inactivation |
0.039650143 |
27.5 |
NaN |
|
MAOA |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.041378401 |
26 |
NaN |
|
NUF2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000413484 |
5 |
NaN |
|
NUF2;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000358072 |
8 |
NaN |
|
NUF2;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000399257 |
10 |
NaN |
|
NUF2;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.043967869 |
21 |
NaN |
|
NUF2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Sister chromatid segregation |
0.000172258 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Sister chromatid segregation |
0.005875567 |
11 |
NaN |
|
PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Sister chromatid segregation |
0.005107525 |
13.5 |
NaN |
|
PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Sister chromatid segregation |
0.00015158 |
9 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Sister chromatid segregation |
0.006960163 |
11.5 |
NaN |
|
PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Sodium transmembrane transport |
0.049247428 |
14 |
NaN |
|
ATP1A2;SLC5A1;SLC9A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Thick myofilament organization |
0.002210018 |
5 |
NaN |
|
MYH7;TTN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thick myofilament organization |
0.001681304 |
3 |
NaN |
|
MYH7;TTN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Thin myofilament organization |
2.36E-07 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2;TPM4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Thin myofilament organization |
1.33E-05 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Thin myofilament organization |
1.82E-05 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Thin myofilament organization |
1.46E-05 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thin myofilament organization |
1.06E-05 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.002332606 |
12.5 |
NaN |
|
THBS1;THBS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Tropoelastin synthesis |
0.025317572 |
14 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.016055046 |
8.5 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Tropoelastin synthesis |
0.027434721 |
11 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.025935074 |
9.5 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.02390614 |
12 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Vascular endothelial growth factor receptor signaling |
0.012331868 |
9 |
NaN |
|
FLT1;KDR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Vascular endothelial growth factor receptor signaling |
0.012914996 |
4 |
NaN |
|
FLT1;KDR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Versican receptor signaling |
0.043967869 |
21 |
NaN |
|
VCAN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Versican synthesis |
0.022230064 |
16 |
NaN |
|
VCAN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Water transmembrane transport |
0.018831061 |
8.5 |
9 |
Down by cardiotoxic TKIs |
AQP1;AQP3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Water transmembrane transport |
0.01692739 |
6 |
9 |
Down by cardiotoxic TKIs |
AQP1;AQP3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.000457851 |
1 |
NaN |
|
APCDD1;DKK2;DKK3;FRZB;FZD1;FZD2;FZD8;SFRP2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.033030217 |
22 |
NaN |
|
FRZB;FZD10;PAX6;SFRP2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.039120547 |
26 |
NaN |
|
FRZB;FZD10;PAX6;SFRP2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.015642737 |
4.5 |
NaN |
|
ACHE;AGRN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Actin filament bundling and crosslinking |
0.029402741 |
13.5 |
NaN |
|
FLNB;TAGLN;USH1C |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Actin filament bundling and crosslinking |
0.023408099 |
9.5 |
NaN |
|
FLNB;TAGLN;USH1C |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Adrenergic receptor signaling |
0.029402741 |
13.5 |
8 |
Down by cardiotoxic TKIs |
RASD1;RGS16;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Adrenergic receptor signaling |
0.033358365 |
13 |
8 |
Down by cardiotoxic TKIs |
PDE4D;RASD1;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Adrenergic receptor signaling |
0.023408099 |
9.5 |
8 |
Down by cardiotoxic TKIs |
GRK5;RGS16;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Aggrecan synthesis |
0.02390614 |
12 |
NaN |
|
ACAN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.020906845 |
20.5 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.020377558 |
15 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.028669725 |
6 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.018966126 |
17.5 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.0200247 |
21.5 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.022230064 |
16 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Alternative complement pathway |
0.00542891 |
4.5 |
NaN |
|
C3;CFH |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.026625456 |
11.5 |
NaN |
|
B2M;HLA-A |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Aspartate and arginine metabolism |
0.017535602 |
18 |
NaN |
|
ARG2;SLC7A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Aspartate and arginine metabolism |
0.01616 |
19 |
NaN |
|
ARG2;SLC7A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Axonal intermediate filament dynamics |
0.015642737 |
4.5 |
NaN |
|
NEFH;NEFL |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Biglycan synthesis |
0.026111503 |
10 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Biglycan synthesis |
0.025317572 |
14 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.016055046 |
8.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Biglycan synthesis |
0.027434721 |
11 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Biglycan synthesis |
0.025935074 |
9.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Biglycan synthesis |
0.02390614 |
12 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Calcitonin receptor signaling |
0.040341633 |
19.5 |
NaN |
|
CALCB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Cardiomyocyte pacemaker current generation |
0.017146691 |
8.5 |
NaN |
|
CACNA1G;HCN4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Cardiomyocyte pacemaker current generation |
0.000818308 |
3 |
NaN |
|
CACNA1D;CACNA1G;HCN4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Cardiomyocyte pacemaker current generation |
0.001033726 |
3 |
NaN |
|
CACNA1D;CACNA1G;HCN4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.01692739 |
6 |
NaN |
|
CACNA1G;HCN4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.02055093 |
12 |
NaN |
|
KCNIP2;KCNQ1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006449906 |
5 |
NaN |
|
CTGF;CYR61 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00542891 |
4.5 |
NaN |
|
CTGF;CYR61 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
CD44-Mediated leukocyte rolling |
0.047242835 |
17.5 |
NaN |
|
CD44 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Centrosome maturation |
0.001726344 |
9.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Centrosome maturation |
0.001603753 |
8.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Centrosome maturation |
5.53E-05 |
6.5 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome maturation |
6.83E-05 |
6.5 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Centrosome maturation |
0.002058279 |
6.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Centrosome organization |
0.001785173 |
9 |
NaN |
|
ASPM;ATF5;NEK2;PAX6;POC1A;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome organization |
0.011553947 |
18 |
NaN |
|
ASPM;ATF5;NEK2;PAX6;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Centrosome separation |
1.82E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Centrosome separation |
1.32E-08 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Centrosome separation |
8.56E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Centrosome separation |
1.34E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Centrosome separation |
2.22E-08 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Chloride transmembrane transport |
0.041452288 |
16 |
17 |
Down by cardiotoxic TKIs |
SLC12A6;SLC12A7 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Chloride transmembrane transport |
0.047941794 |
14 |
17 |
Down by cardiotoxic TKIs |
SLC12A6;SLC12A7 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Chloride transmembrane transport |
0.037334294 |
14 |
17 |
Down by cardiotoxic TKIs |
ANO1;SLC12A7 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006176635 |
14.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005678798 |
15 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.003685571 |
4.5 |
NaN |
|
INSIG1;SREBF1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Classical complement pathway |
0.008115724 |
12 |
NaN |
|
C1R;C1S |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Classical complement pathway |
0.013083845 |
7 |
NaN |
|
C1QB;C1QC |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Collagen fiber crosslinking |
0.006072761 |
7 |
NaN |
|
LOX;PXDN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006176635 |
14.5 |
NaN |
|
COL9A2;COL9A3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005107525 |
13.5 |
NaN |
|
COL9A2;COL9A3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006960163 |
11.5 |
NaN |
|
COL9A2;COL9A3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009508626 |
6 |
NaN |
|
COL12A1;COL14A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.003685571 |
4.5 |
NaN |
|
COL9A2;COL9A3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009384811 |
3 |
NaN |
|
COL12A1;COL14A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Contractile ring constriction |
0.004175176 |
13 |
NaN |
|
ANLN;ECT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Contractile ring constriction |
0.003448018 |
11.5 |
NaN |
|
ANLN;ECT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Contractile ring constriction |
0.003836392 |
14 |
NaN |
|
ANLN;ECT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Contractile ring constriction |
0.004708979 |
9.5 |
NaN |
|
ANLN;ECT2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Decorin synthesis |
0.020906845 |
20.5 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Decorin synthesis |
0.020377558 |
15 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.018966126 |
17.5 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Decorin synthesis |
0.0200247 |
21.5 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.022230064 |
16 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Decorin synthesis |
0.016055046 |
8.5 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Epithelial intermediate filament dynamics |
0.011215577 |
17 |
NaN |
|
KRT7;TCHH |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Epithelial intermediate filament dynamics |
0.009298267 |
15 |
NaN |
|
KRT7;TCHH |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Epithelial intermediate filament dynamics |
0.010323714 |
17 |
NaN |
|
KRT7;TCHH |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Equatorial RhoA activation |
0.002540098 |
11.5 |
NaN |
|
ECT2;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Equatorial RhoA activation |
0.002094978 |
10 |
NaN |
|
ECT2;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Equatorial RhoA activation |
0.002332606 |
12.5 |
NaN |
|
ECT2;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Equatorial RhoA activation |
0.002867401 |
8 |
NaN |
|
ECT2;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
6.30E-08 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;NUF2;TTK;ZWINT |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Eukaryotic kinetochore dynamics |
9.81E-06 |
4 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;NDC80;NUF2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
4.41E-07 |
4 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;NUF2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
6.66E-07 |
4 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;NUF2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
6.74E-09 |
1 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;NUF2;SPDL1;TTK;ZWINT |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003825399 |
7 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS5;ADAMTS7 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
0.019690847 |
13 |
NaN |
|
CTSF;CTSV |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.001505846 |
3 |
NaN |
|
SULF1;SULF2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.001204532 |
4 |
NaN |
|
MMP14;MMP2;MMP3 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.021394782 |
8 |
NaN |
|
MMP14;MMP2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.002411805 |
2 |
NaN |
|
COL2A1;COL5A1;COL5A2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.026625456 |
11.5 |
NaN |
|
COL1A1;COL1A2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Fibrillar collagen core structure organization |
0.001688656 |
5 |
NaN |
|
COL11A2;COL1A1;COL1A2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.000449564 |
2 |
NaN |
|
COL11A2;COL1A2;COL3A1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.026291036 |
11.5 |
NaN |
|
COL1A1;COL1A2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
G2 M transition checkpoint |
0.001726344 |
9.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
G2 M transition checkpoint |
0.001603753 |
8.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
G2 M transition checkpoint |
5.53E-05 |
6.5 |
NaN |
|
CCNB1;CDC25B;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
G2 M transition checkpoint |
6.83E-05 |
6.5 |
NaN |
|
CCNB1;CDC25B;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
G2 M transition checkpoint |
0.002058279 |
6.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Gap junction organization |
0.047569054 |
17 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJB2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Gap junction organization |
0.049677703 |
15 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJB2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Gap junction organization |
0.042882493 |
15.5 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJB2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.029170805 |
24 |
NaN |
|
SLC1A5;SLC7A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Glutamate and glutamine metabolism |
0.024338824 |
21 |
NaN |
|
SLC1A5;SLC7A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.026929091 |
25 |
NaN |
|
SLC1A5;SLC7A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.017800882 |
11 |
NaN |
|
GLUL;SLC1A5 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Glycogen synthesis and glycogenolysis |
0.026538471 |
13 |
NaN |
|
PPP1R3A;PYGM |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
G-protein coupled receptor signaling pathway |
0.011398387 |
6 |
NaN |
|
GRK5;RGS16;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Growth differentiation factor receptor signaling |
0.010676413 |
13 |
NaN |
|
GDF15;GDF2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Growth differentiation factor receptor signaling |
0.017146691 |
8.5 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Growth differentiation factor receptor signaling |
0.016169721 |
10 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Growth differentiation factor receptor signaling |
0.018831061 |
8.5 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Growth differentiation factor receptor signaling |
0.01692739 |
6 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Growth differentiation factor receptor signaling |
0.014496215 |
7 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Hemoglobin and myoglobin synthesis |
0.047400097 |
16 |
NaN |
|
MB |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.047242835 |
17.5 |
NaN |
|
HGF |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.020906845 |
20.5 |
NaN |
|
HMMR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.018966126 |
17.5 |
NaN |
|
HMMR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.0200247 |
21.5 |
NaN |
|
HMMR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.022230064 |
16 |
NaN |
|
HMMR |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Inhibition of apoptosis |
0.025022959 |
23 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Inhibition of apoptosis |
0.023853258 |
17 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Inhibition of apoptosis |
0.044739094 |
8 |
NaN |
|
IFI6;XAF1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Inhibition of apoptosis |
0.02085161 |
20 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Inhibition of apoptosis |
0.023086706 |
24 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Inhibition of apoptosis |
0.02804976 |
19 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Intracellular bridge assembly |
0.00128782 |
8 |
NaN |
|
INCENP;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Intracellular bridge assembly |
0.001223743 |
7 |
NaN |
|
INCENP;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Intracellular bridge assembly |
0.00118192 |
11 |
NaN |
|
INCENP;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
JAK-STAT signaling pathway |
0.032023829 |
18 |
NaN |
|
STAT1;USP18 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.042882493 |
15.5 |
NaN |
|
SOCS2;STAT4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Lipogenesis |
0.031853721 |
14 |
NaN |
|
FASN |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
3.68E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Metaphase to anaphase checkpoint |
4.48E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Metaphase to anaphase checkpoint |
1.75E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
2.65E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
5.88E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Methionine cycle |
0.041378401 |
26 |
NaN |
|
BHMT |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Methionine cycle |
0.039650143 |
27.5 |
NaN |
|
BHMT |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Methionine cycle |
0.043967869 |
21 |
NaN |
|
BHMT |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Down |
Microfibril scaffold organization |
0.049996342 |
18 |
NaN |
|
FBN1 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic chromosome condensation |
0.00852857 |
16 |
NaN |
|
INCENP;SMC4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic chromosome condensation |
0.007845779 |
16 |
NaN |
|
INCENP;SMC4 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
8.75E-05 |
6 |
NaN |
|
AURKB;CCNA2;INCENP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.003970259 |
10 |
NaN |
|
CCNA2;INCENP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.003448018 |
11.5 |
NaN |
|
AURKB;CCNA2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
7.69E-05 |
8 |
NaN |
|
AURKB;CCNA2;INCENP |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.004708979 |
9.5 |
NaN |
|
AURKB;CCNA2 |
| ponatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitotic spindle assembly |
4.30E-06 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TPX2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN02 |
Up |
Mitotic spindle assembly |
1.02E-07 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Mitotic spindle assembly |
6.67E-08 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitotic spindle assembly |
9.21E-08 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mitotic spindle assembly |
5.80E-06 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TPX2;TTK |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
ER unfolded protein response pathway |
0.00042817 |
3 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.013966639 |
7 |
NaN |
|
ADAM33;ADAMTS14;ADAMTS2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001117947 |
2 |
NaN |
|
ADAM12;ADAM33;ADAMTS14;ADAMTS2 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
6.48E-06 |
1 |
NaN |
|
ADAM12;ADAM19;ADAMTS1;ADAMTS14;ADAMTS5;ADAMTS8 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
0.022575326 |
8.5 |
NaN |
|
CTSD;CTSV |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown by cathepsins |
0.01824187 |
7 |
NaN |
|
CTSF;CTSV |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014799877 |
8 |
NaN |
|
MMP1;MMP2 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014452362 |
9 |
NaN |
|
MMP1;MMP2 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014799877 |
6 |
NaN |
|
MMP1;MMP2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.012553331 |
10 |
NaN |
|
MMP1;MMP2 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.022575326 |
8.5 |
NaN |
|
COL5A1;COL5A2 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.001031906 |
1 |
NaN |
|
COL1A1;COL5A1;COL5A3 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.015490863 |
11.5 |
NaN |
|
COL1A1;COL5A1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
1.66E-06 |
1 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Fibrillar collagen core structure organization |
1.69E-06 |
1 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.00089029 |
4 |
NaN |
|
COL11A1;COL1A2;COL3A1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
4.30E-05 |
1 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
2.06E-06 |
1 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Fibulin receptor signaling |
0.03878543 |
18 |
NaN |
|
FBLN1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Fibulin receptor signaling |
0.040168784 |
12 |
NaN |
|
FBLN1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
GABA metabolism |
0.006799947 |
7 |
NaN |
|
ABAT;SLC6A1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Gap junction organization |
0.042882493 |
17 |
NaN |
|
GJA5;GJD2 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Gap junction organization |
0.002938365 |
4 |
NaN |
|
GJA5;GJC2;GJD2 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.003235004 |
3.5 |
NaN |
|
GLUL;SLC1A5;SLC7A5 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.003167864 |
4 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.003201324 |
4 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Glutamate and glutamine metabolism |
0.003583963 |
7 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Glycogen synthesis and glycogenolysis |
0.040799919 |
14 |
NaN |
|
PPP1R3A;PYGM |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Glycolysis and Gluconeogenesis |
0.009827557 |
9 |
NaN |
|
PCK2;PGK1;TPI1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.047070608 |
21 |
NaN |
|
JUND |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.043450255 |
16.5 |
NaN |
|
JUND |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.046898366 |
19.5 |
NaN |
|
HGF |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Hepatocyte growth factor receptor signaling |
0.047070608 |
21 |
NaN |
|
HGF |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.048964244 |
23.5 |
NaN |
|
HGF |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
HIF-1 receptor signaling pathway |
0.013432039 |
7 |
NaN |
|
CITED2;EGLN3 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.000692213 |
1 |
NaN |
|
INHBB;INHBE;TGFBR3 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001342449 |
2 |
NaN |
|
A2M;PLAT |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001309537 |
2 |
NaN |
|
A2M;PLAT |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001342449 |
2 |
NaN |
|
A2M;PLAT |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001130651 |
3 |
NaN |
|
A2M;PLAT |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Inhibition of apoptosis |
0.023660622 |
9 |
NaN |
|
BIRC3;IFI6 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Insulin receptor signaling |
0.048070612 |
22 |
NaN |
|
IRS1;IRS2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Intrinsic apoptosis pathway |
0.04578962 |
21 |
NaN |
|
BBC3;BCL2L1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.042882493 |
17 |
NaN |
|
SOCS2;SOCS3 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Lipogenesis |
0.040168784 |
12 |
NaN |
|
FASN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Macrophage migration inhibitory factor signaling |
0.005389806 |
5.5 |
NaN |
|
ACKR3;JUND |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Macrophage migration inhibitory factor signaling |
0.004599768 |
5 |
NaN |
|
ACKR3;JUND |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
MAPK signaling pathway |
0.037367454 |
18 |
NaN |
|
DUSP1;MAP2K6;RPS6KA2 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Methionine cycle |
0.042241946 |
13.5 |
NaN |
|
BHMT |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.042241946 |
15.5 |
NaN |
|
FBN1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Microfibril scaffold organization |
0.041723865 |
15.5 |
NaN |
|
FBN1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.03878543 |
18 |
NaN |
|
FBN1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.040168784 |
12 |
NaN |
|
FBN1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Microtubule crosslinking and bundling |
0.007900936 |
6.5 |
NaN |
|
MAP2;MTCL1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Microtubule crosslinking and bundling |
0.007958007 |
7.5 |
NaN |
|
MAP2;MTCL1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Microtubule crosslinking and bundling |
0.000285148 |
4 |
NaN |
|
DCX;MAP2;MTCL1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Mitochondrial fission |
0.032088249 |
15 |
NaN |
|
DNM1;MTFP1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Mitotic spindle assembly |
0.03031943 |
11 |
NaN |
|
DLGAP5;NUSAP1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Myofibril formation |
0.01824187 |
9 |
NaN |
|
DES;KLHL41 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Myofibril formation |
0.017816642 |
10 |
NaN |
|
DES;KLHL41 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Myofibril formation |
0.022575326 |
8.5 |
NaN |
|
DES;KLHL41 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Myofibril formation |
0.015490863 |
11.5 |
NaN |
|
DES;KLHL41 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.005826078 |
5 |
NaN |
|
NPPB;NPR3 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.006799947 |
7 |
NaN |
|
NPPB;NPR3 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Neuregulin receptor signaling |
0.021985266 |
13.5 |
NaN |
|
ERBB3;SH3TC2 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Osteonectin receptor signaling |
5.19E-05 |
2 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Osteonectin receptor signaling |
5.25E-05 |
3 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Osteonectin receptor signaling |
3.25E-05 |
2 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Osteonectin receptor signaling |
0.002800402 |
4 |
NaN |
|
SMOC2;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Osteonectin receptor signaling |
5.92E-05 |
3 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.021347918 |
11 |
NaN |
|
SPP1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Osteopontin receptor signaling |
0.021083275 |
12 |
NaN |
|
SPP1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.021347918 |
9 |
NaN |
|
SPP1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.019583627 |
14 |
NaN |
|
SPP1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Perlecan synthesis |
0.023729711 |
11.5 |
NaN |
|
HSPG2 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Perlecan synthesis |
0.023817925 |
12.5 |
NaN |
|
HSPG2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Perlecan synthesis |
0.024788285 |
14.5 |
NaN |
|
HSPG2 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.021985266 |
13.5 |
NaN |
|
PDGFRA;PDGFRB |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Platelet-derived growth factor receptor signaling |
0.02147651 |
14 |
NaN |
|
PDGFRA;PDGFRB |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Procollagen cleavage into collagen |
0.001806833 |
5 |
NaN |
|
FURIN;PCOLCE |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Progesterone receptor signaling |
0.02390614 |
12.5 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Progesterone receptor signaling |
0.023729711 |
11.5 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Progesterone receptor signaling |
0.023817925 |
12.5 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Progesterone receptor signaling |
0.02196542 |
11 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Progesterone receptor signaling |
0.024788285 |
14.5 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Prostacycline receptor signaling |
0.047242835 |
21.5 |
NaN |
|
PTGIR |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Prostaglandin E2 receptor signaling |
0.006432927 |
5.5 |
NaN |
|
PTGER3;RAPGEF4 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Prostaglandin E2 receptor signaling |
0.006278564 |
5.5 |
NaN |
|
PTGER3;RAPGEF4 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Prostaglandin E2 receptor signaling |
0.00543729 |
6.5 |
NaN |
|
PTGER3;RAPGEF4 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Removal of caspase inhibition |
0.047242835 |
21.5 |
NaN |
|
XAF1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Removal of caspase inhibition |
0.046898366 |
19.5 |
NaN |
|
XAF1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Removal of caspase inhibition |
0.047070608 |
21 |
NaN |
|
XAF1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.048964244 |
23.5 |
NaN |
|
XAF1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Restriction point |
0.022575326 |
8.5 |
NaN |
|
CCND2;CDKN1A |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Retinoic acid receptor signaling |
0.036831666 |
16.5 |
NaN |
|
NCOR2;NR4A1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Retinoic acid receptor signaling |
0.037082638 |
17.5 |
NaN |
|
NCOR2;NR4A1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Retinoic acid receptor signaling |
0.039888032 |
19.5 |
NaN |
|
NCOR2;NR4A1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Retinol metabolism |
0.000124474 |
1 |
NaN |
|
ALDH1A1;RBP1;RPE65;STRA6 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Retinol metabolism |
0.000118607 |
1 |
NaN |
|
ALDH1A1;RBP1;RPE65;STRA6 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Retinol metabolism |
0.003235004 |
3.5 |
NaN |
|
ALDH1A1;ALDH1A3;RLBP1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Retinol metabolism |
0.002345434 |
3 |
NaN |
|
ALDH1A1;ALDH1A3;RBP1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Retinol metabolism |
8.91E-05 |
1 |
NaN |
|
ALDH1A1;RBP1;RPE65;STRA6 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Retinol metabolism |
0.027593758 |
10 |
NaN |
|
ALDH1A2;RPE65 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Semaphorin signaling |
0.046903595 |
19 |
NaN |
|
DPYSL2;NRP2;PLXNB3 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.00193367 |
2 |
NaN |
|
GLDC;PHGDH;SLC1A5 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.02679052 |
15 |
NaN |
|
SHMT2;SLC1A5 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Serine and glycine metabolism |
0.026976171 |
16 |
NaN |
|
SHMT2;SLC1A5 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.023192176 |
14.5 |
NaN |
|
PHGDH;SHMT2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.002145083 |
6 |
NaN |
|
PHGDH;SHMT2;SLC1A5 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Serotonin inactivation |
0.047242835 |
21.5 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Serotonin inactivation |
0.042241946 |
13.5 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Serotonin inactivation |
0.046898366 |
19.5 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Serotonin inactivation |
0.047070608 |
21 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Serotonin inactivation |
0.048964244 |
23.5 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Sulfonation |
0.004349703 |
4 |
NaN |
|
SULT1A1;SULT1E1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Sulfonation |
0.004244577 |
4 |
NaN |
|
SULT1A1;SULT1E1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Sulfonation |
0.003672154 |
5 |
NaN |
|
SULT1A1;SULT1E1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Thin myofilament organization |
0.008668292 |
7.5 |
NaN |
|
ACTA1;TNNI3 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Thin myofilament organization |
0.011045214 |
6 |
NaN |
|
ACTA1;TNNI3 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Thrombospondin receptor signaling |
0.002647061 |
3 |
NaN |
|
THBS1;THBS2 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Thrombospondin receptor signaling |
0.002582626 |
3 |
NaN |
|
THBS1;THBS2 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Thrombospondin receptor signaling |
0.002232086 |
4 |
NaN |
|
THBS1;THBS2 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Tropoelastin synthesis |
0.02390614 |
12.5 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.023729711 |
11.5 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Tropoelastin synthesis |
0.023817925 |
12.5 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.02196542 |
11 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.024788285 |
14.5 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.042241946 |
15.5 |
NaN |
|
VIPR1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041723865 |
15.5 |
NaN |
|
VIPR1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.042241946 |
13.5 |
NaN |
|
VIPR1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.03878543 |
18 |
NaN |
|
VIPR1 |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Versican receptor signaling |
0.047242835 |
21.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Versican receptor signaling |
0.046898366 |
19.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Versican receptor signaling |
0.047070608 |
21 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Versican receptor signaling |
0.043450255 |
16.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Versican receptor signaling |
0.048964244 |
23.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Versican synthesis |
0.02390614 |
12.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Versican synthesis |
0.023729711 |
11.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Versican synthesis |
0.023817925 |
12.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Versican synthesis |
0.02196542 |
11 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Versican synthesis |
0.024788285 |
14.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Vitamin D metabolism |
0.003309507 |
5 |
NaN |
|
CYP24A1;CYP27A1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Z-disc organization |
0.044738024 |
17 |
NaN |
|
DES;TCAP |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Z-disc organization |
0.043740316 |
17 |
NaN |
|
DES;TCAP |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Z-disc organization |
0.044738024 |
16 |
NaN |
|
DES;TCAP |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Z-disc organization |
0.038254008 |
16 |
NaN |
|
DES;TCAP |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Adherens junction organization |
0.009287954 |
6 |
NaN |
|
ARVCF;CDH1;CDH3;RND3 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.023729711 |
11.5 |
NaN |
|
ACAN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Aggrecan synthesis |
0.023817925 |
12.5 |
NaN |
|
ACAN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.02196542 |
11 |
NaN |
|
ACAN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.024788285 |
14.5 |
NaN |
|
ACAN |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.021347918 |
11 |
NaN |
|
ALB |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.021083275 |
12 |
NaN |
|
ALB |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.021347918 |
9 |
NaN |
|
ALB |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.019583627 |
14 |
NaN |
|
ALB |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Amyloid plaque organization |
0.023192176 |
14.5 |
NaN |
|
APBB2;HSPB6 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Axonal intermediate filament dynamics |
0.008668292 |
7.5 |
NaN |
|
NEFH;NES |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Axonal intermediate filament dynamics |
0.007514323 |
8 |
NaN |
|
NEFH;NES |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Basement membrane assembly and organization |
0.022419283 |
9 |
NaN |
|
COL8A2;HSPG2 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Biglycan synthesis |
0.021347918 |
11 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Biglycan synthesis |
0.021083275 |
12 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Biglycan synthesis |
0.02390614 |
12.5 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Biglycan synthesis |
0.021347918 |
9 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Biglycan synthesis |
0.019583627 |
14 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.042882493 |
17 |
NaN |
|
KCNIP2;KCNJ2 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005350837 |
5 |
NaN |
|
CTGF;CYR61 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005389806 |
5.5 |
NaN |
|
CTGF;CYR61 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000101352 |
2 |
NaN |
|
CTGF;CYR61;NOV |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005827311 |
8 |
NaN |
|
CTGF;CYR61 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Cell cycle arrest in response to DNA damage |
0.018503677 |
8 |
NaN |
|
CDKN1A;H2AFX;UHRF1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Cell cycle arrest in response to DNA damage |
0.020755752 |
10 |
NaN |
|
BBC3;CDKN1A;H2AFX |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.036831666 |
16.5 |
NaN |
|
ARL4C;SCARA3 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Cellular cholesterol uptake and efflux |
0.037082638 |
17.5 |
NaN |
|
ARL4C;SCARA3 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Cellular cholesterol uptake and efflux |
0.039888032 |
19.5 |
NaN |
|
ARL4C;SCARA3 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Centrosome separation |
0.02416119 |
11 |
NaN |
|
NEK6;SPAG5 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
Chaperone-mediated autophagy |
0.042241946 |
13.5 |
NaN |
|
HSPA8 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006432927 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006278564 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.00543729 |
6.5 |
NaN |
|
INSIG1;SREBF1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Classical complement pathway |
0.000430925 |
3 |
NaN |
|
C1QA;C1QB;C1QC |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Classical complement pathway |
1.04E-05 |
2 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Classical complement pathway |
0.000343307 |
3 |
NaN |
|
C1QB;C1QC;C1R |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Classical complement pathway |
1.22E-05 |
2 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007900936 |
6.5 |
NaN |
|
COL12A1;COL14A1 |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007958007 |
7.5 |
NaN |
|
COL12A1;COL14A1 |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006799947 |
7 |
NaN |
|
COL12A1;COL14A1 |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.008598393 |
9 |
NaN |
|
COL12A1;COL14A1 |
| pioglitazone |
Antidiabetic |
No |
MSN01 |
Down |
Decorin synthesis |
0.023729711 |
11.5 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
MSN02 |
Down |
Decorin synthesis |
0.023817925 |
12.5 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
MSN05 |
Down |
Decorin synthesis |
0.020289344 |
8 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Down |
Decorin synthesis |
0.02196542 |
11 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
MSN09 |
Down |
Decorin synthesis |
0.024788285 |
14.5 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
MSN08 |
Up |
ER unfolded protein response pathway |
0.011674098 |
5 |
NaN |
|
DDIT3;PPP1R15A |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Actin filament bundling and crosslinking |
0.03875272 |
11.5 |
NaN |
|
FLNA;SYNPO;TAGLN |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Actin filament bundling and crosslinking |
0.026192093 |
9 |
NaN |
|
FLNB;TAGLN;USH1C |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Actin filament bundling and crosslinking |
0.022080775 |
11 |
NaN |
|
SYNPO;TAGLN;USH1C |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Actin filament bundling and crosslinking |
0.025011128 |
10.5 |
NaN |
|
FLNB;TAGLN;USH1C |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Actin filament bundling and crosslinking |
0.021433264 |
10 |
NaN |
|
FLNB;TAGLN;USH1C |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Actin polymerization |
0.020226356 |
5 |
NaN |
|
ACTA1;CYFIP2;FMNL2;HSPB1 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Actin polymerization |
0.003464661 |
3 |
NaN |
|
ABRA;ACTA1;CYFIP2;ENAH;FMNL2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Actin polymerization |
0.002684457 |
2 |
NaN |
|
ABRA;ACTA1;CYFIP2;ENAH;FMNL2 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Adrenergic receptor signaling |
0.03875272 |
11.5 |
NaN |
|
PPP1R9B;RASD1;RGS4 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.014555399 |
9 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.019936486 |
14 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.021347918 |
15 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.020465773 |
14.5 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.021612562 |
13.5 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Alternative complement pathway |
0.004349703 |
8.5 |
NaN |
|
C1S;CFH |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Alternative complement pathway |
0.004004069 |
9.5 |
NaN |
|
C1S;CFH |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.016025171 |
10 |
NaN |
|
HLA-B;HLA-C |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.01824187 |
13 |
NaN |
|
HLA-B;HLA-C |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Biglycan synthesis |
0.024964714 |
7.5 |
NaN |
|
BGN |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Biglycan synthesis |
0.024523641 |
8.5 |
NaN |
|
BGN |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Biglycan synthesis |
0.023112209 |
11.5 |
NaN |
|
BGN |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Cardiomyocyte depolarization during action potential |
0.023376853 |
12.5 |
NaN |
|
SCN5A |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.017084419 |
13 |
NaN |
|
KCNA1;KCNQ5 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030757337 |
19 |
NaN |
|
KCNA1;KCNJ2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.032279631 |
16 |
NaN |
|
KCNA1;KCNJ2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005706386 |
6 |
NaN |
|
CYR61;NOV |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005081819 |
5 |
NaN |
|
CYR61;NOV |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.042241946 |
18.5 |
NaN |
|
CD44 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Cellular fatty acid uptake |
0.048447984 |
14.5 |
NaN |
|
CD36 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Cellular fatty acid uptake |
0.045692235 |
17.5 |
NaN |
|
CD36 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Centrosome maturation |
0.022896737 |
17 |
NaN |
|
PLK1;TPX2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Centrosome separation |
0.000846027 |
3.5 |
NaN |
|
CDK1;ESPL1;KIF11 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Centrosome separation |
0.000912967 |
4.5 |
NaN |
|
ESPL1;KIF11;NEK6 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Centrosome separation |
0.018671484 |
12 |
NaN |
|
ESPL1;NEK6 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Chaperone-mediated autophagy |
0.049308339 |
13 |
NaN |
|
HSPA8 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Cholesterol synthesis |
0.010727279 |
7 |
NaN |
|
FDFT1;NSDHL;SQLE |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Cholesterol synthesis |
0.008661663 |
10 |
NaN |
|
DHCR24;DHCR7;MVD |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Chondroitin sulfate and dermatan sulfate synthesis |
0.010579453 |
5.5 |
NaN |
|
CHST11;SERPIND1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Classical complement pathway |
0.000315641 |
1 |
NaN |
|
C1QB;C1QC;C1S |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Classical complement pathway |
0.000278703 |
2 |
NaN |
|
C1QB;C1QC;C1S |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Classical complement pathway |
0.000327312 |
2 |
NaN |
|
C1QB;C1QC;C1S |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.0087173 |
2.5 |
NaN |
|
COL12A1;COL14A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007506811 |
6.5 |
NaN |
|
COL14A1;COL9A2 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
5.86E-05 |
2 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.0056301 |
7 |
NaN |
|
COL9A1;COL9A3 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005925252 |
11 |
NaN |
|
COL9A1;COL9A3 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.00658905 |
9 |
NaN |
|
COL9A1;COL9A3 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Decorin synthesis |
0.014555399 |
9 |
NaN |
|
DCN |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Decorin synthesis |
0.019936486 |
14 |
NaN |
|
DCN |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Decorin synthesis |
0.021347918 |
15 |
NaN |
|
DCN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Desaturation of fatty acids |
0.016104585 |
8.5 |
NaN |
|
FADS2;FADS3 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Electron transport chain |
0.045993416 |
14 |
NaN |
|
UQCR10;UQCR11 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Epithelial intermediate filament dynamics |
0.015743705 |
4 |
NaN |
|
KRT19;KRT7 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Epithelial intermediate filament dynamics |
0.013889809 |
8.5 |
NaN |
|
KRT19;KRT7 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Epithelial intermediate filament dynamics |
0.015218327 |
7 |
NaN |
|
KRT19;KRT7 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Epithelial intermediate filament dynamics |
0.013590977 |
9 |
NaN |
|
KRT19;KRT7 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
ER unfolded protein response pathway |
0.001227822 |
3 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
ER unfolded protein response pathway |
0.013889809 |
8.5 |
NaN |
|
DDIT3;HERPUD1 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Mitotic spindle assembly |
0.026709042 |
18 |
NaN |
|
DLGAP5;TPX2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Mitotic spindle disassembly |
0.019936486 |
14 |
NaN |
|
CDK1 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Muscarinic receptor signaling |
0.011727351 |
5.5 |
NaN |
|
CHRM4;RGS4 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.011727351 |
5.5 |
NaN |
|
NPPA;NPPB |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.0087173 |
2.5 |
NaN |
|
NPPA;NPPB |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Natriuretic peptide receptor signaling |
0.007674569 |
4 |
NaN |
|
NPPA;NPR3 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.000276247 |
1 |
NaN |
|
NPPA;NPPB;NPR3 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Natriuretic peptide receptor signaling |
0.007506811 |
6.5 |
NaN |
|
NPPA;NPR3 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Nodal growth differentiation factor receptor signaling |
0.046379866 |
10.5 |
NaN |
|
LEFTY2;TGIF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Nodal growth differentiation factor receptor signaling |
0.041174069 |
15.5 |
NaN |
|
LEFTY2;NCLN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Notch receptor signaling |
0.01930118 |
10 |
NaN |
|
JAG2;NOTCH1;NOTCH3 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Osteopontin receptor signaling |
0.014555399 |
9 |
NaN |
|
SPP1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Osteopontin receptor signaling |
0.021347918 |
15 |
NaN |
|
SPP1 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.020465773 |
14.5 |
NaN |
|
SPP1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Osteopontin receptor signaling |
0.021612562 |
13.5 |
NaN |
|
SPP1 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.03906502 |
13 |
NaN |
|
PDGFB;TNK2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.001813406 |
2 |
NaN |
|
PDGFB;PDGFRB;TNK2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.028480684 |
12 |
NaN |
|
PDGFB;PDGFRB |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.02550613 |
13 |
NaN |
|
PDGFB;PDGFRB |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.010624967 |
5 |
NaN |
|
PDGFD;RGS5 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.019331602 |
11 |
NaN |
|
PDGFD;PDGFRA |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.02030943 |
13 |
NaN |
|
PDGFD;PDGFRA |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Procollagen cleavage into collagen |
0.043037442 |
19 |
NaN |
|
PCOLCE |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Progesterone receptor signaling |
0.014555399 |
9 |
NaN |
|
PGR |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.028900203 |
15.5 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.039477231 |
21.5 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.042241946 |
18.5 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.040514466 |
18 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.042759886 |
17 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Protein polyubiquitination |
0.010329076 |
4 |
NaN |
|
ISG15;UBE2S;UCHL1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Regulation of coagulation cascade by protein C |
0.003096266 |
3.5 |
NaN |
|
PROS1;THBD |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Removal of caspase inhibition |
0.042241946 |
18.5 |
NaN |
|
XAF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.040514466 |
18 |
NaN |
|
XAF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.042759886 |
17 |
NaN |
|
XAF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Retinol metabolism |
0.014783725 |
12 |
NaN |
|
ALDH1A1;ALDH1A3 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Retinol metabolism |
9.55E-05 |
2 |
NaN |
|
ALDH1A1;ALDH1A3;DHRS3;TTR |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Retinol metabolism |
0.002345434 |
5 |
NaN |
|
DHRS3;RBP1;TTR |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Retinol metabolism |
0.002079214 |
7 |
NaN |
|
DHRS3;RBP1;TTR |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Retinol metabolism |
0.00242926 |
5 |
NaN |
|
DHRS3;RBP1;TTR |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Serine and glycine metabolism |
0.000197902 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.001146233 |
5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Serine and glycine metabolism |
5.04E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Serine and glycine metabolism |
6.23E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Serotonin inactivation |
0.039477231 |
21.5 |
NaN |
|
MAOA |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Serotonin inactivation |
0.00045389 |
2 |
NaN |
|
MAOA;MAOB |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Serotonin inactivation |
0.000417079 |
3 |
NaN |
|
MAOA;MAOB |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Serotonin inactivation |
0.000465237 |
3 |
NaN |
|
MAOA;MAOB |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.039477231 |
21.5 |
NaN |
|
NUF2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Sodium transmembrane transport |
0.036972701 |
14 |
NaN |
|
ATP1A2;SCN1A;SCN2A |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Syndecan ectodomain shedding |
0.002647061 |
6.5 |
NaN |
|
ADAMTS1;MMP9 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Syndecan receptor signaling |
0.003803269 |
6 |
NaN |
|
SDC1;SDC3 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Syndecan receptor signaling |
0.004349703 |
8.5 |
NaN |
|
SDC1;SDC3 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Syndecan receptor signaling |
0.004004069 |
9.5 |
NaN |
|
SDC1;SDC3 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Syndecan receptor signaling |
0.004456057 |
8 |
NaN |
|
SDC1;SDC3 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Thin myofilament organization |
2.30E-05 |
1 |
NaN |
|
ACTA1;TNNI3;TPM2;TPM4 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Thin myofilament organization |
0.000500164 |
1 |
NaN |
|
ACTA1;LMOD3;TPM2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Thin myofilament organization |
0.010579453 |
5.5 |
NaN |
|
ACTA1;TPM2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Thin myofilament organization |
0.000474665 |
2 |
NaN |
|
ACTA1;LMOD3;TPM2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Thin myofilament organization |
0.010350023 |
8 |
NaN |
|
ACTA1;LMOD3 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Thrombospondin receptor signaling |
0.003166583 |
3 |
NaN |
|
THBS2;THBS4 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.003480103 |
4 |
NaN |
|
THBS2;THBS4 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Thrombospondin receptor signaling |
0.003096266 |
3.5 |
NaN |
|
THBS2;THBS4 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Tight junction organization |
0.044377602 |
17 |
NaN |
|
CGN;CLDN6;CRB2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Tropoelastin synthesis |
0.024964714 |
7.5 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.023376853 |
12.5 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.024523641 |
8.5 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.023112209 |
11.5 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.014555399 |
9 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Vascular endothelial growth factor receptor signaling |
0.016104585 |
8.5 |
NaN |
|
VEGFA;VEGFB |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.048447984 |
14.5 |
NaN |
|
VIPR2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.045692235 |
17.5 |
NaN |
|
VIPR2 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.028900203 |
15.5 |
NaN |
|
VIPR2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Versican receptor signaling |
0.039477231 |
21.5 |
NaN |
|
VCAN |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Versican synthesis |
0.019936486 |
14 |
NaN |
|
VCAN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.004895688 |
4 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS5 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001537967 |
4 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS5;ADAMTS6 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012470268 |
12 |
NaN |
|
ADAM33;ADAMTS12;ADAMTS5 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.002647061 |
6.5 |
NaN |
|
SULF1;SULF2 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.002435279 |
8 |
NaN |
|
SULF1;SULF2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.002712266 |
7 |
NaN |
|
SULF1;SULF2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.012989342 |
9 |
NaN |
|
MMP1;MMP2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.014799877 |
12 |
NaN |
|
MMP1;MMP9 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.015151071 |
11 |
NaN |
|
MMP1;MMP2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.024483872 |
6 |
NaN |
|
COL2A1;COL5A2 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
8.49E-06 |
1 |
NaN |
|
COL11A1;COL11A2;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.000846027 |
3.5 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.001031906 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.000912967 |
4.5 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.001069423 |
4 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Filopodium organization |
0.017785355 |
10 |
NaN |
|
FMNL2;MYL9;TNK2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Glutamate and glutamine metabolism |
0.035834633 |
14 |
NaN |
|
SLC1A3;SLC7A5 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.028900203 |
15.5 |
NaN |
|
JAK2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.042241946 |
18.5 |
NaN |
|
JUND |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.043037442 |
19 |
NaN |
|
HBEGF |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Hippo signaling |
0.025011128 |
10.5 |
NaN |
|
AMOTL1;CRB2;PTPN14 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.019936486 |
14 |
NaN |
|
HMMR |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001608121 |
1 |
NaN |
|
A2M;MME |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001572131 |
1 |
NaN |
|
A2M;MME |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.000625725 |
3 |
NaN |
|
MME;PLAT |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Inhibition of apoptosis |
0.001623789 |
6 |
NaN |
|
BIRC5;IFI6;XAF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Inhibition of apoptosis |
0.026619198 |
15 |
NaN |
|
BIRC5;XAF1 |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Intracellular bridge assembly |
0.043037442 |
19 |
NaN |
|
NEK7 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.046379866 |
10.5 |
NaN |
|
SOCS3;STAT4 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.041174069 |
15.5 |
NaN |
|
SOCS2;STAT4 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.004345619 |
5 |
NaN |
|
SOCS2;STAT3;STAT4 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
JAK-STAT signaling pathway |
0.040330112 |
15 |
NaN |
|
SOCS2;STAT4 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Lipogenesis |
0.040514466 |
18 |
NaN |
|
FASN |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
Lipogenesis |
0.042759886 |
17 |
NaN |
|
FASN |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Up |
Mammalian target of rapamycin signaling pathway |
0.012276145 |
7 |
NaN |
|
DDIT4;EIF4EBP1;FKBP8 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Methionine cycle |
0.049308339 |
13 |
NaN |
|
BHMT |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Methionine cycle |
0.046209242 |
18.5 |
NaN |
|
BHMT |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Methionine cycle |
0.048447984 |
14.5 |
NaN |
|
BHMT |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Methionine cycle |
0.045692235 |
17.5 |
NaN |
|
BHMT |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
Methionine cycle |
0.028900203 |
15.5 |
NaN |
|
BHMT |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.049308339 |
13 |
NaN |
|
FBN1 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Up |
Microfibril scaffold organization |
0.046209242 |
18.5 |
NaN |
|
FBN1 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.048447984 |
14.5 |
NaN |
|
FBN1 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.045692235 |
17.5 |
NaN |
|
FBN1 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
7.59E-05 |
1 |
NaN |
|
AURKB;CCNA2;INCENP |
| phenylephrine |
Sympathomimetic |
No |
MSN01 |
Down |
WNT-Beta-catenin signaling pathway |
0.013976683 |
6 |
NaN |
|
FRZB;FZD10;PAX6;SFRP2 |
| phenylephrine |
Sympathomimetic |
No |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.008849032 |
8 |
NaN |
|
FRZB;FZD10;FZD7;PAX6;SFRP2 |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.011667148 |
11 |
NaN |
|
APCDD1;FRZB;FZD7;SFRP2;SFRP5 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.041836543 |
21 |
NaN |
|
APCDD1;FRZB;FZD7;SFRP2 |
| phenylephrine |
Sympathomimetic |
No |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.002522047 |
6 |
NaN |
|
APCDD1;FRZB;FZD7;SFRP2;SFRP5;WNT9A |
| phenylephrine |
Sympathomimetic |
No |
MSN06 |
Down |
Z-disc organization |
0.004380348 |
10 |
NaN |
|
DES;LDB3;PDLIM3 |
| phenylephrine |
Sympathomimetic |
No |
MSN08 |
Down |
Z-disc organization |
0.041446435 |
20 |
NaN |
|
DES;LDB3 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
WNT-Beta-catenin signaling pathway |
0.006287892 |
2 |
NaN |
|
APCDD1;FZD1;FZD8;SFRP5;TCF7L2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.007314551 |
10 |
NaN |
|
APCDD1;CTHRC1;DKK2;FZD2;FZD8;SFRP5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.041284933 |
12 |
NaN |
|
APCDD1;CDK14;FZD8;SFRP5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Z-disc organization |
0.048469694 |
12 |
NaN |
|
PDLIM3;TCAP |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Myofibril formation |
0.026793335 |
9 |
6 |
Down by cardiotoxic TKIs |
KLHL41;XIRP1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Osteonectin receptor signaling |
0.002647061 |
6 |
NaN |
|
SMOC2;SPARC |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.026905434 |
14.5 |
NaN |
|
SPP1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Peroxisome proliferator-activated receptor alpha signaling |
0.032027317 |
12 |
NaN |
|
PPARA |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Peroxisome proliferator-activated receptor alpha signaling |
0.041723865 |
15.5 |
NaN |
|
PPARA |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Peroxisome proliferator-activated receptor alpha signaling |
0.031506482 |
10.5 |
NaN |
|
PPARA |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.021985266 |
15.5 |
NaN |
|
PDGFD;PDGFRB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.020145007 |
9 |
14 |
Down by cardiotoxic TKIs |
PDGFB;RGS5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Progesterone receptor signaling |
0.026905434 |
14.5 |
NaN |
|
PGR |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Progesterone receptor signaling |
0.026199718 |
7.5 |
NaN |
|
PGR |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Protein folding in mitochondria |
0.001644513 |
5 |
NaN |
|
HSPD1;PPIF |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Protein folding in mitochondria |
0.04765631 |
15 |
NaN |
|
PPIF |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Protein folding in mitochondria |
0.046887533 |
12.5 |
NaN |
|
PPIF |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Recycling endosome dynamics |
0.018799197 |
8 |
NaN |
|
EHD3;RAB15;S100A10 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Recycling endosome dynamics |
0.035973541 |
10 |
NaN |
|
RAB15;S100A10;SNAP23 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Retinoic acid receptor signaling |
0.044111632 |
11 |
NaN |
|
NR4A1;TBL1XR1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Retinol metabolism |
0.03031943 |
17.5 |
NaN |
|
ALDH1A1;DHRS3 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Retinol metabolism |
0.029628054 |
14 |
NaN |
|
DHRS3;RPE65 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.000303147 |
2 |
NaN |
|
ALDH1A1;ALDH1A2;ALDH1A3;RDH10 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Semaphorin signaling |
0.004822239 |
2 |
NaN |
|
CRMP1;DPYSL4;PLXNA2;PLXNC1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Semaphorin signaling |
0.039540041 |
9 |
NaN |
|
CRMP1;DPYSL3;SEMA6B |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Serine and glycine metabolism |
8.84E-05 |
4 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serine and glycine metabolism |
0.000620716 |
1 |
19 |
Up by cardiotoxic TKIs |
AMT;PHGDH;SHMT2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Serine and glycine metabolism |
5.94E-05 |
3 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serine and glycine metabolism |
0.001347236 |
5 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Serine and glycine metabolism |
1.86E-05 |
1 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serotonin inactivation |
0.032027317 |
12 |
NaN |
|
MAOB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Serotonin inactivation |
0.042241946 |
19.5 |
NaN |
|
MAOB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tenascin receptor signaling |
0.002889904 |
2 |
NaN |
|
TENM1;TNC |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Thin myofilament organization |
0.010811186 |
11 |
NaN |
|
TNNI3;TPM2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tight junction organization |
0.002000361 |
3 |
NaN |
|
CLDN1;CLDN6;CRB2;EMP1;MPP5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Transamination pathways |
0.010811186 |
11 |
25 |
Up by cardiotoxic TKIs |
GOT1;GOT2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Transamination pathways |
0.005160336 |
5.5 |
25 |
Up by cardiotoxic TKIs |
GOT1;GOT2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Transamination pathways |
0.008879841 |
10 |
25 |
Up by cardiotoxic TKIs |
BCAT1;GOT1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Transamination pathways |
0.008668292 |
9.5 |
25 |
Up by cardiotoxic TKIs |
GOT1;GOT2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Translation initiation |
0.01976951 |
15 |
NaN |
|
EIF1;EIF2S2;EIF3K;EIF4EBP1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Transmembrane glucose transport |
0.003237663 |
6 |
NaN |
|
SLC2A3;SLC2A4 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Tropoelastin synthesis |
0.023641496 |
18.5 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.021347918 |
13 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Tropoelastin synthesis |
0.021083275 |
11.5 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.026905434 |
14.5 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.026199718 |
7.5 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Vascular endothelial growth factor receptor signaling |
0.010811186 |
11 |
12 |
Up by cardiotoxic TKIs |
VEGFA;VEGFB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Vascular endothelial growth factor receptor signaling |
0.005160336 |
5.5 |
12 |
Up by cardiotoxic TKIs |
VEGFA;VEGFB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Vascular endothelial growth factor receptor signaling |
0.008879841 |
10 |
12 |
Up by cardiotoxic TKIs |
VEGFA;VEGFB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Vascular endothelial growth factor receptor signaling |
0.008668292 |
9.5 |
12 |
Up by cardiotoxic TKIs |
VEGFA;VEGFB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Water transmembrane transport |
0.010676413 |
4 |
9 |
Down by cardiotoxic TKIs |
AQP1;AQP7 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Alternative complement pathway |
0.006837765 |
7.5 |
NaN |
|
C3;CFH |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Amyloid plaque organization |
0.021985266 |
15.5 |
NaN |
|
APBB2;APOE |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Aspartate and arginine metabolism |
0.022108594 |
16.5 |
NaN |
|
ARG2;SLC7A1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Basement membrane attachment to cell surface |
0.007844056 |
8 |
NaN |
|
BSG;ITGA5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.026905434 |
14.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.012712092 |
5 |
NaN |
|
CACNA1G;HCN4 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.032023829 |
10 |
NaN |
|
KCND3;KCNQ5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.037839911 |
8 |
NaN |
|
KCNA5;KCNQ5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Caveolin-mediated endocytosis |
0.002016908 |
2 |
NaN |
|
CAV1;CAV2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003230669 |
1 |
NaN |
|
CTGF;CYR61 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006837765 |
7.5 |
NaN |
|
CTGF;CYR61 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006492473 |
3 |
NaN |
|
CTGF;CYR61 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
CD44-Mediated leukocyte rolling |
0.044140376 |
10.5 |
NaN |
|
CD44 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cellular cholesterol uptake and efflux |
0.017433217 |
8 |
NaN |
|
ABCA1;ABCG1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol synthesis |
0.011059837 |
13 |
22 |
Up by cardiotoxic TKIs |
DHCR24;DHCR7;EBP |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cholesterol synthesis |
5.07E-05 |
2 |
22 |
Up by cardiotoxic TKIs |
CYP27A1;DHCR24;DHCR7;EBP;MVD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol synthesis |
0.000244132 |
2 |
22 |
Up by cardiotoxic TKIs |
DHCR24;DHCR7;LSS;MVD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.007844056 |
8 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.003725413 |
3.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006432927 |
8 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006278564 |
7.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.003606501 |
4.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Citric acid cycle |
2.47E-07 |
1 |
1 |
Up by cardiotoxic TKIs |
ACO2;CS;OGDH;PDHA1;SDHA;SDHB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Citric acid cycle |
0.001050588 |
2 |
1 |
Up by cardiotoxic TKIs |
ACO2;CS;OGDH |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Citric acid cycle |
0.000118607 |
1 |
1 |
Up by cardiotoxic TKIs |
ACO2;CS;OGDH;SDHD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Citric acid cycle |
0.001001483 |
3 |
1 |
Up by cardiotoxic TKIs |
ACO2;CS;OGDH |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fiber crosslinking |
0.006837765 |
7.5 |
NaN |
|
LOX;PXDN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010075061 |
11.5 |
NaN |
|
COL12A1;COL9A2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009570814 |
4.5 |
NaN |
|
COL12A1;COL19A1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.021347918 |
13 |
NaN |
|
DCN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Desaturation of fatty acids |
0.008879841 |
10 |
11 |
Up by cardiotoxic TKIs |
FADS1;SCD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Desaturation of fatty acids |
0.000304244 |
2 |
11 |
Up by cardiotoxic TKIs |
FADS1;FADS2;SCD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Desaturation of fatty acids |
0.004996504 |
6.5 |
11 |
Up by cardiotoxic TKIs |
FADS2;SCD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Electron transport chain |
4.92E-06 |
3 |
NaN |
|
COX7A1;SDHA;SDHB;UQCR10;UQCRQ |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Electron transport chain |
0.015380525 |
8 |
NaN |
|
COX7A1;UQCR10 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Electron transport chain |
0.025418115 |
13 |
NaN |
|
NDUFA4;SDHD |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
ER unfolded protein response pathway |
0.006807667 |
7 |
NaN |
|
DDIT3;HERPUD1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
ER unfolded protein response pathway |
0.00049707 |
5 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
ER unfolded protein response pathway |
0.000479218 |
3 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003567478 |
4 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS12;ADAMTS8 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012326034 |
5 |
NaN |
|
ADAMTS1;ADAMTS8;ADAMTS9 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by cathepsins |
0.022108594 |
16.5 |
NaN |
|
CTSB;CTSL |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by serine proteases |
0.004996504 |
6.5 |
NaN |
|
HPN;PRSS8 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Fatty acid elongation |
0.000707656 |
4 |
NaN |
|
ELOVL6;ELOVL7;HSD17B12 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Fibrillar collagen core structure organization |
3.85E-05 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
3.08E-06 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL5A1;COL5A2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.019838394 |
7 |
NaN |
|
COL2A1;COL5A2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Gap junction organization |
0.002574736 |
1 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJC1;PANX1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Gap junction organization |
0.003332429 |
3 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJD2;PANX1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Gastric inhibitory polypeptide receptor signaling |
0.04765631 |
15 |
NaN |
|
GIPR |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Gastric inhibitory polypeptide receptor signaling |
0.046887533 |
12.5 |
NaN |
|
GIPR |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.036581377 |
21 |
NaN |
|
GLUL;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Glutamate and glutamine metabolism |
0.03031943 |
17.5 |
NaN |
|
GLUL;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.02287923 |
4 |
NaN |
|
SLC1A3;SLC38A2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Glycolysis and Gluconeogenesis |
6.77E-07 |
2 |
NaN |
|
ALDOA;ENO1;GPI;PCK2;PFKP;PGAM1;TPI1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.021393109 |
6 |
NaN |
|
ENO1;HK2;LDHA |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.036362165 |
6 |
NaN |
|
JAK2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040341633 |
11 |
NaN |
|
JAK2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.044140376 |
10.5 |
NaN |
|
JAK2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Heme degradation to bilirubin |
0.04765631 |
15 |
NaN |
|
BLVRB |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
HIF-1 receptor signaling pathway |
0.013543754 |
6 |
20 |
Down by cardiotoxic TKIs |
CITED2;EGLN3 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
HIF-1 receptor signaling pathway |
0.016105455 |
6 |
20 |
Down by cardiotoxic TKIs |
CITED2;EGLN3 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
HIF-1 receptor signaling pathway |
0.001329993 |
1 |
20 |
Down by cardiotoxic TKIs |
CITED2;EGLN1;EGLN3 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Hippo signaling |
0.011600606 |
3 |
13 |
Down by cardiotoxic TKIs |
AJUBA;AMOTL1;AMOTL2 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Hippo signaling |
0.004811885 |
5 |
13 |
Down by cardiotoxic TKIs |
AJUBA;AMOTL2;CRB2;PTPN14 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Hippo signaling |
0.015369641 |
7 |
13 |
Down by cardiotoxic TKIs |
AJUBA;AMOTL1;PTPN14 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Intrinsic apoptosis pathway |
0.026374299 |
5 |
NaN |
|
BMF;MCL1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Lipogenesis |
0.032027317 |
12 |
NaN |
|
FASN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Lipogenesis |
0.042241946 |
19.5 |
NaN |
|
FASN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Lipogenesis |
0.041723865 |
15.5 |
NaN |
|
FASN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Lipogenesis |
0.031506482 |
10.5 |
NaN |
|
FASN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Lysosomal glycoprotein degradation |
0.007844056 |
8 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Lysosomal glycoprotein degradation |
0.003725413 |
3.5 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Lysosomal glycoprotein degradation |
0.000183256 |
4 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30;TPP1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Lysosomal glycoprotein degradation |
0.006278564 |
7.5 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Lysosomal glycoprotein degradation |
0.003606501 |
4.5 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Lysosomal glycosaminoglycan degradation |
0.031435723 |
20 |
NaN |
|
ARSB;NAGLU |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.006837765 |
7.5 |
NaN |
|
ACKR3;CXCR4 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Macrophage migration inhibitory factor signaling |
0.000106279 |
1 |
NaN |
|
ACKR3;CXCR2;CXCR4 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mammalian target of rapamycin signaling pathway |
0.030066821 |
10 |
NaN |
|
EIF4EBP1;FLCN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Mammalian target of rapamycin signaling pathway |
0.005235988 |
7 |
NaN |
|
DDIT4;EIF4EBP1;FLCN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mammalian target of rapamycin signaling pathway |
0.005056937 |
6 |
NaN |
|
DDIT4;EIF4EBP1;FLCN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Mammalian target of rapamycin signaling pathway |
0.029162896 |
9 |
NaN |
|
EIF4EBP1;FLCN |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Mammalian target of rapamycin signaling pathway |
0.038028136 |
7 |
NaN |
|
PIK3R1;RICTOR |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Microtubule crosslinking and bundling |
0.010075061 |
11.5 |
NaN |
|
MAP2;MTCL1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Microtubule crosslinking and bundling |
0.005875567 |
3 |
NaN |
|
MAP2;MTCL1 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Microtubule polymerization |
0.007013957 |
4 |
NaN |
|
DCLK1;TUBA1A |
| pazopanib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Microtubule polymerization |
0.009570814 |
4.5 |
NaN |
|
DCLK1;TUBA1A |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitochondrial ADP import and ATP export |
0.023641496 |
18.5 |
NaN |
|
SLC25A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Mitochondrial ADP import and ATP export |
0.01614326 |
9 |
NaN |
|
SLC25A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Mitochondrial ADP import and ATP export |
0.021347918 |
13 |
NaN |
|
SLC25A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Mitochondrial ADP import and ATP export |
0.021083275 |
11.5 |
NaN |
|
SLC25A5 |
| pazopanib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Mitochondrial fusion |
0.017964125 |
14 |
NaN |
|
MFN2;PHB |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
0.002283887 |
3 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;TTK |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.014277759 |
8 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS2 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017257201 |
10 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS2 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.013507381 |
6 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS7 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002029311 |
3 |
NaN |
|
ADAMTS14;ADAMTS17;ADAMTS4;ADAMTS8 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.014751879 |
9 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS8 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.017964125 |
11 |
NaN |
|
MMP1;MMP12 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Extracellular matrix breakdown by serine proteases |
0.009601976 |
7 |
NaN |
|
KLK5;PRSS12 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.019690847 |
9 |
NaN |
|
COL1A2;COL3A1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.000995243 |
2 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.001386247 |
2.5 |
NaN |
|
COL11A1;COL1A1;COL1A2 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.00128425 |
1.5 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
1.09E-06 |
1 |
NaN |
|
COL11A1;COL1A1;COL2A1;COL5A2;COL5A3 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Fibroblast growth factor receptor signaling |
0.026417399 |
13 |
NaN |
|
FGF1;FGF18 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Fibroblast growth factor receptor signaling |
0.030147281 |
14 |
NaN |
|
FGF1;FGF18 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Fibronectin synthesis and extracellular assembly |
0.005786869 |
8 |
NaN |
|
FN1;ITGA5 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Fibulin receptor signaling |
0.043967869 |
11 |
NaN |
|
FBLN1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Fibulin receptor signaling |
0.042587255 |
15.5 |
NaN |
|
FBLN1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.038266416 |
13.5 |
NaN |
|
FBLN1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Fibulin receptor signaling |
0.045692235 |
17.5 |
NaN |
|
FBLN1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Filopodium organization |
0.010671147 |
7 |
NaN |
|
ENAH;GPM6A;TNK2 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
G2 M transition checkpoint |
0.002453841 |
4 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
G2 M transition checkpoint |
0.029934709 |
11 |
NaN |
|
CCNB1;CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
G2 M transition checkpoint |
0.027024728 |
16 |
NaN |
|
CCNB1;CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.03055135 |
10.5 |
NaN |
|
SLC38A2;SLC7A5 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.025189984 |
11 |
NaN |
|
SLC38A2;SLC7A5 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Glutamate and glutamine metabolism |
0.003548064 |
5 |
NaN |
|
GLS2;SLC1A3;SLC1A5 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
6.16E-06 |
1 |
NaN |
|
ALDOA;ENO1;LDHA;PCK2;PGK1;TPI1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
0.015201431 |
5 |
NaN |
|
ENO1;LDHA;PFKFB3 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.01311516 |
8 |
NaN |
|
ENO1;LDHA;PFKFB3 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.041723865 |
13.5 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.046726108 |
20 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045519869 |
15 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048792173 |
18 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.043105102 |
20 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Growth differentiation factor receptor signaling |
0.011766804 |
5 |
NaN |
|
GDF11;GDF6 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.009634616 |
6 |
NaN |
|
GDF2;GDF6 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.041723865 |
13.5 |
NaN |
|
HGF |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.048792173 |
18 |
NaN |
|
HGF |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001353509 |
2 |
NaN |
|
A2M;PLAT |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001364613 |
1 |
NaN |
|
A2M;PLAT |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001100428 |
2 |
NaN |
|
A2M;PLAT |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001572131 |
2 |
NaN |
|
A2M;PLAT |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Inositol metabolism and transport |
0.043967869 |
11 |
NaN |
|
INPP5D |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.035413375 |
14 |
NaN |
|
SOCS3;STAT4 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Ketone body metabolism |
0.021436133 |
7.5 |
NaN |
|
OXCT1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Ketone body metabolism |
0.021524347 |
10 |
NaN |
|
OXCT1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Ketone body metabolism |
0.023112209 |
11.5 |
NaN |
|
OXCT1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Lamellipodium organization |
0.01967162 |
10 |
NaN |
|
ARAP3;ENAH;TIAM2 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Lipogenesis |
0.042587255 |
15.5 |
NaN |
|
FASN |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Lipogenesis |
0.045692235 |
17.5 |
NaN |
|
FASN |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Macrophage migration inhibitory factor signaling |
0.004244577 |
3 |
NaN |
|
CXCR4;JUND |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.005312003 |
6 |
NaN |
|
CXCR4;JUND |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Macrophage migration inhibitory factor signaling |
0.004527641 |
3.5 |
NaN |
|
CXCR4;JUND |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
0.045631721 |
17 |
NaN |
|
BUB1;PTTG1;TTK |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
0.001371996 |
1 |
NaN |
|
BUB1;CENPE;MAD2L1;PTTG1;TTK |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Mitotic spindle assembly |
7.84E-06 |
1 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Mitotic spindle assembly |
0.034848653 |
12.5 |
NaN |
|
DLGAP5;TPX2 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Mitotic spindle assembly |
0.003548064 |
5 |
NaN |
|
DLGAP5;TPX2;TTK |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Mitotic spindle assembly |
0.031486283 |
17.5 |
NaN |
|
DLGAP5;TPX2 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Mitotic spindle disassembly |
0.023641496 |
13.5 |
NaN |
|
CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Mitotic spindle disassembly |
0.023023994 |
7.5 |
NaN |
|
CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Mitotic spindle disassembly |
0.024700071 |
14 |
NaN |
|
CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Mitotic spindle disassembly |
0.021788991 |
12.5 |
NaN |
|
CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.006960163 |
4.5 |
NaN |
|
NPPA;NPPB |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.007844056 |
8 |
NaN |
|
NPPA;NPPB |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.007451277 |
4 |
NaN |
|
NPPA;NPPB |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.006694109 |
5.5 |
NaN |
|
NPPA;NPPB |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Nodal growth differentiation factor receptor signaling |
0.042024881 |
16 |
NaN |
|
DACT2;LEFTY2 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.023112209 |
11.5 |
NaN |
|
SPP1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.00156935 |
3 |
NaN |
|
FOSL1;PDGFRB;RGS5 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.022155988 |
9 |
NaN |
|
PDGFRB;RGS5 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.022327276 |
12 |
NaN |
|
PDGFRB;RGS5 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.001046445 |
1 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.02550613 |
13 |
NaN |
|
PDGFRB;RGS5 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Progesterone receptor signaling |
0.023641496 |
13.5 |
NaN |
|
PGR |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Progesterone receptor signaling |
0.023023994 |
7.5 |
NaN |
|
PGR |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Progesterone receptor signaling |
0.024700071 |
14 |
NaN |
|
PGR |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Prostaglandin E2 receptor signaling |
0.006536814 |
3 |
NaN |
|
PTGER2;PTGER3 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Prostaglandin E2 receptor signaling |
0.007506811 |
3.5 |
NaN |
|
PTGER2;PTGER3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.046726108 |
20 |
NaN |
|
PTGFR |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.045519869 |
15 |
NaN |
|
PTGFR |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.048792173 |
18 |
NaN |
|
PTGFR |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.043105102 |
20 |
NaN |
|
PTGFR |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Proteasomal regulatory particle organization |
0.009601976 |
7 |
NaN |
|
PSMC4;PSMD14 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Proteasomal regulatory particle organization |
0.009022183 |
5 |
NaN |
|
PSMC4;PSMD14 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Proteasomal regulatory particle organization |
0.010350023 |
6.5 |
NaN |
|
PSMC4;PSMD14 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Retinol metabolism |
0.029628054 |
11 |
NaN |
|
ALDH1A1;RDH10 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Retinol metabolism |
0.003134623 |
5 |
NaN |
|
ALDH1A2;ALDH1A3;TTR |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Retinol metabolism |
0.034848653 |
12.5 |
NaN |
|
STRA6;TTR |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Retinol metabolism |
0.003548064 |
5 |
NaN |
|
ALDH1A1;ALDH1A2;TTR |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Retinol metabolism |
0.031486283 |
17.5 |
NaN |
|
STRA6;TTR |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Roundabout signaling |
0.008950881 |
4 |
NaN |
|
ROBO1;ROBO2 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Roundabout signaling |
0.009022183 |
5 |
NaN |
|
ROBO1;ROBO2 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Roundabout signaling |
0.007318648 |
5 |
NaN |
|
ROBO1;ROBO2 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Roundabout signaling |
0.010350023 |
6.5 |
NaN |
|
ROBO1;ROBO2 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Semaphorin signaling |
0.005764974 |
3 |
NaN |
|
DPYSL4;NRP2;PLXNA2;SEMA3A |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Semaphorin signaling |
0.043141308 |
16 |
NaN |
|
DPYSL4;PLXNA2;SEMA3F |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.02147651 |
10 |
NaN |
|
PHGDH;SHMT2 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.028862138 |
16 |
NaN |
|
PHGDH;SLC1A5 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.022844529 |
15 |
NaN |
|
PHGDH;SHMT2 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Serotonin inactivation |
0.041723865 |
13.5 |
NaN |
|
MAOA |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Serotonin inactivation |
0.046726108 |
20 |
NaN |
|
MAOA |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Serotonin inactivation |
0.045519869 |
15 |
NaN |
|
MAOA |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Serotonin inactivation |
0.043105102 |
20 |
NaN |
|
MAOA |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.046726108 |
20 |
NaN |
|
TACC3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Sister chromatid segregation |
0.007844056 |
8 |
NaN |
|
PTTG1;TOP2A |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Sister chromatid segregation |
0.008539224 |
10 |
NaN |
|
PTTG1;TOP2A |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Sister chromatid segregation |
0.006694109 |
5.5 |
NaN |
|
PTTG1;TOP2A |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Thin myofilament organization |
0.009601976 |
7 |
NaN |
|
ACTA1;LMOD3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Thin myofilament organization |
0.010811186 |
10 |
NaN |
|
TNNI3;TPM1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.021083275 |
8 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.023641496 |
13.5 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.023023994 |
7.5 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.024700071 |
14 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.021788991 |
12.5 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Versican receptor signaling |
0.038266416 |
13.5 |
NaN |
|
VCAN |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Versican receptor signaling |
0.041723865 |
13.5 |
NaN |
|
VCAN |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Versican synthesis |
0.019318984 |
8.5 |
NaN |
|
VCAN |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Versican synthesis |
0.021083275 |
8 |
NaN |
|
VCAN |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.048181864 |
12 |
NaN |
|
APCDD1;PAX6;SFRP2;SFRP5 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.034993337 |
12 |
NaN |
|
LRP4;PAX6;SFRP2;SFRP5 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Z-disc organization |
0.048125749 |
13 |
NaN |
|
BAG3;LDB3 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Z-disc organization |
0.046420056 |
22 |
NaN |
|
DES;PDLIM3 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Actin polymerization |
0.047049834 |
15 |
NaN |
|
ABRA;ACTA1;ENAH |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Adrenergic receptor signaling |
0.01758165 |
6 |
NaN |
|
ADCY2;GPR3;RAPGEF4 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.021524347 |
10 |
NaN |
|
ALB |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.021788991 |
12.5 |
NaN |
|
ALB |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Amyloid plaque organization |
0.025324824 |
10 |
NaN |
|
COL25A1;VSNL1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Basement membrane assembly and organization |
0.024000534 |
11.5 |
NaN |
|
COL4A3;COL4A4 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Biglycan synthesis |
0.021083275 |
8 |
NaN |
|
BGN |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Biglycan synthesis |
0.023641496 |
13.5 |
NaN |
|
BGN |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Biglycan synthesis |
0.023023994 |
7.5 |
NaN |
|
BGN |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Biglycan synthesis |
0.021788991 |
12.5 |
NaN |
|
BGN |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Cardiomyocyte pacemaker current generation |
0.011397983 |
4.5 |
NaN |
|
CACNA1G;HCN4 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.043967869 |
11 |
NaN |
|
CD44 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.046726108 |
20 |
NaN |
|
CD44 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Cellular cholesterol uptake and efflux |
0.03055135 |
10.5 |
NaN |
|
ABCA7;ABCG1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.002401113 |
2 |
NaN |
|
ABCA7;ABCG1;ARL4C |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Cellular cholesterol uptake and efflux |
0.001762747 |
3 |
NaN |
|
ABCA1;ABCA7;ABCG1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Cellular cholesterol uptake and efflux |
0.035094106 |
15 |
NaN |
|
ABCA7;ARL4C |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Centrosome separation |
0.001386247 |
2.5 |
NaN |
|
CCNB1;CDK1;KIF11 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Down |
Centrosome separation |
0.00128425 |
1.5 |
NaN |
|
CCNB1;CDK1;KIF11 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Centrosome separation |
0.024000534 |
11.5 |
NaN |
|
CDK1;KIF11 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Centrosome separation |
0.018960318 |
10 |
NaN |
|
CCNB1;CDK1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Cholesterol synthesis |
3.39E-06 |
1 |
NaN |
|
CYP51A1;HMGCR;HMGCS1;MSMO1;SC5D;SQLE |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Cholesterol synthesis |
0.00100893 |
1 |
NaN |
|
DHCR7;HMGCR;MSMO1;SQLE |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.007506811 |
3.5 |
NaN |
|
INSIG1;SREBF1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Classical complement pathway |
0.000355631 |
2 |
NaN |
|
C1QB;C1QC;C1R |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Classical complement pathway |
0.010350023 |
6.5 |
NaN |
|
C1QB;C1R |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Collagen fiber crosslinking |
0.005786869 |
8 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Collagen fiber crosslinking |
0.004527641 |
3.5 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006960163 |
4.5 |
NaN |
|
COL14A1;COL9A3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000185509 |
1 |
NaN |
|
COL12A1;COL9A2;COL9A3 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005294767 |
4 |
NaN |
|
COL9A2;COL9A3 |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007844056 |
8 |
NaN |
|
COL14A1;COL9A1 |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Contractile ring constriction |
0.005786869 |
8 |
NaN |
|
ANLN;MYLK |
| olmesartan |
Antihypertensive |
No |
MSN05 |
Up |
Decorin synthesis |
0.021436133 |
7.5 |
NaN |
|
DCN |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Decorin synthesis |
0.021524347 |
10 |
NaN |
|
DCN |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Up |
Decorin synthesis |
0.019318984 |
8.5 |
NaN |
|
DCN |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Desaturation of fatty acids |
0.009022183 |
5 |
NaN |
|
FADS2;SCD |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Desaturation of fatty acids |
0.010350023 |
6.5 |
NaN |
|
FADS2;SCD |
| olmesartan |
Antihypertensive |
No |
MSN08 |
Down |
Elastin cross-linking and assembly |
0.00179408 |
2 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Elastin cross-linking and assembly |
0.001398195 |
2 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
MSN06 |
Up |
Epithelial intermediate filament dynamics |
0.011859842 |
7 |
NaN |
|
KRT4;TCHH |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Up |
Epithelial intermediate filament dynamics |
0.013590977 |
9 |
NaN |
|
KRT4;TCHH |
| olmesartan |
Antihypertensive |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.011397983 |
4.5 |
NaN |
|
KRT19;KRT8 |
| olmesartan |
Antihypertensive |
No |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.012140948 |
7 |
NaN |
|
KRT19;KRT8 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Actin polymerization |
0.031680878 |
12 |
NaN |
|
ABRA;ACTA1;ENAH |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Adrenergic receptor signaling |
0.033631608 |
27 |
NaN |
|
GRK5;RGS16;RGS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.016496119 |
8 |
NaN |
|
ALB |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.020201129 |
10 |
NaN |
|
ALB |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.018877911 |
11.5 |
NaN |
|
ALB |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.021083275 |
10 |
NaN |
|
ALB |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Antigen presentation via MHC class I molecules |
0.029364515 |
26 |
NaN |
|
B2M;HLA-C |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Aspartate and arginine metabolism |
0.032033347 |
25 |
NaN |
|
ARG2;SLC7A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Aspartate and arginine metabolism |
0.02729964 |
27 |
NaN |
|
ARG2;SLC7A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Aspartate and arginine metabolism |
0.024808376 |
24 |
NaN |
|
ARG2;SLC7A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Biglycan synthesis |
0.028846154 |
23 |
NaN |
|
BGN |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Biglycan synthesis |
0.027258292 |
29.5 |
NaN |
|
BGN |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cardiomyocyte pacemaker current generation |
0.010499387 |
6.5 |
NaN |
|
CACNA1G;TRPM4 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Cardiomyocyte pacemaker current generation |
0.009215038 |
8 |
NaN |
|
CACNA1G;TRPM4 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cardiomyocyte pacemaker current generation |
0.011397983 |
4.5 |
NaN |
|
CACNA1G;TRPM4 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.021622693 |
11 |
NaN |
|
KCNIP2;KCNQ5 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003416552 |
5 |
NaN |
|
CYR61;WISP1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
CD44-Mediated leukocyte rolling |
0.039477231 |
12.5 |
NaN |
|
CD44 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.039995919 |
13 |
NaN |
|
CD44 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
CD44-Mediated leukocyte rolling |
0.037401081 |
14.5 |
NaN |
|
CD44 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
CD44-Mediated leukocyte rolling |
0.041723865 |
13 |
NaN |
|
CD44 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Cell cycle arrest in response to DNA damage |
0.026579947 |
27 |
NaN |
|
CDKN1A;GADD45A;H2AFX |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome duplication |
0.004355947 |
16 |
NaN |
|
CDKN1A;GADD45A;PLK2;PLK4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome maturation |
0.003776716 |
11 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome maturation |
0.004310912 |
14 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome maturation |
0.003380484 |
14.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome maturation |
0.003675094 |
12.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Centrosome maturation |
0.002923036 |
13.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome organization |
0.010849095 |
17 |
NaN |
|
ASPM;ATF5;GRK5;NEK2;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome organization |
0.046142207 |
29 |
NaN |
|
ASPM;ATF5;NEK2;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome organization |
0.002064787 |
13 |
NaN |
|
ASPM;ATF5;NEK2;PLK4;POC1A;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome organization |
0.002439115 |
11 |
NaN |
|
ASPM;ATF5;NEK2;PLK4;POC1A;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Centrosome organization |
0.007112445 |
17 |
NaN |
|
ASPM;ATF5;NEK2;POC1A;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome separation |
1.25E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome separation |
1.89E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome separation |
9.43E-12 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Centrosome separation |
1.20E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Centrosome separation |
6.24E-12 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol synthesis |
1.52E-05 |
5 |
NaN |
|
DHCR24;DHCR7;FDPS;MVD;MVK;SQLE |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.010526062 |
15 |
NaN |
|
INSIG1;SREBF1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.011523002 |
17.5 |
NaN |
|
INSIG1;SREBF1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Classical complement pathway |
0.012167509 |
21.5 |
NaN |
|
C1R;C1S |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.010526062 |
15 |
NaN |
|
COL9A1;COL9A3 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
8.52E-05 |
2 |
NaN |
|
COL12A1;COL9A2;COL9A3 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005776787 |
5 |
NaN |
|
COL12A1;COL9A3 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Contractile ring constriction |
0.007146805 |
13 |
NaN |
|
ANLN;ECT2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring constriction |
3.32E-06 |
2 |
NaN |
|
ANLN;ECT2;MYH14;MYLK |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Contractile ring constriction |
0.000176406 |
6.5 |
NaN |
|
ANLN;ECT2;MYLK |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Contractile ring constriction |
0.007013572 |
18 |
NaN |
|
ANLN;ECT2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Contractile ring constriction |
0.000151472 |
6.5 |
NaN |
|
ANLN;ECT2;MYLK |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring formation |
0.007830627 |
16 |
NaN |
|
MYH14;RACGAP1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Decorin synthesis |
0.027522936 |
23.5 |
NaN |
|
DCN |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Decorin synthesis |
0.016496119 |
8 |
NaN |
|
DCN |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Decorin synthesis |
0.020201129 |
10 |
NaN |
|
DCN |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Decorin synthesis |
0.021083275 |
10 |
NaN |
|
DCN |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Desaturation of fatty acids |
0.015826754 |
19.5 |
NaN |
|
FADS2;SCD |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Desaturation of fatty acids |
0.013424521 |
21 |
NaN |
|
FADS2;SCD |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Desaturation of fatty acids |
0.014205479 |
23.5 |
NaN |
|
FADS2;SCD |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Desaturation of fatty acids |
0.012167509 |
21.5 |
NaN |
|
FADS2;SCD |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Drug and toxin export via membrane transport proteins |
0.049098649 |
14 |
NaN |
|
ABCA1;ABCC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Epithelial intermediate filament dynamics |
0.017589037 |
22.5 |
NaN |
|
KRT4;TCHH |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.007099288 |
5 |
NaN |
|
KRT19;KRT7 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.010499387 |
6.5 |
NaN |
|
KRT19;KRT7 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.011397983 |
4.5 |
NaN |
|
KRT19;KRT7 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Equatorial RhoA activation |
0.004367359 |
12 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Equatorial RhoA activation |
0.0047895 |
15 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Equatorial RhoA activation |
0.004043143 |
16.5 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Equatorial RhoA activation |
0.004285177 |
14.5 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Equatorial RhoA activation |
0.003654836 |
15.5 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
ER unfolded protein response pathway |
0.01894582 |
20.5 |
NaN |
|
ATF4;DDIT3 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
ER unfolded protein response pathway |
0.001195745 |
12 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
ER unfolded protein response pathway |
0.000930974 |
11 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
ER unfolded protein response pathway |
0.001014528 |
9 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
ER unfolded protein response pathway |
0.000801798 |
11 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.027522936 |
23.5 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle disassembly |
0.028846154 |
23 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle disassembly |
0.026464361 |
25 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic spindle disassembly |
0.027258292 |
29.5 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic spindle disassembly |
0.025141143 |
26 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Muscarinic receptor signaling |
0.0056301 |
4 |
NaN |
|
CHRM4;RGS5 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Myofibril formation |
0.016431153 |
8 |
NaN |
|
DES;KLHL41 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.010526062 |
15 |
NaN |
|
NPPA;NPPB |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Nuclear envelope maintenance |
0.009758505 |
19.5 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Nuclear envelope maintenance |
0.010331661 |
21 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Nuclear envelope maintenance |
0.008836966 |
19 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Nuclear intermediate filaments |
0.009758505 |
19.5 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Nuclear intermediate filaments |
0.010331661 |
21 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Nuclear intermediate filaments |
0.008836966 |
19 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Osteonectin receptor signaling |
0.00231233 |
2.5 |
NaN |
|
SPARC;SPOCK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.016496119 |
8 |
NaN |
|
SPP1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Osteopontin receptor signaling |
0.020201129 |
10 |
NaN |
|
SPP1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.018877911 |
11.5 |
NaN |
|
SPP1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.038417822 |
26 |
NaN |
|
PDGFB;TNK2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Potassium transmembrane transport |
0.010022636 |
9 |
NaN |
|
ABCC9;ATP1A2;FXYD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Potassium transmembrane transport |
0.013507381 |
6.5 |
NaN |
|
ABCC9;ATP1A2;FXYD1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Progesterone receptor signaling |
0.016496119 |
8 |
NaN |
|
PGR |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Progesterone receptor signaling |
0.021083275 |
10 |
NaN |
|
PGR |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Protein polyubiquitination |
0.000939844 |
11 |
NaN |
|
ISG15;UBC;UBE2S;UCHL1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Protein polyubiquitination |
0.008629766 |
19 |
NaN |
|
ISG15;UBC;UBE2S |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Pyrimidine synthesis and salvage |
0.018602463 |
25.5 |
NaN |
|
TK1;TYMS |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.037401081 |
14.5 |
NaN |
|
XAF1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Retinol metabolism |
0.001118414 |
3 |
NaN |
|
ALDH1A1;ALDH1A3;STRA6 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Retinol metabolism |
0.001649697 |
4 |
NaN |
|
ALDH1A1;ALDH1A3;STRA6 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Serine and glycine metabolism |
0.002891019 |
10 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Serine and glycine metabolism |
7.76E-06 |
4 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Serine and glycine metabolism |
5.09E-06 |
5 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Serine and glycine metabolism |
5.88E-06 |
5 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serine and glycine metabolism |
3.96E-06 |
5 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Serotonin and melatonin synthesis |
0.048680702 |
16.5 |
NaN |
|
SLC6A4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000755151 |
7 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000829629 |
10 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000698089 |
10 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000740675 |
8 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000629915 |
10 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid segregation |
0.000388293 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid segregation |
0.000445876 |
9 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid segregation |
0.000345895 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Sister chromatid segregation |
0.000377393 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Sister chromatid segregation |
0.000297304 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Thick myofilament organization |
0.001202742 |
4 |
NaN |
|
MYBPC3;MYH7 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thick myofilament organization |
0.001050954 |
3 |
NaN |
|
MYBPC3;MYH7 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Thin myofilament organization |
0.0002682 |
2 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thin myofilament organization |
0.006997877 |
6.5 |
NaN |
|
ACTA1;TPM2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Thin myofilament organization |
0.000304244 |
2 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Thrombospondin receptor signaling |
0.004043143 |
16.5 |
NaN |
|
THBS1;THBS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.004285177 |
14.5 |
NaN |
|
THBS1;THBS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Thrombospondin receptor signaling |
0.003654836 |
15.5 |
NaN |
|
THBS1;THBS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Thrombospondin receptor signaling |
0.00231233 |
2.5 |
NaN |
|
THBS2;THBS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Tropoelastin synthesis |
0.027522936 |
23.5 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.026464361 |
25 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.027258292 |
29.5 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.025141143 |
26 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.016496119 |
8 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Vascular endothelial growth factor receptor signaling |
0.007778956 |
6 |
NaN |
|
FLT1;KDR |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Vascular endothelial growth factor receptor signaling |
0.006997877 |
6.5 |
NaN |
|
FLT1;KDR |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.032721547 |
14 |
NaN |
|
VIPR2 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.039995919 |
13 |
NaN |
|
VIPR2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.037401081 |
14.5 |
NaN |
|
VIPR2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.041723865 |
13 |
NaN |
|
VIPR2 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
5.15E-08 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;MAD2L1;NDC80;NUF2;SPC24;TTK;ZWINT |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Eukaryotic kinetochore dynamics |
9.10E-05 |
7 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
1.39E-10 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;KNSTRN;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
1.95E-10 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;KNSTRN;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
1.38E-09 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;KNSTRN;MAD2L1;NDC80;NUF2;SPC24;TTK;ZWINT |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01161951 |
8 |
NaN |
|
ADAMTS1;ADAMTS5;ADAMTS6 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000975308 |
2 |
NaN |
|
ADAM12;ADAM19;ADAMTS5;ADAMTS6 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.013507381 |
6.5 |
NaN |
|
ADAM19;ADAMTS5;ADAMTS6 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.012989342 |
9 |
NaN |
|
MMP2;MMP3 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extracellular matrix breakdown by serine proteases |
0.007778956 |
6 |
NaN |
|
HTRA1;PRSS12 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Extrinsic apoptosis pathway |
0.007778956 |
6 |
NaN |
|
FAS;TNFRSF10A |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.002146032 |
8 |
NaN |
|
COL11A2;COL1A2;COL2A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.016025171 |
10 |
NaN |
|
COL5A1;COL5A2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
1.39E-05 |
1 |
NaN |
|
COL11A1;COL11A2;COL1A1;COL3A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.000879088 |
3 |
NaN |
|
COL11A2;COL1A1;COL2A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.014446446 |
10 |
NaN |
|
COL11A1;COL2A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.000995243 |
3 |
NaN |
|
COL11A2;COL1A1;COL2A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
G2 M transition checkpoint |
0.041541674 |
28.5 |
NaN |
|
CCNB1;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
G2 M transition checkpoint |
0.045239205 |
27.5 |
NaN |
|
CCNB1;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
G2 M transition checkpoint |
0.003380484 |
14.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
G2 M transition checkpoint |
0.003675094 |
12.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
G2 M transition checkpoint |
0.002923036 |
13.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
GABA metabolism |
0.011523002 |
17.5 |
NaN |
|
ABAT;SLC6A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
GABA metabolism |
0.010331661 |
21 |
NaN |
|
ABAT;SLC6A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
GABA metabolism |
0.008836966 |
19 |
NaN |
|
ABAT;SLC6A1 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Glutamate and glutamine metabolism |
0.004309257 |
18 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.004682035 |
17 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.040928231 |
29 |
NaN |
|
SLC1A5;SLC7A5 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
G-protein coupled receptor signaling pathway |
0.016635949 |
19 |
NaN |
|
GRK5;RGS16;RGS4 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.032721547 |
14 |
NaN |
|
JAK2 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039995919 |
13 |
NaN |
|
JAK2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.037401081 |
14.5 |
NaN |
|
JAK2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.041723865 |
13 |
NaN |
|
JAK2 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Growth differentiation factor receptor signaling |
0.01894582 |
20.5 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Growth differentiation factor receptor signaling |
0.020703758 |
21 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Growth differentiation factor receptor signaling |
0.017589037 |
22.5 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.018602463 |
25.5 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Growth differentiation factor receptor signaling |
0.01595608 |
23 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.048680702 |
16.5 |
NaN |
|
HBEGF |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.032721547 |
14 |
NaN |
|
MET |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
HIF-1 receptor signaling pathway |
0.014452362 |
8 |
NaN |
|
CITED2;EGLN3 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.027522936 |
23.5 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.028846154 |
23 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.026464361 |
25 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.027258292 |
29.5 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.025141143 |
26 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
7.82E-06 |
1 |
NaN |
|
A2M;MME;PLAT |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Inhibition of apoptosis |
0.041541674 |
28.5 |
NaN |
|
BIRC5;IFI6 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Inhibition of apoptosis |
0.045239205 |
27.5 |
NaN |
|
BIRC5;IFI6 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Inhibition of apoptosis |
0.038673865 |
28 |
NaN |
|
BIRC5;IFI6 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Inhibition of apoptosis |
0.035205397 |
28 |
NaN |
|
BIRC5;IFI6 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Intracellular bridge assembly |
0.002224143 |
9 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Intracellular bridge assembly |
0.002441309 |
13 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Intracellular bridge assembly |
0.002057559 |
12 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Intracellular bridge assembly |
0.002181901 |
10 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Intracellular bridge assembly |
0.001858288 |
12 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.030757337 |
11 |
NaN |
|
SOCS2;STAT4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
2.93E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Metaphase to anaphase checkpoint |
4.15E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MXD3;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Metaphase to anaphase checkpoint |
1.66E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
2.13E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
1.07E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Microfibril scaffold organization |
0.039477231 |
12.5 |
NaN |
|
FBN1 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic chromosome condensation |
0.014470218 |
18 |
NaN |
|
INCENP;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic chromosome condensation |
0.015826754 |
19.5 |
NaN |
|
INCENP;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic chromosome condensation |
0.000593464 |
9 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic chromosome condensation |
0.014205479 |
23.5 |
NaN |
|
INCENP;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic chromosome condensation |
0.000510607 |
9 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000198188 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000227809 |
8 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000176406 |
6.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000192586 |
6 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000151472 |
6.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle assembly |
1.64E-05 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle assembly |
2.06E-05 |
6 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle assembly |
4.80E-07 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Mitotic spindle assembly |
5.71E-07 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mitotic spindle assembly |
3.55E-07 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Z-disc organization |
0.002111529 |
4 |
NaN |
|
CSRP3;PDLIM3;TCAP |
| nilotinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Z-disc organization |
1.17E-05 |
1 |
NaN |
|
ACTN2;CSRP3;DES;PDLIM3;TCAP |
| nilotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Z-disc organization |
8.44E-06 |
1 |
NaN |
|
ACTN2;CSRP3;LDB3;PDLIM3;TCAP |
| nilotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Z-disc organization |
0.000287224 |
1 |
NaN |
|
ACTN2;CSRP3;PDLIM3;TCAP |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.020122326 |
9 |
NaN |
|
AMER1;FRZB;FZD1;SFRP2;SFRP5 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.020402338 |
11 |
NaN |
|
APCDD1;FZD7;SFRP1;SFRP2;SFRP5 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.000123641 |
1 |
NaN |
|
AMER1;FRZB;FZD7;PAX6;SFRP2;SFRP5;WNT5A;WNT9A |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Z-disc organization |
0.035163828 |
18 |
NaN |
|
DES;TCAP |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Z-disc organization |
0.039201142 |
13.5 |
NaN |
|
DES;TCAP |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Z-disc organization |
0.003524647 |
2 |
NaN |
|
CSRP3;DES;TCAP |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Mitotic spindle assembly |
0.038858469 |
14.5 |
NaN |
|
TACC3;TPX2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Mitotic spindle assembly |
0.039114857 |
18.5 |
NaN |
|
TACC3;TPX2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.004969189 |
5 |
NaN |
|
NPPA;NPR1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Natriuretic peptide receptor signaling |
0.0055816 |
5 |
NaN |
|
NPPA;NPPB |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Osteonectin receptor signaling |
0.003455479 |
3 |
NaN |
|
SMOC2;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Osteonectin receptor signaling |
0.003190191 |
6 |
NaN |
|
SPARC;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Osteonectin receptor signaling |
0.003480103 |
6.5 |
NaN |
|
SMOC2;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Osteonectin receptor signaling |
0.003455479 |
6 |
NaN |
|
SMOC2;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Osteonectin receptor signaling |
5.79E-05 |
1 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Osteonectin receptor signaling |
0.003237663 |
6.5 |
NaN |
|
SPARC;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Osteopontin receptor signaling |
0.0200247 |
9.5 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Osteopontin receptor signaling |
0.018701482 |
15 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Osteopontin receptor signaling |
0.019848271 |
8 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Osteopontin receptor signaling |
0.019760056 |
9 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Osteopontin receptor signaling |
0.020289344 |
6 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Phase I biotransformation via cytochrome P450 |
0.010587731 |
3 |
NaN |
|
CYP1A1;CYP1B1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.018691388 |
7 |
NaN |
|
PDGFRA;RGS5 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.017132206 |
13 |
NaN |
|
PDGFRB;RGS5 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.026236809 |
14 |
NaN |
|
FOSL1;PDGFB |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.002058855 |
4 |
NaN |
|
PDGFB;PDGFRA;TNK2 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.00210169 |
5 |
NaN |
|
FOSL1;PDGFB;TNK2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Potassium transmembrane transport |
0.001274711 |
1 |
NaN |
|
ABCC9;ATP1A2;ATP1A3;KCNE4 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Progesterone receptor signaling |
0.024435427 |
11 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Progesterone receptor signaling |
0.023465067 |
12.5 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Progesterone receptor signaling |
0.024523641 |
14 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Progesterone receptor signaling |
0.024435427 |
14 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Progesterone receptor signaling |
0.024611856 |
15 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Progesterone receptor signaling |
0.023641496 |
12 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.03878543 |
13 |
NaN |
|
PTGFR |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Protein polyubiquitination |
0.039201142 |
13.5 |
NaN |
|
ISG15;UBC |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Protein polyubiquitination |
0.006383649 |
6 |
NaN |
|
ISG15;UBE2S;UCHL1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Removal of caspase inhibition |
0.046381546 |
20 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Removal of caspase inhibition |
0.048447984 |
23 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Removal of caspase inhibition |
0.048275867 |
22 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Removal of caspase inhibition |
0.048620086 |
21.5 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Removal of caspase inhibition |
0.046726108 |
18.5 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Restriction point |
0.015490863 |
6 |
NaN |
|
CDKN2A;PFKFB3 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Restriction point |
0.014190421 |
12 |
NaN |
|
CDKN2A;PFKFB3 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Restriction point |
0.023680597 |
10.5 |
NaN |
|
CCND2;CDKN1A |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Retinol metabolism |
0.02648975 |
10 |
NaN |
|
ALDH1A2;RBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Retinol metabolism |
0.038858469 |
14.5 |
NaN |
|
ALDH1A1;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Retinol metabolism |
0.036082859 |
15.5 |
NaN |
|
ALDH1A3;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.039114857 |
18.5 |
NaN |
|
ALDH1A1;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Retinol metabolism |
0.000209572 |
2 |
NaN |
|
ALDH1A3;CYP26A1;DHRS3;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Retinol metabolism |
0.00351239 |
6.5 |
NaN |
|
ALDH1A3;RLBP1;TTR |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.036581377 |
15 |
NaN |
|
ALDH1A1;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Semaphorin signaling |
0.030054908 |
12 |
NaN |
|
NRP2;PLXNC1;PLXND1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Serine and glycine metabolism |
0.019493118 |
8 |
NaN |
|
PHGDH;PSAT1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Serine and glycine metabolism |
0.028290753 |
13 |
NaN |
|
PHGDH;SHMT2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Serine and glycine metabolism |
0.001833111 |
4 |
NaN |
|
GLDC;SHMT2;SLC1A5 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Serine and glycine metabolism |
0.000101959 |
1 |
NaN |
|
GLDC;PHGDH;SHMT2;SLC1A5 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Serine and glycine metabolism |
0.000100542 |
1 |
NaN |
|
GLDC;PHGDH;SHMT2;SLC1A5 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Serine and glycine metabolism |
0.00010339 |
3 |
NaN |
|
GLDC;PHGDH;SHMT2;SLC1A5 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Serine and glycine metabolism |
0.001872928 |
4 |
NaN |
|
GLDC;PHGDH;SHMT2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Serotonin inactivation |
0.039650143 |
16.5 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Serotonin inactivation |
0.048275867 |
18.5 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Serotonin inactivation |
0.048447984 |
23 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Serotonin inactivation |
0.048275867 |
22 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Serotonin inactivation |
0.046726108 |
18.5 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.048275867 |
18.5 |
NaN |
|
TACC3 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.048447984 |
23 |
NaN |
|
TACC3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Sodium transmembrane transport |
0.042501734 |
19 |
NaN |
|
ATP1A2;SCN3A;SLC38A2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Tenascin receptor signaling |
0.003480103 |
6.5 |
NaN |
|
TENM1;TNC |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Tenascin receptor signaling |
0.003237663 |
6.5 |
NaN |
|
TENM1;TNC |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Thin myofilament organization |
0.007845779 |
5.5 |
NaN |
|
ACTA1;LMOD3 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Thin myofilament organization |
0.006871448 |
8 |
NaN |
|
ACTA1;LMOD3 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.010811186 |
8 |
NaN |
|
ACTA1;TNNI3 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Thrombospondin receptor signaling |
0.002232086 |
1 |
NaN |
|
THBS1;THBS2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Thrombospondin receptor signaling |
0.002037514 |
3.5 |
NaN |
|
THBS1;THBS2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Tight junction organization |
0.044793664 |
17 |
NaN |
|
CLDN19;CRB2;MYLK |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Tight junction organization |
0.049939927 |
27 |
NaN |
|
CLDN19;CRB2;MYLK |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Tight junction organization |
0.045631721 |
16 |
NaN |
|
CGNL1;CLDN19;MYLK |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.024435427 |
11 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Tropoelastin synthesis |
0.023465067 |
12.5 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.024523641 |
14 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Tropoelastin synthesis |
0.024435427 |
14 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.024611856 |
15 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Vascular endothelial growth factor receptor signaling |
0.006871448 |
8 |
NaN |
|
KDR;VEGFA |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.046381546 |
20 |
NaN |
|
VIPR2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.048447984 |
23 |
NaN |
|
VIPR2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Versican receptor signaling |
0.048275867 |
18.5 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Versican receptor signaling |
0.048447984 |
23 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Versican receptor signaling |
0.048275867 |
22 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Versican receptor signaling |
0.048620086 |
21.5 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Versican receptor signaling |
0.046726108 |
18.5 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Versican synthesis |
0.024435427 |
11 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Versican synthesis |
0.024523641 |
14 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Versican synthesis |
0.024435427 |
14 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Versican synthesis |
0.024611856 |
15 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Versican synthesis |
0.023641496 |
12 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Actin filament severing and depolymerization |
0.036082859 |
15.5 |
NaN |
|
SCIN;TAGLN2 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Actin filament severing and depolymerization |
0.038858469 |
18 |
NaN |
|
SCIN;TAGLN2 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Actin filament severing and depolymerization |
0.039371914 |
18.5 |
NaN |
|
SCIN;TAGLN2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Adenylyl cyclase signaling pathway |
0.004865296 |
2 |
NaN |
|
ADCY1;PDE3A;RAPGEF4 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Adenylyl cyclase signaling pathway |
0.04375734 |
23 |
NaN |
|
PDE3A;RAPGEF4 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Adenylyl cyclase signaling pathway |
0.048709404 |
19 |
NaN |
|
PDE3A;RAPGEF4 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Adrenergic receptor signaling |
0.013821647 |
5 |
NaN |
|
ADCY2;GPR3;RAPGEF4 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Adrenergic receptor signaling |
0.022299004 |
11 |
NaN |
|
ADRB1;ADRB3;ARRB1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Aggrecan synthesis |
0.024523641 |
14 |
NaN |
|
ACAN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Aggrecan synthesis |
0.024435427 |
14 |
NaN |
|
ACAN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Aggrecan synthesis |
0.024611856 |
15 |
NaN |
|
ACAN |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.019583627 |
8.5 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.018701482 |
15 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.019848271 |
8 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.019760056 |
9 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.020289344 |
6 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Alternative complement pathway |
0.003836392 |
3 |
NaN |
|
C3;CFH |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Androgen synthesis |
0.019383609 |
9 |
NaN |
|
HSD17B2;SRD5A2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Antigen presentation via MHC class I molecules |
0.001356597 |
2 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.023680597 |
10.5 |
NaN |
|
HLA-B;HLA-C |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.023521317 |
10.5 |
NaN |
|
HLA-A;HLA-C |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.023840336 |
12 |
NaN |
|
HLA-A;HLA-C |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.022108594 |
10 |
NaN |
|
HLA-B;HLA-C |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Axonal intermediate filament dynamics |
0.007845779 |
5.5 |
NaN |
|
NEFH;NEFM |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Axonal intermediate filament dynamics |
0.007646107 |
7 |
NaN |
|
NEFH;NES |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Biglycan synthesis |
0.019583627 |
8.5 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Biglycan synthesis |
0.0200247 |
9.5 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Biglycan synthesis |
0.018701482 |
15 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Biglycan synthesis |
0.019848271 |
8 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Biglycan synthesis |
0.019760056 |
9 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Biglycan synthesis |
0.020289344 |
6 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Bone morphogenetic protein receptor signaling |
0.001553323 |
3 |
NaN |
|
BMP2;BMP6;BMP7;NOG |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.029759296 |
10 |
NaN |
|
KCNIP2;KCNJ12 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.031008959 |
13.5 |
NaN |
|
KCNIP2;KCNJ2 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.030506558 |
11.5 |
NaN |
|
KCNIP2;KCNJ2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.031768858 |
10.5 |
NaN |
|
KCNA1;KCNIP2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005234736 |
7.5 |
NaN |
|
CYR61;WISP1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005666345 |
7 |
NaN |
|
CYR61;NOV |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000142188 |
4 |
NaN |
|
CTGF;CYR61;NOV |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.046381546 |
20 |
NaN |
|
CD44 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.048275867 |
22 |
NaN |
|
CD44 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
CD44-Mediated leukocyte rolling |
0.048620086 |
21.5 |
NaN |
|
CD44 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Cellular cholesterol uptake and efflux |
0.003068795 |
5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Cellular cholesterol uptake and efflux |
0.003476939 |
5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Cellular cholesterol uptake and efflux |
0.003134623 |
5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Cellular iron uptake and export |
0.026929091 |
11 |
NaN |
|
RASD1;TFRC |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Cellular iron uptake and export |
0.027593758 |
8 |
NaN |
|
TF;TFRC |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Cellular iron uptake and export |
0.039371914 |
18.5 |
NaN |
|
CP;TFRC |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Centrosome separation |
0.01616 |
7 |
NaN |
|
KIF11;SPAG5 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Centrosome separation |
0.023521317 |
10.5 |
NaN |
|
CCNB1;NEK6 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Chaperone-mediated autophagy |
0.03878543 |
13 |
NaN |
|
HSPA8 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Chaperone-mediated autophagy |
0.037054838 |
20 |
NaN |
|
HSPA8 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Chaperone-mediated autophagy |
0.039304304 |
16.5 |
NaN |
|
HSPA8 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Chaperone-mediated autophagy |
0.040168784 |
14.5 |
NaN |
|
HSPA8 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Cholesterol synthesis |
0.000589508 |
1 |
NaN |
|
FDPS;HMGCR;HMGCS1;MVD |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Cholesterol synthesis |
0.005812705 |
6 |
NaN |
|
HMGCS1;MSMO1;SC5D |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Cholesterol synthesis |
0.012093552 |
8 |
NaN |
|
FDFT1;MVD;MVK |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005533298 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Classical complement pathway |
0.007514323 |
3 |
NaN |
|
C4A;C4B |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Classical complement pathway |
0.006871448 |
8 |
NaN |
|
C4A;C4B |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Classical complement pathway |
0.010656442 |
9 |
NaN |
|
C1R;C1S |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Classical complement pathway |
0.011680465 |
8 |
NaN |
|
C1QB;C1QC |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Clathrin-mediated vesicle traffic from TGN to endosomal lysosomal system |
0.031768858 |
10.5 |
NaN |
|
AP1G2;AP1S2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005678798 |
4 |
NaN |
|
COL9A1;COL9A2 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005533298 |
5.5 |
NaN |
|
COL9A1;COL9A2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.008362857 |
7 |
NaN |
|
COL14A1;COL9A2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Contractile ring constriction |
0.005234736 |
7.5 |
NaN |
|
MYH14;MYLK |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Decorin synthesis |
0.024523641 |
14 |
NaN |
|
DCN |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Decorin synthesis |
0.024435427 |
14 |
NaN |
|
DCN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Decorin synthesis |
0.024611856 |
15 |
NaN |
|
DCN |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Decorin synthesis |
0.023641496 |
12 |
NaN |
|
DCN |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Eicosanoid metabolism |
0.034464443 |
11 |
NaN |
|
PLA2G2A;PTGS1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Endogenous control of complement activity |
0.003737436 |
3.5 |
NaN |
|
CFH;CFI |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.011071787 |
4 |
NaN |
|
ADAM12;ADAMTS12;ADAMTS14 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001175038 |
2 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS2;ADAMTS5 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001155785 |
1 |
NaN |
|
ADAM33;ADAMTS14;ADAMTS2;ADAMTS5 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.019988845 |
9 |
NaN |
|
ADAMTS1;ADAMTS7;ADAMTS8 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.020370269 |
10 |
NaN |
|
ADAMTS1;ADAMTS7;ADAMTS8 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.011492797 |
10.5 |
NaN |
|
MMP1;MMP2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.016567476 |
4 |
NaN |
|
COL2A1;COL5A2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.023521317 |
9 |
NaN |
|
COL11A1;COL1A1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Fibrillar collagen core structure organization |
5.57E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL5A1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.001540682 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.00152477 |
3 |
NaN |
|
COL1A2;COL2A1;COL3A1 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Fibrillar collagen core structure organization |
6.71E-05 |
2 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL5A2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.001386247 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Fibronectin synthesis and extracellular assembly |
0.003770283 |
4 |
NaN |
|
FN1;ITGB3 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Fibronectin synthesis and extracellular assembly |
0.003737436 |
3.5 |
NaN |
|
FN1;ITGB3 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Fibronectin synthesis and extracellular assembly |
0.003936586 |
2 |
NaN |
|
FN1;ITGB3 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Fibulin receptor signaling |
0.046381546 |
20 |
NaN |
|
FBLN1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Fibulin receptor signaling |
0.046726108 |
18.5 |
NaN |
|
FBLN1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
GABA metabolism |
0.008362857 |
8 |
NaN |
|
ABAT;SLC6A1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Gap junction organization |
0.027324073 |
17 |
NaN |
|
GJA1;GJA5 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Gap junction organization |
0.031768858 |
10.5 |
NaN |
|
GJA1;GJA5 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.003441711 |
2 |
NaN |
|
SLC1A3;SLC38A2;SLC7A5 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.000212495 |
2 |
NaN |
|
SLC1A3;SLC1A5;SLC38A2;SLC7A5 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.003441711 |
5 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Glutamate and glutamine metabolism |
0.00351239 |
6.5 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Glycolysis and Gluconeogenesis |
0.015989849 |
10 |
NaN |
|
LDHA;PFKL;TPI1 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.002169178 |
4 |
NaN |
|
ALDOA;LDHA;PCK2;PFKL |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.016311637 |
9 |
NaN |
|
ALDOA;LDHA;PFKL |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039650143 |
16.5 |
NaN |
|
JAK2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.037054838 |
20 |
NaN |
|
JAK2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040168784 |
14.5 |
NaN |
|
JAK2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048275867 |
18.5 |
NaN |
|
JUND |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048447984 |
23 |
NaN |
|
JUND |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048275867 |
22 |
NaN |
|
JUND |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.011492797 |
10.5 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.012879711 |
6 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.000594987 |
1 |
NaN |
|
HGF;MET |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.048447984 |
23 |
NaN |
|
MET |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.000556884 |
2 |
NaN |
|
HGF;MET |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.00118192 |
2 |
NaN |
|
A2M;MME |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
6.45E-06 |
1 |
NaN |
|
A2M;MME;PLAT |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001161278 |
1 |
NaN |
|
A2M;MME |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Inhibition of apoptosis |
0.031435723 |
14 |
NaN |
|
IFI6;XAF1 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Inositol metabolism and transport |
0.048275867 |
18.5 |
NaN |
|
SLC5A3 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Down |
Inositol metabolism and transport |
0.048620086 |
21.5 |
NaN |
|
INPP5D |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Insulin receptor signaling |
0.04710941 |
23 |
NaN |
|
IRS1;IRS2 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Down |
Insulin receptor signaling |
0.047749388 |
21 |
NaN |
|
IRS1;IRS2 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Interleukin 6 receptor signaling |
0.03878543 |
13 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Interleukin 6 receptor signaling |
0.039304304 |
16.5 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Interleukin 6 receptor signaling |
0.039131362 |
13 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Interleukin 7 receptor signaling |
0.03878543 |
13 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Interleukin 7 receptor signaling |
0.039304304 |
16.5 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Interleukin 7 receptor signaling |
0.039131362 |
13 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
JAK-STAT signaling pathway |
0.031008959 |
13.5 |
NaN |
|
SOCS2;STAT4 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.002015723 |
2 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.030506558 |
11.5 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
JAK-STAT signaling pathway |
0.031768858 |
10.5 |
NaN |
|
SOCS3;STAT4 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Leptin receptor signaling |
0.002037514 |
3.5 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Leptin receptor signaling |
0.00229214 |
3 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Lipogenesis |
0.048275867 |
18.5 |
NaN |
|
FASN |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
Macrophage migration inhibitory factor signaling |
0.005666345 |
4 |
NaN |
|
CXCR4;JUND |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.005706386 |
8 |
NaN |
|
CXCR4;JUND |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Mammalian target of rapamycin signaling pathway |
0.044565529 |
19 |
NaN |
|
DDIT4;RICTOR |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Mammalian target of rapamycin signaling pathway |
0.039370586 |
22 |
NaN |
|
DDIT4;RICTOR |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Mammalian target of rapamycin signaling pathway |
0.045634248 |
17 |
NaN |
|
DDIT4;RICTOR |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Down |
MAPK signaling pathway |
0.005795587 |
5 |
NaN |
|
DUSP1;FOXM1;MAP2K6;RPS6KA2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Down |
MAPK signaling pathway |
0.036370558 |
17 |
NaN |
|
DUSP1;MAP2K6;RPS6KA2 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Down |
MAPK signaling pathway |
0.036041409 |
17 |
NaN |
|
DUSP1;MAP2K6;RPS6KA2 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Methionine cycle |
0.039650143 |
16.5 |
NaN |
|
BHMT |
| milrinone |
Vasodilatator |
Yes |
MSN08 |
Up |
Methionine cycle |
0.039131362 |
13 |
NaN |
|
BHMT |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Methionine cycle |
0.040168784 |
14.5 |
NaN |
|
BHMT |
| milrinone |
Vasodilatator |
Yes |
MSN01 |
Up |
Microfibril scaffold organization |
0.03878543 |
13 |
NaN |
|
FBN1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Up |
Microfibril scaffold organization |
0.039650143 |
16.5 |
NaN |
|
MFAP2 |
| milrinone |
Vasodilatator |
Yes |
MSN05 |
Up |
Microfibril scaffold organization |
0.037054838 |
20 |
NaN |
|
FBN1 |
| milrinone |
Vasodilatator |
Yes |
MSN06 |
Up |
Microfibril scaffold organization |
0.039304304 |
16.5 |
NaN |
|
FBN1 |
| milrinone |
Vasodilatator |
Yes |
MSN09 |
Up |
Microfibril scaffold organization |
0.040168784 |
14.5 |
NaN |
|
FBN1 |
| milrinone |
Vasodilatator |
Yes |
MSN02 |
Down |
Microfibril scaffold organization |
0.046381546 |
20 |
NaN |
|
FBN1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
6.94E-08 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;MAD2L1;NDC80;NUF2;SPC24;TTK;ZWINT |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
5.78E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;NDC80;SPC24;TTK;ZWINT |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
0.000534725 |
3 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;SPC24;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017257201 |
13 |
NaN |
|
ADAM33;ADAMTS10;ADAMTS7 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.008219515 |
6.5 |
NaN |
|
ADAM33;ADAMTS14;ADAMTS5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012182779 |
9.5 |
NaN |
|
ADAM12;ADAM33;ADAMTS2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000941768 |
3 |
NaN |
|
ADAM33;ADAMTS10;ADAMTS2;ADAMTS5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002829744 |
4 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS15;ADAMTS17 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.027026538 |
18 |
NaN |
|
ADAM19;ADAMTS12;ADAMTS8 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.02497131 |
15 |
NaN |
|
CTSB;CTSF |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by cathepsins |
0.02780993 |
22.5 |
NaN |
|
CTSB;CTSV |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.003096266 |
5.5 |
NaN |
|
SULF1;SULF2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.001192421 |
3 |
NaN |
|
MMP14;MMP2;MMP3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.00072133 |
11 |
NaN |
|
BRCA2;BRIP1;FANCD2;FANCI;UBE2T |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.031215289 |
24 |
NaN |
|
BRIP1;FANCD2;FANCI |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.016567476 |
12 |
NaN |
|
COL11A1;COL2A1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Fibrillar collagen core structure organization |
7.39E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.029190037 |
24 |
NaN |
|
COL1A2;COL2A1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Fibroblast growth factor receptor signaling |
0.027637833 |
14 |
NaN |
|
FGF1;FGF10 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Fibroblast growth factor receptor signaling |
0.035432532 |
21 |
NaN |
|
FGF1;FGF10 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Fibulin receptor signaling |
0.045692235 |
18.5 |
NaN |
|
FBLN1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Fibulin receptor signaling |
0.040168784 |
15 |
NaN |
|
FBLN1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
G2 M transition checkpoint |
0.039383166 |
25.5 |
NaN |
|
CCNB1;CDK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.0025731 |
3.5 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.003766836 |
6 |
NaN |
|
SLC1A3;SLC1A5;SLC7A5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Glutamate and glutamine metabolism |
0.045738032 |
27 |
NaN |
|
SLC1A5;SLC7A5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Glutamate and glutamine metabolism |
0.047941794 |
25.5 |
NaN |
|
SLC1A5;SLC38A2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.026402563 |
24 |
NaN |
|
ENO1;LDHA;PGAM1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.003257229 |
6 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
G-protein coupled receptor signaling pathway |
0.009153583 |
6 |
NaN |
|
GRK5;PDE4D;RGS4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045692235 |
18.5 |
NaN |
|
JUND |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.03480274 |
15 |
NaN |
|
JUND |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040168784 |
15 |
NaN |
|
JUND |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.017209911 |
12 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.010177876 |
8 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.013432039 |
11 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.011492797 |
7 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Growth differentiation factor receptor signaling |
0.012425035 |
8 |
NaN |
|
GDF2;GDF6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Growth differentiation factor receptor signaling |
0.017924062 |
14 |
NaN |
|
GDF2;GDF6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Hedgehog receptor signaling |
0.006058183 |
6 |
NaN |
|
BOC;CDON;GAS1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hedgehog receptor signaling |
0.048315957 |
14 |
NaN |
|
BOC;CDON |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Heme degradation to bilirubin |
0.00118192 |
3.5 |
NaN |
|
BLVRB;HMOX1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Hepatocyte growth factor receptor signaling |
0.000348126 |
2 |
NaN |
|
HGF;MET |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.043622809 |
20 |
NaN |
|
HGF |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.028405081 |
27.5 |
NaN |
|
HMMR |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.027434721 |
21 |
NaN |
|
HMMR |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Inhibin receptor signaling |
0.017924062 |
14 |
NaN |
|
INHBA;INHBE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
5.33E-06 |
2 |
NaN |
|
A2M;MME;PLAT |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.00118192 |
3.5 |
NaN |
|
A2M;MME |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Interferon alpha receptor signaling |
0.010587731 |
8 |
NaN |
|
IRF9;STAT1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Interferon beta receptor signaling |
0.010350023 |
11 |
NaN |
|
IFIT2;IRF9 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Interferon beta receptor signaling |
0.006076013 |
5 |
NaN |
|
IFIT2;IRF9 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Interferon beta receptor signaling |
0.008047841 |
7 |
NaN |
|
IFIT2;IRF9 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Intracellular bridge assembly |
2.27E-05 |
6 |
NaN |
|
INCENP;KIF23;NEK7 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Intracellular bridge assembly |
0.002210018 |
4.5 |
NaN |
|
KIF23;NEK7 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Intrinsic apoptosis pathway |
0.031008959 |
8 |
NaN |
|
BCL2L11;BMF |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Intrinsic apoptosis pathway |
0.027324073 |
10.5 |
NaN |
|
BCL2L11;BMF |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.040330112 |
16 |
NaN |
|
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.024289095 |
11 |
NaN |
|
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.000140829 |
2 |
NaN |
|
SOCS3;STAT1;STAT3;USP18 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
JAK-STAT signaling pathway |
0.027324073 |
10.5 |
NaN |
|
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.037023918 |
16 |
NaN |
|
SOCS2;STAT4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Leptin receptor signaling |
0.003096266 |
5.5 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Leptin receptor signaling |
0.001797512 |
3 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Leptin receptor signaling |
0.002393952 |
5 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Leptin receptor signaling |
0.002037514 |
5 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Lipogenesis |
0.000532182 |
4 |
NaN |
|
ACLY;FASN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Lipogenesis |
0.03480274 |
15 |
NaN |
|
FASN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Lipogenesis |
0.040168784 |
15 |
NaN |
|
FASN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Lipogenesis |
0.039650143 |
10 |
NaN |
|
FASN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Lipogenesis |
0.037054838 |
12.5 |
NaN |
|
FASN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
3.70E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
2.63E-05 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Metaphase to anaphase checkpoint |
0.013476514 |
15 |
NaN |
|
BUB1;CENPE;PTTG1;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Methionine cycle |
0.043622809 |
20 |
NaN |
|
BHMT |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Microfibril scaffold organization |
0.045692235 |
18.5 |
NaN |
|
MFAP2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Microfibril scaffold organization |
0.049824365 |
25 |
NaN |
|
FBN1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Microtubule crosslinking and bundling |
0.011186086 |
21 |
NaN |
|
MAP1B;MAP2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic chromosome condensation |
0.000730004 |
12 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.007599426 |
19 |
NaN |
|
CCNA2;INCENP |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic spindle assembly |
1.91E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mitotic spindle assembly |
0.000295616 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mitotic spindle assembly |
0.004767473 |
10.5 |
NaN |
|
DLGAP5;NUSAP1;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Mitotic spindle disassembly |
0.028405081 |
27.5 |
NaN |
|
CDK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Mitotic spindle disassembly |
0.026729005 |
18.5 |
NaN |
|
CDK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Mitotic spindle disassembly |
0.027434721 |
21 |
NaN |
|
CDK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Muscarinic receptor signaling |
0.008897083 |
7.5 |
NaN |
|
RGS4;RGS5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.006853158 |
5 |
NaN |
|
NPPA;NPPB |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.000426104 |
9 |
NaN |
|
NPPA;NPPB;NPR3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.008897083 |
7.5 |
NaN |
|
NPPA;NPPB |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.009947879 |
9 |
NaN |
|
NPPA;NPPB |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.010461076 |
13.5 |
NaN |
|
NPPA;NPPB |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Necroptosis induction |
0.023112209 |
15 |
NaN |
|
TNFRSF1A |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Non-vesicular phospholipid transport |
0.012249563 |
11.5 |
NaN |
|
PITPNM1;PLTP |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Notch receptor signaling |
0.047356994 |
18 |
NaN |
|
DLK1;MIB2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Osteonectin receptor signaling |
0.004646709 |
16.5 |
NaN |
|
SPARC;SPOCK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Osteonectin receptor signaling |
0.003680135 |
5 |
NaN |
|
SPARC;SPOCK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Osteonectin receptor signaling |
0.004339881 |
7.5 |
NaN |
|
SPARC;SPOCK1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Osteopontin receptor signaling |
0.022053634 |
11.5 |
NaN |
|
SPP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.028405081 |
27.5 |
NaN |
|
SPP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Osteopontin receptor signaling |
0.026729005 |
18.5 |
NaN |
|
SPP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Osteopontin receptor signaling |
0.027434721 |
21 |
NaN |
|
SPP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Perlecan synthesis |
0.025229358 |
17.5 |
NaN |
|
HSPG2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.030019151 |
20 |
14 |
Down by cardiotoxic TKIs |
RGS5;TNK2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Potassium transmembrane transport |
0.008219515 |
6.5 |
7 |
Up by cardiotoxic TKIs |
ABCC9;FXYD1;SLC12A6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Potassium transmembrane transport |
0.012182779 |
9.5 |
7 |
Up by cardiotoxic TKIs |
ABCC9;ATP1A3;KCNQ1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Proteasomal regulatory particle organization |
0.012249563 |
11.5 |
NaN |
|
PSMC4;PSMD14 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Pyrimidine synthesis and salvage |
0.020110197 |
23 |
NaN |
|
TK1;TYMS |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Pyrimidine synthesis and salvage |
0.017924062 |
14 |
NaN |
|
TK1;TYMS |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Removal of caspase inhibition |
0.043622809 |
20 |
NaN |
|
XAF1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Retinol metabolism |
0.0044314 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;RDH10 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.004767473 |
10.5 |
NaN |
|
ALDH1A1;ALDH1A3;RPE65 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Semaphorin signaling |
0.025210977 |
9 |
NaN |
|
NRP2;SEMA6A;SEMA6D |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Semaphorin signaling |
0.038375695 |
17 |
NaN |
|
PLXNA2;PLXNC1;SEMA5A |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Serine and glycine metabolism |
6.75E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Serotonin inactivation |
0.03480274 |
15 |
NaN |
|
MAOA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Serotonin inactivation |
0.039650143 |
10 |
NaN |
|
MAOA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Serotonin inactivation |
0.043622809 |
20 |
NaN |
|
MAOA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Serotonin inactivation |
0.049824365 |
25 |
NaN |
|
MAOA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000804414 |
13 |
NaN |
|
NUF2;TACC3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Sister chromatid segregation |
0.000426104 |
9 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Sister chromatid segregation |
0.009947879 |
9 |
NaN |
|
PTTG1;TOP2A |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Thin myofilament organization |
0.009455468 |
7 |
21 |
Down by cardiotoxic TKIs |
TPM2;TPM4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Thin myofilament organization |
0.012249563 |
11.5 |
21 |
Down by cardiotoxic TKIs |
ACTA1;TPM2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.014381727 |
16.5 |
21 |
Down by cardiotoxic TKIs |
ACTA1;TNNI3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Thrombospondin receptor signaling |
0.004339881 |
7.5 |
NaN |
|
CD47;THBS4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Tight junction organization |
0.010141758 |
9 |
NaN |
|
CGNL1;CLDN6;CRB2;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tight junction organization |
0.012342235 |
11 |
NaN |
|
CLDN1;CLDN6;CRB2;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.022053634 |
11.5 |
NaN |
|
ELN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.028405081 |
27.5 |
NaN |
|
ELN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Tropoelastin synthesis |
0.025229358 |
17.5 |
NaN |
|
ELN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Tropoelastin synthesis |
0.026729005 |
18.5 |
NaN |
|
ELN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.045692235 |
18.5 |
NaN |
|
VIPR2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.03480274 |
15 |
NaN |
|
VIPR1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.037054838 |
12.5 |
NaN |
|
VIPR1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Versican receptor signaling |
0.043622809 |
20 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Versican receptor signaling |
0.049824365 |
25 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Versican synthesis |
0.022053634 |
11.5 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Versican synthesis |
0.028405081 |
27.5 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Versican synthesis |
0.025229358 |
17.5 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Versican synthesis |
0.026729005 |
18.5 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Versican synthesis |
0.027434721 |
21 |
NaN |
|
VCAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.040737529 |
17 |
NaN |
|
CTHRC1;FZD7;SFRP2;WNT2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.001211189 |
4 |
NaN |
|
AMER1;CTHRC1;FZD1;SFRP2;SFRP4;WNT2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Z-disc organization |
0.005468709 |
9 |
NaN |
|
CSRP3;DES;TCAP |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Z-disc organization |
0.031304625 |
12 |
NaN |
|
DES;TCAP |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Actin filament severing and depolymerization |
0.032195057 |
15 |
NaN |
|
LIMA1;TAGLN2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Actin filament severing and depolymerization |
0.047941794 |
25.5 |
NaN |
|
CFL2;TAGLN2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Adrenergic receptor signaling |
0.018950674 |
9 |
8 |
Down by cardiotoxic TKIs |
GRK5;PDE4D;RGS4 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Aggrecan synthesis |
0.020289344 |
13 |
NaN |
|
ACAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Aggrecan synthesis |
0.022053634 |
11.5 |
NaN |
|
ACAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Aggrecan synthesis |
0.026729005 |
18.5 |
NaN |
|
ACAN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.017554693 |
9.5 |
NaN |
|
ALB |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Alternative complement pathway |
0.005081819 |
7.5 |
NaN |
|
C3;CFH |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Antigen presentation via MHC class I molecules |
0.02118776 |
14 |
NaN |
|
HLA-B;HLA-C |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Aspartate and arginine metabolism |
0.02780993 |
22.5 |
NaN |
|
ARG2;DDAH1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Axonal intermediate filament dynamics |
0.012249563 |
11.5 |
NaN |
|
NEFM;NES |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Axonal intermediate filament dynamics |
0.013682625 |
12 |
NaN |
|
NEFM;NES |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Axonal intermediate filament dynamics |
0.014381727 |
16.5 |
NaN |
|
NEFM;NES |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Biglycan synthesis |
0.028405081 |
27.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Biglycan synthesis |
0.025229358 |
17.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Biglycan synthesis |
0.026729005 |
18.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Biglycan synthesis |
0.027434721 |
21 |
18 |
Down by cardiotoxic TKIs |
BGN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Calcitonin receptor signaling |
0.03480274 |
15 |
NaN |
|
RAMP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Calcitonin receptor signaling |
0.039650143 |
10 |
NaN |
|
RAMP1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002543158 |
6 |
NaN |
|
KCNA1;KCNIP2;KCNQ1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.049824365 |
25 |
NaN |
|
CD44 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.0025731 |
3.5 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ABCG1;ARL4C |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Cellular cholesterol uptake and efflux |
0.041189931 |
22 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ABCG1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome maturation |
0.004127977 |
15 |
NaN |
|
AURKA;PLK1;TPX2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome maturation |
0.039383166 |
25.5 |
NaN |
|
PLK1;TPX2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome organization |
0.012534315 |
22 |
NaN |
|
ASPM;NEK2;NEK7;PAX6;TACC3;WDR62 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Centrosome separation |
1.67E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Centrosome separation |
2.98E-06 |
1 |
NaN |
|
CCNB1;CDK1;KIF11;NEK6;SPAG5 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Chaperone-mediated autophagy |
0.049824365 |
25 |
NaN |
|
HSPA8 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol synthesis |
2.69E-21 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SC5D;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cholesterol synthesis |
3.52E-13 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MVD;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cholesterol synthesis |
4.69E-20 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cholesterol synthesis |
2.34E-14 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol synthesis |
1.09E-14 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.000231836 |
2 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1;SREBF2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.004390599 |
4 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.000157602 |
3 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1;SREBF2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005678798 |
5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.004969189 |
6 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Down |
Classical complement pathway |
0.000347383 |
2 |
NaN |
|
C1QA;C1QB;C1QC |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fiber crosslinking |
0.007599426 |
19 |
NaN |
|
LOX;LOXL1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Collagen fiber crosslinking |
0.000196309 |
1.5 |
NaN |
|
LOX;LOXL1;PLOD1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007506811 |
10 |
NaN |
|
COL14A1;COL9A3 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000426104 |
9 |
NaN |
|
COL12A1;COL9A1;COL9A2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009947879 |
9 |
NaN |
|
COL9A1;COL9A2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010461076 |
13.5 |
NaN |
|
COL9A1;COL9A2 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.000217634 |
7 |
NaN |
|
ANLN;ECT2;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Contractile ring constriction |
0.000153057 |
2 |
NaN |
|
ANLN;MYH14;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
Contractile ring constriction |
0.000181696 |
5 |
NaN |
|
ANLN;MYH14;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Contractile ring constriction |
0.000196309 |
1.5 |
NaN |
|
ANLN;MYH14;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Up |
Decorin synthesis |
0.017554693 |
9.5 |
NaN |
|
DCN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
Decorin synthesis |
0.0200247 |
7 |
NaN |
|
DCN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.018701482 |
8 |
NaN |
|
DCN |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Desaturation of fatty acids |
0.000398781 |
3 |
11 |
Up by cardiotoxic TKIs |
FADS1;FADS2;SCD |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Up |
Desaturation of fatty acids |
0.000271672 |
4 |
11 |
Up by cardiotoxic TKIs |
FADS1;FADS2;SCD |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
DNA replication elongation |
0.007599426 |
19 |
NaN |
|
MCM5;PCNA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
DNA replication elongation |
0.007102263 |
12 |
NaN |
|
MCM5;PCNA |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
DNA replication initiation |
4.32E-06 |
4 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM5;MCM6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Down |
DNA replication initiation |
4.00E-05 |
4 |
NaN |
|
CDC45;CDC6;GINS1;MCM10;MCM5;MCM6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
DNA replication initiation |
0.004457113 |
9 |
NaN |
|
CDC6;GINS2;MCM5;MCM6 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Eicosanoid metabolism |
0.045839398 |
21 |
NaN |
|
CYP2J2;PLA2G2A |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Elastin cross-linking and assembly |
0.002367819 |
14 |
NaN |
|
LOX;LOXL1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN09 |
Down |
Elastin cross-linking and assembly |
0.002210018 |
4.5 |
NaN |
|
LOX;LOXL1 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN01 |
Up |
Endogenous control of complement activity |
0.005081819 |
7.5 |
NaN |
|
CFH;CFI |
| lapatinib |
Kinase inhibitor |
Yes |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.016062742 |
14 |
NaN |
|
KRT7;KRT8 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN05 |
Down |
Equatorial RhoA activation |
0.004646709 |
16.5 |
NaN |
|
ECT2;KIF23 |
| lapatinib |
Kinase inhibitor |
Yes |
MSN08 |
Up |
ER unfolded protein response pathway |
0.000411975 |
2 |
NaN |
|
DDIT3;HERPUD1;PPP1R15A |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Actin filament bundling and crosslinking |
0.004924637 |
7.5 |
NaN |
|
ACTN2;SYNPO;TAGLN;USH1C |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Adenylyl cyclase signaling pathway |
0.00647259 |
8 |
NaN |
|
PDE3A;PDE4D;RAPGEF4 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Adrenergic receptor signaling |
0.004924637 |
7.5 |
NaN |
|
GNB3;GRK5;PDE4D;RGS4 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Adrenergic receptor signaling |
0.026915049 |
12 |
NaN |
|
PDE4D;RASD1;RGS16 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Adrenergic receptor signaling |
0.000209285 |
4 |
NaN |
|
GRK5;PDE4D;RAPGEF4;RASD1;RGS16 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Adrenergic receptor signaling |
0.003732001 |
7 |
NaN |
|
GNB3;GRK5;PDE4D;RASD1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Aggrecan synthesis |
0.027081863 |
19 |
NaN |
|
ACAN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Aggrecan synthesis |
0.025052929 |
13.5 |
NaN |
|
ACAN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.021700776 |
15 |
NaN |
|
ALB |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.018348624 |
10 |
NaN |
|
ALB |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.019318984 |
6.5 |
NaN |
|
ALB |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Alternative complement pathway |
0.003230669 |
4 |
NaN |
|
C1S;CFH |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Amyloid plaque organization |
0.034215437 |
21 |
NaN |
|
COL25A1;HSPB6 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Amyloid plaque organization |
0.029631379 |
16 |
NaN |
|
COL25A1;HSPB6 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Androgen receptor signaling |
0.049824365 |
19 |
NaN |
|
AR |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Androgen receptor signaling |
0.042932502 |
17 |
NaN |
|
AR |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Androgen receptor signaling |
0.049480363 |
24 |
NaN |
|
AR |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.01368451 |
7 |
NaN |
|
HLA-B;HLA-C |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.000846027 |
2 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.001270083 |
3.5 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.015095412 |
2 |
NaN |
|
HLA-B;HLA-C |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Axonal intermediate filament dynamics |
0.010198353 |
8 |
NaN |
|
NEFH;NES |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Basement membrane assembly and organization |
0.01368451 |
7 |
NaN |
|
COL4A4;COL8A2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Basement membrane assembly and organization |
0.016025171 |
6 |
NaN |
|
COL4A4;COL8A2 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Basement membrane assembly and organization |
0.02088458 |
10.5 |
NaN |
|
COL4A4;COL8A2 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Basement membrane assembly and organization |
0.015095412 |
2 |
NaN |
|
COL4A4;COL8A2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Biglycan synthesis |
0.019936486 |
9 |
NaN |
|
BGN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Biglycan synthesis |
0.02293578 |
13 |
NaN |
|
BGN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Biglycan synthesis |
0.019318984 |
6.5 |
NaN |
|
BGN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Calcitonin receptor signaling |
0.049480363 |
24 |
NaN |
|
RAMP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.00018891 |
3 |
NaN |
|
CTGF;CYR61;NOV |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.000153057 |
3 |
NaN |
|
CTGF;CYR61;WISP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.004491781 |
7 |
NaN |
|
CYR61;WISP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005949437 |
8 |
NaN |
|
CTGF;CYR61 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
CD44-Mediated leukocyte rolling |
0.049824365 |
19 |
NaN |
|
CD44 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
CD44-Mediated leukocyte rolling |
0.049480363 |
24 |
NaN |
|
CD44 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Cellular fatty acid uptake |
0.049824365 |
19 |
NaN |
|
CD36 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Cellular fatty acid uptake |
0.042932502 |
17 |
NaN |
|
CD36 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Cellular fatty acid uptake |
0.049480363 |
24 |
NaN |
|
CD36 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Cellular iron uptake and export |
0.041189931 |
15.5 |
NaN |
|
RASD1;TFRC |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Cellular iron uptake and export |
0.002457614 |
6 |
NaN |
|
RASD1;SLC40A1;TFRC |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Cellular iron uptake and export |
0.04066719 |
19.5 |
NaN |
|
RASD1;TFRC |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Centrosome maturation |
0.02972276 |
16 |
NaN |
|
PLK1;TPX2 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Centrosome organization |
0.010070134 |
10 |
NaN |
|
ASPM;GRK5;HOOK2;PAX6;PLK3;WDR62 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Centrosome separation |
0.02088458 |
10.5 |
NaN |
|
CCNB1;NEK6 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Chaperone-mediated autophagy |
0.045347487 |
22.5 |
NaN |
|
HSPA8 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Cholesterol synthesis |
9.01E-10 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;HMGCR;HMGCS1;MSMO1;MVD;NSDHL;SQLE |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Cholesterol synthesis |
1.04E-18 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Cholesterol synthesis |
5.69E-14 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVD;SQLE |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Cholesterol synthesis |
9.46E-19 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006641482 |
10 |
NaN |
|
INSIG1;SREBF1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.008777038 |
9.5 |
NaN |
|
INSIG1;SREBF1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Classical complement pathway |
0.006621825 |
5 |
NaN |
|
C1R;C1S |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Coagulation cascade |
0.034978854 |
18 |
NaN |
|
F2RL1;TFPI |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.010202989 |
12 |
NaN |
|
COL12A1;COL14A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000300395 |
4 |
NaN |
|
COL12A1;COL14A1;COL19A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000192378 |
3 |
NaN |
|
COL12A1;COL14A1;COL19A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000294233 |
2 |
NaN |
|
COL12A1;COL14A1;COL19A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000149607 |
1 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Contractile ring constriction |
0.00500617 |
5.5 |
NaN |
|
ANLN;MYH14 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Decorin synthesis |
0.018348624 |
10 |
NaN |
|
DCN |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Desaturation of fatty acids |
0.014030212 |
14 |
NaN |
|
FADS2;SCD |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Desaturation of fatty acids |
0.000515881 |
5 |
NaN |
|
FADS1;FADS2;SCD |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Desaturation of fatty acids |
0.009165569 |
13 |
NaN |
|
FADS1;SCD |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Desaturation of fatty acids |
0.000505368 |
3 |
NaN |
|
FADS1;FADS2;SCD |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Drug and toxin export via membrane transport proteins |
0.049098649 |
15 |
NaN |
|
ABCA1;ABCC3 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Epithelial intermediate filament dynamics |
0.018375096 |
16 |
NaN |
|
KRT7;KRT8 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.010236386 |
4 |
NaN |
|
KRT19;KRT7 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
0.000613265 |
2 |
NaN |
|
KRT19;KRT7;TCHH |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Mitotic spindle assembly |
0.000164225 |
1 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Mitotic spindle assembly |
0.025189984 |
9 |
NaN |
|
DLGAP5;NUSAP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.027081863 |
19 |
NaN |
|
CDK1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Muscarinic receptor signaling |
0.010202989 |
12 |
NaN |
|
CHRM4;RGS4 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Muscarinic receptor signaling |
0.008897083 |
8.5 |
NaN |
|
CHRM1;CHRM4 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Muscarinic receptor signaling |
0.006641482 |
10 |
NaN |
|
CHRM1;CHRM4 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Muscarinic receptor signaling |
0.008777038 |
9.5 |
NaN |
|
CHRM1;CHRM4 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.010202989 |
12 |
NaN |
|
NPPA;NPPB |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.008897083 |
8.5 |
NaN |
|
NPPA;NPPB |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.007395936 |
7 |
NaN |
|
NPPA;NPPB |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Neuregulin receptor signaling |
0.019331602 |
7 |
NaN |
|
ERBB3;NRG1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
NOD-like receptor signaling |
0.02287923 |
12 |
NaN |
|
NLRC5;NOD1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.027081863 |
19 |
NaN |
|
SPP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Perlecan synthesis |
0.025052929 |
13.5 |
NaN |
|
HSPG2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.030019151 |
13.5 |
NaN |
|
PDGFRA;PDGFRB |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.029631379 |
16 |
NaN |
|
PDGFRA;PDGFRB |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Prostaglandin E2 receptor signaling |
0.006641482 |
10 |
NaN |
|
PTGER3;RAPGEF4 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Retinol metabolism |
0.046834922 |
23 |
NaN |
|
ALDH1A1;ALDH1A3 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Retinol metabolism |
0.041189931 |
15.5 |
NaN |
|
DHRS3;RLBP1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Retinol metabolism |
0.04066719 |
19.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Semaphorin signaling |
0.042327049 |
19.5 |
NaN |
|
CRMP1;DPYSL4;PLXNA2 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Semaphorin signaling |
0.027413967 |
10 |
NaN |
|
CRMP1;DPYSL4;NRP2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.030019151 |
13.5 |
NaN |
|
PHGDH;SLC1A4 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.001464159 |
5 |
NaN |
|
PHGDH;SHMT2;SLC1A4 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Serine and glycine metabolism |
0.029631379 |
16 |
NaN |
|
PHGDH;SLC1A4 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.000901167 |
2 |
NaN |
|
PHGDH;SHMT2;SLC1A5 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.018217405 |
4 |
NaN |
|
SHMT2;SLC1A5 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Serotonin inactivation |
0.049480363 |
24 |
NaN |
|
MAOA |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Serotonin inactivation |
0.039477231 |
13 |
NaN |
|
MAOA |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.045347487 |
22.5 |
NaN |
|
TACC3 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Sodium transmembrane transport |
0.025353723 |
11 |
NaN |
|
ATP1A2;FXYD5;SCN1A |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Sodium transmembrane transport |
0.036265819 |
18 |
NaN |
|
ATP1A2;FXYD5;SCN1A |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Thin myofilament organization |
1.73E-05 |
2 |
NaN |
|
ACTA1;TNNI3;TPM2;TPM4 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Thrombospondin receptor signaling |
0.003680135 |
7 |
NaN |
|
THBS1;THBS2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.019936486 |
9 |
NaN |
|
ELN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.02293578 |
13 |
NaN |
|
ELN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.019318984 |
6.5 |
NaN |
|
ELN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Vascular endothelial growth factor receptor signaling |
0.012085707 |
11 |
NaN |
|
FLT1;KDR |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Versican receptor signaling |
0.036362165 |
14 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Versican receptor signaling |
0.039477231 |
13 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Versican receptor signaling |
0.045347487 |
22.5 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Versican receptor signaling |
0.038266416 |
11 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Versican synthesis |
0.018348624 |
10 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Versican synthesis |
0.019936486 |
9 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Versican synthesis |
0.02293578 |
13 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Versican synthesis |
0.019318984 |
6.5 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003652082 |
6 |
NaN |
|
ADAM19;ADAMTS14;ADAMTS8;ADAMTS9 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.021737239 |
11 |
NaN |
|
ADAM19;ADAMTS14;ADAMTS8 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.014592845 |
14 |
NaN |
|
ADAMTS14;ADAMTS15;ADAMTS8 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
6.34E-05 |
1 |
NaN |
|
ADAM33;ADAMTS10;ADAMTS2;ADAMTS5;ADAMTS6 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Down |
Extracellular matrix breakdown by cathepsins |
0.015095412 |
2 |
NaN |
|
CTSF;CTSV |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.012989342 |
5 |
NaN |
|
MMP1;MMP2 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Fatty acid elongation |
0.023206981 |
17 |
NaN |
|
ELOVL5;ELOVL6 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Fatty acid elongation |
0.020044392 |
12 |
NaN |
|
ELOVL5;ELOVL6 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
7.39E-05 |
2 |
NaN |
|
COL11A2;COL1A2;COL2A1;COL3A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
1.07E-06 |
2 |
NaN |
|
COL11A1;COL11A2;COL1A2;COL2A1;COL3A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.001638373 |
5 |
NaN |
|
COL11A1;COL2A1;COL3A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.01368451 |
7 |
NaN |
|
COL2A1;COL5A1 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.001270083 |
3.5 |
NaN |
|
COL1A1;COL5A1;COL5A2 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
G2 M transition checkpoint |
0.02972276 |
16 |
NaN |
|
CCNB1;CDC25C |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
Gap junction organization |
0.001908818 |
3 |
NaN |
|
GJA1;GJA3;GJC2 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
G-protein coupled receptor signaling pathway |
0.01593556 |
15 |
NaN |
|
GRK5;PDE4D;RGS4 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
G-protein coupled receptor signaling pathway |
0.008758754 |
12 |
NaN |
|
GRK5;PDE4D;RGS16 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049824365 |
19 |
NaN |
|
JAK2 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049480363 |
24 |
NaN |
|
JAK2 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039477231 |
13 |
NaN |
|
JUND |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045347487 |
22.5 |
NaN |
|
JUND |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.016062742 |
10 |
NaN |
|
INHBA;INHBB |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001845357 |
6 |
NaN |
|
A2M;PLAT |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Inhibition of apoptosis |
0.040336864 |
22 |
NaN |
|
BIRC5;PEA15 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Inhibition of apoptosis |
0.02972276 |
16 |
NaN |
|
BIRC3;BIRC5 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.026374299 |
13 |
NaN |
|
SOCS2;SOCS3 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Lipogenesis |
0.000731103 |
4 |
NaN |
|
ACLY;FASN |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Lipogenesis |
0.000634351 |
6 |
NaN |
|
ACLY;FASN |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Up |
Lipogenesis |
0.042932502 |
17 |
NaN |
|
FASN |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Lipogenesis |
0.000625494 |
4 |
NaN |
|
ACLY;FASN |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.003803269 |
3 |
NaN |
|
CXCR4;JUND |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Macrophage migration inhibitory factor signaling |
0.00500617 |
5.5 |
NaN |
|
CXCR4;JUND |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
0.042327049 |
19.5 |
NaN |
|
BUB1;CCNB2;PTTG1 |
| isoprenaline |
Sympathomimetic |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.049824365 |
19 |
NaN |
|
FBN1 |
| isoprenaline |
Sympathomimetic |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.049480363 |
24 |
NaN |
|
FBN1 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.006925405 |
9 |
NaN |
|
CCNA2;RPS6KA3 |
| isoprenaline |
Sympathomimetic |
No |
MSN08 |
Down |
WNT-Beta-catenin signaling pathway |
0.015509275 |
9 |
NaN |
|
APCDD1;DACT1;FZD2;PAX6;SFRP5 |
| isoprenaline |
Sympathomimetic |
No |
MSN01 |
Up |
Z-disc organization |
0.000741893 |
5 |
NaN |
|
ACTN2;CSRP3;PDLIM3;TCAP |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Z-disc organization |
0.019421788 |
5 |
NaN |
|
LDB3;MYPN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Mitotic spindle assembly |
0.041452288 |
20.5 |
NaN |
|
DLGAP5;TACC3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Mitotic spindle disassembly |
0.031404375 |
21 |
NaN |
|
CDK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Mitotic spindle disassembly |
0.025317572 |
16.5 |
NaN |
|
CDK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Muscarinic receptor signaling |
0.024055739 |
24.5 |
NaN |
|
RGS4;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Muscarinic receptor signaling |
0.024434507 |
25 |
NaN |
|
RGS4;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Myofibril formation |
0.038158302 |
10.5 |
NaN |
|
KLHL41 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Myofibril formation |
0.033889149 |
7 |
NaN |
|
KLHL41 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Natriuretic peptide receptor signaling |
0.000572396 |
6 |
NaN |
|
NPPA;NPPB;NPR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.017688551 |
14.5 |
NaN |
|
NPPA;NPPB |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.008957388 |
7 |
NaN |
|
NPPA;NPPB |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Natriuretic peptide receptor signaling |
0.024055739 |
24.5 |
NaN |
|
NPPA;NPPB |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.00141304 |
7.5 |
NaN |
|
NPPA;NPPB;NPR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Neuregulin receptor signaling |
0.000792034 |
1 |
NaN |
|
ERBB3;ERBB4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Neuregulin receptor signaling |
0.000622044 |
1 |
NaN |
|
ERBB4;SH3TC2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Non-vesicular phospholipid transport |
0.024178298 |
18 |
NaN |
|
PITPNM1;PLTP |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Non-vesicular phospholipid transport |
0.021680107 |
16.5 |
NaN |
|
PITPNM1;PLTP |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Non-vesicular phospholipid transport |
0.03274279 |
27 |
NaN |
|
PITPNM1;PLTP |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Non-vesicular phospholipid transport |
0.033250529 |
26.5 |
NaN |
|
PITPNM1;PLTP |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Notch receptor signaling |
0.029047606 |
20 |
NaN |
|
DLK1;MIB2;NOTCH3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Notch receptor signaling |
0.009286612 |
14 |
NaN |
|
DLK1;JAG1;LFNG;NOTCH3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Osteonectin receptor signaling |
0.002114306 |
3 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Osteonectin receptor signaling |
0.00565842 |
10.5 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Osteonectin receptor signaling |
0.000181529 |
4 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Osteonectin receptor signaling |
0.006629833 |
11.5 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Osteonectin receptor signaling |
0.010183037 |
17.5 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Osteonectin receptor signaling |
0.010348289 |
18 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.036079746 |
28.5 |
NaN |
|
SPP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.034050812 |
23 |
NaN |
|
SPP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.042784051 |
30 |
NaN |
|
SPP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Perlecan synthesis |
0.034050812 |
23 |
NaN |
|
HSPG2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.004199738 |
8 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.006196866 |
9 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.005271496 |
10 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.009707562 |
15.5 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.009930881 |
15.5 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Potassium transmembrane transport |
0.041630095 |
10 |
NaN |
|
ABCC9;ATP1A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Potassium transmembrane transport |
0.021280067 |
6.5 |
NaN |
|
ATP1A3;SLC12A6 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Procollagen processing in the ER |
0.005238589 |
10.5 |
NaN |
|
P3H1;SERPINH1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Procollagen processing in the ER |
0.005324882 |
11.5 |
NaN |
|
P3H1;SERPINH1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Progestagen synthesis |
0.037229472 |
12.5 |
NaN |
|
HSD17B2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Progestagen synthesis |
0.037229472 |
9 |
NaN |
|
HSD17B2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Proline metabolism |
0.000712142 |
6 |
NaN |
|
ALDH18A1;OAT;PYCR1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.018789642 |
4.5 |
NaN |
|
PTGFR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.018789642 |
6.5 |
NaN |
|
PTGFR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Pyrimidine synthesis and salvage |
0.024293237 |
18.5 |
NaN |
|
TK1;TYMS |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Pyrimidine synthesis and salvage |
0.031477664 |
23 |
NaN |
|
TK1;TYMS |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Removal of caspase inhibition |
0.037747261 |
10.5 |
NaN |
|
XAF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Restriction point |
0.037460883 |
23.5 |
NaN |
|
CDKN2A;E2F1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Restriction point |
0.04343155 |
26.5 |
NaN |
|
CDKN1A;CDKN2A |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Retinol metabolism |
3.10E-05 |
4 |
NaN |
|
ALDH1A1;ALDH1A2;ALDH1A3;DHRS3;RDH10 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Retinol metabolism |
0.000921206 |
5 |
NaN |
|
ALDH1A1;ALDH1A2;RBP1;RPE65 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Retinol metabolism |
0.000741131 |
5 |
NaN |
|
ALDH1A2;DHRS3;RDH10;RPE65 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Retinol metabolism |
0.041452288 |
20.5 |
NaN |
|
ALDH1A3;TTR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Retinol metabolism |
0.015797741 |
20 |
NaN |
|
ALDH1A1;ALDH1A3;TTR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Retinol metabolism |
0.016152676 |
21 |
NaN |
|
ALDH1A1;ALDH1A3;TTR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
RIG-I-like receptor signaling |
0.037229472 |
12.5 |
NaN |
|
MAVS |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.000115374 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.009930881 |
15.5 |
NaN |
|
PSAT1;SHMT2;SLC1A5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.000374503 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.000127684 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.000127684 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Serotonin and melatonin synthesis |
0.040207462 |
8.5 |
NaN |
|
SLC6A4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Serotonin inactivation |
0.037747261 |
10.5 |
NaN |
|
MAOA |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.049996342 |
24 |
NaN |
|
TACC3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Sister chromatid cohesion |
0.046821378 |
27 |
NaN |
|
CDCA5;CHTF18;RFC3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Syndecan ectodomain shedding |
0.037229472 |
12.5 |
NaN |
|
ADAMTS1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Thick myofilament organization |
0.0116002 |
4 |
NaN |
|
MYH7 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Thick myofilament organization |
0.000545195 |
2 |
NaN |
|
MYH7;TTN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Thin myofilament organization |
0.026862767 |
8.5 |
NaN |
|
TNNI3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Thin myofilament organization |
0.024178298 |
18 |
NaN |
|
ACTA1;TPM2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Thin myofilament organization |
0.012331868 |
8.5 |
NaN |
|
ACTA1;TPM4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Thin myofilament organization |
0.03274279 |
27 |
NaN |
|
TPM2;TPM4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Thin myofilament organization |
0.00239445 |
10 |
NaN |
|
ACTA1;TPM2;TPM4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.00742401 |
10.5 |
NaN |
|
THBS1;THBS2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.010348289 |
18 |
NaN |
|
THBS2;THBS4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Tight junction organization |
0.032967469 |
25 |
NaN |
|
CLDN11;CLDN6;CRB2;EMP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Tight junction organization |
0.027422091 |
18 |
NaN |
|
CLDN11;CLDN4;CLDN6;CRB2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.031404375 |
21 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.036079746 |
28.5 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.034050812 |
23 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.025317572 |
16.5 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.042784051 |
30 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Tyrosine metabolism |
0.046320227 |
17 |
NaN |
|
TYR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Tyrosine metabolism |
0.046320227 |
10 |
NaN |
|
TYR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Versican synthesis |
0.036079746 |
28.5 |
NaN |
|
VCAN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Versican synthesis |
0.034050812 |
23 |
NaN |
|
VCAN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.02741903 |
21 |
NaN |
|
APCDD1;CTHRC1;DACT1;FRZB;PAX6;SFRP2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.021357683 |
15 |
NaN |
|
APCDD1;CTHRC1;FRZB;SFRP2;SFRP4;WNT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
WNT-Beta-catenin signaling pathway |
0.005436307 |
13 |
NaN |
|
CTHRC1;DKK2;DKK3;FRZB;FZD7;SFRP2;SFRP4;WNT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.019022812 |
24 |
NaN |
|
CTHRC1;DKK2;FRZB;FZD7;SFRP2;SFRP4;WNT2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Actin filament bundling and crosslinking |
0.022802563 |
23 |
NaN |
|
FLNA;PLS3;SYNPO;TAGLN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Actin filament bundling and crosslinking |
0.048169549 |
11 |
NaN |
|
SYNPO2;USH1C |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Acute-phase response |
0.040207462 |
8.5 |
NaN |
|
TTR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.025317572 |
16.5 |
NaN |
|
ACAN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.042784051 |
30 |
NaN |
|
ACAN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.009438956 |
3 |
NaN |
|
ACAN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.01905434 |
6.5 |
NaN |
|
ALB |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.013585039 |
4 |
NaN |
|
ALB |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Alternative complement pathway |
0.010801555 |
13 |
NaN |
|
C1S;C3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Alternative complement pathway |
0.016496966 |
21.5 |
NaN |
|
C1S;CFH |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Alternative complement pathway |
0.016760685 |
22.5 |
NaN |
|
C1S;CFH |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Amyloid plaque organization |
0.009707562 |
15.5 |
NaN |
|
APBB2;APOE;VSNL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Androgen receptor signaling |
0.026986707 |
6 |
NaN |
|
AR |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.025134697 |
13.5 |
NaN |
|
HLA-A;HLA-C |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Antigen presentation via MHC class I molecules |
0.007287079 |
14 |
NaN |
|
B2M;HLA-B;HLA-C |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.007456689 |
13 |
NaN |
|
B2M;HLA-B;HLA-C |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Aspartate and arginine metabolism |
0.025134697 |
13.5 |
NaN |
|
ARG2;SLC7A1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Aspartate and arginine metabolism |
0.007681705 |
3 |
NaN |
|
ARG2;SLC7A1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Aspartate and arginine metabolism |
0.003780508 |
3 |
NaN |
|
ARG2;SLC7A1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Axonal intermediate filament dynamics |
0.024178298 |
18 |
NaN |
|
NEFH;NES |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Axonal intermediate filament dynamics |
0.012331868 |
8.5 |
NaN |
|
NEFL;NES |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Basement membrane assembly and organization |
0.038158302 |
10.5 |
NaN |
|
LAMA2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Basement membrane assembly and organization |
0.04343155 |
26.5 |
NaN |
|
COL8A2;HSPG2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Betaglycan signaling |
0.017086874 |
4 |
NaN |
|
TGFBR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Betaglycan signaling |
0.046320227 |
17 |
NaN |
|
TGFBR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Bicarbonate transmembrane transport |
0.013593392 |
5 |
NaN |
|
CA9;SLC4A5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Biglycan synthesis |
0.036079746 |
28.5 |
NaN |
|
BGN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Biglycan synthesis |
0.025317572 |
16.5 |
NaN |
|
BGN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Biglycan synthesis |
0.042784051 |
30 |
NaN |
|
BGN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Cardiomyocyte depolarization during action potential |
0.00388144 |
2 |
NaN |
|
SCN5A |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.001022508 |
2 |
NaN |
|
KCNIP2;KCNQ5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000154653 |
2 |
NaN |
|
CTGF;CYR61;NOV |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000712142 |
6 |
NaN |
|
CTGF;CYR61;WISP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
1.60E-05 |
2 |
NaN |
|
CTGF;CYR61;NOV;WISP1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.046320227 |
17 |
NaN |
|
CYR61 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.037747261 |
10.5 |
NaN |
|
CD44 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Centrosome separation |
0.037460883 |
23.5 |
NaN |
|
CCNB1;CDK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Centrosome separation |
0.001688656 |
5 |
NaN |
|
CCNB1;CDK1;KIF11 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Cholesterol synthesis |
3.90E-06 |
3 |
NaN |
|
DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MSMO1;MVD |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.023068859 |
7 |
NaN |
|
INSIG1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.020469948 |
5 |
NaN |
|
INSIG1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.01356683 |
16.5 |
NaN |
|
INSIG1;SREBF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.017688551 |
14.5 |
NaN |
|
INSIG1;SREBF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.015839486 |
14 |
NaN |
|
INSIG1;SREBF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Classical complement pathway |
0.021680107 |
16.5 |
NaN |
|
C1R;C1S |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Classical complement pathway |
0.000101168 |
3 |
NaN |
|
C1QB;C1QC;C1R;C1S |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Classical complement pathway |
0.000104494 |
4 |
NaN |
|
C1QB;C1QC;C1R;C1S |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Coagulation cascade |
0.021034131 |
8 |
NaN |
|
F5;TFPI |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Collagen fiber crosslinking |
0.009235352 |
14.5 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Collagen fiber crosslinking |
0.012078917 |
13 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Collagen fiber crosslinking |
0.000372249 |
3 |
NaN |
|
LOX;LOXL1;PXDN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Collagen fiber crosslinking |
0.000712142 |
6 |
NaN |
|
LOX;LOXL1;PXDN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Collagen fiber crosslinking |
0.000729697 |
6 |
NaN |
|
LOX;LOXL1;PXDN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005154036 |
4 |
NaN |
|
COL14A1;COL9A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.01356683 |
16.5 |
NaN |
|
COL9A2;COL9A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
3.48E-07 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1;COL9A2;COL9A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000725692 |
4 |
NaN |
|
COL14A1;COL9A2;COL9A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.001379421 |
8 |
NaN |
|
COL14A1;COL9A1;COL9A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.00141304 |
7.5 |
NaN |
|
COL14A1;COL9A1;COL9A2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Contractile ring constriction |
0.019260498 |
5.5 |
NaN |
|
MYH14 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Contractile ring constriction |
0.046320227 |
17 |
NaN |
|
MYLK |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Contractile ring formation |
0.019260498 |
5.5 |
NaN |
|
MYH14 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Decorin synthesis |
0.01905434 |
6.5 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Decorin synthesis |
0.031404375 |
21 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Decorin synthesis |
0.036079746 |
28.5 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Decorin synthesis |
0.034050812 |
23 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Decorin synthesis |
0.042784051 |
30 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Desaturation of fatty acids |
0.026862767 |
8.5 |
NaN |
|
SCD |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Desaturation of fatty acids |
0.024178298 |
18 |
NaN |
|
FADS2;SCD |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Discoidin domain receptor signaling |
0.003391299 |
8 |
NaN |
|
DDR1;DDR2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
DNA cleavage |
0.044852248 |
26 |
NaN |
|
ENDOG;FEN1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
DNA replication elongation |
0.009235352 |
14.5 |
NaN |
|
MCM2;PCNA |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
DNA replication initiation |
9.82E-05 |
5 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Elastin cross-linking and assembly |
0.002889214 |
7 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Elastin cross-linking and assembly |
0.003802769 |
7.5 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Elastin cross-linking and assembly |
0.003391299 |
8 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Elastin cross-linking and assembly |
0.005238589 |
10.5 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Elastin cross-linking and assembly |
0.005324882 |
11.5 |
NaN |
|
LOX;LOXL1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Endogenous control of complement activity |
0.016496966 |
21.5 |
NaN |
|
CFH;CFI |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Endogenous control of complement activity |
0.016760685 |
22.5 |
NaN |
|
CFH;CFI |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Epithelial intermediate filament dynamics |
0.024293237 |
18.5 |
NaN |
|
KRT19;KRT7 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Epithelial intermediate filament dynamics |
0.031477664 |
23 |
NaN |
|
KRT19;KRT7 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.000818308 |
4 |
NaN |
|
KRT7;KRT8;TCHH |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
1.96E-06 |
2 |
NaN |
|
BUB1;CENPU;MAD2L1;NDC80;NUF2;SKA3;SPC24;ZWILCH;ZWINT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.010279166 |
5 |
NaN |
|
ADAM15;ADAM33;ADAMTS14 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003034624 |
3 |
NaN |
|
ADAMTS14;ADAMTS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.038149737 |
25 |
NaN |
|
ADAM12;ADAM33;ADAMTS14 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.010005113 |
12 |
NaN |
|
ADAM12;ADAM33;ADAMTS12;ADAMTS2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001109954 |
6 |
NaN |
|
ADAM12;ADAM33;ADAMTS14;ADAMTS2;ADAMTS6 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000396138 |
4 |
NaN |
|
ADAM12;ADAM33;ADAMTS10;ADAMTS12;ADAMTS2;ADAMTS4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000414113 |
5 |
NaN |
|
ADAM12;ADAM33;ADAMTS12;ADAMTS2;ADAMTS4;ADAMTS8 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.021280067 |
6.5 |
NaN |
|
ADAMTS1;ADAMTS5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.00565842 |
10.5 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.00742401 |
10.5 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.006629833 |
11.5 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.010183037 |
17.5 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.010348289 |
18 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000526515 |
2 |
NaN |
|
MMP14;MMP2;MMP3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
3.37E-06 |
3 |
NaN |
|
MMP1;MMP12;MMP14;MMP2;MMP3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000145581 |
2 |
NaN |
|
MMP12;MMP14;MMP2;MMP3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.005265369 |
12 |
NaN |
|
MMP1;MMP14;MMP2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Extracellular matrix breakdown by serine proteases |
0.024178298 |
18 |
NaN |
|
HTRA1;PRSS12 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Extracellular matrix breakdown by serine proteases |
0.03274279 |
27 |
NaN |
|
HTRA1;PRSS12 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Extracellular matrix breakdown by serine proteases |
0.033250529 |
26.5 |
NaN |
|
HTRA1;PRSS12 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Fanconi anemia interstrand cross-link repair pathway |
0.008273573 |
13 |
NaN |
|
BRCA2;BRIP1;FANCI;UBE2T |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
8.80E-09 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
3.73E-11 |
1 |
NaN |
|
COL11A1;COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1;COL5A2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
8.27E-09 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1;COL5A2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
2.81E-07 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Fibrillar collagen core structure organization |
2.55E-08 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
2.70E-08 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Fibroblast growth factor receptor signaling |
0.005476881 |
4 |
NaN |
|
FGF1;FGF18 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
G2 M transition checkpoint |
0.005470465 |
9 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
G2 M transition checkpoint |
0.035660258 |
19 |
NaN |
|
CCNB1;CDK1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Gap junction organization |
0.047129162 |
8 |
NaN |
|
GJA5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.00380409 |
6 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Glycolysis and Gluconeogenesis |
0.00117197 |
6 |
NaN |
|
ENO1;LDHA;PGAM1;PGK1;TPI1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Glycolysis and Gluconeogenesis |
0.019552723 |
12 |
NaN |
|
ENO1;LDHA;PCK2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
0.038497269 |
7 |
NaN |
|
HK2;PCK2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.001262037 |
2 |
NaN |
|
HK2;PFKFB3;PFKFB4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049996342 |
24 |
NaN |
|
JAK2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.031477664 |
23 |
NaN |
|
GDF15;GDF6 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Growth differentiation factor receptor signaling |
0.028263201 |
19 |
NaN |
|
GDF15;GDF6 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Growth differentiation factor receptor signaling |
0.016169721 |
10.5 |
NaN |
|
GDF2;GDF6 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.028052877 |
8.5 |
NaN |
|
HBEGF |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.000638802 |
3 |
NaN |
|
HGF;MET |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.018789642 |
4.5 |
NaN |
|
MET |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.018789642 |
6.5 |
NaN |
|
MET |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.027202094 |
6 |
NaN |
|
TGFBR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Inhibin receptor signaling |
0.016169721 |
10.5 |
NaN |
|
INHBA;INHBE |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Inhibin receptor signaling |
0.002381506 |
2 |
NaN |
|
INHBE;TGFBR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.003802769 |
7.5 |
NaN |
|
MME;PLAT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.003391299 |
8 |
NaN |
|
MME;PLAT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
7.59E-05 |
2 |
NaN |
|
A2M;MME;PLAT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
7.79E-05 |
3 |
NaN |
|
A2M;MME;PLAT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.028052877 |
8.5 |
NaN |
|
A2M |
| insulin-like growth factor 1 |
Hormone |
No |
MSN09 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.028052877 |
8 |
NaN |
|
A2M |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Inhibition of apoptosis |
0.012541065 |
19 |
NaN |
|
IFI6;PEA15;XAF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Inhibition of apoptosis |
0.01282619 |
20 |
NaN |
|
IFI6;PEA15;XAF1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
JAK-STAT signaling pathway |
0.047569054 |
22 |
NaN |
|
SOCS2;STAT4 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Up |
Ketone body metabolism |
0.036079746 |
28.5 |
NaN |
|
OXCT1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Leptin receptor signaling |
0.037229472 |
12.5 |
NaN |
|
SOCS3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Up |
Lipogenesis |
0.007748155 |
3 |
NaN |
|
FASN |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
Macrophage migration inhibitory factor signaling |
0.046320227 |
17 |
NaN |
|
ACKR3 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN08 |
Down |
MAPK signaling pathway |
0.03233682 |
10 |
NaN |
|
MAP2K6;RPS6KA2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Down |
Methionine cycle |
0.049996342 |
24 |
NaN |
|
BHMT |
| insulin-like growth factor 1 |
Hormone |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.037747261 |
10.5 |
NaN |
|
FBN1 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN02 |
Down |
Microfibril scaffold organization |
0.001796822 |
9 |
NaN |
|
FBN1;MFAP2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.001826862 |
9 |
NaN |
|
FBN1;MFAP2 |
| insulin-like growth factor 1 |
Hormone |
No |
MSN06 |
Up |
Mitotic spindle assembly |
0.006947804 |
12 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Eukaryotic kinetochore dynamics |
0.00579113 |
10 |
NaN |
|
BUB1;CENPF;NDC80;NUF2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Eukaryotic kinetochore dynamics |
0.001386982 |
6 |
NaN |
|
BUB1;CENPE;CENPF;NDC80 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
8.59E-05 |
4 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;SPC24 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.009275913 |
5 |
NaN |
|
ADAM12;ADAM33;ADAMTS5 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001046931 |
4 |
NaN |
|
ADAM12;ADAM33;ADAMTS2;ADAMTS4;ADAMTS8 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.019611477 |
8 |
NaN |
|
ADAMTS14;ADAMTS2;ADAMTS8 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.010046743 |
5 |
NaN |
|
CTSF;CTSV |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.004703576 |
16 |
NaN |
|
SULF1;SULF2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.006462844 |
9.5 |
NaN |
|
SULF1;SULF2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.002720354 |
7 |
NaN |
|
MMP1;MMP14;MMP2 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.01368451 |
6 |
NaN |
|
COL1A1;COL5A2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
5.05E-09 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Fibroblast growth factor receptor signaling |
0.032966818 |
12.5 |
NaN |
|
FGF10;FGFR3 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
G2 M transition checkpoint |
0.001339555 |
8 |
NaN |
|
CCNB1;CDC25B;CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
G2 M transition checkpoint |
0.00999102 |
12 |
NaN |
|
CCNB1;CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
G2 M transition checkpoint |
0.000270376 |
7.5 |
NaN |
|
CCNB1;CDC25B;CDC25C;CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
GABA metabolism |
0.004787543 |
2.5 |
NaN |
|
ABAT;SLC6A1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Gap junction organization |
0.026374299 |
13.5 |
NaN |
|
GJA1;GJA5 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Gap junction organization |
0.042309999 |
12 |
NaN |
|
GJC2;PANX1 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.036831666 |
11 |
NaN |
|
GLS;SLC38A2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.016888017 |
7 |
NaN |
|
SLC1A5;SLC7A5 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Glycogen synthesis and glycogenolysis |
0.017564804 |
16 |
NaN |
|
PPP1R3C;PYGM |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
5.20E-11 |
1 |
NaN |
|
ALDOA;ENO1;HK2;LDHA;PFKFB3;PFKFB4;PFKL;PGAM1;PGK1;TPI1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
G-protein coupled receptor signaling pathway |
0.03831226 |
11.5 |
NaN |
|
PDE4D;RGS6 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.046898366 |
15.5 |
NaN |
|
JAK2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Growth differentiation factor receptor signaling |
0.027583816 |
14.5 |
NaN |
|
GDF15;GDF6 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.001126749 |
5 |
NaN |
|
HGF;MET |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.047931585 |
16 |
NaN |
|
HGF |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
HIF-1 receptor signaling pathway |
0.018861962 |
7 |
NaN |
|
EGLN1;EGLN3 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Hyaluronan synthesis |
0.046118342 |
13.5 |
NaN |
|
HAS2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.003304892 |
8 |
NaN |
|
MME;PLAT |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Inhibition of apoptosis |
0.00999102 |
12 |
NaN |
|
BIRC5;IFI6 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of apoptosis |
0.031652619 |
10 |
NaN |
|
IFI6;XAF1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Intracellular bridge assembly |
0.038145795 |
20 |
NaN |
|
KIF23 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Intracellular bridge assembly |
0.002397082 |
13.5 |
NaN |
|
INCENP;KIF23 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
JAK-STAT signaling pathway |
0.026374299 |
13.5 |
NaN |
|
SOCS2;STAT4 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Lamellipodium organization |
0.035387843 |
14 |
NaN |
|
ARAP3;ENAH;TIAM2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Lipid droplet mitochondria interaction |
0.046118342 |
13.5 |
NaN |
|
SNAP23 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Lipogenesis |
0.037920328 |
13 |
NaN |
|
FASN |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Lipogenesis |
0.02559389 |
17.5 |
NaN |
|
FASN |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Lipogenesis |
0.036362165 |
16 |
NaN |
|
FASN |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Metaphase to anaphase checkpoint |
3.94E-05 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;MXD3;PTTG1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Metaphase to anaphase checkpoint |
6.81E-05 |
4 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;PTTG1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Metaphase to anaphase checkpoint |
3.88E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitochondrial ADP import and ATP export |
0.012879323 |
14.5 |
NaN |
|
SLC25A5 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitochondrial ADP import and ATP export |
0.02858151 |
24.5 |
NaN |
|
SLC25A5 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitochondrial fission |
0.032966818 |
12.5 |
NaN |
|
DNM1;MTFP1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic chromosome condensation |
0.000743334 |
11 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.001606083 |
7 |
NaN |
|
AURKB;CCNA2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000221667 |
5.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle assembly |
8.15E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle assembly |
1.73E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle assembly |
0.000381785 |
9 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.019142555 |
12 |
NaN |
|
CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Mitotic spindle disassembly |
0.012879323 |
14.5 |
NaN |
|
CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Mitotic spindle disassembly |
0.02858151 |
24.5 |
NaN |
|
CDK1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Neuregulin receptor signaling |
0.000563125 |
2 |
NaN |
|
ERBB3;ERBB4;SH3TC2 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Neuronal membrane repolarization during action potential and hyperpolarization |
0.010261464 |
6 |
NaN |
|
KCNA1;KCNC3;KCNQ3 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Osteonectin receptor signaling |
0.004703576 |
16 |
NaN |
|
SMOC2;SPARC |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Osteonectin receptor signaling |
0.006462844 |
9.5 |
NaN |
|
SMOC2;SPARC |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.033609739 |
18 |
NaN |
|
SPP1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Osteopontin receptor signaling |
0.024258998 |
10.5 |
NaN |
|
SPP1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Phosphoglyceride biosynthesis |
0.016525253 |
7 |
NaN |
|
PCYT2;PTDSS1 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
PI3 kinase AKT signaling pathway |
0.02679052 |
8.5 |
NaN |
|
FOXO1;INPP4B |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.037774969 |
27 |
NaN |
|
PDGFRA;PDGFRB |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.02679052 |
8.5 |
NaN |
|
PDGFRB;RGS5 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Progesterone receptor signaling |
0.033609739 |
18 |
NaN |
|
PGR |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.046898366 |
15.5 |
NaN |
|
PTGFR |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Protein folding in mitochondria |
0.038145795 |
20 |
NaN |
|
PPIF |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Protein folding in mitochondria |
0.002397082 |
13.5 |
NaN |
|
HSPD1;PPIF |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Removal of caspase inhibition |
0.046898366 |
15.5 |
NaN |
|
XAF1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.047931585 |
16 |
NaN |
|
XAF1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Restriction point |
0.023204138 |
9 |
NaN |
|
E2F1;PFKFB3 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Retinol metabolism |
0.02287923 |
11.5 |
NaN |
|
ALDH1A2;TTR |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Retinol metabolism |
0.003167864 |
2 |
NaN |
|
ALDH1A1;RDH10;STRA6 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Retinol metabolism |
0.000203815 |
3 |
NaN |
|
ALDH1A1;LRAT;RBP1;STRA6 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Ribonucleotide reduction |
0.038145795 |
20 |
NaN |
|
RRM2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Semaphorin signaling |
0.015704931 |
6 |
NaN |
|
CRMP1;SEMA6A;SEMA6D |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.001893039 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Serine and glycine metabolism |
1.74E-05 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serotonin inactivation |
0.036362165 |
16 |
NaN |
|
MAOA |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Serotonin inactivation |
0.046898366 |
15.5 |
NaN |
|
MAOA |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid attachment to mitotic spindle |
0.000364781 |
7 |
NaN |
|
NUF2;TACC3 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid attachment to mitotic spindle |
0.02559389 |
17.5 |
NaN |
|
TACC3 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Sister chromatid segregation |
0.000132602 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Sister chromatid segregation |
0.002388781 |
8.5 |
NaN |
|
PTTG1;TOP2A |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Sister chromatid segregation |
0.000433942 |
10 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tenascin receptor signaling |
0.003406483 |
5 |
NaN |
|
TENM1;TNC |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Thin myofilament organization |
0.007189535 |
11 |
NaN |
|
TNNI3;TPM1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thin myofilament organization |
0.021152788 |
13 |
NaN |
|
ACTA1;TPM4 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Thrombospondin receptor signaling |
0.003261527 |
3 |
NaN |
|
THBS1;THBS2 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tight junction organization |
0.04605371 |
13 |
NaN |
|
CLDN6;EMP1;MPP5 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Transamination pathways |
0.015551089 |
21.5 |
NaN |
|
GOT1;GOT2 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Transamination pathways |
0.006621825 |
4 |
NaN |
|
GOT1;GOT2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.02858151 |
24.5 |
NaN |
|
ELN |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.018348624 |
9 |
NaN |
|
ELN |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.033609739 |
18 |
NaN |
|
ELN |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Urea cycle |
0.007900936 |
4 |
NaN |
|
ARG2;ASS1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.036362165 |
16 |
NaN |
|
VIPR1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.047931585 |
16 |
NaN |
|
VIPR2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Versican synthesis |
0.02858151 |
24.5 |
NaN |
|
VCAN |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Vitamin K metabolism |
0.024258998 |
10.5 |
NaN |
|
VKORC1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
WNT-Beta-catenin signaling pathway |
0.001291241 |
6 |
NaN |
|
CTHRC1;DKK1;DKK2;FRZB;PAX6;SFRP2;SFRP4;WNT2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.003178244 |
3 |
NaN |
|
FZD1;FZD2;PAX6;SFRP2;WNT5A |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.000147732 |
2 |
NaN |
|
APCDD1;DACT1;FZD2;FZD7;KREMEN1;PAX6;SFRP2;SFRP5 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Adherens junction organization |
0.02585162 |
9 |
NaN |
|
ALCAM;CDH3;CTNNA3 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Aggrecan synthesis |
0.018348624 |
9 |
NaN |
|
ACAN |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.023729711 |
7 |
NaN |
|
ALB |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Alternative complement pathway |
0.007691516 |
18.5 |
NaN |
|
C3;CFH |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.002390663 |
12 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Aspartate and arginine metabolism |
0.022263706 |
6 |
NaN |
|
ARG2;ASS1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Biglycan synthesis |
0.018348624 |
9 |
NaN |
|
BGN |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Biglycan synthesis |
0.033609739 |
18 |
NaN |
|
BGN |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.019502664 |
8 |
NaN |
|
KCND3;KCNQ5 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000358176 |
3 |
NaN |
|
CYR61;NOV;WISP1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cellular fatty acid uptake |
0.030985506 |
10 |
NaN |
|
CD36 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cellular iron uptake and export |
0.02287923 |
11.5 |
NaN |
|
SLC39A14;TFRC |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome maturation |
5.73E-05 |
4 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome maturation |
0.000422825 |
5 |
NaN |
|
AURKA;PLK1;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome maturation |
0.000270376 |
7.5 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome organization |
0.044652112 |
28 |
NaN |
|
ASPM;NEK2;POC1A;TACC3;WDR62 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Centrosome separation |
9.05E-09 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;NEK2;SPAG5 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Centrosome separation |
8.29E-10 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Centrosome separation |
1.63E-09 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Chaperone mediated protein folding in ER |
0.01117202 |
5 |
NaN |
|
DNAJB9;ERO1A;ERO1B |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Chaperone mediated protein folding in ER |
0.03831226 |
11.5 |
NaN |
|
DNAJB9;ERO1B |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cholesterol synthesis |
1.42E-14 |
1 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MVD;MVK;NSDHL;SQLE |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol synthesis |
1.68E-16 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MSMO1;MVD;MVK;NSDHL;SQLE |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cholesterol synthesis |
6.11E-18 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cholesterol synthesis |
5.49E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MSMO1;MVK;NSDHL;SQLE |
| imatinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005200747 |
9 |
NaN |
|
INSIG1;SREBF1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.002388781 |
8.5 |
NaN |
|
INSIG1;SREBF1 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.011320302 |
20 |
NaN |
|
INSIG1;SREBF1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.004787543 |
2.5 |
NaN |
|
INSIG1;SREBF1 |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fiber crosslinking |
0.010532622 |
11.5 |
NaN |
|
LOX;PXDN |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
1.79E-05 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A2;COL9A3 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.003489434 |
4 |
NaN |
|
COL12A1;COL19A1 |
| imatinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.00026753 |
4 |
NaN |
|
COL14A1;COL9A1;COL9A2 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Contractile ring constriction |
0.000221667 |
5.5 |
NaN |
|
ANLN;ECT2;MYLK |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Decorin synthesis |
0.033609739 |
18 |
NaN |
|
DCN |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Desaturation of fatty acids |
0.003316081 |
10 |
NaN |
|
FADS2;SCD |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Desaturation of fatty acids |
0.015551089 |
21.5 |
NaN |
|
FADS2;SCD |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Electron transport chain |
0.00999102 |
12 |
NaN |
|
COX7A1;SDHA |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Endogenous control of complement activity |
0.007691516 |
18.5 |
NaN |
|
CFH;CFI |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Endogenous control of complement activity |
0.010532622 |
11.5 |
NaN |
|
CFH;CFI |
| imatinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.027583816 |
14.5 |
NaN |
|
KRT19;KRT7 |
| imatinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Equatorial RhoA activation |
0.004703576 |
16 |
NaN |
|
ECT2;KIF23 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.008950881 |
6.5 |
NaN |
|
AGRN;MUSK |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Actin filament severing and depolymerization |
0.009710724 |
12.5 |
NaN |
|
LIMA1;LIMK2;TAGLN2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Aggrecan synthesis |
0.035462244 |
28 |
NaN |
|
ACAN |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Alternative complement pathway |
0.01168318 |
14.5 |
NaN |
|
C1S;CFH |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Axonal intermediate filament dynamics |
0.008950881 |
6.5 |
NaN |
|
NEFL;NES |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Bicarbonate transmembrane transport |
0.011961902 |
5.5 |
NaN |
|
SLC26A3;SLC26A8;SLC4A10 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Bicarbonate transmembrane transport |
0.02812372 |
22.5 |
NaN |
|
SLC26A8;SLC26A9;SLC4A10 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Biglycan synthesis |
0.035462244 |
28 |
NaN |
|
BGN |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Calcitonin receptor signaling |
0.042414608 |
19.5 |
NaN |
|
CALCB |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Calcitonin receptor signaling |
0.044140376 |
10 |
NaN |
|
CALCB |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.03648388 |
12.5 |
NaN |
|
KCNIP2;KCNQ5 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Cell cycle arrest in response to DNA damage |
0.014121703 |
9.5 |
NaN |
|
BBC3;CDKN1A;MDM2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Cell cycle arrest in response to DNA damage |
0.00301256 |
4 |
NaN |
|
BBC3;CDKN1A;GADD45A;MDM2 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Cell cycle arrest in response to DNA damage |
0.001810808 |
5 |
NaN |
|
BBC3;CDKN1A;GADD45A;MDM2 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Cellular cholesterol uptake and efflux |
0.03055135 |
15.5 |
NaN |
|
ABCA12;MSR1 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Centrosome maturation |
0.017179159 |
15.5 |
NaN |
|
PLK1;TPX2 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Centrosome maturation |
0.028881222 |
18.5 |
NaN |
|
PLK1;TPX2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Centrosome maturation |
0.006300921 |
10.5 |
NaN |
|
PLK1;TPX2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Centrosome separation |
0.000541998 |
4 |
NaN |
|
CCNB1;CDK1;SPAG5 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Centrosome separation |
2.44E-08 |
1 |
NaN |
|
CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Centrosome separation |
2.01E-06 |
2 |
NaN |
|
CCNB1;CDK1;KIF11;SPAG5 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Chaperone-mediated autophagy |
0.033935849 |
18.5 |
NaN |
|
HSPA8 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Chaperone-mediated autophagy |
0.044657802 |
20.5 |
NaN |
|
HSPA8 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Chaperone-mediated autophagy |
0.020187315 |
13.5 |
NaN |
|
HSPA8 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Chloride transmembrane transport |
0.03055135 |
15.5 |
NaN |
|
CLCN5;SLC26A8 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Chloride transmembrane transport |
0.042508252 |
10 |
NaN |
|
CFTR;SLC26A8 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Classical complement pathway |
0.023405457 |
18.5 |
NaN |
|
C1R;C1S |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Coagulation cascade |
0.036577041 |
9 |
NaN |
|
F11;KLKB1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Coagulation cascade |
3.53E-05 |
2 |
NaN |
|
F11;F2RL1;F5;KLKB1;TFPI |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Coagulation factor synthesis and vitamin K metabolism |
0.01711611 |
16 |
NaN |
|
F11;F5 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Collagen fiber crosslinking |
0.01168318 |
14.5 |
NaN |
|
LOX;PXDN |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Contractile ring constriction |
0.004563637 |
2 |
NaN |
|
ANLN;MYH14 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.002816438 |
9 |
NaN |
|
ANLN;MYH14 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Contractile ring constriction |
0.004856492 |
9 |
NaN |
|
ANLN;MYH14 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Contractile ring constriction |
0.001000091 |
6 |
NaN |
|
ANLN;MYH14 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Contractile ring formation |
0.004856492 |
9 |
NaN |
|
MYH14;RACGAP1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Contractile ring formation |
0.001000091 |
6 |
NaN |
|
MYH14;RACGAP1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Decorin synthesis |
0.035462244 |
28 |
NaN |
|
DCN |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Desmosome organization |
0.011961902 |
5.5 |
NaN |
|
DSG1;DSG3;DSG4 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Desmosome organization |
0.02812372 |
22.5 |
NaN |
|
DSC3;DSG1;DSG3 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
DNA replication elongation |
4.81E-05 |
2 |
NaN |
|
MCM2;MCM5;MCM7 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
DNA replication elongation |
0.000110076 |
4 |
NaN |
|
MCM2;MCM5;MCM7 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
DNA replication elongation |
0.049713197 |
21.5 |
NaN |
|
MCM5 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
DNA replication initiation |
0.000793672 |
5 |
NaN |
|
MCM2;MCM5;MCM6;MCM7 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
DNA replication initiation |
0.000207233 |
6 |
NaN |
|
CDC6;GINS2;MCM2;MCM5;MCM7 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Drug and toxin export via membrane transport proteins |
0.000979254 |
1 |
NaN |
|
ABCB1;ABCC11;ABCC3;ABCG8 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Drug and toxin export via membrane transport proteins |
0.024307475 |
21 |
NaN |
|
ABCA1;ABCC3;ABCG8 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Eicosanoid metabolism |
0.039992364 |
18 |
NaN |
|
CYP2J2;PTGS1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Epithelial intermediate filament dynamics |
0.011766804 |
8 |
NaN |
|
KRT19;KRT8 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Equatorial RhoA activation |
0.039970575 |
18.5 |
NaN |
|
KIF23 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
0.000442261 |
3 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Eukaryotic kinetochore dynamics |
1.22E-07 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;MAD2L1;MTUS2;NDC80;TTK;ZWINT |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
0.000568558 |
4 |
NaN |
|
BUB1;CENPE;CENPF;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.014911907 |
5 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS5 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
4.55E-05 |
1 |
NaN |
|
ADAM12;ADAM15;ADAM19;ADAMTS1;ADAMTS14 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01622804 |
13 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS14 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.007177789 |
9.5 |
NaN |
|
SULF1;SULF2 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000742746 |
2 |
NaN |
|
MMP1;MMP13;MMP2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.001253764 |
2 |
NaN |
|
MMP1;MMP12;MMP13 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown by meprins |
0.044140376 |
10 |
NaN |
|
MEP1A |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by serine proteases |
0.023405457 |
18.5 |
NaN |
|
HTRA1;PRSS12 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Extrinsic apoptosis pathway |
0.000319501 |
1 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Extrinsic apoptosis pathway |
0.012663587 |
7 |
NaN |
|
FAS;TNFRSF10A |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Extrinsic apoptosis pathway |
0.000359802 |
1 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.018384589 |
11.5 |
NaN |
|
COL1A2;MMP13 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Fibrillar collagen core structure organization |
7.33E-09 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Fibrillin synthesis |
0.000864304 |
6 |
NaN |
|
FBN1;FBN2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Fibulin receptor signaling |
0.033935849 |
18.5 |
NaN |
|
FBLN1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Focal adhesion organization |
0.012006745 |
4 |
NaN |
|
DLC1;LPP;RSU1;TLN2 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
G2 M transition checkpoint |
0.027228456 |
8.5 |
NaN |
|
CCNB1;WEE1 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
G2 M transition checkpoint |
0.017179159 |
15.5 |
NaN |
|
CCNB1;CDK1 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
G2 M transition checkpoint |
0.002153085 |
7 |
NaN |
|
CCNB1;CDK1;WEE1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
G2 M transition checkpoint |
0.006300921 |
10.5 |
NaN |
|
CCNB1;CDK1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Gap junction organization |
0.03648388 |
12.5 |
NaN |
|
GJA1;GJA5 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.031721823 |
10.5 |
NaN |
|
SLC1A3;SLC1A5 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Glutamate-mediated control of postsynaptic potential |
0.021644876 |
7 |
NaN |
|
GRIA1;GRID2;GRIN2B |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.043277686 |
15 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.033935849 |
18.5 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.044657802 |
20.5 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.020187315 |
13.5 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.030483957 |
24 |
NaN |
|
GDF15;GDF6 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Histamine metabolism |
0.042414608 |
19.5 |
NaN |
|
HDC |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Hyaluronan receptor CD44 signaling |
0.003675108 |
6.5 |
NaN |
|
CD44;PTPRC |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Hyaluronan-mediated motility receptor signaling |
0.022582922 |
14.5 |
NaN |
|
HMMR |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001353509 |
4 |
NaN |
|
A2M;PLAT |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001466565 |
3 |
NaN |
|
A2M;PLAT |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
4.43E-05 |
3 |
NaN |
|
A2M;MME;PLAT |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Inositol metabolism and transport |
0.044140376 |
10 |
NaN |
|
INPP5D |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Integrin-mediated leukocyte rolling |
0.023405457 |
18.5 |
NaN |
|
ICAM1;VCAM1 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Intracellular bridge abscission |
0.024592889 |
17 |
NaN |
|
CEP55;EXOC6B;TEX14 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Intracellular bridge assembly |
0.030128947 |
16.5 |
NaN |
|
KIF23 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Intrinsic apoptosis pathway |
0.002972918 |
5 |
NaN |
|
BAK1;BAX;BBC3 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Intrinsic apoptosis pathway |
0.04876973 |
12 |
NaN |
|
BAX;BBC3 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Intrinsic apoptosis pathway |
0.003332429 |
6 |
NaN |
|
BAX;BBC3;BCL2L1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.035147755 |
17 |
NaN |
|
STAT1;USP18 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Leukocyte transmigration through endothelium |
0.049713197 |
21.5 |
NaN |
|
MCAM |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
0.002580751 |
8 |
NaN |
|
BUB1;CDC20;CENPE;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Metaphase to anaphase checkpoint |
8.81E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
1.02E-06 |
1 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Microfibril scaffold organization |
0.001254553 |
5 |
NaN |
|
FBN1;MFAP2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Microfibril scaffold organization |
0.033935849 |
18.5 |
NaN |
|
FBN1 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.004856492 |
9 |
NaN |
|
AURKB;CCNA2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.001000091 |
6 |
NaN |
|
AURKB;CCNA2 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Mitotic spindle assembly |
0.031721823 |
10.5 |
NaN |
|
NUSAP1;TPX2 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Mitotic spindle assembly |
0.001243697 |
7 |
NaN |
|
NUSAP1;TPX2;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Mitotic spindle assembly |
0.000154691 |
5 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Mitotic spindle assembly |
6.70E-06 |
3 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Z-disc organization |
0.004691376 |
3 |
NaN |
|
ACTN2;LDB3;PDLIM5 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Z-disc organization |
0.049507089 |
22 |
NaN |
|
ACTN2;PDLIM5 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Mitotic spindle disassembly |
0.01711362 |
13 |
NaN |
|
CDK1 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Mitotic spindle disassembly |
0.022582922 |
14.5 |
NaN |
|
CDK1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Mitotic spindle disassembly |
0.010144672 |
12 |
NaN |
|
CDK1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Myofibril formation |
0.01910546 |
6 |
NaN |
|
PDLIM5;TMOD1 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.004177141 |
10 |
NaN |
|
NPPA;NPPB |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Necroptosis induction |
0.021436133 |
13.5 |
NaN |
|
TNFRSF1A |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Neuregulin receptor signaling |
0.024426533 |
16 |
NaN |
|
ERBB3;ERBB4 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Neuregulin receptor signaling |
0.005285654 |
9 |
NaN |
|
ERBB3;ERBB4 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Notch receptor signaling |
0.032238557 |
25 |
NaN |
|
DLK1;JAG1;NOTCH3 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Nucleotide excision repair |
0.001323288 |
3 |
NaN |
|
DDB2;PCNA;POLH;XPC |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Nucleotide excision repair |
0.001535642 |
4 |
NaN |
|
DDB2;PCNA;POLH;XPC |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Osteonectin receptor signaling |
0.007177789 |
9.5 |
NaN |
|
SMOC2;SPARC |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Osteopontin receptor signaling |
0.035462244 |
28 |
NaN |
|
SPP1 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.01711362 |
13 |
NaN |
|
SPP1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Polyol pathway |
0.007177789 |
9.5 |
NaN |
|
AKR1B1;AKR1B10 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Potassium transmembrane transport |
0.014121703 |
9.5 |
NaN |
|
SLC12A1;SLC12A4;SLC24A4 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Potassium transmembrane transport |
0.024346481 |
15 |
NaN |
|
ATP1A3;FXYD1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Procollagen processing in the ER |
0.003675108 |
6.5 |
NaN |
|
P3H1;PPIB |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Ras signaling pathway |
0.009710724 |
12.5 |
NaN |
|
KSR1;KSR2;SHC1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Recycling endosome dynamics |
0.022644486 |
7 |
NaN |
|
ASAP1;KIF13A;SNAP23 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
RNA editing |
0.018384589 |
11.5 |
NaN |
|
APOBEC2;APOBEC3C |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
RNA editing |
0.001757209 |
3 |
NaN |
|
A1CF;APOBEC2;APOBEC3H |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
RNA editing |
0.001173699 |
2 |
NaN |
|
APOBEC2;APOBEC3C;APOBEC3H |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Selectin-mediated Leukocyte rolling |
0.00081732 |
4 |
NaN |
|
ICAM1;SELP;VCAM1 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Semaphorin signaling |
0.037609535 |
14 |
NaN |
|
NRP1;PLXNA4;SEMA5A |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Sister chromatid segregation |
0.007176501 |
11 |
NaN |
|
ESPL1;TOP2A |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Sodium transmembrane transport |
0.048020416 |
11 |
NaN |
|
SCN3A;SCNN1A;SLC13A1 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Tenascin receptor signaling |
0.007177789 |
9.5 |
NaN |
|
TNC;TNR |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Thick myofilament organization |
0.001409479 |
1 |
NaN |
|
MYH7;TTN |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Thick myofilament organization |
0.030128947 |
16.5 |
NaN |
|
MYH7 |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Thin myofilament organization |
0.005782315 |
11 |
NaN |
|
ACTA1;TNNI3 |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Thin myofilament organization |
0.009898099 |
12 |
NaN |
|
ACTA1;TNNI3 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Thin myofilament organization |
0.002072439 |
8 |
NaN |
|
ACTA1;TNNI3 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Thrombopoietin receptor signaling |
0.039970575 |
18.5 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Thyroid-hormone synthesis |
0.023405457 |
18.5 |
NaN |
|
IYD;TG |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Tight junction organization |
0.039540041 |
8 |
NaN |
|
CLDN1;F11R;MYLK |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Tight junction organization |
0.046359007 |
20 |
NaN |
|
CLDN6;CRB2 |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Tropoelastin synthesis |
0.021436133 |
13.5 |
NaN |
|
ELN |
| idarubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Tropoelastin synthesis |
0.035462244 |
28 |
NaN |
|
ELN |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.01711362 |
13 |
NaN |
|
ELN |
| idarubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Vesicle tethering at plasma membrane |
0.027228456 |
8.5 |
NaN |
|
EXOC6B;RHOQ |
| idarubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Vesicle tethering at plasma membrane |
0.028881222 |
18.5 |
NaN |
|
EXOC6B;RHOQ |
| idarubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Water transmembrane transport |
0.016600789 |
8 |
NaN |
|
AQP4;AQP9 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic spindle disassembly |
0.02664079 |
21 |
NaN |
|
CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Mitotic spindle disassembly |
0.028757939 |
24.5 |
NaN |
|
CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic spindle disassembly |
0.02858151 |
25 |
NaN |
|
CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic spindle disassembly |
0.027699365 |
27.5 |
NaN |
|
CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.009884567 |
14.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.010986142 |
22.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.011455252 |
17.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.011320302 |
17.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.010656589 |
20.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Osteonectin receptor signaling |
0.002114306 |
1 |
NaN |
|
SMOC2;SPARC |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Osteopontin receptor signaling |
0.02664079 |
21 |
NaN |
|
SPP1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Osteopontin receptor signaling |
0.028757939 |
24.5 |
NaN |
|
SPP1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.02858151 |
25 |
NaN |
|
SPP1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Osteopontin receptor signaling |
0.027699365 |
27.5 |
NaN |
|
SPP1 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Progesterone receptor signaling |
0.018613267 |
8.5 |
NaN |
|
PGR |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Protein polyubiquitination |
0.031304625 |
7 |
NaN |
|
ISG15;UCHL1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Pyrimidine synthesis and salvage |
0.017812077 |
18 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Pyrimidine synthesis and salvage |
0.01975769 |
27.5 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Pyrimidine synthesis and salvage |
0.020584442 |
21.5 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Pyrimidine synthesis and salvage |
0.020346716 |
21.5 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Pyrimidine synthesis and salvage |
0.019176257 |
24.5 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Removal of caspase inhibition |
0.037747261 |
8.5 |
NaN |
|
XAF1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Retinol metabolism |
0.045465381 |
27 |
NaN |
|
ALDH1A1;ALDH1A3 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Retinol metabolism |
0.000359811 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;RLBP1;RPE65 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Retinol metabolism |
0.000390839 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;RLBP1;RPE65 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Retinol metabolism |
0.005346195 |
14 |
NaN |
|
ALDH1A1;ALDH1A3;RPE65 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Retinol metabolism |
0.004897419 |
18 |
NaN |
|
ALDH1A1;ALDH1A3;RPE65 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Semaphorin signaling |
0.026457494 |
6 |
NaN |
|
NRP2;RND1;SEMA6A |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Semaphorin signaling |
0.003492829 |
2 |
NaN |
|
NRP2;RND1;SEMA6A;SEMA6D |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Semaphorin signaling |
0.002580751 |
3 |
NaN |
|
NRP2;RND1;SEMA6A;SEMA6D |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Semaphorin signaling |
0.002829489 |
3 |
NaN |
|
NRP2;RND1;SEMA6A;SEMA6D |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Semaphorin signaling |
0.003433854 |
2 |
NaN |
|
NRP2;RND1;SEMA6A;SEMA6D |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.016979566 |
7 |
NaN |
|
PHGDH;PSAT1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Serine and glycine metabolism |
0.000735879 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.000792452 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serine and glycine metabolism |
0.016827526 |
6 |
NaN |
|
PHGDH;PSAT1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000707444 |
9 |
NaN |
|
NUF2;TACC3 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000789471 |
10.5 |
NaN |
|
NUF2;TACC3 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000824555 |
9.5 |
NaN |
|
NUF2;TACC3 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000764879 |
10.5 |
NaN |
|
NUF2;TACC3 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Sister chromatid segregation |
0.00035274 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Sister chromatid segregation |
0.000414519 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Sister chromatid segregation |
0.000441875 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sister chromatid segregation |
0.000433942 |
5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sister chromatid segregation |
0.000395672 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Syndecan receptor signaling |
0.006707292 |
12 |
NaN |
|
SDC1;SDC3 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Tenascin receptor signaling |
0.00456203 |
17.5 |
NaN |
|
TENM1;TNC |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Tenascin receptor signaling |
0.004760776 |
15.5 |
NaN |
|
TENM1;TNC |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Tenascin receptor signaling |
0.004703576 |
12.5 |
NaN |
|
TENM1;TNC |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tenascin receptor signaling |
0.004422563 |
16 |
NaN |
|
TENM1;TNC |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.00456203 |
17.5 |
NaN |
|
THBS1;THBS4 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.004703576 |
12.5 |
NaN |
|
THBS1;THBS4 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Transmembrane glucose transport |
0.00456203 |
17.5 |
NaN |
|
SLC2A1;SLC2A3 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Transmembrane glucose transport |
0.004422563 |
16 |
NaN |
|
SLC2A1;SLC2A3 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.02664079 |
21 |
NaN |
|
ELN |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.028757939 |
24.5 |
NaN |
|
ELN |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.027699365 |
27.5 |
NaN |
|
ELN |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Versican synthesis |
0.02664079 |
21 |
NaN |
|
VCAN |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Versican synthesis |
0.028757939 |
24.5 |
NaN |
|
VCAN |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Versican synthesis |
0.02858151 |
25 |
NaN |
|
VCAN |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Versican synthesis |
0.027699365 |
27.5 |
NaN |
|
VCAN |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Water transmembrane transport |
0.009381839 |
2 |
NaN |
|
AQP3;AQP7 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Water transmembrane transport |
0.008967419 |
4 |
NaN |
|
AQP3;AQP7 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Water transmembrane transport |
0.008885569 |
4 |
NaN |
|
AQP3;AQP7 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.030670085 |
9 |
NaN |
|
DKK2;FZD1;SFRP4;WNT2 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
4.96E-07 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;NDC80;NUF2;SPC24;TTK;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
8.43E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Eukaryotic kinetochore dynamics |
9.88E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
0.000663612 |
6 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;SPC24;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
7.51E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.009644999 |
5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.007665244 |
6 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.008219515 |
5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.009521023 |
5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.031852436 |
28 |
NaN |
|
CTSB;CTSV |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.011389077 |
6 |
NaN |
|
MMP14;MMP2 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.024935716 |
29 |
NaN |
|
MMP12;MMP3 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.025671642 |
23 |
NaN |
|
MMP1;MMP12 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.01470451 |
3 |
NaN |
|
COL5A1;COL5A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.000541998 |
1 |
NaN |
|
COL1A1;COL5A1;COL5A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.027639392 |
24 |
NaN |
|
COL11A1;COL2A1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.031852436 |
28 |
NaN |
|
COL11A1;COL2A1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.031491887 |
27.5 |
NaN |
|
COL11A1;COL2A1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.029714771 |
30 |
NaN |
|
COL11A1;COL2A1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
G2 M transition checkpoint |
0.039146161 |
25.5 |
NaN |
|
CCNB1;CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
G2 M transition checkpoint |
0.044988879 |
30 |
NaN |
|
CCNB1;CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
G2 M transition checkpoint |
0.044489851 |
29 |
NaN |
|
CCNB1;CDK1 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
GABA metabolism |
0.010986142 |
22.5 |
NaN |
|
ABAT;SLC6A1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Gap junction organization |
0.028287811 |
7 |
NaN |
|
GJA5;GJB2 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Gap junction organization |
0.027085315 |
11 |
NaN |
|
GJA5;GJB2 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Gap junction organization |
0.023162096 |
8 |
NaN |
|
GJA5;GJB2 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Gap junction organization |
0.026847432 |
8 |
NaN |
|
GJA5;GJB2 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.023500077 |
10 |
NaN |
|
SLC1A3;SLC7A5 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.003568606 |
14 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
0.003857319 |
13 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Glycolysis and Gluconeogenesis |
0.003773255 |
10 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.003371709 |
13 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Hedgehog receptor signaling |
0.049963218 |
10 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Hedgehog receptor signaling |
0.047907402 |
13 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Hedgehog receptor signaling |
0.041167145 |
10 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Hedgehog receptor signaling |
0.043108677 |
8 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Hedgehog receptor signaling |
0.047500161 |
11 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Hepatocyte growth factor receptor signaling |
0.036881693 |
12 |
NaN |
|
HGF |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Hepatocyte growth factor receptor signaling |
0.033935849 |
9 |
NaN |
|
HGF |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Inhibition of apoptosis |
0.021034131 |
5 |
NaN |
|
IFI6;XAF1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Intracellular bridge assembly |
0.002084881 |
10 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Intracellular bridge assembly |
0.002324253 |
13 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Intracellular bridge assembly |
0.002426522 |
12 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Intracellular bridge assembly |
0.002397082 |
8 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Intracellular bridge assembly |
0.002252526 |
12 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Lipogenesis |
0.000789471 |
10.5 |
NaN |
|
ACLY;FASN |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Lipogenesis |
0.000824555 |
9.5 |
NaN |
|
ACLY;FASN |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Lipogenesis |
0.000764879 |
10.5 |
NaN |
|
ACLY;FASN |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
2.30E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PLK3;PTTG1;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
3.66E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Metaphase to anaphase checkpoint |
4.20E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
0.000355871 |
3 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;PLK3;PTTG1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Metaphase to anaphase checkpoint |
3.31E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000179921 |
5.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000211674 |
5.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000225749 |
5.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000221667 |
2 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000201982 |
6.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic spindle assembly |
1.40E-05 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Mitotic spindle assembly |
1.83E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Mitotic spindle assembly |
2.03E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic spindle assembly |
0.000381785 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic spindle assembly |
1.69E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.01905434 |
4 |
NaN |
|
ALB |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Alternative complement pathway |
6.19E-05 |
1 |
NaN |
|
C1S;C3;CFH |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Alternative complement pathway |
0.002816438 |
4 |
NaN |
|
C1S;CFH |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Alternative complement pathway |
5.19E-05 |
1 |
NaN |
|
C1S;C3;CFH |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Alternative complement pathway |
6.10E-05 |
1 |
NaN |
|
C1S;C3;CFH |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Androgen receptor signaling |
0.037747261 |
8.5 |
NaN |
|
AR |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Androgen receptor signaling |
0.036708532 |
10 |
NaN |
|
AR |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.031852436 |
28 |
NaN |
|
HLA-B;HLA-C |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.031491887 |
27.5 |
NaN |
|
HLA-B;HLA-C |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Axonal intermediate filament dynamics |
0.013596343 |
16.5 |
NaN |
|
NEFM;NES |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Axonal intermediate filament dynamics |
0.015551089 |
19.5 |
NaN |
|
NEFM;NES |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Biglycan synthesis |
0.02664079 |
21 |
NaN |
|
BGN |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.007691516 |
15.5 |
NaN |
|
CTGF;CYR61 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome maturation |
0.039146161 |
25.5 |
NaN |
|
PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Centrosome maturation |
0.004020563 |
15 |
NaN |
|
AURKA;PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Centrosome maturation |
0.004273932 |
14 |
NaN |
|
AURKA;PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome maturation |
0.004200562 |
11 |
NaN |
|
AURKA;PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome maturation |
0.003845422 |
14 |
NaN |
|
AURKA;PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome organization |
0.009332058 |
13 |
NaN |
|
ASPM;NEK2;PAX6;PLK3;TACC3;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Centrosome organization |
0.012010543 |
25 |
NaN |
|
ASPM;NEK2;PAX6;TACC3;TUBG1;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Centrosome organization |
0.013257546 |
19 |
NaN |
|
ASPM;NEK2;PAX6;TACC3;TUBG1;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome organization |
0.003177341 |
9 |
NaN |
|
ASPM;NEK2;PAX6;PLK3;TACC3;TUBG1;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome organization |
0.011172389 |
22 |
NaN |
|
ASPM;NEK2;PAX6;TACC3;TUBG1;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome separation |
6.53E-08 |
1 |
NaN |
|
CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Centrosome separation |
1.46E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Centrosome separation |
1.70E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome separation |
9.93E-08 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome separation |
1.31E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Cholesterol synthesis |
0.002086621 |
12 |
NaN |
|
DHCR24;DHCR7;MVK;NSDHL |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Cholesterol synthesis |
0.002258742 |
11 |
NaN |
|
DHCR24;DHCR7;MVK;NSDHL |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Cholesterol synthesis |
0.002208592 |
7 |
NaN |
|
DHCR24;DHCR7;MVK;NSDHL |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Cholesterol synthesis |
0.000173848 |
5 |
NaN |
|
DHCR24;DHCR7;MSMO1;MVK;NSDHL |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.010986142 |
22.5 |
NaN |
|
INSIG1;SREBF1 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Classical complement pathway |
0.006808638 |
3 |
NaN |
|
C1R;C1S |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Classical complement pathway |
0.005782315 |
5 |
NaN |
|
C1R;C1S |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Classical complement pathway |
0.006076013 |
4 |
NaN |
|
C1R;C1S |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Classical complement pathway |
0.006746097 |
3 |
NaN |
|
C1R;C1S |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fiber crosslinking |
0.007462268 |
20 |
NaN |
|
LOXL1;PLOD1 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fiber crosslinking |
0.007236283 |
19 |
NaN |
|
LOXL1;PLOD1 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009884567 |
14.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010986142 |
22.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.011455252 |
17.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.011320302 |
17.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010656589 |
20.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Contractile ring constriction |
0.000179921 |
5.5 |
NaN |
|
ANLN;ECT2;MYLK |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Contractile ring constriction |
0.000211674 |
5.5 |
NaN |
|
ANLN;ECT2;MYLK |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Contractile ring constriction |
0.000225749 |
5.5 |
NaN |
|
ANLN;ECT2;MYLK |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Contractile ring constriction |
0.007691516 |
15.5 |
NaN |
|
ANLN;MYLK |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Contractile ring constriction |
0.000201982 |
6.5 |
NaN |
|
ANLN;ECT2;MYLK |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Decorin synthesis |
0.018613267 |
8.5 |
NaN |
|
DCN |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Up |
Decorin synthesis |
0.01711362 |
7 |
NaN |
|
DCN |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Decorin synthesis |
0.017554693 |
6 |
NaN |
|
DCN |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Decorin synthesis |
0.018525053 |
7 |
NaN |
|
DCN |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Desaturation of fatty acids |
0.013596343 |
16.5 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Desaturation of fatty acids |
0.015096478 |
26 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Desaturation of fatty acids |
0.015734625 |
20 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Desaturation of fatty acids |
0.015551089 |
19.5 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Desaturation of fatty acids |
0.014647932 |
23 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
DNA replication initiation |
0.000444888 |
8 |
NaN |
|
CDC45;CDC6;GINS2;MCM10;MCM5 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
DNA replication initiation |
0.000571445 |
9 |
NaN |
|
CDC45;CDC6;GINS2;MCM10;MCM5 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
DNA replication initiation |
0.000531713 |
9 |
NaN |
|
CDC45;CDC6;GINS2;MCM10;MCM5 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.01975769 |
27.5 |
NaN |
|
KRT19;KRT7 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.020584442 |
21.5 |
NaN |
|
KRT19;KRT7 |
| gefitinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
0.020346716 |
21.5 |
NaN |
|
KRT19;KRT7 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Epithelial intermediate filament dynamics |
0.019176257 |
24.5 |
NaN |
|
KRT19;KRT7 |
| gefitinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Equatorial RhoA activation |
0.004096343 |
11 |
NaN |
|
ECT2;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Equatorial RhoA activation |
0.00456203 |
17.5 |
NaN |
|
ECT2;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN06 |
Down |
Equatorial RhoA activation |
0.004760776 |
15.5 |
NaN |
|
ECT2;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Equatorial RhoA activation |
0.004422563 |
16 |
NaN |
|
ECT2;KIF23 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Adrenergic receptor signaling |
0.037291758 |
20 |
NaN |
|
RAPGEF4;RGS16;RGS4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Aggrecan synthesis |
0.028669725 |
13 |
NaN |
|
ACAN |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Aggrecan synthesis |
0.027964008 |
18.5 |
NaN |
|
ACAN |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Aggrecan synthesis |
0.028669725 |
16 |
NaN |
|
ACAN |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.024788285 |
15 |
NaN |
|
ALB |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.028669725 |
16 |
NaN |
|
ALB |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Alternative complement pathway |
0.002298245 |
3 |
NaN |
|
C3;CFH |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Alternative complement pathway |
0.002787899 |
3 |
NaN |
|
C3;CFH |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Alternative complement pathway |
0.002990614 |
6.5 |
NaN |
|
C3;CFH |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Alternative complement pathway |
0.00237668 |
5.5 |
NaN |
|
C3;CFH |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.031671949 |
17.5 |
NaN |
|
HLA-B;HLA-C |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.002245939 |
7 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.031671949 |
21.5 |
NaN |
|
HLA-B;HLA-C |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Aspartate and arginine metabolism |
0.031671949 |
17.5 |
NaN |
|
ARG2;SLC7A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Aspartate and arginine metabolism |
0.030243397 |
20.5 |
NaN |
|
ARG2;SLC7A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Aspartate and arginine metabolism |
0.029364515 |
18 |
NaN |
|
ARG2;SLC7A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Aspartate and arginine metabolism |
0.031671949 |
21.5 |
NaN |
|
ARG2;SLC7A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Basement membrane assembly and organization |
0.031671949 |
21.5 |
NaN |
|
COL4A4;HSPG2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Biglycan synthesis |
0.015437544 |
8 |
NaN |
|
BGN |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Biglycan synthesis |
0.017642908 |
14 |
NaN |
|
BGN |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Biglycan synthesis |
0.020289344 |
9 |
NaN |
|
BGN |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Cardiomyocyte depolarization during action potential |
0.024788285 |
15 |
NaN |
|
SCN5A |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.048964244 |
19 |
NaN |
|
CD44 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.019882363 |
10.5 |
NaN |
|
ABCA1;ABCG1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Cellular iron storage |
0.045605319 |
13.5 |
NaN |
|
FTH1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Cellular iron storage |
0.046374785 |
20 |
NaN |
|
FTH1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Centrosome maturation |
0.018196826 |
17 |
NaN |
|
PLK1;TPX2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Centrosome separation |
1.82E-05 |
3 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Centrosome separation |
0.010156124 |
10.5 |
NaN |
|
CDK1;KIF11 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Cholesterol synthesis |
0.002039177 |
6 |
NaN |
|
DHCR24;DHCR7;FDFT1;MSMO1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Cholesterol synthesis |
7.77E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SQLE |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Class switch recombination |
0.01609249 |
12 |
NaN |
|
BCL6;IL7R;IRF4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.004135058 |
5 |
NaN |
|
COL14A1;COL9A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.004433898 |
9 |
NaN |
|
COL14A1;COL9A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.011387686 |
8.5 |
NaN |
|
COL12A1;COL9A2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010526062 |
10.5 |
NaN |
|
COL12A1;COL9A2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Connection of muscle sarcomere to plasma membrane |
0.031671949 |
17.5 |
NaN |
|
ANK3;TLN2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Contractile ring constriction |
0.00237668 |
5.5 |
NaN |
|
MYH14;MYLK |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Decorin synthesis |
0.015437544 |
8 |
NaN |
|
DCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.017025406 |
8.5 |
NaN |
|
DCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Decorin synthesis |
0.017642908 |
14 |
NaN |
|
DCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.015702188 |
12.5 |
NaN |
|
DCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Endogenous control of complement activity |
0.002990614 |
6.5 |
NaN |
|
CFH;CFI |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Epithelial intermediate filament dynamics |
0.0155326 |
9.5 |
NaN |
|
KRT19;KRT7 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
ER unfolded protein response pathway |
0.001174661 |
2 |
NaN |
|
ATF4;HERPUD1;PPP1R15A |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
ER unfolded protein response pathway |
0.019524203 |
14 |
NaN |
|
ATF4;HERPUD1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
ER unfolded protein response pathway |
0.01894582 |
14 |
NaN |
|
ATF4;HERPUD1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
ER unfolded protein response pathway |
0.001174661 |
3 |
NaN |
|
ATF4;HERPUD1;PPP1R15A |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Eukaryotic kinetochore dynamics |
0.003823979 |
4 |
NaN |
|
CENPE;CENPF;CENPU;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
1.45E-08 |
1 |
NaN |
|
BUB1;CENPE;CENPF;MAD2L1;NDC80;NUF2;SPC24;TTK;ZWINT |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Eukaryotic kinetochore dynamics |
1.75E-06 |
1 |
NaN |
|
BUB1;CENPF;CENPU;MAD2L1;NDC80;NUF2;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002654739 |
2 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS15;ADAMTS6 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012182779 |
5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.030266806 |
15 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000454539 |
4 |
NaN |
|
ADAM19;ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003869591 |
6 |
NaN |
|
ADAM19;ADAMTS1;ADAMTS12;ADAMTS14 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.030266806 |
19 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.002393952 |
3 |
NaN |
|
SULF1;SULF2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.019646762 |
11 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.007943821 |
5 |
NaN |
|
MMP1;MMP2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.009595627 |
7 |
NaN |
|
MMP1;MMP2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000298278 |
3 |
NaN |
|
MMP1;MMP14;MMP2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.013432039 |
6 |
NaN |
|
MMP14;MMP2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.02581992 |
11 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.024643906 |
16.5 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.023920818 |
16 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.02581992 |
13 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.02416119 |
12.5 |
NaN |
|
COL5A1;COL5A2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.000400702 |
1 |
NaN |
|
COL1A1;COL2A1;COL3A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.01269743 |
12 |
NaN |
|
COL1A1;COL3A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.010156124 |
10.5 |
NaN |
|
COL1A1;COL3A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.016567476 |
7 |
NaN |
|
COL1A1;COL2A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.031671949 |
17.5 |
NaN |
|
COL11A1;COL5A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.030243397 |
20.5 |
NaN |
|
COL11A1;COL1A2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.031671949 |
21.5 |
NaN |
|
COL11A1;COL5A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Fibrillin synthesis |
0.00241178 |
4 |
NaN |
|
FBN2;FBN3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Folate cycle |
0.046374785 |
20 |
NaN |
|
DHFR |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
G2 M transition checkpoint |
0.018196826 |
17 |
NaN |
|
CCNB1;CDK1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
GABA metabolism |
0.008598393 |
4.5 |
NaN |
|
ABAT;SLC6A1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.027593758 |
11 |
NaN |
|
SLC1A5;SLC7A5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
2.46E-06 |
1 |
NaN |
|
ENO1;HK2;LDHA;PCK2;PFKFB3;PFKFB4;PFKP |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Glycolysis and Gluconeogenesis |
0.000368197 |
3 |
NaN |
|
HK2;LDHA;PCK2;PFKFB3;PFKFB4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Glycolysis and Gluconeogenesis |
2.82E-05 |
2 |
NaN |
|
ENO1;HK2;LDHA;PCK2;PFKFB3;PFKFB4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.00041294 |
2 |
NaN |
|
HK2;LDHA;PCK2;PFKFB3;PFKFB4 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.030638111 |
11 |
NaN |
|
JUND |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.033762424 |
13.5 |
NaN |
|
JUND |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040168784 |
12 |
NaN |
|
JAK2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.024643906 |
16.5 |
NaN |
|
SOCS3;STAT3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Hedgehog receptor signaling |
0.034114417 |
12 |
NaN |
|
GAS1;MYCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Hedgehog receptor signaling |
0.035192892 |
18 |
NaN |
|
GAS1;MYCN |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Hepatocyte growth factor receptor signaling |
0.033762424 |
13.5 |
NaN |
|
HGF |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Hepatocyte growth factor receptor signaling |
0.034976072 |
20 |
NaN |
|
HGF |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Hepatocyte growth factor receptor signaling |
0.03115918 |
16.5 |
NaN |
|
HGF |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Inhibin receptor signaling |
0.019524203 |
14 |
NaN |
|
INHBA;INHBE |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Inhibin receptor signaling |
0.01894582 |
14 |
NaN |
|
INHBE;TGFBR3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Inhibition of apoptosis |
0.018196826 |
17 |
NaN |
|
BIRC5;XAF1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Integrin-mediated leukocyte rolling |
0.011841806 |
7 |
NaN |
|
SELPLG;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Integrin-mediated leukocyte rolling |
0.01491633 |
12 |
NaN |
|
ICAM1;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Integrin-mediated leukocyte rolling |
0.015642737 |
11 |
NaN |
|
ICAM1;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Interferon alpha receptor signaling |
0.0155326 |
9.5 |
NaN |
|
IRF9;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Interferon alpha receptor signaling |
0.020465429 |
10 |
NaN |
|
IRF9;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Interferon alpha receptor signaling |
0.019524203 |
14 |
NaN |
|
IRF9;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Interferon alpha receptor signaling |
0.01894582 |
14 |
NaN |
|
IRF9;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Interferon beta receptor signaling |
0.011841806 |
7 |
NaN |
|
IFIT2;IRF9 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Interferon beta receptor signaling |
0.014470218 |
12 |
NaN |
|
IFIT2;IRF9 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.04578962 |
17.5 |
NaN |
|
SOCS2;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
JAK-STAT signaling pathway |
0.006718883 |
6 |
NaN |
|
SOCS2;SOCS3;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
JAK-STAT signaling pathway |
0.000481016 |
5 |
NaN |
|
SOCS3;STAT1;STAT3;USP18 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
JAK-STAT signaling pathway |
0.000452858 |
4 |
NaN |
|
SOCS2;SOCS3;STAT1;USP18 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
JAK-STAT signaling pathway |
0.006718883 |
8 |
NaN |
|
SOCS2;STAT1;USP18 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Leptin receptor signaling |
0.004505994 |
8 |
NaN |
|
SOCS3;STAT3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Lipogenesis |
0.000755151 |
5 |
NaN |
|
ACLY;FASN |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
2.49E-05 |
4 |
NaN |
|
BUB1;CCNB2;CENPE;MAD2L1;PTTG1;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Metaphase to anaphase checkpoint |
0.015941817 |
14 |
NaN |
|
BUB1;MAD2L1;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Microtubule destabilization |
0.004433898 |
9 |
NaN |
|
KIF2C;STMN1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Mitotic spindle assembly |
5.16E-05 |
1 |
NaN |
|
CKAP2;DLGAP5;TACC3;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Mitotic spindle assembly |
1.87E-06 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TPX2;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Mitotic spindle assembly |
3.76E-05 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TTK |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Mitotic spindle disassembly |
0.015437544 |
8 |
NaN |
|
CDK1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Mitotic spindle disassembly |
0.017642908 |
14 |
NaN |
|
CDK1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Mitotic spindle disassembly |
0.015702188 |
12.5 |
NaN |
|
CDK1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Myofibril formation |
0.02416119 |
12.5 |
NaN |
|
KLHL41;XIRP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.011387686 |
8.5 |
NaN |
|
NPPA;NPPB |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.010853767 |
10.5 |
NaN |
|
NPPA;NPPB |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.010526062 |
10.5 |
NaN |
|
NPPA;NPPB |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.011387686 |
9.5 |
NaN |
|
NPPA;NPPB |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Nodal growth differentiation factor receptor signaling |
0.04578962 |
17.5 |
NaN |
|
LEFTY2;TCEA3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Nuclear envelope maintenance |
0.003528251 |
7.5 |
NaN |
|
LMNB1;TMPO |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Nuclear intermediate filaments |
0.003528251 |
7.5 |
NaN |
|
LMNB1;TMPO |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Oncostatin-M receptor signaling |
0.007371482 |
9 |
NaN |
|
OSMR;STAT3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Osteonectin receptor signaling |
0.001393088 |
2 |
NaN |
|
SMOC2;SPARC |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Osteonectin receptor signaling |
0.001691693 |
2 |
NaN |
|
SMOC2;SPARC |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Osteonectin receptor signaling |
0.001815452 |
5 |
NaN |
|
SMOC2;SPARC |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Osteonectin receptor signaling |
0.001440887 |
4 |
NaN |
|
SMOC2;SPARC |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Osteopontin receptor signaling |
0.024788285 |
15 |
NaN |
|
SPP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Osteopontin receptor signaling |
0.028669725 |
13 |
NaN |
|
SPP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Osteopontin receptor signaling |
0.027522936 |
17 |
NaN |
|
SPP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Osteopontin receptor signaling |
0.028669725 |
16 |
NaN |
|
SPP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Perlecan synthesis |
0.028669725 |
16 |
NaN |
|
HSPG2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
4.87E-05 |
1.5 |
NaN |
|
PDGFD;PDGFRA;PDGFRB;RGS5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.036292017 |
22 |
NaN |
|
FOSL1;PDGFRB |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Polyol pathway |
5.92E-05 |
1 |
NaN |
|
AKR1A1;AKR1B10;SORD |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Progesterone receptor signaling |
0.020289344 |
9 |
NaN |
|
PGR |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Prolactin receptor signaling |
0.005827311 |
3 |
NaN |
|
PRLR;SOCS2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Prolactin receptor signaling |
0.007737756 |
7 |
NaN |
|
PRLR;SOCS2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Pyrimidine synthesis and salvage |
0.006241574 |
4 |
NaN |
|
TK1;TYMS |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Pyrimidine synthesis and salvage |
0.007547364 |
6 |
NaN |
|
TK1;TYMS |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Pyrimidine synthesis and salvage |
0.00808616 |
11 |
NaN |
|
TK1;TYMS |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Pyrimidine synthesis and salvage |
0.00645117 |
9 |
NaN |
|
TK1;TYMS |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Removal of caspase inhibition |
0.034976072 |
20 |
NaN |
|
XAF1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Retinol metabolism |
0.016528769 |
10 |
NaN |
|
ALDH1A2;RDH10 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Retinol metabolism |
0.019882363 |
10.5 |
NaN |
|
ALDH1A2;RDH10 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Retinol metabolism |
0.005392406 |
5 |
NaN |
|
ALDH1A1;ALDH1A3;TTR |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Retinol metabolism |
0.000351283 |
2 |
NaN |
|
ALDH1A1;DHRS3;STRA6;TTR |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Retinol metabolism |
0.04822006 |
19 |
NaN |
|
ALDH1A1;ALDH1A3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Retinol metabolism |
0.000386293 |
1 |
NaN |
|
ALDH1A1;DHRS3;STRA6;TTR |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Ribonucleotide reduction |
0.045605319 |
13.5 |
NaN |
|
RRM2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Ribonucleotide reduction |
0.046374785 |
20 |
NaN |
|
RRM2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Selectin-mediated Leukocyte rolling |
0.008598393 |
4.5 |
NaN |
|
SELPLG;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Selectin-mediated Leukocyte rolling |
0.010853767 |
10.5 |
NaN |
|
ICAM1;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Selectin-mediated Leukocyte rolling |
0.011387686 |
9.5 |
NaN |
|
ICAM1;VCAM1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Serine and glycine metabolism |
4.87E-05 |
1.5 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Serine and glycine metabolism |
0.003246259 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Serine and glycine metabolism |
0.00016949 |
1 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Serine and glycine metabolism |
0.000159398 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Serine and glycine metabolism |
0.003246259 |
5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Sister chromatid attachment to mitotic spindle |
0.033762424 |
13.5 |
NaN |
|
TACC3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Sister chromatid attachment to mitotic spindle |
0.034976072 |
20 |
NaN |
|
NUF2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
Sister chromatid attachment to mitotic spindle |
0.03115918 |
16.5 |
NaN |
|
NUF2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Up |
Sister chromatid segregation |
0.004433898 |
9 |
NaN |
|
PTTG1;TOP2A |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Tenascin receptor signaling |
0.004367359 |
8 |
NaN |
|
TENM1;TNC |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Tenascin receptor signaling |
0.004732134 |
6.5 |
NaN |
|
TENM1;TNC |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.004367359 |
8 |
NaN |
|
THBS1;THBS2 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Up |
Tight junction organization |
0.015237229 |
6 |
NaN |
|
CLDN11;CRB2;EMP1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Transmembrane glucose transport |
0.004732134 |
4 |
NaN |
|
SLC2A1;SLC2A3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN08 |
Down |
Transmembrane glucose transport |
0.004367359 |
8 |
NaN |
|
SLC2A1;SLC2A3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Transmembrane glucose transport |
0.004732134 |
6.5 |
NaN |
|
SLC2A1;SLC2A3 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
Tropoelastin synthesis |
0.020289344 |
9 |
NaN |
|
ELN |
| flecainide |
Antiarrhythmic |
Yes |
MSN05 |
Down |
Tropoelastin synthesis |
0.028669725 |
13 |
NaN |
|
ELN |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Down |
Tropoelastin synthesis |
0.027964008 |
18.5 |
NaN |
|
ELN |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Down |
Tropoelastin synthesis |
0.028669725 |
16 |
NaN |
|
ELN |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Up |
Vascular endothelial growth factor receptor signaling |
0.011841806 |
7 |
NaN |
|
FLT1;KDR |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Versican receptor signaling |
0.033762424 |
13.5 |
NaN |
|
VCAN |
| flecainide |
Antiarrhythmic |
Yes |
MSN06 |
Up |
Versican synthesis |
0.017025406 |
8.5 |
NaN |
|
VCAN |
| flecainide |
Antiarrhythmic |
Yes |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.017982282 |
15 |
NaN |
|
FRZB;FZD7;SFRP4;WNT1 |
| flecainide |
Antiarrhythmic |
Yes |
MSN01 |
Down |
WNT-Beta-catenin signaling pathway |
0.009503625 |
4 |
NaN |
|
FZD10;FZD7;MSX2;SFRP5;WNT1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.000130795 |
2 |
NaN |
|
NPPA;NPPB;NPR1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.000100982 |
3 |
NaN |
|
NPPA;NPPB;NPR1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.000165872 |
2 |
NaN |
|
NPPA;NPPB;NPR1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.004787543 |
6 |
NaN |
|
NPPA;NPPB |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Notch receptor signaling |
0.046930028 |
21.5 |
NaN |
|
DLK1;NOTCH3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Osteonectin receptor signaling |
0.003705518 |
4.5 |
NaN |
|
SMOC2;SPOCK1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Osteonectin receptor signaling |
7.86E-05 |
1 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Osteonectin receptor signaling |
0.003072996 |
5 |
NaN |
|
SMOC2;SPOCK1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.025317572 |
11.5 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.027258292 |
13.5 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.025494001 |
14 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.023023994 |
12 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.025052929 |
8.5 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.002278637 |
3 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.002812672 |
6 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
0.025324824 |
14 |
NaN |
|
PDGFRA;RGS5 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Progesterone receptor signaling |
0.027258292 |
13.5 |
NaN |
|
PGR |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Progesterone receptor signaling |
0.023023994 |
12 |
NaN |
|
PGR |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Prostacycline receptor signaling |
0.037920328 |
16.5 |
NaN |
|
PTGIR |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Prostaglandin E2 receptor signaling |
0.008957388 |
8.5 |
NaN |
|
PTGER3;RAPGEF4 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Prostaglandin E2 receptor signaling |
0.010331661 |
9.5 |
NaN |
|
PTGER3;RAPGEF4 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Prostaglandin E2 receptor signaling |
0.007451277 |
6.5 |
NaN |
|
PTGER3;RAPGEF4 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.049996342 |
17.5 |
NaN |
|
PTGFR |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.045519869 |
16.5 |
NaN |
|
PTGFR |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Protein polyubiquitination |
0.042096917 |
21 |
NaN |
|
ISG15;UCHL1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Removal of caspase inhibition |
0.049996342 |
17.5 |
NaN |
|
XAF1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Removal of caspase inhibition |
0.049480363 |
14.5 |
NaN |
|
XAF1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Removal of caspase inhibition |
0.037920328 |
16.5 |
NaN |
|
XAF1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Restriction point |
0.025462828 |
11 |
NaN |
|
CDKN2A;PFKFB3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Restriction point |
0.01470451 |
11 |
NaN |
|
CCND2;PFKFB3 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Restriction point |
0.014834304 |
5.5 |
NaN |
|
CCND2;CDKN1A |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Restriction point |
0.01368451 |
11 |
NaN |
|
CCND1;CCND2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Retinol metabolism |
0.041452288 |
14 |
NaN |
|
ALDH1A1;RPE65 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Retinol metabolism |
0.047387116 |
16.5 |
NaN |
|
ALDH1A1;RPE65 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Retinol metabolism |
0.00387928 |
4 |
NaN |
|
ALDH1A1;RPE65;STRA6 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Retinol metabolism |
0.002908016 |
4 |
NaN |
|
ALDH1A1;RDH10;RPE65 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Retinol metabolism |
0.04066719 |
11.5 |
NaN |
|
ALDH1A1;RLBP1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Retinol metabolism |
0.024550455 |
16.5 |
NaN |
|
ALDH1A2;DHRS3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Retinol metabolism |
0.001319125 |
6 |
NaN |
|
ALDH1A2;ALDH1A3;DHRS3 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Retinol metabolism |
0.02476286 |
11 |
NaN |
|
ALDH1A3;DHRS3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Retinol metabolism |
0.028490468 |
17.5 |
NaN |
|
ALDH1A2;DHRS3 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Retinol metabolism |
0.02287923 |
15 |
NaN |
|
ALDH1A2;DHRS3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Roundabout signaling |
0.01027406 |
8.5 |
NaN |
|
ROBO1;ROBO2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Selectin-mediated Leukocyte rolling |
0.005154036 |
7.5 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Selectin-mediated Leukocyte rolling |
0.004347503 |
10 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Selectin-mediated Leukocyte rolling |
0.006025215 |
7 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Selectin-mediated Leukocyte rolling |
0.004787543 |
6 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.015050282 |
13 |
NaN |
|
PHGDH;PSAT1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.017904373 |
7 |
NaN |
|
PHGDH;SLC1A5 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.001267475 |
4 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.000901167 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Serotonin inactivation |
0.049996342 |
17.5 |
NaN |
|
MAOA |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Serotonin inactivation |
0.000647752 |
1 |
NaN |
|
MAOA;MAOB |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Serotonin inactivation |
0.045519869 |
16.5 |
NaN |
|
MAOA |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Serotonin inactivation |
0.000303564 |
4 |
NaN |
|
MAOA;MAOB |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.037747261 |
20 |
NaN |
|
TACC3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.040860087 |
19.5 |
NaN |
|
TACC3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Sister chromatid segregation |
0.005154036 |
7.5 |
NaN |
|
PTTG1;TOP2A |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Tenascin receptor signaling |
0.003705518 |
4.5 |
NaN |
|
TENM1;TNC |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Thin myofilament organization |
0.006016727 |
11.5 |
NaN |
|
ACTA1;TNNI3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Thin myofilament organization |
0.008320961 |
8.5 |
NaN |
|
ACTA1;TNNI3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Thrombospondin receptor signaling |
0.004285177 |
7 |
NaN |
|
THBS2;THBS4 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Thrombospondin receptor signaling |
6.11E-05 |
2 |
NaN |
|
THBS1;THBS2;THBS4 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.01905434 |
14 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.017466478 |
15 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.019142555 |
9 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.020642202 |
13.5 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.018348624 |
13.5 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Urea cycle |
0.004787543 |
6 |
NaN |
|
ARG2;ASS1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Vascular endothelial growth factor receptor signaling |
0.012331868 |
10 |
NaN |
|
FLT1;KDR |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.037747261 |
20 |
NaN |
|
VIPR2 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Versican receptor signaling |
0.037920328 |
16.5 |
NaN |
|
VCAN |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Versican receptor signaling |
0.036362165 |
17 |
NaN |
|
VCAN |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Versican synthesis |
0.019142555 |
9 |
NaN |
|
VCAN |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Versican synthesis |
0.018348624 |
13.5 |
NaN |
|
VCAN |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.005475082 |
6 |
NaN |
|
APCDD1;DKK2;FRZB;PAX6;SFRP2;WNT9A |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.007777734 |
8 |
NaN |
|
APCDD1;DKK2;FRZB;PAX6;SFRP2;WNT9A |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
WNT-Beta-catenin signaling pathway |
0.02184092 |
7 |
NaN |
|
APCDD1;DACT1;DKK2;FRZB;WNT2 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.001365143 |
2 |
NaN |
|
CXXC5;FRAT1;FRZB;FZD8;SFRP2;WNT9A |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.026579947 |
12 |
NaN |
|
ADAM12;ADAM33;ADAMTS14 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002938485 |
2.5 |
NaN |
|
ADAM33;ADAMTS13;ADAMTS2;ADAMTS5 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002029311 |
2 |
NaN |
|
ADAM15;ADAM33;ADAMTS14;ADAMTS5 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Extracellular matrix breakdown by cathepsins |
0.025462828 |
11 |
NaN |
|
CTSF;CTSV |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Extracellular matrix breakdown by cathepsins |
0.01470451 |
11 |
NaN |
|
CTSF;CTSL |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Extracellular matrix breakdown by cathepsins |
0.017117729 |
11 |
NaN |
|
CTSL;CTSV |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.023491402 |
11 |
NaN |
|
MMP1;MMP2 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.011080479 |
9 |
NaN |
|
MMP1;MMP14 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.025462828 |
11 |
NaN |
|
COL1A1;COL2A1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.021035933 |
10 |
NaN |
|
COL11A1;COL5A1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
0.000741619 |
4 |
NaN |
|
COL1A1;COL2A1;COL5A2 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.000575325 |
5 |
NaN |
|
COL1A2;COL2A1;COL3A1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.014834304 |
5.5 |
NaN |
|
COL1A2;COL3A1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
3.37E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
2.12E-05 |
1 |
NaN |
|
COL1A2;COL2A1;COL3A1;COL5A2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Fibroblast growth factor receptor signaling |
0.035660258 |
13 |
NaN |
|
FGF18;FGFR3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Fibroblast growth factor receptor signaling |
0.000225406 |
3 |
NaN |
|
FGF1;FGF10;FGF18;FGFR3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Fibroblast growth factor receptor signaling |
0.002275399 |
3 |
NaN |
|
FGF10;FGF18;FGFR3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.045519869 |
16.5 |
NaN |
|
FBLN1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Filopodium organization |
0.002938485 |
2.5 |
NaN |
|
GAP43;MYO3A;RHOU;TXNRD1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.001716959 |
3 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Glycolysis and Gluconeogenesis |
0.019913353 |
8 |
NaN |
|
LDHA;PCK2;PFKFB3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
G-protein coupled receptor signaling pathway |
0.046930028 |
21.5 |
NaN |
|
GRK5;RGS4 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049996342 |
17.5 |
NaN |
|
JAK2 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049480363 |
14.5 |
NaN |
|
JAK2 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.034629393 |
18.5 |
NaN |
|
JUND |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.020044392 |
5.5 |
NaN |
|
SOCS3;STAT3 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Hepatocyte growth factor receptor signaling |
0.037920328 |
16.5 |
NaN |
|
HGF |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Inhibin receptor signaling |
0.009465755 |
4 |
NaN |
|
INHBB;TGFBR3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001884281 |
2 |
NaN |
|
MME;PLAT |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.21E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.56E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001080503 |
1 |
NaN |
|
MME;PLAT |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Inhibition of apoptosis |
0.034978854 |
10 |
NaN |
|
BIRC5;XAF1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Inositol metabolism and transport |
0.049996342 |
17.5 |
NaN |
|
SLC5A3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Integrin-mediated leukocyte rolling |
0.007125381 |
9 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Integrin-mediated leukocyte rolling |
0.006016727 |
11.5 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Integrin-mediated leukocyte rolling |
0.008320961 |
8.5 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Integrin-mediated leukocyte rolling |
0.006621825 |
8 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
JAK-STAT signaling pathway |
0.046676079 |
13 |
NaN |
|
SOCS3;STAT3 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
JAK-STAT signaling pathway |
0.028530911 |
12.5 |
NaN |
|
SOCS2;SOCS3 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Leptin receptor signaling |
0.003629621 |
3 |
NaN |
|
SOCS3;STAT3 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Lipogenesis |
0.037747261 |
20 |
NaN |
|
FASN |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Macrophage migration inhibitory factor signaling |
0.006155642 |
5.5 |
NaN |
|
CXCR4;JUND |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
MAPK signaling pathway |
0.023390507 |
16 |
NaN |
|
DUSP1;FOXM1;MAP2K6 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Methionine cycle |
0.034629393 |
18.5 |
NaN |
|
BHMT |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Methionine cycle |
0.037920328 |
16.5 |
NaN |
|
BHMT |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Methionine cycle |
0.040860087 |
19.5 |
NaN |
|
BHMT |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.049996342 |
17.5 |
NaN |
|
FBN1 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.045519869 |
16.5 |
NaN |
|
FBN1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Microfibril scaffold organization |
0.037920328 |
16.5 |
NaN |
|
FBN1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Mitotic spindle assembly |
0.024550455 |
16.5 |
NaN |
|
TACC3;TPX2 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Mitotic spindle assembly |
0.028490468 |
17.5 |
NaN |
|
TACC3;TPX2 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Adherens junction organization |
0.00985309 |
10 |
NaN |
|
CDH1;CDH3;CDH5;PLEKHA7 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.01905434 |
14 |
NaN |
|
ACAN |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.025317572 |
11.5 |
NaN |
|
ALB |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Albumin mediated blood protein transport |
0.023023994 |
12 |
NaN |
|
ALB |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Alternative complement pathway |
0.006155642 |
5.5 |
NaN |
|
C3;CFH |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Alternative complement pathway |
0.003479622 |
5.5 |
NaN |
|
C3;CFH |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Alternative complement pathway |
0.002931996 |
8 |
NaN |
|
C3;CFH |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Alternative complement pathway |
0.004072101 |
5.5 |
NaN |
|
C3;CFH |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Androgen synthesis |
0.020044392 |
5.5 |
NaN |
|
HSD17B2;SRD5A2 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.025462828 |
11 |
NaN |
|
B2M;HLA-B |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.01470451 |
11 |
NaN |
|
B2M;HLA-B |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Aspartate and arginine metabolism |
0.01368451 |
11 |
NaN |
|
ARG2;ASS1 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Axonal intermediate filament dynamics |
0.00052119 |
1 |
NaN |
|
NEFH;NEFM;NES |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Axonal intermediate filament dynamics |
0.000647115 |
5 |
NaN |
|
NEFH;NEFL;NEFM |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Axonal intermediate filament dynamics |
0.01027406 |
8.5 |
NaN |
|
NEFH;NEFM |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Basement membrane assembly and organization |
0.028842387 |
15 |
NaN |
|
COL4A4;COL8A2 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Basement membrane assembly and organization |
0.01368451 |
11 |
NaN |
|
COL4A4;COL4A5 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Bicarbonate transmembrane transport |
0.04668964 |
18 |
NaN |
|
CA9;SLC4A5 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Biglycan synthesis |
0.025052929 |
8.5 |
NaN |
|
BGN |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Biglycan synthesis |
0.017466478 |
15 |
NaN |
|
BGN |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Biglycan synthesis |
0.020642202 |
13.5 |
NaN |
|
BGN |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Cardiomyocyte depolarization during action potential |
0.020642202 |
13.5 |
NaN |
|
SCN5A |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.028530911 |
12.5 |
NaN |
|
KCNA1;KCNJ2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003479622 |
5.5 |
NaN |
|
CTGF;CYR61 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.002931996 |
8 |
NaN |
|
CTGF;CYR61 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004072101 |
5.5 |
NaN |
|
CTGF;CYR61 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Cellular cholesterol uptake and efflux |
0.04066719 |
11.5 |
NaN |
|
ABCA1;ABCG1 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Centrosome separation |
0.025462828 |
11 |
NaN |
|
AURKA;CCNB1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Chloride transmembrane transport |
0.047387116 |
16.5 |
NaN |
|
BEST1;SLC12A7 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Cholesterol synthesis |
2.94E-05 |
1 |
NaN |
|
CYP27A1;DHCR24;DHCR7;FDFT1;SQLE |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Cholesterol synthesis |
2.85E-08 |
1 |
NaN |
|
DHCR24;DHCR7;FDFT1;FDPS;HMGCS1;MVD;SQLE |
| estradiol |
Female sex hormone |
No |
MSN06 |
Up |
Cholesterol transport by lipoproteins |
0.016384625 |
7 |
NaN |
|
APOD;APOE |
| estradiol |
Female sex hormone |
No |
MSN09 |
Up |
Classical complement pathway |
0.012085707 |
4 |
NaN |
|
C1QB;C1QC |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Collagen fiber crosslinking |
0.002931996 |
8 |
NaN |
|
LOXL1;PXDN |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Collagen fiber crosslinking |
0.003230669 |
4 |
NaN |
|
LOXL1;PXDN |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.008957388 |
8.5 |
NaN |
|
COL9A2;COL9A3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000377393 |
4 |
NaN |
|
COL12A1;COL9A2;COL9A3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007451277 |
6.5 |
NaN |
|
COL12A1;COL9A2 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000116919 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Connection of muscle sarcomere to extracellular matrix |
0.010331661 |
9.5 |
NaN |
|
AGRN;SGCD |
| estradiol |
Female sex hormone |
No |
MSN01 |
Up |
Contractile ring constriction |
0.006072761 |
7 |
NaN |
|
MYH14;MYLK |
| estradiol |
Female sex hormone |
No |
MSN05 |
Up |
Contractile ring constriction |
0.000192586 |
2 |
NaN |
|
ANLN;MYH14;MYLK |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Decorin synthesis |
0.01905434 |
14 |
NaN |
|
DCN |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Decorin synthesis |
0.017466478 |
15 |
NaN |
|
DCN |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Decorin synthesis |
0.019142555 |
9 |
NaN |
|
DCN |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Decorin synthesis |
0.020642202 |
13.5 |
NaN |
|
DCN |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Drug and toxin export via membrane transport proteins |
0.038656545 |
20 |
NaN |
|
ABCC3;ABCG2 |
| estradiol |
Female sex hormone |
No |
MSN06 |
Down |
Drug and toxin export via membrane transport proteins |
0.045637959 |
20 |
NaN |
|
ABCC4;ABCG2 |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.000356006 |
3 |
NaN |
|
KRT4;KRT7;TCHH |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
5.98E-06 |
2 |
NaN |
|
KRT19;KRT4;KRT7;TCHH |
| estradiol |
Female sex hormone |
No |
MSN01 |
Down |
Z-disc organization |
0.036387431 |
18 |
NaN |
|
DES;PDLIM3 |
| estradiol |
Female sex hormone |
No |
MSN05 |
Down |
Z-disc organization |
0.031015341 |
17 |
NaN |
|
LDB3;PDLIM3 |
| estradiol |
Female sex hormone |
No |
MSN08 |
Down |
Z-disc organization |
0.000264919 |
3 |
NaN |
|
DES;LDB3;MYPN;PDLIM3 |
| estradiol |
Female sex hormone |
No |
MSN09 |
Down |
Z-disc organization |
0.033957087 |
16 |
NaN |
|
DES;MYPN |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
4.34E-11 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPI;CENPU;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Eukaryotic kinetochore dynamics |
5.98E-06 |
4 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;NDC80;NUF2;SPC24;TTK;ZWINT |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Eukaryotic kinetochore dynamics |
1.36E-09 |
3 |
NaN |
|
BUB1;CENPE;CENPF;CENPI;CENPU;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Eukaryotic kinetochore dynamics |
2.09E-13 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPI;CENPU;CENPW;KIF15;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.005062955 |
6 |
NaN |
|
ADAMTS1;ADAMTS2;ADAMTS5 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.03825978 |
8.5 |
NaN |
|
ADAM33;ADAMTS5 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000247135 |
4 |
NaN |
|
MMP14;MMP2;MMP3 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.000106227 |
7 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.002073589 |
13 |
NaN |
|
BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.000144661 |
8 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Fanconi anemia interstrand cross-link repair pathway |
1.22E-05 |
6 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCG;FANCI;UBE2T |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.007020173 |
3 |
NaN |
|
COL1A2;COL3A1 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.000292192 |
8 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
G2 M transition checkpoint |
0.005910219 |
19.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
G2 M transition checkpoint |
0.005687739 |
19.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Glutamate and glutamine metabolism |
0.015125858 |
9 |
NaN |
|
SLC1A5;SLC7A5 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.013943597 |
5 |
NaN |
|
SLC1A5;SLC7A5 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Glycogen synthesis and glycogenolysis |
0.017792498 |
6 |
NaN |
|
PPP1R3A;PYGM |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Glycolysis and Gluconeogenesis |
0.005818361 |
18 |
NaN |
|
ENO1;LDHA;PFKFB3;PFKFB4 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.000667411 |
13 |
NaN |
|
ENO1;LDHA;PFKFB4;PGK1;TPI1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.028030666 |
10.5 |
NaN |
|
JAK2 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Heme degradation to bilirubin |
0.043551386 |
14.5 |
NaN |
|
HMOX1 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Heme degradation to bilirubin |
0.0298696 |
8 |
NaN |
|
HMOX1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Heme degradation to bilirubin |
0.038403665 |
10.5 |
NaN |
|
HMOX1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Heme degradation to bilirubin |
0.041751778 |
16 |
NaN |
|
HMOX1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Heparin-binding EGF-like growth factor receptor signaling |
0.043551386 |
14.5 |
NaN |
|
HBEGF |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Heparin-binding EGF-like growth factor receptor signaling |
0.041751778 |
16 |
NaN |
|
HBEGF |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Homologous recombination DSB repair |
0.002587189 |
15 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RMI2;XRCC2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Homologous recombination DSB repair |
0.00062358 |
14 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RECQL4;RMI2;XRCC2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Homologous recombination DSB repair |
0.000574555 |
11 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RECQL4;RMI2;XRCC2 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Hyaluronan receptor CD44 signaling |
0.043551386 |
14.5 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Hyaluronan receptor CD44 signaling |
0.041751778 |
16 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.003784402 |
14.5 |
NaN |
|
A2M;PLAT |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Inhibition of apoptosis |
0.005051379 |
18.5 |
NaN |
|
BIRC5;IFI6;XAF1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Intracellular bridge assembly |
0.002730596 |
16 |
NaN |
|
INCENP;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Intracellular bridge assembly |
0.00305221 |
16.5 |
NaN |
|
INCENP;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Intracellular bridge assembly |
0.002970165 |
17 |
NaN |
|
INCENP;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Intrinsic apoptosis pathway |
0.013722762 |
5 |
NaN |
|
BMF;PMAIP1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Lipogenesis |
0.029247909 |
11 |
NaN |
|
FASN |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Macrophage migration inhibitory factor signaling |
0.049289604 |
12 |
NaN |
|
ACKR3 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Mammalian target of rapamycin signaling pathway |
0.023432976 |
8 |
NaN |
|
DDIT4;EIF4EBP1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Metaphase to anaphase checkpoint |
6.30E-06 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Metaphase to anaphase checkpoint |
0.000172103 |
7 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Metaphase to anaphase checkpoint |
8.87E-07 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PLK3;PTTG1;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Metaphase to anaphase checkpoint |
7.90E-07 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PLK3;PTTG1;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Microtubule destabilization |
0.012844883 |
23 |
NaN |
|
KIF2C;STMN2 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Microtubule destabilization |
0.017606258 |
25 |
NaN |
|
KIF2C;STMN1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Microtubule destabilization |
0.000620884 |
12.5 |
NaN |
|
KIF2C;STMN1;STMN2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Microtubule destabilization |
0.013934524 |
26.5 |
NaN |
|
KIF2C;STMN1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic chromosome condensation |
0.017622656 |
26 |
NaN |
|
INCENP;SMC4 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic chromosome condensation |
0.019605117 |
29.5 |
NaN |
|
INCENP;SMC4 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic chromosome condensation |
0.001018951 |
15 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000269315 |
8.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.012022011 |
21.5 |
NaN |
|
AURKB;CCNA2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000318058 |
10.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000305372 |
9.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Mitotic spindle assembly |
2.71E-05 |
6 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Mitotic spindle assembly |
5.97E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Mitotic spindle assembly |
3.55E-05 |
6 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Mitotic spindle assembly |
3.32E-05 |
8 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.00052644 |
10.5 |
NaN |
|
NPPA;NPPB;NPR3 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Natriuretic peptide receptor signaling |
0.017606258 |
25 |
NaN |
|
NPPA;NPPB |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Natriuretic peptide receptor signaling |
0.014306674 |
27 |
NaN |
|
NPPA;NPPB |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.013934524 |
26.5 |
NaN |
|
NPPA;NPPB |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Neuregulin receptor signaling |
0.010015357 |
4 |
NaN |
|
ERBB3;ERBB4 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Notch receptor signaling |
0.021860488 |
28 |
NaN |
|
DLK1;JAG1;LFNG |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Notch receptor signaling |
0.033481638 |
30 |
NaN |
|
DLK1;JAG1;NOTCH1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Nuclear intermediate filaments |
0.012844883 |
23 |
NaN |
|
LMNB1;LMNB2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Nuclear intermediate filaments |
0.014306674 |
27 |
NaN |
|
LMNB1;LMNB2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Nuclear intermediate filaments |
0.013934524 |
26.5 |
NaN |
|
LMNB1;LMNB2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Nucleosome assembly |
0.004694952 |
18 |
NaN |
|
ASF1B;CHAF1A;CHAF1B;HIST1H1C |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.000446155 |
10 |
NaN |
|
PDGFB;PDGFRA;PDGFRB;TNK2 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Potassium transmembrane transport |
0.04817565 |
17 |
NaN |
|
ABCC9;ATP1A3 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Potassium transmembrane transport |
0.03825978 |
8.5 |
NaN |
|
ABCC9;ATP1A3 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Proline metabolism |
0.049289604 |
12 |
NaN |
|
PYCR1 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Protein polyubiquitination |
0.010972286 |
4 |
NaN |
|
UBC;UCHL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Protein polyubiquitination |
0.020867035 |
7 |
NaN |
|
ISG15;UCHL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Pyrimidine synthesis and salvage |
0.02302747 |
29 |
NaN |
|
TK1;TYMS |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Pyrimidine synthesis and salvage |
0.031334889 |
29 |
NaN |
|
TK1;TYMS |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Retinol metabolism |
0.010112539 |
19 |
NaN |
|
ALDH1A1;ALDH1A3;RBP1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Ribonucleotide reduction |
3.20E-05 |
7 |
NaN |
|
RRM1;RRM2;RRM2B |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Serine and glycine metabolism |
1.38E-05 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.000154114 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.00032663 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serine and glycine metabolism |
2.27E-07 |
1 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Serotonin inactivation |
0.028030666 |
10.5 |
NaN |
|
MAOA |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Sister chromatid attachment to mitotic spindle |
0.000928996 |
13 |
NaN |
|
NUF2;TACC3 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Sister chromatid attachment to mitotic spindle |
0.001292329 |
12 |
NaN |
|
NUF2;TACC3 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sister chromatid attachment to mitotic spindle |
0.001039663 |
15 |
NaN |
|
NUF2;TACC3 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sister chromatid attachment to mitotic spindle |
0.001011413 |
14 |
NaN |
|
NUF2;TACC3 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sister chromatid cohesion |
0.009104659 |
23 |
NaN |
|
CDCA5;CHTF18;ESCO2;WDHD1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sister chromatid cohesion |
0.008682532 |
22 |
NaN |
|
CDCA5;CHTF18;ESCO2;WDHD1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Sister chromatid segregation |
0.00052644 |
10.5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Sister chromatid segregation |
0.000853518 |
11 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Sister chromatid segregation |
0.000620884 |
12.5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Sister chromatid segregation |
0.00059632 |
12 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Telomere replication and maintenance |
0.018281238 |
27 |
NaN |
|
EXO1;PIF1;RECQL4 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Telomere replication and maintenance |
0.013672665 |
25 |
NaN |
|
EXO1;PIF1;RECQL4 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Telomere replication and maintenance |
0.013175198 |
24 |
NaN |
|
EXO1;PIF1;RECQL4 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Tenascin receptor signaling |
0.005350967 |
20.5 |
NaN |
|
TENM1;TNC |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Tenascin receptor signaling |
0.00597407 |
21.5 |
NaN |
|
TENM1;TNC |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Thin myofilament organization |
0.000900451 |
12 |
NaN |
|
ACTA1;TPM2;TPM4 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.007388595 |
16.5 |
NaN |
|
THBS2;THBS4 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Tropoelastin synthesis |
0.014731828 |
8 |
NaN |
|
ELN |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.014114326 |
6 |
NaN |
|
ELN |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Vascular endothelial growth factor receptor signaling |
0.017622656 |
26 |
NaN |
|
FLT1;KDR |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.000215746 |
3 |
NaN |
|
VIPR1;VIPR2 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.020012661 |
5.5 |
NaN |
|
VIPR1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.025768046 |
7 |
NaN |
|
VIPR1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.028030666 |
10.5 |
NaN |
|
VIPR1 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
VDJ recombination |
0.049289604 |
12 |
NaN |
|
PAX5 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Androgen receptor signaling |
0.029247909 |
11 |
NaN |
|
AR |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Androgen receptor signaling |
0.020012661 |
5.5 |
NaN |
|
AR |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Apoptosome assembly |
0.012022011 |
21.5 |
NaN |
|
CDC6;CYCS |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Aspartate and arginine metabolism |
0.008982766 |
7 |
NaN |
|
ARG2;SLC7A1 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Aspartate and arginine metabolism |
0.004279686 |
3 |
NaN |
|
ARG2;SLC7A1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Aspartate and arginine metabolism |
0.00827056 |
3 |
NaN |
|
ARG2;SLC7A1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Axonal intermediate filament dynamics |
0.017622656 |
26 |
NaN |
|
NEFL;NES |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Axonal intermediate filament dynamics |
0.024067226 |
28 |
NaN |
|
NEFL;NES |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Axonal intermediate filament dynamics |
0.019605117 |
29.5 |
NaN |
|
NEFL;NES |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Axonal intermediate filament dynamics |
0.019100753 |
29.5 |
NaN |
|
NEFL;NES |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Base excision repair |
0.011313575 |
23 |
NaN |
|
FEN1;NEIL3;PCNA;POLQ |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.012022011 |
21.5 |
NaN |
|
CTGF;CYR61 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.029247909 |
11 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
CD44-Mediated leukocyte rolling |
0.028030666 |
10.5 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cellular iron storage |
0.043551386 |
14.5 |
NaN |
|
FTL |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Cellular iron storage |
0.0298696 |
8 |
NaN |
|
FTL |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Cellular iron storage |
0.041751778 |
16 |
NaN |
|
FTL |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome maturation |
0.005051379 |
18.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Centrosome maturation |
0.007989519 |
18 |
NaN |
|
AURKA;PLK1;TPX2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome maturation |
0.005910219 |
19.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome maturation |
0.005687739 |
19.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome organization |
0.004556707 |
17 |
NaN |
|
ASPM;NEK2;PLK4;POC1A;STIL;TACC3;WDR62 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome organization |
0.000316324 |
9 |
NaN |
|
ASPM;NEK2;PAX6;PLK3;PLK4;POC1A;STIL;TACC3;WDR62 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome organization |
0.001365192 |
16 |
NaN |
|
ASPM;NEK2;PLK3;PLK4;POC1A;STIL;TACC3;WDR62 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Centrosome separation |
2.58E-09 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Centrosome separation |
8.13E-09 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Centrosome separation |
4.66E-11 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Centrosome separation |
3.47E-09 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
Cholesterol synthesis |
0.002977256 |
5 |
NaN |
|
DHCR7;HMGCR;HMGCS1 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Class switch recombination |
0.028927884 |
13 |
NaN |
|
BCL6;IL7R |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fiber crosslinking |
0.012022011 |
21.5 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Collagen fiber crosslinking |
0.009744744 |
24 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.012844883 |
23 |
NaN |
|
COL9A1;COL9A2 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.017606258 |
25 |
NaN |
|
COL9A1;COL9A2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.014306674 |
27 |
NaN |
|
COL9A1;COL9A2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.013934524 |
26.5 |
NaN |
|
COL9A1;COL9A2 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring constriction |
0.049289604 |
12 |
NaN |
|
MYH14 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Contractile ring constriction |
0.000269315 |
8.5 |
NaN |
|
ANLN;ECT2;MYLK |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Contractile ring constriction |
0.000438469 |
9 |
NaN |
|
ANLN;ECT2;MYLK |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Contractile ring constriction |
0.000318058 |
10.5 |
NaN |
|
ANLN;ECT2;MYLK |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Contractile ring constriction |
0.000305372 |
9.5 |
NaN |
|
ANLN;ECT2;MYLK |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Contractile ring formation |
0.049289604 |
12 |
NaN |
|
MYH14 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Decorin synthesis |
0.012967537 |
4 |
NaN |
|
DCN |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Desaturation of fatty acids |
0.019100753 |
29.5 |
NaN |
|
FADS2;SCD |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
Discoidin domain receptor signaling |
0.0298696 |
8 |
NaN |
|
DDR2 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
Discoidin domain receptor signaling |
0.038403665 |
10.5 |
NaN |
|
DDR2 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
Discoidin domain receptor signaling |
0.041751778 |
16 |
NaN |
|
DDR2 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
DNA replication elongation |
2.58E-08 |
4 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
DNA replication elongation |
5.90E-08 |
3 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
DNA replication elongation |
3.42E-08 |
4 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
DNA replication elongation |
3.19E-08 |
4 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
DNA replication initiation |
5.56E-11 |
2 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM2;MCM4;MCM5;MCM6;MCM7;ORC6 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
DNA replication initiation |
1.37E-11 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM4;MCM5;MCM6;MCM7;ORC6 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
DNA replication initiation |
3.82E-12 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM4;MCM5;MCM6;MCM7;ORC6 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
DNA replication initiation |
2.79E-15 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM3;MCM4;MCM5;MCM6;MCM7;ORC6;TICRR |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Elastin cross-linking and assembly |
0.003784402 |
14.5 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Elastin cross-linking and assembly |
0.00305221 |
16.5 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Epithelial intermediate filament dynamics |
0.001408213 |
14 |
NaN |
|
KRT19;KRT7;KRT8 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.000103168 |
6 |
NaN |
|
KRT19;KRT7;KRT8;TCHH |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Epithelial intermediate filament dynamics |
6.75E-05 |
7 |
NaN |
|
KRT19;KRT7;KRT8;TCHH |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Down |
Equatorial RhoA activation |
0.005350967 |
20.5 |
NaN |
|
ECT2;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Down |
Equatorial RhoA activation |
0.007388595 |
16.5 |
NaN |
|
ECT2;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Down |
Equatorial RhoA activation |
0.00597407 |
21.5 |
NaN |
|
ECT2;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Down |
Equatorial RhoA activation |
0.005815223 |
21 |
NaN |
|
ECT2;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
MSN01 |
Up |
ER unfolded protein response pathway |
3.04E-06 |
1 |
NaN |
|
ATF4;DDIT3;HERPUD1;PPP1R15A |
| erlotinib |
Kinase inhibitor |
No |
MSN05 |
Up |
ER unfolded protein response pathway |
5.35E-05 |
1 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| erlotinib |
Kinase inhibitor |
No |
MSN08 |
Up |
ER unfolded protein response pathway |
1.83E-06 |
1 |
NaN |
|
ATF4;DDIT3;HERPUD1;PPP1R15A |
| erlotinib |
Kinase inhibitor |
No |
MSN09 |
Up |
ER unfolded protein response pathway |
2.56E-06 |
2 |
NaN |
|
ATF4;DDIT3;HERPUD1;PPP1R15A |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Actin filament severing and depolymerization |
0.001130494 |
7 |
NaN |
|
CFL1;CFL2;DSTN;GSN |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Actin filament severing and depolymerization |
0.013122147 |
18.5 |
NaN |
|
CFL2;DSTN;GSN |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Actin filament severing and depolymerization |
0.01562199 |
17 |
NaN |
|
CFL1;DSTN;GSN |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Actin polymerization |
0.004845366 |
9 |
NaN |
|
BRK1;CTTN;EVL;HSPB1;PFN1;TMSB10 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.033874382 |
14 |
NaN |
|
ALB |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.042254764 |
26.5 |
NaN |
|
ALB |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Amination of alpha-keto acids and deamination of amino acids |
0.008260669 |
11 |
NaN |
|
GLUD1;LOXL2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Amination of alpha-keto acids and deamination of amino acids |
0.00890615 |
13.5 |
NaN |
|
GLUD1;LOXL2 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Amination of alpha-keto acids and deamination of amino acids |
0.010100879 |
14 |
NaN |
|
GLUD1;LOXL2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Amyloid plaque organization |
0.000554461 |
6 |
NaN |
|
APOE;APP;HSPB6;SNCA |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Amyloid plaque organization |
0.000641825 |
5 |
NaN |
|
APOE;APP;HSPB6;SNCA |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Amyloid plaque organization |
0.00035402 |
3 |
NaN |
|
APOE;APP;HSPB6;SNCA |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Amyloid plaque organization |
0.000819486 |
5.5 |
NaN |
|
APP;HSPB6;SNCA;SOD1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Antigen presentation via MHC class I molecules |
0.000421575 |
3.5 |
NaN |
|
B2M;ERAP1;HLA-B;HLA-C |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Antigen presentation via MHC class I molecules |
0.00387498 |
7 |
NaN |
|
B2M;HLA-B;HLA-C |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Apoptosome assembly |
0.046744878 |
8.5 |
NaN |
|
BAG3 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Basement membrane assembly and organization |
0.000363747 |
4.5 |
NaN |
|
COL4A1;ITGB1;LAMC1;NID1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Basement membrane assembly and organization |
0.000421575 |
3.5 |
NaN |
|
COL4A1;ITGB1;LAMC1;NID1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Basement membrane attachment to cell surface |
2.94E-05 |
2.5 |
NaN |
|
BCAM;BSG;CD151;NID1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Basement membrane attachment to cell surface |
3.42E-05 |
2 |
NaN |
|
BCAM;BSG;CD151;NID1 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Basement membrane attachment to cell surface |
1.84E-05 |
2 |
NaN |
|
BCAM;BSG;CD151;NID1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Basement membrane attachment to cell surface |
0.023867324 |
21 |
NaN |
|
BCAM;CD151 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Beta-oxidation |
0.021264329 |
18.5 |
NaN |
|
ACADM;ACADVL;DECR1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Beta-oxidation |
3.08E-05 |
3 |
NaN |
|
ACAA2;ACADM;ACADVL;DECR1;HADH;HADHA |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Biglycan synthesis |
0.039608327 |
28.5 |
NaN |
|
BGN |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Biglycan synthesis |
0.033874382 |
14 |
NaN |
|
BGN |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Cannabinoid receptor signaling |
0.014455899 |
21 |
NaN |
|
CNR1;CNR2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.030931719 |
6.5 |
NaN |
|
CYR61 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Chaperone mediated protein folding in ER |
0.007100524 |
10 |
NaN |
|
CANX;ERP29;FKBP10;PDIA3 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Chaperone mediated protein folding in ER |
0.00889488 |
12 |
NaN |
|
CANX;CLGN;ERP29;PDIA3 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Cholesterol synthesis |
0.015278792 |
4 |
NaN |
|
NSDHL;SQLE |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Chromatin organization by insulator proteins |
0.018673895 |
4.5 |
NaN |
|
CTCF |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Chromatin targeting to lamina |
0.006263232 |
2 |
NaN |
|
CTCF |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Citric acid cycle |
0.001659686 |
9 |
NaN |
|
DLD;FH;PDHA1;PDHB |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.021119418 |
23.5 |
NaN |
|
COL9A1;COL9A2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.015683041 |
9 |
NaN |
|
COL9A1;COL9A3 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.023867324 |
21 |
NaN |
|
COL14A1;COL9A1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Contractile ring constriction |
0.013421778 |
15.5 |
NaN |
|
CDC42;MYLK |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Contractile ring constriction |
0.014455899 |
21 |
NaN |
|
ANLN;MYLK |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Cytosolic protein folding |
0.03810868 |
23 |
NaN |
|
HSP90AA1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Cytosolic protein folding |
0.042254764 |
26.5 |
NaN |
|
HSP90AA1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Decorin synthesis |
0.03810868 |
23 |
NaN |
|
DCN |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Decorin synthesis |
0.033874382 |
14 |
NaN |
|
DCN |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Decorin synthesis |
0.042254764 |
26.5 |
NaN |
|
DCN |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Electron transport chain |
0.001188415 |
7 |
NaN |
|
COX7A1;NDUFA4;UQCR10;UQCR11 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Endogenous control of complement activity |
0.014455899 |
21 |
NaN |
|
CD46;CD59 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Endogenous control of complement activity |
0.016365818 |
18.5 |
NaN |
|
CD59;CFI |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by cathepsins |
0.000363747 |
4.5 |
NaN |
|
CTSB;CTSF;CTSV;CTSZ |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by cathepsins |
2.04E-05 |
1 |
NaN |
|
CTSB;CTSF;CTSL;CTSV;CTSZ |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown by cathepsins |
0.043022614 |
18 |
NaN |
|
CTSB;CTSF |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
2.79E-05 |
2 |
NaN |
|
CTSB;CTSF;CTSL;CTSV;CTSZ |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.00890615 |
13.5 |
NaN |
|
SULF1;SULF2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.043677795 |
26 |
NaN |
|
BSG;MMP2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.002781922 |
6 |
NaN |
|
BSG;MMP14;MMP2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Fibrillar collagen core structure organization |
5.46E-07 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1;COL5A1;COL5A2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.006014756 |
9 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Fibrillar collagen core structure organization |
2.72E-07 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.000539428 |
4 |
NaN |
|
COL11A2;COL1A2;COL3A1;COL5A2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Fibulin receptor signaling |
0.001144587 |
5 |
NaN |
|
EFEMP2;FBLN1 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
GABA-mediated control of postsynaptic potential |
0.028312548 |
6 |
NaN |
|
GABARAP |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Glycogen synthesis and glycogenolysis |
0.004385318 |
1 |
NaN |
|
PPP1R3B;PPP1R3C |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Glycolysis and Gluconeogenesis |
0.010357425 |
14 |
NaN |
|
LDHB;PFKP;PGAM1;PGK1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
GPI-anchor synthesis and attachment to protein |
0.009351581 |
13 |
NaN |
|
GPAA1;PIGS;PIGT |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
GPI-anchor synthesis and attachment to protein |
0.010395217 |
16.5 |
NaN |
|
PIGK;PIGS;PIGT |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
GPI-anchor synthesis and attachment to protein |
0.01239992 |
16 |
NaN |
|
PIGK;PIGS;PIGT |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.009153673 |
2 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.002820997 |
1 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Immunoproteasome organization |
0.023867324 |
21 |
NaN |
|
PSME1;PSME2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Inhibition of apoptosis |
0.010395217 |
16.5 |
NaN |
|
BIRC5;IFI6;PEA15 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Insulin receptor signaling |
0.020976416 |
5 |
NaN |
|
IRS2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Integrin-mediated leukocyte rolling |
0.043038559 |
9 |
NaN |
|
VCAM1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Ketone body metabolism |
0.03810868 |
23 |
NaN |
|
OXCT1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Ketone body metabolism |
0.039608327 |
28.5 |
NaN |
|
OXCT1 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Ketone body metabolism |
0.033874382 |
14 |
NaN |
|
OXCT1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Ketone body metabolism |
0.042254764 |
26.5 |
NaN |
|
OXCT1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Lamellipodium organization |
0.036152236 |
24 |
NaN |
|
BRK1;EVL;MEMO1;RHOA |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Lamellipodium organization |
0.041539781 |
6 |
NaN |
|
TIAM2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Large ribosomal subunit organization |
0.002316603 |
1 |
NaN |
|
RPL11;RPL3;RPL7A |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Leukocyte transmigration through endothelium |
0.030931719 |
6.5 |
NaN |
|
VCAM1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lipid droplet fusion |
0.039608327 |
28.5 |
NaN |
|
CIDEC |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Lipid droplet mitochondria interaction |
0.004237163 |
8 |
NaN |
|
SCP2;SNAP23 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lipid droplet mitochondria interaction |
0.004572911 |
8 |
NaN |
|
SCP2;SNAP23 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Lipid droplet mitochondria interaction |
0.005195699 |
10.5 |
NaN |
|
SCP2;SNAP23 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Lysosomal acidification |
0.008260669 |
11 |
NaN |
|
ATP6AP1;ATP6AP2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lysosomal acidification |
0.00890615 |
13.5 |
NaN |
|
ATP6AP1;ATP6AP2 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Lysosomal acidification |
0.010100879 |
14 |
NaN |
|
ATP6AP1;ATP6AP2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lysosomal glycosaminoglycan degradation |
0.00093277 |
6 |
NaN |
|
ARSB;GNS;IDS;SUMF1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Lysosomal lipid degradation |
2.94E-05 |
2.5 |
NaN |
|
ARSA;GALC;HEXA;PSAP |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lysosomal lipid degradation |
0.001128862 |
7 |
NaN |
|
GALC;HEXA;PSAP |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Lysosomal lipid degradation |
0.000714731 |
4 |
NaN |
|
ARSA;HEXA;PSAP |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Lysosomal lipid degradation |
0.001362806 |
8 |
NaN |
|
GALC;HEXA;PSAP |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Macroautophagy |
0.038706404 |
25 |
NaN |
|
BECN1;MAP1LC3A;MAP1LC3B |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Macroautophagy |
0.028661431 |
11 |
NaN |
|
BECN1;MAP1LC3A;MAP1LC3B |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.022730297 |
3 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Macrophage migration inhibitory factor signaling |
0.007038508 |
2 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Metabolism of branched-chain amino acids |
0.028800167 |
25.5 |
NaN |
|
ACADSB;ECHS1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Metabolism of branched-chain amino acids |
2.58E-06 |
1 |
NaN |
|
ACAD8;ACADSB;ECHS1;HIBCH;MCCC1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Myelin biogenesis and maturation |
0.027215163 |
4 |
NaN |
|
PMP22 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Myofibril formation |
0.000907157 |
1 |
NaN |
|
KLHL41;XIRP1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Myofibril formation |
0.014030551 |
4 |
NaN |
|
XIRP1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.01962834 |
17 |
NaN |
|
NPPA;NPPB |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.021119418 |
23.5 |
NaN |
|
NPPA;NPPB |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.008440625 |
3 |
NaN |
|
NPR3 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Necroptosis induction |
0.00952717 |
3 |
NaN |
|
TNFRSF1A |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Non-vesicular phospholipid transport |
0.026793551 |
20 |
NaN |
|
PITPNM1;SCP2 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Non-vesicular phospholipid transport |
0.028800167 |
25.5 |
NaN |
|
PLTP;SCP2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Non-vesicular phospholipid transport |
0.021468498 |
10 |
NaN |
|
PITPNM1;SCP2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Nucleosome assembly |
0.04946113 |
27 |
NaN |
|
HIST2H2BE;HMGB1;TSPYL2 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Nucleosome assembly |
0.036848196 |
17 |
NaN |
|
HIST1H1D;HIST1H1E;HIST2H2BE |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Osteonectin receptor signaling |
0.00890615 |
13.5 |
NaN |
|
SPARC;SPOCK1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Phase I biotransformation via alcohol dehydrogenases |
0.008260669 |
11 |
NaN |
|
ALDH2;ALDH9A1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Phase I biotransformation via alcohol dehydrogenases |
0.010100879 |
14 |
NaN |
|
ALDH2;ALDH9A1 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Pre-mRNA capping |
0.046744878 |
8.5 |
NaN |
|
CMTR2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Protein acylation |
0.018673895 |
4.5 |
NaN |
|
EP300 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Protein acylation |
0.028312548 |
6 |
NaN |
|
NAA15 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Protein folding in mitochondria |
0.005195699 |
10.5 |
NaN |
|
HSPD1;PPIF |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Protein N-linked glycosylation in ER |
0.008029605 |
11 |
NaN |
|
DDOST;RPN2;TUSC3 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Protein N-linked glycosylation in ER |
0.000819486 |
5.5 |
NaN |
|
DDOST;OSTC;RPN1;TUSC3 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Protein polyubiquitination |
0.021264329 |
18.5 |
NaN |
|
NEDD8;SKP1;UCHL1 |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Protein polyubiquitination |
0.027852981 |
23 |
NaN |
|
NEDD8;SKP1;UCHL1 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Purinergic P1 receptor signaling |
0.028312548 |
6 |
NaN |
|
ADORA1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Pyrimidine synthesis and salvage |
0.034835676 |
21 |
NaN |
|
TYMS;UPP1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Retinol metabolism |
0.013122147 |
18.5 |
NaN |
|
ALDH1A1;CYP26A1;RBP1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
RNA editing |
0.044953641 |
6 |
NaN |
|
APOBEC2 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Selectin-mediated Leukocyte rolling |
0.037003897 |
8 |
NaN |
|
VCAM1 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Down |
Sister chromatid cohesion |
0.011407434 |
3 |
NaN |
|
NIPBL;SMC3 |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Small ribosomal subunit organization |
0.002566131 |
2 |
NaN |
|
RPS16;RPS4Y1;RPS7 |
| epirubicin |
Anthracycline |
Yes |
MSN01 |
Up |
Syndecan receptor signaling |
0.013421778 |
15.5 |
NaN |
|
SDC4;SDCBP |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Syndecan receptor signaling |
0.010693605 |
8 |
NaN |
|
SDC4;SDCBP |
| epirubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Syndecan receptor signaling |
0.016365818 |
18.5 |
NaN |
|
SDC4;SDCBP |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Thin myofilament organization |
0.031679842 |
5 |
NaN |
|
ACTA1 |
| epirubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Tropoelastin synthesis |
0.039608327 |
28.5 |
NaN |
|
ELN |
| epirubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.033874382 |
14 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Mitotic spindle disassembly |
0.023200423 |
13 |
NaN |
|
CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Mitotic spindle disassembly |
0.024788285 |
12.5 |
NaN |
|
CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Mitotic spindle disassembly |
0.024523641 |
10.5 |
NaN |
|
CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Mitotic spindle disassembly |
0.026287932 |
17 |
NaN |
|
CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.007562538 |
6 |
NaN |
|
NPPA;NPPB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Natriuretic peptide receptor signaling |
0.008598393 |
5.5 |
NaN |
|
NPPA;NPR3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.000276247 |
2 |
NaN |
|
NPPA;NPPB;NPR3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Natriuretic peptide receptor signaling |
0.008598393 |
6.5 |
NaN |
|
NPPA;NPR3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.000339137 |
7 |
NaN |
|
NPPA;NPPB;NPR3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Osteopontin receptor signaling |
0.024788285 |
12.5 |
NaN |
|
SPP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.024788285 |
11.5 |
NaN |
|
SPP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Osteopontin receptor signaling |
0.02196542 |
7.5 |
NaN |
|
SPP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.02099506 |
9.5 |
NaN |
|
SPP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Parathyroid hormone receptor signaling |
0.0085983 |
6 |
NaN |
|
PTHLH;SLC9A3R1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.001516175 |
3.5 |
NaN |
|
FOSL1;PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.019010322 |
7.5 |
NaN |
|
PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Platelet-derived growth factor receptor signaling |
0.001331035 |
3 |
NaN |
|
FOSL1;PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.017285445 |
8.5 |
NaN |
|
PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.000952391 |
3 |
NaN |
|
FOSL1;PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Prostaglandin E2 receptor signaling |
0.008598393 |
6.5 |
NaN |
|
PTGER3;RAPGEF4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Prostaglandin E2 receptor signaling |
0.009633191 |
12 |
NaN |
|
PTGER3;RAPGEF4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.041551141 |
17 |
NaN |
|
PTGFR |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Protein polyubiquitination |
0.035163828 |
15 |
NaN |
|
UBC;UCHL1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Pyrimidine synthesis and salvage |
0.013690263 |
8 |
NaN |
|
TK1;TYMP |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Pyrimidine synthesis and salvage |
0.017367241 |
14.5 |
NaN |
|
TK1;TYMP |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Removal of caspase inhibition |
0.045864587 |
17.5 |
NaN |
|
XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Removal of caspase inhibition |
0.048964244 |
18 |
NaN |
|
XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Removal of caspase inhibition |
0.048447984 |
17 |
NaN |
|
XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Removal of caspase inhibition |
0.048964244 |
16 |
NaN |
|
XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Retinol metabolism |
0.031958081 |
10.5 |
NaN |
|
ALDH1A1;ALDH1A3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Retinol metabolism |
0.002236525 |
4 |
NaN |
|
ALDH1A1;ALDH1A3;DHRS3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Retinol metabolism |
0.023708594 |
13 |
NaN |
|
ALDH1A1;ALDH1A3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Selectin-mediated Leukocyte rolling |
0.008598393 |
5.5 |
NaN |
|
ICAM1;SELP |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Selectin-mediated Leukocyte rolling |
0.008598393 |
6.5 |
NaN |
|
ICAM1;SELP |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Semaphorin signaling |
0.043551421 |
15 |
NaN |
|
DPYSL4;FARP1;PLXND1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.001516175 |
3.5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.021308064 |
12 |
NaN |
|
PHGDH;PSAT1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.017285445 |
8.5 |
NaN |
|
PHGDH;SLC1A5 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Serine and glycine metabolism |
0.017132206 |
7 |
NaN |
|
PHGDH;PSAT1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Serotonin inactivation |
0.048447984 |
17 |
NaN |
|
MAOA |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Serotonin inactivation |
0.043450255 |
15.5 |
NaN |
|
MAOA |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Serotonin inactivation |
0.039131362 |
14 |
NaN |
|
MAOA |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Serotonin inactivation |
0.037227967 |
15 |
NaN |
|
MAOB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Sister chromatid segregation |
0.008598393 |
5.5 |
NaN |
|
ESPL1;TOP2A |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Tight junction organization |
0.037991607 |
12 |
NaN |
|
CLDN1;CLDN4;MYLK |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.02196542 |
7.5 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.02099506 |
9.5 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Tropoelastin synthesis |
0.018789697 |
11 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.018701482 |
9.5 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.045864587 |
17.5 |
NaN |
|
VIPR2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.048447984 |
17 |
NaN |
|
VIPR2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Actin polymerization |
0.049732167 |
17 |
NaN |
|
ACTA1;FMNL2;INF2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Adrenergic receptor signaling |
0.025716112 |
13 |
NaN |
|
RAPGEF4;RASD1;RGS4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Aggrecan synthesis |
0.023200423 |
13 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Aggrecan synthesis |
0.024788285 |
12.5 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Aggrecan synthesis |
0.024523641 |
10.5 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Aggrecan synthesis |
0.024788285 |
11.5 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Aggrecan synthesis |
0.026287932 |
17 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Albumin mediated blood protein transport |
0.023200423 |
13 |
NaN |
|
ALB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Albumin mediated blood protein transport |
0.024788285 |
12.5 |
NaN |
|
ALB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Amyloid plaque organization |
0.032389398 |
20 |
NaN |
|
APBB2;APOE |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Amyloid plaque organization |
0.019010322 |
7.5 |
NaN |
|
HSPB6;VSNL1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Antigen presentation via MHC class I molecules |
0.021340058 |
10 |
NaN |
|
HLA-B;HLA-C |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Antigen presentation via MHC class I molecules |
0.026961659 |
19 |
NaN |
|
HLA-B;HLA-C |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Biglycan synthesis |
0.02196542 |
7.5 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Biglycan synthesis |
0.019760056 |
9.5 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Biglycan synthesis |
0.02099506 |
9.5 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Biglycan synthesis |
0.018789697 |
11 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Biglycan synthesis |
0.018701482 |
9.5 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Calcitonin receptor signaling |
0.039131362 |
14 |
NaN |
|
RAMP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Calcitonin receptor signaling |
0.037054838 |
18.5 |
NaN |
|
RAMP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Carnitine shuttle |
0.006934528 |
5 |
NaN |
|
CPT1A;SLC25A20 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005706386 |
7 |
NaN |
|
CTGF;CYR61 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005827311 |
4 |
NaN |
|
CYR61;NOV |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
CD44-Mediated leukocyte rolling |
0.043450255 |
15.5 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.039131362 |
14 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.041551141 |
17 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
CD44-Mediated leukocyte rolling |
0.037227967 |
15 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
CD44-Mediated leukocyte rolling |
0.037054838 |
18.5 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.039888032 |
14 |
NaN |
|
ABCA12;ARL4C |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.031958081 |
10.5 |
NaN |
|
ABCA1;ABCG1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Cellular cholesterol uptake and efflux |
0.001627653 |
2 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.023708594 |
13 |
NaN |
|
ABCA1;SCARA3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Cellular iron storage |
0.001420807 |
2 |
NaN |
|
FTH1;FTL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Cellular iron storage |
0.001298656 |
2 |
NaN |
|
FTH1;FTL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Cellular iron storage |
0.001031479 |
4 |
NaN |
|
FTH1;FTL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Centrosome maturation |
0.0336321 |
12.5 |
NaN |
|
PLK1;TPX2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Centrosome maturation |
0.038203861 |
21.5 |
NaN |
|
PLK1;TPX2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Centrosome separation |
0.021340058 |
10 |
NaN |
|
CDK1;NEK2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Centrosome separation |
0.02416119 |
10 |
NaN |
|
CDK1;ESPL1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Centrosome separation |
0.001540682 |
5 |
NaN |
|
CCNB1;CDK1;NEK2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Centrosome separation |
8.67E-05 |
5 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Chaperone-mediated autophagy |
0.043450255 |
15.5 |
NaN |
|
HSPA8 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Chaperone-mediated autophagy |
0.039131362 |
14 |
NaN |
|
HSPA8 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Chaperone-mediated autophagy |
0.037054838 |
18.5 |
NaN |
|
HSP90AA1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Chloride transmembrane transport |
0.023917892 |
13 |
NaN |
|
BEST1;SLC26A8 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Chloride transmembrane transport |
0.023708594 |
13 |
NaN |
|
BEST1;SLC26A8 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Cholesterol synthesis |
5.74E-12 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVD;NSDHL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Cholesterol synthesis |
2.46E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SQLE |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Cholesterol synthesis |
2.46E-13 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;SQLE |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Cholesterol synthesis |
1.99E-08 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDPS;HMGCR;HMGCS1;MSMO1;MVD |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.008598393 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Cholesterol-sensitive control of SREBP activation |
0.008598393 |
6.5 |
NaN |
|
INSIG1;SREBF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Class switch recombination |
0.048725822 |
17.5 |
NaN |
|
BCL6;IL7R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Class switch recombination |
0.048315957 |
22.5 |
NaN |
|
BCL6;IL7R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Classical complement pathway |
0.010426243 |
7 |
NaN |
|
C1QA;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Classical complement pathway |
1.22E-05 |
2 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Classical complement pathway |
0.000474665 |
3 |
NaN |
|
C1QB;C1QC;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Classical complement pathway |
1.22E-05 |
2 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Classical complement pathway |
1.54E-05 |
3 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Collagen fiber crosslinking |
0.005119846 |
5 |
NaN |
|
LOXL1;PXDN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Collagen fiber crosslinking |
0.006535173 |
10.5 |
NaN |
|
LOXL1;PXDN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006799947 |
5 |
NaN |
|
COL14A1;COL9A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005533298 |
2 |
NaN |
|
COL12A1;COL14A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006227501 |
5 |
NaN |
|
COL14A1;COL9A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005015101 |
4 |
NaN |
|
COL12A1;COL14A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000123729 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Contractile ring constriction |
0.006535173 |
10.5 |
NaN |
|
ANLN;ECT2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Cytosolic protein folding |
0.018701482 |
9.5 |
NaN |
|
HSP90AA1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Decorin synthesis |
0.02196542 |
7.5 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Decorin synthesis |
0.019760056 |
9.5 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Decorin synthesis |
0.02099506 |
9.5 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Decorin synthesis |
0.018789697 |
11 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Decorin synthesis |
0.018701482 |
9.5 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Desaturation of fatty acids |
0.011841806 |
8 |
NaN |
|
FADS2;SCD |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Desaturation of fatty acids |
0.00048986 |
3 |
NaN |
|
FADS1;FADS2;SCD |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Endogenous control of complement activity |
0.003385224 |
3 |
NaN |
|
CFH;CFI |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Endogenous control of complement activity |
0.003354036 |
5 |
NaN |
|
CFH;CFI |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Epithelial intermediate filament dynamics |
0.011306612 |
7 |
NaN |
|
KRT19;KRT7 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Epithelial intermediate filament dynamics |
0.009132153 |
6 |
NaN |
|
KRT7;TCHH |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Eukaryotic kinetochore dynamics |
5.11E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;DYNLT3;NUF2;SPC24;TTK |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01134371 |
4 |
NaN |
|
ADAMTS1;ADAMTS5;ADAMTS7 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.009769926 |
6 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS5 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Extracellular matrix breakdown by cathepsins |
0.015757014 |
6 |
NaN |
|
CTSF;CTSV |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.014318179 |
7 |
NaN |
|
CTSF;CTSL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.012770499 |
5 |
NaN |
|
MMP2;MMP3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
0.021340058 |
10 |
NaN |
|
COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.00158905 |
3 |
NaN |
|
COL11A2;COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.023680597 |
9 |
NaN |
|
COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.02416119 |
10 |
NaN |
|
COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.00188137 |
8 |
NaN |
|
COL11A2;COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
4.30E-05 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Fibrillar collagen core structure organization |
2.84E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
0.00098321 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.000712003 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
2.29E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Fibulin receptor signaling |
0.045864587 |
17.5 |
NaN |
|
FBLN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Fibulin receptor signaling |
0.048447984 |
17 |
NaN |
|
FBLN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
G2 M transition checkpoint |
0.0336321 |
12.5 |
NaN |
|
CCNB1;CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
G2 M transition checkpoint |
0.038203861 |
21.5 |
NaN |
|
CCNB1;CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Gap junction organization |
0.033831795 |
13.5 |
NaN |
|
GJA5;GJB2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.026271217 |
11 |
NaN |
|
SLC1A5;SLC7A5 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Glycolysis and Gluconeogenesis |
0.001770826 |
4 |
NaN |
|
ALDOA;ENO1;LDHA;PGK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Glycolysis and Gluconeogenesis |
0.000200326 |
1 |
NaN |
|
ENO1;HK2;LDHA;PGK1;TPI1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Glycolysis and Gluconeogenesis |
2.17E-05 |
4 |
NaN |
|
ALDOA;ENO1;HK2;LDHA;PGK1;TPI1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Glycolysis and Gluconeogenesis |
0.01007022 |
3 |
NaN |
|
PCK2;PFKFB3;PFKFB4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.048964244 |
18 |
NaN |
|
JUND |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Growth differentiation factor receptor signaling |
0.015218327 |
8 |
NaN |
|
GDF2;GDF6 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.017367241 |
14.5 |
NaN |
|
GDF2;GDF6 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Hedgehog receptor signaling |
0.048725822 |
17.5 |
NaN |
|
BOC;GAS1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Hedgehog receptor signaling |
0.048315957 |
22.5 |
NaN |
|
CDON;GAS1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Hepatocyte growth factor receptor signaling |
0.045864587 |
17.5 |
NaN |
|
HGF |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Hepatocyte growth factor receptor signaling |
0.048964244 |
18 |
NaN |
|
HGF |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Hepatocyte growth factor receptor signaling |
0.048447984 |
17 |
NaN |
|
HGF |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Hepatocyte growth factor receptor signaling |
0.048964244 |
16 |
NaN |
|
HGF |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.043450255 |
15.5 |
NaN |
|
MET |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.041551141 |
17 |
NaN |
|
MET |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.037054838 |
18.5 |
NaN |
|
MET |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Hyaluronan-mediated motility receptor signaling |
0.026287932 |
17 |
NaN |
|
HMMR |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Inhibin receptor signaling |
0.0155326 |
9 |
NaN |
|
INHBA;INHBB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Inhibin receptor signaling |
0.0155326 |
9 |
NaN |
|
INHBA;INHBB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Inhibition of apoptosis |
0.000121035 |
2 |
NaN |
|
BIRC5;IFI6;PEA15;XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Inhibition of apoptosis |
0.03430279 |
15 |
NaN |
|
IFI6;XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Inhibition of apoptosis |
0.002723606 |
6 |
NaN |
|
BIRC5;IFI6;XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Inhibition of apoptosis |
0.003317085 |
9 |
NaN |
|
BIRC5;IFI6;XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Inositol metabolism and transport |
0.048964244 |
18 |
NaN |
|
SLC5A3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
JAK-STAT signaling pathway |
0.033831795 |
13.5 |
NaN |
|
SOCS3;STAT4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Up |
Lipogenesis |
0.00053626 |
3 |
NaN |
|
ACLY;FASN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Up |
Lipogenesis |
0.048964244 |
18 |
NaN |
|
FASN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Lipogenesis |
0.000599299 |
4 |
NaN |
|
ACLY;FASN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Up |
Lipogenesis |
0.048964244 |
16 |
NaN |
|
FASN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Metaphase to anaphase checkpoint |
0.049939927 |
20 |
NaN |
|
BUB1;CCNB2;CDC20 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
0.011665755 |
13 |
NaN |
|
BUB1;CDC20;CENPE;TTK |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Methionine cycle |
0.043450255 |
15.5 |
NaN |
|
BHMT |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Methionine cycle |
0.041551141 |
17 |
NaN |
|
BHMT |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Methionine cycle |
0.037054838 |
18.5 |
NaN |
|
BHMT |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN01 |
Down |
Microfibril scaffold organization |
0.043450255 |
15.5 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN02 |
Down |
Microfibril scaffold organization |
0.039131362 |
14 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.041551141 |
17 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN06 |
Down |
Microfibril scaffold organization |
0.037227967 |
15 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Down |
Microfibril scaffold organization |
0.037054838 |
18.5 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN05 |
Up |
Mitotic spindle assembly |
0.039114857 |
14 |
NaN |
|
NUSAP1;TPX2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
MSN08 |
Up |
Mitotic spindle assembly |
0.00027738 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
ER unfolded protein response pathway |
0.027202094 |
10 |
NaN |
|
DDIT3 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
ER unfolded protein response pathway |
0.024442263 |
9 |
NaN |
|
DDIT3 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.018322582 |
10.5 |
NaN |
|
ADAMTS15;ADAMTS17;ADAMTS7 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000662661 |
2 |
NaN |
|
ADAMTS1;ADAMTS10;ADAMTS12;ADAMTS14 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.032866596 |
15.5 |
NaN |
|
MMP1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.030551239 |
11 |
NaN |
|
MMP1 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.027456433 |
10 |
NaN |
|
MMP1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Extracellular matrix breakdown by meprins |
0.046726108 |
16 |
NaN |
|
MEP1A |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Extracellular matrix breakdown by serine proteases |
0.025301145 |
9 |
NaN |
|
HTRA1;ST14 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Extracellular matrix breakdown by serine proteases |
0.026677448 |
8 |
NaN |
|
HTRA1;ST14 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Extrinsic apoptosis pathway |
0.027730132 |
10.5 |
NaN |
|
TNFRSF10A;TNFRSF10B |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Extrinsic apoptosis pathway |
0.000426234 |
2 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Gap junction organization |
0.013466483 |
7 |
NaN |
|
GJA5;GJB2;PRKCG |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Gap junction organization |
0.014531343 |
6 |
NaN |
|
GJA5;GJB2;PRKCG |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Glutamate and glutamine metabolism |
0.036581377 |
15 |
NaN |
|
GLS2;SLC1A5 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Glycogen synthesis and glycogenolysis |
0.029585472 |
11.5 |
NaN |
|
GYG2;PYGM |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
G-protein coupled receptor signaling pathway |
0.03848067 |
14 |
NaN |
|
RGS16;RGS4;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.033762424 |
14 |
NaN |
|
JAK2 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Hedgehog receptor signaling |
0.005455717 |
6 |
NaN |
|
FOXA2;MYCN;PTCH1;SHH |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Hedgehog receptor signaling |
0.033631101 |
9.5 |
NaN |
|
GAS1;MYCN;PTCH1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Heme degradation to bilirubin |
0.010286538 |
3.5 |
NaN |
|
HMOX1 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.00739662 |
4.5 |
NaN |
|
MET |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.006165756 |
2.5 |
NaN |
|
MET |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.033762424 |
14 |
NaN |
|
MET |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Hyaluronan receptor CD44 signaling |
0.011074875 |
6.5 |
NaN |
|
CD44 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Inhibin receptor signaling |
0.036036556 |
12 |
NaN |
|
INHA;INHBB |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Inositol metabolism and transport |
0.000556884 |
3 |
NaN |
|
INPP5D;SLC5A3 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Intrinsic apoptosis pathway |
0.003920354 |
5 |
NaN |
|
BBC3;BIK;PMAIP1 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Leukocyte transmigration through endothelium |
0.012654774 |
5.5 |
NaN |
|
PECAM1;VCAM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Lipid droplet fusion |
0.036961891 |
11 |
NaN |
|
CIDEC |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Lipid droplet fusion |
0.038020466 |
12.5 |
NaN |
|
CIDEC |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Microtubule crosslinking and bundling |
0.022029985 |
11.5 |
NaN |
|
MAP2 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Microtubule crosslinking and bundling |
0.020469948 |
7.5 |
NaN |
|
MAP2 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Microtubule crosslinking and bundling |
0.018386674 |
7.5 |
NaN |
|
MAP2 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Mitochondrial fission |
0.040531407 |
14 |
NaN |
|
DNM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Mitochondrial fission |
0.017012043 |
9 |
NaN |
|
DNM1;MTFR2 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Mitochondrial transport |
0.033889149 |
12.5 |
NaN |
|
KIF1A |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Mitotic spindle disassembly |
0.038814397 |
13.5 |
NaN |
|
CDK1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Mitotic spindle disassembly |
0.023641496 |
13 |
NaN |
|
CDK1 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Muscarinic receptor signaling |
0.018520889 |
8 |
NaN |
|
CHRM4;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Muscarinic receptor signaling |
0.019542138 |
7 |
NaN |
|
RGS4;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Muscarinic receptor signaling |
0.007844056 |
7 |
NaN |
|
CHRM4;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.000922544 |
1 |
NaN |
|
NPPA;NPPB;NPPC |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Natriuretic peptide receptor signaling |
0.001064134 |
3 |
NaN |
|
NPPA;NPPB;NPPC |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.001001852 |
2 |
NaN |
|
NPPA;NPPB;NPPC |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.004135058 |
5 |
NaN |
|
NPPB;NPPC |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Necroptosis induction |
0.003440367 |
1 |
NaN |
|
TNFRSF1A |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Neuregulin receptor signaling |
0.014335775 |
8 |
NaN |
|
ERBB3;SH3TC2 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
NFkB signaling pathway |
0.022029985 |
11.5 |
NaN |
|
SQSTM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
NFkB signaling pathway |
0.020469948 |
7.5 |
NaN |
|
SQSTM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
NFkB signaling pathway |
0.018386674 |
7.5 |
NaN |
|
SQSTM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Nodal growth differentiation factor receptor signaling |
0.001522291 |
3 |
NaN |
|
LEFTY1;LEFTY2;TGIF1;ZIC3 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Nucleosome assembly |
0.001053325 |
2 |
NaN |
|
ASF1B;BAZ1A;HIST1H1D;HIST1H1E;HIST2H2BE |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Nucleosome assembly |
0.001311187 |
4 |
NaN |
|
ASF1B;BAZ1A;HIST1H1D;HIST1H1E;HIST2H2BE |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Nucleosome assembly |
0.008745821 |
5 |
NaN |
|
ASF1B;HIST1H1D;HIST1H1E;HIST2H2BE |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Nucleotide excision repair |
0.000168813 |
1 |
NaN |
|
DDB2;PCNA;POLH;RPA1;XPC |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.026605409 |
14 |
NaN |
|
PDGFB;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Progestagen synthesis |
0.014739823 |
8 |
NaN |
|
HSD17B2 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Prostaglandin E2 receptor signaling |
0.020324006 |
8.5 |
NaN |
|
PTGER2;PTGER4 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Proteasomal regulatory particle organization |
0.025655293 |
13.5 |
NaN |
|
PSMD14 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Proteasomal regulatory particle organization |
0.023841676 |
9 |
NaN |
|
PSMD14 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Proteasomal regulatory particle organization |
0.005724397 |
6.5 |
NaN |
|
PSMC4;PSMD14 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Protein polyubiquitination |
0.001556081 |
2 |
NaN |
|
UBC;UCHL1 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Protein polyubiquitination |
0.001081551 |
1 |
NaN |
|
UBC;UCHL1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Protein polyubiquitination |
0.029585472 |
11.5 |
NaN |
|
UBC;UCHL1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Restriction point |
0.033889149 |
12.5 |
NaN |
|
CDKN1A |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Restriction point |
0.030461556 |
11 |
NaN |
|
CDKN1A |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Ribonucleotide reduction |
0.001644513 |
4 |
NaN |
|
RRM2;RRM2B |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Selectin-mediated Leukocyte rolling |
0.020324006 |
8.5 |
NaN |
|
SELE;VCAM1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Syndecan receptor signaling |
0.00054785 |
2 |
NaN |
|
SDC1;SDC4;SDCBP |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Thick myofilament organization |
0.003988825 |
4 |
NaN |
|
MYBPC3;MYH7 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Thick myofilament organization |
0.004393611 |
5 |
NaN |
|
MYBPC3;MYH7 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Thick myofilament organization |
0.004217801 |
4 |
NaN |
|
MYBPC3;MYH7 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Thin myofilament organization |
0.027730132 |
10.5 |
NaN |
|
TPM1;TPM2 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Thin myofilament organization |
0.005724397 |
6.5 |
NaN |
|
ACTA1;TNNI3 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Transamination pathways |
0.025655293 |
13.5 |
NaN |
|
BCAT1 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Tropoelastin synthesis |
0.038814397 |
13.5 |
NaN |
|
ELN |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Tropoelastin synthesis |
0.038020466 |
12.5 |
NaN |
|
ELN |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.002350796 |
3 |
NaN |
|
APCDD1;DKK2;DKK3;FZD1;FZD8;LEF1;SFRP5;WNT3A |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
5.28E-06 |
1 |
NaN |
|
APCDD1;AXIN2;DKK2;FRAT1;FZD1;FZD10;FZD7;FZD8;LEF1;MSX2;SFRP2;SFRP5 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.000136638 |
1 |
NaN |
|
APCDD1;AXIN2;DKK2;FZD1;FZD7;FZD8;LEF1;MSX2;SFRP2;SFRP5 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Z-disc organization |
0.00231055 |
3 |
NaN |
|
BAG3;LDB3;TCAP |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Acetylcholine-mediated control of postsynaptic potential |
0.010811186 |
8 |
NaN |
|
ACHE;AGRN |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Androgen synthesis |
0.032866596 |
15.5 |
NaN |
|
HSD17B2 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Cannabinoid receptor signaling |
0.012654774 |
5.5 |
NaN |
|
CNR1;CNR2 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Up |
Cardiomyocyte pacemaker current generation |
0.032920279 |
10 |
NaN |
|
CACNA1G;KCNJ5 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Cardiomyocyte pacemaker current generation |
0.034686748 |
11 |
NaN |
|
CACNA1G;KCNJ5 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Cardiomyocyte pacemaker current generation |
0.014191558 |
9 |
NaN |
|
CACNA1G;KCNJ5 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
CD44-Mediated leukocyte rolling |
0.00739662 |
4.5 |
NaN |
|
CD44 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
CD44-Mediated leukocyte rolling |
0.033762424 |
14 |
NaN |
|
CD44 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Cell cycle arrest in response to DNA damage |
0.018322582 |
10.5 |
NaN |
|
BBC3;CDKN1A;MDM2 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Cellular iron storage |
0.011074875 |
6.5 |
NaN |
|
FTL |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Cellular iron storage |
0.010286538 |
3.5 |
NaN |
|
FTL |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Cellular iron storage |
0.00923477 |
4 |
NaN |
|
FTL |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
Centrosome separation |
0.022108594 |
12 |
NaN |
|
CDK1;CROCC |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Chaperone-mediated autophagy |
1.34E-05 |
1 |
NaN |
|
HSP90AA1;HSPA8 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Chaperone-mediated autophagy |
0.0068692 |
2 |
NaN |
|
HSPA8 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Chaperone-mediated autophagy |
0.006165756 |
2.5 |
NaN |
|
HSPA8 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Chaperone-mediated autophagy |
0.000288388 |
1 |
NaN |
|
HSP90AA1;HSPA8 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Up |
Class switch recombination |
0.033631101 |
9.5 |
NaN |
|
BCL6;IRF4;IRF8 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Collagen fiber crosslinking |
0.002787899 |
4 |
NaN |
|
PLOD1;PXDN |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Up |
Contractile ring constriction |
0.013904049 |
7 |
NaN |
|
ANLN;MYLK |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Contractile ring constriction |
0.018391511 |
9.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Contractile ring constriction |
0.017086874 |
5.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Contractile ring constriction |
0.015345202 |
5.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Contractile ring formation |
0.018391511 |
9.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN06 |
Down |
Contractile ring formation |
0.017086874 |
5.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN08 |
Down |
Contractile ring formation |
0.015345202 |
5.5 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
MSN05 |
Down |
Cytosolic protein folding |
0.003705011 |
3 |
NaN |
|
HSP90AA1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Down |
Cytosolic protein folding |
0.017025406 |
10 |
NaN |
|
HSP90AA1 |
| doxorubicin |
Anthracycline |
Yes |
MSN09 |
Up |
DNA replication elongation |
0.005312003 |
6 |
NaN |
|
MCM4;PCNA |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Actin filament bundling and crosslinking |
0.003112458 |
3 |
NaN |
|
EPS8;FLNA;TAGLN;USH1C |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Actin filament bundling and crosslinking |
0.000322287 |
3 |
NaN |
|
EPS8;FLNA;FSCN2;TAGLN;USH1C |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Aggrecan synthesis |
0.024964714 |
8 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Aggrecan synthesis |
0.020465773 |
9 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Aggrecan synthesis |
0.020289344 |
11.5 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Aggrecan synthesis |
0.021524347 |
9.5 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Aggrecan synthesis |
0.020553987 |
9.5 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.020465773 |
9 |
NaN |
|
ALB |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Albumin mediated blood protein transport |
0.020289344 |
11.5 |
NaN |
|
ALB |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.021524347 |
9.5 |
NaN |
|
ALB |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Alternative complement pathway |
0.004420469 |
5.5 |
NaN |
|
C1S;CFH |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Amyloid plaque organization |
0.02587038 |
12.5 |
NaN |
|
APOE;HSPB6 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Bicarbonate transmembrane transport |
0.006282675 |
6 |
NaN |
|
CA9;SLC26A7;SLC4A8 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Biglycan synthesis |
0.018877911 |
6 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Biglycan synthesis |
0.023817925 |
9.5 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Biglycan synthesis |
0.023288638 |
10 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Biglycan synthesis |
0.023817925 |
11.5 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Biglycan synthesis |
0.023023994 |
7.5 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Calcitonin receptor signaling |
0.049308339 |
11 |
NaN |
|
RAMP1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Cannabinoid receptor signaling |
0.003936586 |
4.5 |
NaN |
|
CNR1;CNRIP1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.04259587 |
16.5 |
NaN |
|
KCNA1;KCNJ2 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.04259587 |
17.5 |
NaN |
|
KCNA1;KCNJ2 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005389806 |
4 |
NaN |
|
CTGF;CYR61 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000148334 |
1 |
NaN |
|
CTGF;CYR61;NOV |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003936586 |
4.5 |
NaN |
|
CTGF;NOV |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004420469 |
5.5 |
NaN |
|
NOV;WISP1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004038016 |
4 |
NaN |
|
CYR61;WISP1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
CD44-Mediated leukocyte rolling |
0.037401081 |
9 |
NaN |
|
CD44 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Cellular cholesterol uptake and efflux |
0.035587098 |
14 |
NaN |
|
ABCA1;ABCA12 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Cellular cholesterol uptake and efflux |
0.037082638 |
15 |
NaN |
|
ABCA1;ABCA12 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Centrosome separation |
0.018527793 |
8 |
NaN |
|
AURKA;NEK2 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Chloride transmembrane transport |
0.027593758 |
13 |
NaN |
|
ANO1;SLC12A6 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Classical complement pathway |
0.000500164 |
2 |
NaN |
|
C1QB;C1QC;C1R |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Classical complement pathway |
0.008183872 |
5.5 |
NaN |
|
C1R;C1S |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007958007 |
5 |
NaN |
|
COL12A1;COL9A1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000253405 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.0087173 |
6.5 |
NaN |
|
COL14A1;COL9A2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005975135 |
5.5 |
NaN |
|
COL14A1;COL9A2 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Decorin synthesis |
0.018877911 |
6 |
NaN |
|
DCN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Decorin synthesis |
0.020465773 |
9 |
NaN |
|
DCN |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Decorin synthesis |
0.020553987 |
9.5 |
NaN |
|
DCN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Discoidin domain receptor signaling |
0.001668996 |
6 |
NaN |
|
DDR1;DDR2 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
DNA replication elongation |
0.005158008 |
4.5 |
NaN |
|
MCM5;MCM7 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
DNA replication initiation |
0.019672168 |
8 |
NaN |
|
CDC6;MCM5;MCM7 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
ER unfolded protein response pathway |
0.013492017 |
3 |
NaN |
|
DDIT3;PPP1R15A |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Myofibril formation |
0.016979423 |
7 |
NaN |
|
DES;XIRP1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Natriuretic peptide receptor signaling |
0.0087173 |
6.5 |
NaN |
|
NPPA;NPR3 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.005975135 |
5.5 |
NaN |
|
NPPA;NPPB |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
NOD-like receptor signaling |
0.037082638 |
14.5 |
NaN |
|
NLRP3;NOD2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
NOD-like receptor signaling |
0.002908016 |
1 |
NaN |
|
NLRC5;NLRP3;NOD2 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Osteonectin receptor signaling |
0.002690445 |
3.5 |
NaN |
|
SMOC2;SPARC |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Osteonectin receptor signaling |
0.002456071 |
3 |
NaN |
|
SPARC;SPOCK1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.023817925 |
9.5 |
NaN |
|
SPP1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Osteopontin receptor signaling |
0.023288638 |
10 |
NaN |
|
SPP1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.023817925 |
11.5 |
NaN |
|
SPP1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.026976171 |
13 |
NaN |
|
FOSL1;PDGFRB |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.02587038 |
12.5 |
NaN |
|
FOSL1;PDGFRA |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
9.10E-05 |
1 |
NaN |
|
FOSL1;PDGFB;PDGFRA;PDGFRB |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.025324824 |
9 |
NaN |
|
FOSL1;PDGFRB |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Progesterone receptor signaling |
0.023817925 |
9.5 |
NaN |
|
PGR |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Prolactin receptor signaling |
0.005158008 |
4.5 |
NaN |
|
PRLR;SOCS2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Prostaglandin E2 receptor signaling |
0.007451277 |
2 |
NaN |
|
PTGER3;RAPGEF4 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Removal of caspase inhibition |
0.049308339 |
11 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Removal of caspase inhibition |
0.040514466 |
13.5 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Removal of caspase inhibition |
0.040168784 |
15 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.042587255 |
12.5 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Removal of caspase inhibition |
0.040687284 |
15 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Restriction point |
0.021035933 |
5.5 |
NaN |
|
CDKN1A;E2F1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Retinol metabolism |
0.037082638 |
15 |
NaN |
|
RPE65;STRA6 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Retinol metabolism |
0.034848653 |
10 |
NaN |
|
RPE65;STRA6 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Retinol metabolism |
0.003656435 |
4 |
NaN |
|
ALDH1A3;CYP26A1;RBP1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Retinol metabolism |
0.002079214 |
3 |
NaN |
|
ALDH1A3;DHRS3;RBP1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Retinol metabolism |
0.028265172 |
11 |
NaN |
|
ALDH1A3;DHRS3 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Roundabout signaling |
0.008047841 |
7 |
NaN |
|
ROBO1;ROBO2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Semaphorin signaling |
0.032121671 |
12 |
NaN |
|
NRP2;PLXNB3;RND1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Serine and glycine metabolism |
0.019981164 |
10 |
NaN |
|
PHGDH;SHMT2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Serine and glycine metabolism |
0.02047443 |
8 |
NaN |
|
PHGDH;SHMT2 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Serotonin inactivation |
0.046036922 |
16.5 |
NaN |
|
MAOA |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Serotonin inactivation |
0.045519869 |
11.5 |
NaN |
|
MAOA |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Serotonin inactivation |
0.049308339 |
11 |
NaN |
|
MAOA |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Serotonin inactivation |
0.040514466 |
13.5 |
NaN |
|
MAOB |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Serotonin inactivation |
0.042587255 |
12.5 |
NaN |
|
MAOB |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Thin myofilament organization |
0.008183872 |
5.5 |
NaN |
|
LMOD3;TPM4 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Thin myofilament organization |
0.009022183 |
7 |
NaN |
|
LMOD3;TPM4 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Thrombospondin receptor signaling |
0.002435279 |
4 |
NaN |
|
THBS2;THBS4 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Thrombospondin receptor signaling |
0.002393952 |
3 |
NaN |
|
THBS2;THBS4 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.002690445 |
3.5 |
NaN |
|
THBS2;THBS4 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Tropoelastin synthesis |
0.018877911 |
6 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Tropoelastin synthesis |
0.023817925 |
9.5 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Tropoelastin synthesis |
0.023288638 |
10 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Tropoelastin synthesis |
0.023817925 |
11.5 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.023023994 |
7.5 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Vasoactive intestinal peptide receptor signaling |
0.047070608 |
19.5 |
NaN |
|
VIPR2 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Versican receptor signaling |
0.047070608 |
19.5 |
NaN |
|
VCAN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Versican receptor signaling |
0.047070608 |
20.5 |
NaN |
|
VCAN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Versican synthesis |
0.023817925 |
9.5 |
NaN |
|
VCAN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Versican synthesis |
0.023817925 |
11.5 |
NaN |
|
VCAN |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.007074109 |
4 |
NaN |
|
FRZB;FZD2;LEF1;SFRP2;WNT3A |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017608297 |
7 |
NaN |
|
ADAM15;ADAMTS12;ADAMTS14 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002296357 |
8 |
NaN |
|
ADAMTS1;ADAMTS14;ADAMTS4;ADAMTS5 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.012182779 |
8 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016841612 |
7 |
NaN |
|
CTSF;CTSZ |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016567476 |
9 |
NaN |
|
CTSF;CTSZ |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000512369 |
2 |
NaN |
|
MMP12;MMP2;MMP3 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.001009123 |
1 |
NaN |
|
MMP12;MMP2;MMP3 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000945368 |
2 |
NaN |
|
MMP12;MMP2;MMP3 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.001009123 |
4 |
NaN |
|
MMP12;MMP2;MMP3 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.017085597 |
4 |
NaN |
|
MMP12;MMP3 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
8.32E-09 |
1 |
NaN |
|
COL11A2;COL1A1;COL2A1;COL3A1;COL5A1;COL5A2 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
0.001416306 |
2 |
NaN |
|
COL11A2;COL2A1;COL5A2 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
5.41E-05 |
1 |
NaN |
|
COL11A1;COL11A2;COL2A1;COL5A2 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.001416306 |
5 |
NaN |
|
COL11A2;COL2A1;COL5A2 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.021035933 |
5.5 |
NaN |
|
COL11A2;COL2A1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Fibrillar collagen core structure organization |
3.26E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A3 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.00089029 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
3.97E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A3 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.000924443 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Fibroblast growth factor receptor signaling |
0.020669774 |
8 |
NaN |
|
FGF1;FGF18 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Fibulin receptor signaling |
0.046036922 |
16.5 |
NaN |
|
FBLN1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Fibulin receptor signaling |
0.047070608 |
20.5 |
NaN |
|
FBLN1 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Glucagon receptor signaling |
0.023817925 |
9.5 |
NaN |
|
GCGR |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Glutamate and glutamine metabolism |
0.037082638 |
14.5 |
NaN |
|
SLC1A3;SLC1A5 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Glutamate and glutamine metabolism |
0.037082638 |
15 |
NaN |
|
SLC1A3;SLC38A2 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Glycogen synthesis and glycogenolysis |
0.041446435 |
16 |
NaN |
|
PPP1R3A;PYGM |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Glycogen synthesis and glycogenolysis |
0.045407974 |
15 |
NaN |
|
PPP1R3A;PYGM |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Glycolysis and Gluconeogenesis |
0.001949718 |
7 |
NaN |
|
ENO1;HK2;PFKFB3;PFKFB4 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049308339 |
11 |
NaN |
|
JUND |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040514466 |
13.5 |
NaN |
|
JUND |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.040168784 |
15 |
NaN |
|
JUND |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.042587255 |
12.5 |
NaN |
|
JUND |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.01439434 |
9 |
NaN |
|
GDF15;GDF6 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
Hedgehog receptor signaling |
0.04913699 |
10 |
NaN |
|
DHH;MYCN |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Hepatocyte growth factor receptor signaling |
0.000621089 |
3 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.000417079 |
2 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Hepatocyte growth factor receptor signaling |
0.000409904 |
1 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Hepatocyte growth factor receptor signaling |
0.000461439 |
2 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Hepatocyte growth factor receptor signaling |
0.00042069 |
1 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Hippo signaling |
0.023183885 |
6 |
NaN |
|
AMOTL1;FAT4;WWC1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Histamine metabolism |
0.046036922 |
16.5 |
NaN |
|
HNMT |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Inhibition of apoptosis |
0.024046558 |
11 |
NaN |
|
IFI6;XAF1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Interferon alpha receptor signaling |
0.013789873 |
6 |
NaN |
|
IRF9;STAT1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Intrinsic apoptosis pathway |
0.032536263 |
13 |
NaN |
|
BCL2L1;BMF |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.002070557 |
3 |
NaN |
|
SOCS2;STAT1;STAT4 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.04259587 |
16.5 |
NaN |
|
SOCS2;STAT4 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
JAK-STAT signaling pathway |
0.003757771 |
3 |
NaN |
|
SOCS2;STAT1;STAT4 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.04259587 |
17.5 |
NaN |
|
SOCS2;STAT4 |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Lipogenesis |
0.047070608 |
19.5 |
NaN |
|
FASN |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Lipogenesis |
0.047070608 |
20.5 |
NaN |
|
FASN |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Up |
Methionine cycle |
0.047070608 |
19.5 |
NaN |
|
BHMT |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Up |
Methionine cycle |
0.046036922 |
16.5 |
NaN |
|
BHMT |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Up |
Methionine cycle |
0.047070608 |
20.5 |
NaN |
|
BHMT |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Up |
Methionine cycle |
0.045519869 |
11.5 |
NaN |
|
BHMT |
| dobutamine |
Sympathomimetic |
No |
MSN05 |
Down |
Microfibril scaffold organization |
0.040514466 |
13.5 |
NaN |
|
FBN1 |
| dobutamine |
Sympathomimetic |
No |
MSN06 |
Down |
Microfibril scaffold organization |
0.040168784 |
15 |
NaN |
|
FBN1 |
| dobutamine |
Sympathomimetic |
No |
MSN08 |
Down |
Microfibril scaffold organization |
0.042587255 |
12.5 |
NaN |
|
FBN1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Microfibril scaffold organization |
0.040687284 |
15 |
NaN |
|
FBN1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Mineralocorticoid receptor signaling |
0.049308339 |
11 |
NaN |
|
GPER1 |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Mineralocorticoid receptor signaling |
0.040687284 |
15 |
NaN |
|
GPER1 |
| dobutamine |
Sympathomimetic |
No |
MSN01 |
Down |
Z-disc organization |
0.006773923 |
5 |
NaN |
|
DES;LDB3;TCAP |
| dobutamine |
Sympathomimetic |
No |
MSN09 |
Down |
Z-disc organization |
0.041771182 |
17 |
NaN |
|
DES;MYPN |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Z-disc organization |
0.00389081 |
1 |
NaN |
|
CSRP3;DES;TCAP |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Z-disc organization |
0.003614093 |
1 |
NaN |
|
CSRP3;DES;TCAP |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Z-disc organization |
0.04507252 |
16 |
NaN |
|
DES;TCAP |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Z-disc organization |
0.035163828 |
12 |
NaN |
|
DES;TCAP |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Mitotic spindle disassembly |
0.018701482 |
7 |
NaN |
|
CDK1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.007451277 |
9 |
NaN |
|
NPPB;NPR3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Natriuretic peptide receptor signaling |
0.007730873 |
9 |
NaN |
|
NPPB;NPR3 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Neuronal membrane repolarization during action potential and hyperpolarization |
0.010261464 |
8 |
NaN |
|
KCNA1;KCNA4;KCNQ3 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Osteopontin receptor signaling |
0.020465773 |
6 |
NaN |
|
SPP1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Osteopontin receptor signaling |
0.021612562 |
5 |
NaN |
|
SPP1 |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Osteopontin receptor signaling |
0.019936486 |
8 |
NaN |
|
SPP1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Osteopontin receptor signaling |
0.021436133 |
6 |
NaN |
|
SPP1 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Perlecan synthesis |
0.025935074 |
12.5 |
NaN |
|
HSPG2 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Platelet-derived growth factor receptor signaling |
0.001974848 |
4 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Platelet-derived growth factor receptor signaling |
0.002058855 |
4 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Platelet-derived growth factor receptor signaling |
0.001735926 |
4 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Platelet-derived growth factor receptor signaling |
0.002016575 |
4 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Platelet-derived growth factor receptor signaling |
8.59E-05 |
1 |
NaN |
|
PDGFB;PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Platelet-derived growth factor receptor signaling |
0.000126667 |
1 |
NaN |
|
PDGFB;PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Platelet-derived growth factor receptor signaling |
0.02030943 |
3.5 |
NaN |
|
FOSL1;PDGFRA |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.019331602 |
5.5 |
NaN |
|
FOSL1;PDGFRA |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Platelet-derived growth factor receptor signaling |
0.022155988 |
8.5 |
NaN |
|
PDGFD;PDGFRA |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.017132206 |
4.5 |
NaN |
|
FOSL1;PDGFRA |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Progesterone receptor signaling |
0.024435427 |
14.5 |
NaN |
|
PGR |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Progesterone receptor signaling |
0.025935074 |
12.5 |
NaN |
|
PGR |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.045519869 |
19 |
NaN |
|
PTGFR |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.047931585 |
17 |
NaN |
|
PTGFR |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Retinol metabolism |
0.034848653 |
14 |
NaN |
|
ALDH1A2;ALDH1A3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Retinol metabolism |
0.036082859 |
14 |
NaN |
|
ALDH1A2;ALDH1A3 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Retinol metabolism |
0.043307043 |
17 |
NaN |
|
ALDH1A1;ALDH1A2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Retinol metabolism |
0.028040621 |
10 |
NaN |
|
RDH10;TTR |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Retinol metabolism |
0.031017368 |
9 |
NaN |
|
ALDH1A1;TTR |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Retinol metabolism |
0.026709042 |
10.5 |
NaN |
|
RDH10;RPE65 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Retinol metabolism |
0.000126476 |
1 |
NaN |
|
ALDH1A1;RDH10;RPE65;TTR |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Roundabout signaling |
0.011202506 |
10.5 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Roundabout signaling |
0.011520133 |
11 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Roundabout signaling |
0.01027406 |
10 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Roundabout signaling |
0.011360812 |
9.5 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Roundabout signaling |
0.010656442 |
10 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Serotonin inactivation |
0.042759886 |
12 |
NaN |
|
MAOA |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Serotonin inactivation |
0.039477231 |
13.5 |
NaN |
|
MAOA |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Serotonin inactivation |
0.042414608 |
14 |
NaN |
|
MAOA |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Sulfonation |
0.005666345 |
8 |
NaN |
|
SULT1A1;SULT1E1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Sulfonation |
0.005234736 |
7.5 |
NaN |
|
SULT1A1;SULT1E1 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Thrombospondin receptor signaling |
0.003357826 |
5.5 |
NaN |
|
CD47;THBS2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Thrombospondin receptor signaling |
0.003455479 |
5 |
NaN |
|
CD47;THBS2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Thrombospondin receptor signaling |
0.003072996 |
5.5 |
NaN |
|
THBS1;THBS2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Thrombospondin receptor signaling |
0.003406483 |
5 |
NaN |
|
CD47;THBS2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Thrombospondin receptor signaling |
0.003190191 |
4.5 |
NaN |
|
THBS2;THBS4 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Tropoelastin synthesis |
0.025935074 |
12.5 |
NaN |
|
ELN |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.039995919 |
11 |
NaN |
|
VIPR2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
WNT-Beta-catenin signaling pathway |
0.041836543 |
15 |
NaN |
|
FRAT1;FRZB;PAX6;SFRP5 |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.038589958 |
12 |
NaN |
|
FRAT1;FRZB;PAX6;SFRP5 |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
WNT-Beta-catenin signaling pathway |
0.031601666 |
11 |
NaN |
|
FRAT1;FRZB;PAX6;SFRP5 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Aggrecan synthesis |
0.024082569 |
15 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Aggrecan synthesis |
0.024435427 |
14.5 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Aggrecan synthesis |
0.023023994 |
12.5 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Aggrecan synthesis |
0.024258998 |
13 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Aggrecan synthesis |
0.023465067 |
13 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Aggrecan synthesis |
0.025935074 |
12.5 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Albumin mediated blood protein transport |
0.023023994 |
12.5 |
NaN |
|
ALB |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.020201129 |
7 |
NaN |
|
ALB |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Albumin mediated blood protein transport |
0.018701482 |
7 |
NaN |
|
ALB |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Alternative complement pathway |
0.005507519 |
9 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Alternative complement pathway |
0.005666345 |
8 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Alternative complement pathway |
0.005043927 |
7.5 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Alternative complement pathway |
0.005586664 |
7 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Alternative complement pathway |
0.006365168 |
5.5 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Amyloid plaque organization |
0.019817901 |
5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Amyloid plaque organization |
0.02030943 |
3.5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Amyloid plaque organization |
0.02249913 |
7 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Amyloid plaque organization |
0.019331602 |
5.5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Amyloid plaque organization |
0.022155988 |
8.5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Amyloid plaque organization |
0.017132206 |
4.5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Androgen receptor signaling |
0.047587241 |
17.5 |
NaN |
|
AR |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Androgen receptor signaling |
0.048275867 |
17.5 |
NaN |
|
AR |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Androgen receptor signaling |
0.045519869 |
19 |
NaN |
|
AR |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Androgen receptor signaling |
0.047931585 |
17 |
NaN |
|
AR |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Antigen presentation via MHC class I molecules |
0.016431153 |
4 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Antigen presentation via MHC class I molecules |
0.016841612 |
2 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Antigen presentation via MHC class I molecules |
0.018671484 |
3 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Antigen presentation via MHC class I molecules |
0.016025171 |
3.5 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Antigen presentation via MHC class I molecules |
0.018384589 |
3.5 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Antigen presentation via MHC class I molecules |
0.014190421 |
3 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Basement membrane assembly and organization |
0.026291036 |
15.5 |
NaN |
|
COL4A1;HSPG2 |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Biglycan synthesis |
0.020201129 |
7 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Biglycan synthesis |
0.020465773 |
6 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Biglycan synthesis |
0.021612562 |
5 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Biglycan synthesis |
0.019936486 |
8 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Biglycan synthesis |
0.021436133 |
6 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Biglycan synthesis |
0.018701482 |
7 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Cardiomyocyte pacemaker current generation |
0.014700929 |
12 |
NaN |
|
CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Cardiomyocyte pacemaker current generation |
0.015114208 |
13 |
NaN |
|
CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Cardiomyocyte pacemaker current generation |
0.014906928 |
11 |
NaN |
|
CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Cardiomyocyte pacemaker current generation |
0.000655562 |
3 |
NaN |
|
CACNA1D;CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Cardiomyocyte pacemaker current generation |
0.01692739 |
9 |
NaN |
|
CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.004129607 |
7.5 |
NaN |
|
KCNA1;KCNA4;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.004301872 |
6 |
NaN |
|
KCNA1;KCNA4;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.040050325 |
15.5 |
NaN |
|
KCNA1;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.004215197 |
6 |
NaN |
|
KCNA1;KCNA4;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.041456914 |
15 |
NaN |
|
KCNA1;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.005083083 |
4 |
NaN |
|
KCNA1;KCNA4;KCNIP2 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005666345 |
8 |
NaN |
|
CTGF;CYR61 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005043927 |
7.5 |
NaN |
|
CTGF;WISP1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005234736 |
7.5 |
NaN |
|
CTGF;CYR61 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
CCN intercellular signaling protein family receptor signaling |
0.006365168 |
5.5 |
NaN |
|
CTGF;CYR61 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
CD44-Mediated leukocyte rolling |
0.040514466 |
13 |
NaN |
|
SPN |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
CD44-Mediated leukocyte rolling |
0.037054838 |
13.5 |
NaN |
|
SPN |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Cellular cholesterol uptake and efflux |
0.02737145 |
9 |
NaN |
|
ABCA1;ABCG1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Cellular cholesterol uptake and efflux |
0.03055135 |
11 |
NaN |
|
ABCA1;ABCG1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Cellular iron uptake and export |
0.031017368 |
9 |
NaN |
|
CP;TFRC |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Cellular iron uptake and export |
0.03055135 |
11 |
NaN |
|
CD163;TFRC |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.0056301 |
2 |
NaN |
|
INSIG1;SREBF1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Cholesterol-sensitive control of SREBP activation |
0.006484773 |
2 |
NaN |
|
INSIG1;SREBF1 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Classical complement pathway |
0.011202506 |
10.5 |
NaN |
|
C1R;C1S |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Classical complement pathway |
0.011520133 |
11 |
NaN |
|
C1R;C1S |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Classical complement pathway |
0.011360812 |
9.5 |
NaN |
|
C1R;C1S |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Classical complement pathway |
0.012914996 |
8 |
NaN |
|
C1R;C1S |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Collagen fiber crosslinking |
0.003903051 |
3 |
NaN |
|
LOX;LOXL1 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Collagen fibril organization by fibril-associated bridges |
4.75E-06 |
2 |
NaN |
|
COL12A1;COL14A1;COL19A1;COL9A3 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Collagen fibril organization by fibril-associated bridges |
5.04E-06 |
1 |
NaN |
|
COL12A1;COL14A1;COL19A1;COL9A3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Collagen fibril organization by fibril-associated bridges |
3.97E-06 |
1 |
NaN |
|
COL12A1;COL14A1;COL19A1;COL9A3 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Collagen fibril organization by fibril-associated bridges |
4.89E-06 |
1 |
NaN |
|
COL12A1;COL14A1;COL19A1;COL9A3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000242463 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A3 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Collagen fibril organization by fibril-associated bridges |
0.009384811 |
7 |
NaN |
|
COL12A1;COL14A1 |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Decorin synthesis |
0.020201129 |
7 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Decorin synthesis |
0.020465773 |
6 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Decorin synthesis |
0.021612562 |
5 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Decorin synthesis |
0.019936486 |
8 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Decorin synthesis |
0.021436133 |
6 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Desaturation of fatty acids |
0.011520133 |
11 |
NaN |
|
FADS2;SCD |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Elastin cross-linking and assembly |
0.001202742 |
2 |
NaN |
|
LOX;LOXL1 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
ER unfolded protein response pathway |
0.000877812 |
2 |
NaN |
|
ATF4;HERPUD1;PPP1R15A |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Eukaryotic kinetochore dynamics |
0.040875895 |
13 |
NaN |
|
BUB1;CENPF;NDC80 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Extracellular matrix breakdown by cathepsins |
0.026291036 |
15.5 |
NaN |
|
CTSD;CTSF |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.016025171 |
3.5 |
NaN |
|
CTSF;CTSH |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.002037514 |
2 |
NaN |
|
SULF1;SULF2 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.018603478 |
13.5 |
NaN |
|
MMP1;MMP2 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Fibrillar collagen core structure organization |
1.78E-06 |
1 |
NaN |
|
COL11A1;COL1A1;COL2A1;COL5A2;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Fibrillar collagen core structure organization |
0.00152477 |
2 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Fibrillar collagen core structure organization |
5.17E-05 |
2 |
NaN |
|
COL1A1;COL2A1;COL5A2;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.023204138 |
12 |
NaN |
|
COL2A1;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Fibrillar collagen core structure organization |
0.021799773 |
12 |
NaN |
|
COL2A1;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.001809764 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Fibrillar collagen core structure organization |
0.018384589 |
3.5 |
NaN |
|
COL1A1;COL1A2 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Fibrillin synthesis |
0.001730983 |
2.5 |
NaN |
|
FBN1;FBN3 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Fibroblast growth factor receptor signaling |
0.032966818 |
14 |
NaN |
|
FGF10;FGF18 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Fibroblast growth factor receptor signaling |
0.024046558 |
8 |
NaN |
|
ANOS1;FGF7 |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Fibroblast growth factor receptor signaling |
0.020308164 |
9 |
NaN |
|
ANOS1;FGF7 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Fibulin receptor signaling |
0.047587241 |
17.5 |
NaN |
|
FBLN1 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Fibulin receptor signaling |
0.048275867 |
17.5 |
NaN |
|
FBLN1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Fibulin receptor signaling |
0.045519869 |
19 |
NaN |
|
FBLN1 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Fibulin receptor signaling |
0.047931585 |
17 |
NaN |
|
FBLN1 |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Glutamate and glutamine metabolism |
0.000100501 |
1 |
NaN |
|
SLC1A3;SLC1A5;SLC38A2;SLC7A5 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.028040621 |
10 |
NaN |
|
SLC1A5;SLC7A5 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.00242926 |
1 |
NaN |
|
SLC1A3;SLC1A5;SLC7A5 |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Glutamate and glutamine metabolism |
0.026709042 |
10.5 |
NaN |
|
SLC1A5;SLC7A5 |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Glutamate and glutamine metabolism |
0.001605797 |
1 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| diclofenac |
Nsaid |
No |
MSN09 |
Up |
Glycolysis and Gluconeogenesis |
0.020831213 |
10 |
NaN |
|
HK2;LDHA;PGK1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.042759886 |
12 |
NaN |
|
JUND |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.018603478 |
13.5 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.017085597 |
11 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.017711138 |
11 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Hepatocyte growth factor receptor signaling |
0.047587241 |
17.5 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Hepatocyte growth factor receptor signaling |
0.048275867 |
17.5 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Hepatocyte growth factor receptor signaling |
0.045519869 |
19 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Hepatocyte growth factor receptor signaling |
0.047931585 |
17 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Hepatocyte growth factor receptor signaling |
0.046381546 |
16.5 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001706055 |
3 |
NaN |
|
MME;PLAT |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001756088 |
3 |
NaN |
|
A2M;MME |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001560223 |
3 |
NaN |
|
A2M;MME |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001730983 |
2.5 |
NaN |
|
MME;PLAT |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.004129607 |
7.5 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
JAK-STAT signaling pathway |
0.040050325 |
15.5 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.00383853 |
6 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Leptin receptor signaling |
0.003357826 |
5.5 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Leptin receptor signaling |
0.003072996 |
5.5 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Leptin receptor signaling |
0.003190191 |
4.5 |
NaN |
|
SOCS3;STAT3 |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Lipogenesis |
0.039995919 |
11 |
NaN |
|
FASN |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Lipogenesis |
0.040514466 |
13 |
NaN |
|
FASN |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Lipogenesis |
0.042759886 |
12 |
NaN |
|
FASN |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Lipogenesis |
0.042414608 |
14 |
NaN |
|
FASN |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Macrophage migration inhibitory factor signaling |
0.004456057 |
2 |
NaN |
|
CXCR4;JUND |
| diclofenac |
Nsaid |
No |
MSN01 |
Down |
Methionine cycle |
0.039995919 |
11 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Methionine cycle |
0.040514466 |
13 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
MSN06 |
Down |
Methionine cycle |
0.039477231 |
13.5 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Methionine cycle |
0.042414608 |
14 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Methionine cycle |
0.037054838 |
13.5 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.047587241 |
17.5 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
MSN02 |
Up |
Microfibril scaffold organization |
0.048275867 |
17.5 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.045519869 |
19 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
MSN06 |
Up |
Microfibril scaffold organization |
0.047931585 |
17 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.046381546 |
16.5 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
MSN02 |
Down |
Mitotic spindle assembly |
0.028040621 |
10 |
NaN |
|
NUSAP1;TPX2 |
| diclofenac |
Nsaid |
No |
MSN05 |
Down |
Mitotic spindle assembly |
0.031017368 |
9 |
NaN |
|
KIFC1;TPX2 |
| diclofenac |
Nsaid |
No |
MSN08 |
Down |
Mitotic spindle assembly |
0.03055135 |
11 |
NaN |
|
NUSAP1;TPX2 |
| diclofenac |
Nsaid |
No |
MSN09 |
Down |
Mitotic spindle assembly |
0.023708594 |
10 |
NaN |
|
NUSAP1;TPX2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.009034585 |
5 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.024408174 |
13.5 |
NaN |
|
ADAMTS14;ADAMTS4;ADAMTS7 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.027026538 |
9.5 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS7 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Extracellular matrix breakdown by cathepsins |
0.027130428 |
17 |
NaN |
|
CTSD;CTSV |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.015984742 |
14.5 |
NaN |
|
MMP1;MMP2 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.01622657 |
10 |
NaN |
|
MMP7;MMP9 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.000976912 |
1 |
NaN |
|
BSG;MMP7;MMP9 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.022084252 |
12 |
NaN |
|
MMP12;MMP2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Fibrillar collagen core structure organization |
0.013434638 |
7 |
NaN |
|
COL1A1;COL1A2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Fibrillar collagen core structure organization |
0.000525812 |
2.5 |
NaN |
|
COL1A1;COL1A2;COL2A1 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Fibrillar collagen core structure organization |
9.13E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Fibrillar collagen core structure organization |
0.001899548 |
1 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Fibrillar collagen core structure organization |
0.029190037 |
13 |
NaN |
|
COL11A1;COL5A2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Fibrillin synthesis |
0.04996016 |
21 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Fibronectin synthesis and extracellular assembly |
0.0027595 |
6 |
NaN |
|
FN1;ITGB3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Filopodium organization |
0.024408174 |
13.5 |
NaN |
|
ENAH;GPM6A;TNK2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Filopodium organization |
0.027026538 |
9.5 |
NaN |
|
ENAH;GPM6A;TNK2 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
GABA metabolism |
0.009884567 |
4 |
NaN |
|
ABAT;SLC6A1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
GABA metabolism |
0.007067944 |
8 |
NaN |
|
ABAT;SLC6A1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
GABA metabolism |
0.007787369 |
6 |
NaN |
|
ABAT;SLC6A1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Glutamate and glutamine metabolism |
0.033150099 |
16 |
NaN |
|
SLC1A5;SLC7A5 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Glutamate and glutamine metabolism |
0.036331775 |
19 |
NaN |
|
SLC1A5;SLC7A5 |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Glutamate and glutamine metabolism |
0.041452288 |
11 |
NaN |
|
SLC38A2;SLC7A5 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Glycogen synthesis and glycogenolysis |
0.048814568 |
23 |
NaN |
|
AGL;PYGM |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Glycolysis and Gluconeogenesis |
8.74E-06 |
1 |
NaN |
|
ENO1;HK2;LDHA;PCK2;PFKFB3;PFKFB4 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Glycolysis and Gluconeogenesis |
0.001871577 |
2 |
NaN |
|
HK2;LDHA;PFKFB3;PFKFB4 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Glycolysis and Gluconeogenesis |
0.003257229 |
3 |
NaN |
|
HK2;PCK2;PFKFB3;PFKFB4 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.015984742 |
14.5 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.010876887 |
6 |
NaN |
|
CSF3R;SOCS3 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.013881385 |
12 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.017837434 |
12 |
NaN |
|
CSF3R;INPP5D |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Growth differentiation factor receptor signaling |
0.010944482 |
10.5 |
NaN |
|
GDF2;GDF6 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Growth differentiation factor receptor signaling |
0.012808436 |
9 |
NaN |
|
GDF15;GDF2 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Growth differentiation factor receptor signaling |
0.014090651 |
10 |
NaN |
|
GDF15;GDF2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Heme degradation to bilirubin |
0.04996016 |
21 |
NaN |
|
HMOX1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Hepatocyte growth factor receptor signaling |
0.043967869 |
22.5 |
NaN |
|
MET |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Hepatocyte growth factor receptor signaling |
0.044312867 |
20.5 |
NaN |
|
HGF |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Hepatocyte growth factor receptor signaling |
0.046553835 |
24 |
NaN |
|
HGF |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Hippo signaling |
0.02715843 |
10 |
NaN |
|
AMOTL1;CRB2;WWC1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Hippo signaling |
0.033358365 |
14 |
NaN |
|
AMOTL1;CRB2;WWC1 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Inhibin receptor signaling |
0.000346395 |
2 |
NaN |
|
INHBA;INHBE;TGFBR3 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Inhibin receptor signaling |
0.012616077 |
13 |
NaN |
|
INHBE;TGFBR3 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Inhibin receptor signaling |
0.010765432 |
11.5 |
NaN |
|
INHBE;TGFBR3 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Inhibin receptor signaling |
0.010944482 |
10.5 |
NaN |
|
INHBE;TGFBR3 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.04996016 |
21 |
NaN |
|
A2M |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002084881 |
3 |
NaN |
|
MME;PLAT |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002043965 |
2 |
NaN |
|
MME;PLAT |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001884281 |
1 |
NaN |
|
MME;PLAT |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Inhibition of apoptosis |
0.02804976 |
19 |
NaN |
|
BIRC5;IFI6 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Inhibition of apoptosis |
0.024046558 |
17 |
NaN |
|
BIRC5;IFI6 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Inhibition of apoptosis |
0.04129959 |
17 |
NaN |
|
IFI6;XAF1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Inositol metabolism and transport |
0.046553835 |
24 |
NaN |
|
INPP5D |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Inositol metabolism and transport |
0.00075031 |
2 |
NaN |
|
INPP5D;SLC5A3 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
JAK-STAT signaling pathway |
0.027804205 |
15 |
NaN |
|
SOCS2;SOCS3 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
JAK-STAT signaling pathway |
0.037567125 |
21 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
JAK-STAT signaling pathway |
0.032793723 |
18 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
JAK-STAT signaling pathway |
0.038113484 |
17 |
NaN |
|
SOCS2;STAT4 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Leptin receptor signaling |
0.002867401 |
5 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Leptin receptor signaling |
0.002476949 |
2.5 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Lipogenesis |
0.033588983 |
16.5 |
NaN |
|
FASN |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Macrophage migration inhibitory factor signaling |
0.003416552 |
5 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Macrophage migration inhibitory factor signaling |
0.004708979 |
7.5 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Macrophage migration inhibitory factor signaling |
0.004004069 |
3.5 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Macrophage migration inhibitory factor signaling |
0.004072101 |
5 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Macrophage migration inhibitory factor signaling |
0.0027595 |
6 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Metaphase to anaphase checkpoint |
0.032473286 |
17 |
NaN |
|
CCNB2;CDC20;PTTG1 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Microfibril scaffold organization |
0.037401081 |
17 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Microfibril scaffold organization |
0.000492258 |
2 |
NaN |
|
FBN1;MFAP2 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Microfibril scaffold organization |
0.000417079 |
1 |
NaN |
|
FBN1;MFAP2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Microfibril scaffold organization |
0.036015735 |
13 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Microfibril scaffold organization |
0.040860087 |
20 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Microfibril scaffold organization |
0.033588983 |
16.5 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Muscarinic receptor signaling |
0.009695754 |
7 |
NaN |
|
CHRM4;RGS5 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Natriuretic peptide receptor signaling |
0.005061213 |
7.5 |
NaN |
|
NPPA;NPPB |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Natriuretic peptide receptor signaling |
0.006960163 |
11 |
NaN |
|
NPPB;NPR3 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Natriuretic peptide receptor signaling |
0.005925252 |
6.5 |
NaN |
|
NPPB;NPR3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Natriuretic peptide receptor signaling |
0.009695754 |
7 |
NaN |
|
NPPA;NPPB |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Natriuretic peptide receptor signaling |
0.010461076 |
5 |
NaN |
|
NPPA;NPPB |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Necroptosis induction |
0.018172195 |
9 |
NaN |
|
TNFRSF1A |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Neuregulin receptor signaling |
0.0350401 |
15.5 |
NaN |
|
ERBB3;NRG1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Notch receptor signaling |
0.01094832 |
8.5 |
NaN |
|
DLK1;JAG1;LFNG |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Notch receptor signaling |
0.000166205 |
1 |
NaN |
|
DLK1;JAG1;JAG2;LFNG;MIB2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Osteonectin receptor signaling |
0.001924922 |
2.5 |
NaN |
|
SMOC2;SPARC |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Osteonectin receptor signaling |
0.002476949 |
2.5 |
NaN |
|
SPARC;SPOCK1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Osteonectin receptor signaling |
0.001674362 |
4 |
NaN |
|
SMOC2;SPARC |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Osteopontin receptor signaling |
0.018877911 |
11.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Osteopontin receptor signaling |
0.020465773 |
15.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Osteopontin receptor signaling |
0.020642202 |
14.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Osteopontin receptor signaling |
0.016937191 |
13 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Osteopontin receptor signaling |
0.022406493 |
12.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Osteopontin receptor signaling |
0.026376147 |
15.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Platelet-derived growth factor receptor signaling |
0.033195907 |
11.5 |
NaN |
|
PDGFRA;PDGFRB |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Platelet-derived growth factor receptor signaling |
0.002561173 |
3 |
NaN |
|
PDGFRA;RGS5;TNK2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Platelet-derived growth factor receptor signaling |
0.0350401 |
15.5 |
NaN |
|
PDGFRA;TNK2 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Potassium transmembrane transport |
0.018142498 |
13 |
NaN |
|
ATP1A3;KCNE4;KCNK2 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Progesterone receptor signaling |
0.022230064 |
17.5 |
NaN |
|
PGR |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Prostacycline receptor signaling |
0.044312867 |
20.5 |
NaN |
|
PTGIR |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Proteasomal regulatory particle organization |
0.013338981 |
10 |
NaN |
|
PSMC4;PSMD14 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Protein polyubiquitination |
0.004906048 |
10 |
NaN |
|
ISG15;UBC;UCHL1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Protein polyubiquitination |
0.041446435 |
22 |
NaN |
|
UBC;UCHL1 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Protein polyubiquitination |
0.042096917 |
22 |
NaN |
|
UBC;UCHL1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Removal of caspase inhibition |
0.044312867 |
20.5 |
NaN |
|
XAF1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Removal of caspase inhibition |
0.046553835 |
24 |
NaN |
|
XAF1 |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Removal of caspase inhibition |
0.049996342 |
12.5 |
NaN |
|
XAF1 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Retinol metabolism |
0.024127969 |
13.5 |
NaN |
|
ALDH1A1;STRA6 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Retinol metabolism |
0.002632093 |
4 |
NaN |
|
ALDH1A1;ALDH1A3;STRA6 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Retinol metabolism |
0.028040621 |
18.5 |
NaN |
|
ALDH1A1;STRA6 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Retinol metabolism |
0.045465381 |
13 |
NaN |
|
DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Retinol metabolism |
0.002691927 |
2 |
NaN |
|
ALDH1A2;DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Retinol metabolism |
0.0031016 |
3 |
NaN |
|
ALDH1A2;DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Retinol metabolism |
0.00380409 |
3 |
NaN |
|
ALDH1A3;DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Retinol metabolism |
0.047941794 |
18 |
NaN |
|
DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Semaphorin signaling |
0.006731385 |
7 |
NaN |
|
CRMP1;DPYSL2;DPYSL4;SEMA6B |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Semaphorin signaling |
0.045211705 |
21 |
NaN |
|
CRMP1;DPYSL4;SEMA6B |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Semaphorin signaling |
0.013476514 |
6 |
NaN |
|
CRMP1;DPYSL4;PLXNC1;SEMA6B |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Serine and glycine metabolism |
0.017439282 |
10 |
NaN |
|
PHGDH;SHMT2 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Serine and glycine metabolism |
0.02030943 |
14 |
NaN |
|
PHGDH;SHMT2 |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Serine and glycine metabolism |
0.020640007 |
13 |
NaN |
|
PHGDH;SHMT2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Serine and glycine metabolism |
0.01419473 |
10.5 |
NaN |
|
PHGDH;SHMT2 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Serine and glycine metabolism |
0.033195907 |
11.5 |
NaN |
|
PSAT1;SLC1A5 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Serine and glycine metabolism |
0.02407108 |
15 |
NaN |
|
PSAT1;SLC1A5 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Serine and glycine metabolism |
0.026420838 |
18 |
NaN |
|
PSAT1;SLC1A5 |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Serotonin inactivation |
0.000354742 |
3 |
NaN |
|
MAOA;MAOB |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Serotonin inactivation |
0.040514466 |
20.5 |
NaN |
|
MAOA |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Serotonin inactivation |
0.040860087 |
20 |
NaN |
|
MAOA |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Serotonin inactivation |
0.044312867 |
20.5 |
NaN |
|
MAOA |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Sister chromatid segregation |
0.006025215 |
7.5 |
NaN |
|
ESPL1;PTTG1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Syndecan ectodomain shedding |
0.002912493 |
3.5 |
NaN |
|
MMP7;MMP9 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Syndecan ectodomain shedding |
0.003213885 |
4 |
NaN |
|
MMP7;MMP9 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Thin myofilament organization |
0.010733686 |
7 |
NaN |
|
ACTA1;TNNI3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Thrombospondin receptor signaling |
0.001924922 |
2.5 |
NaN |
|
THBS2;THBS4 |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Thrombospondin receptor signaling |
0.002912493 |
3.5 |
NaN |
|
THBS1;THBS2 |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Thrombospondin receptor signaling |
0.003705518 |
2 |
NaN |
|
THBS1;THBS2 |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Tropoelastin synthesis |
0.02664079 |
8.5 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Tropoelastin synthesis |
0.022406493 |
12.5 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Tropoelastin synthesis |
0.023553282 |
15.5 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Tropoelastin synthesis |
0.025317572 |
8 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Tropoelastin synthesis |
0.027434721 |
11 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Vascular endothelial growth factor receptor signaling |
0.013596343 |
5.5 |
NaN |
|
FLT1;KDR |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Vascular endothelial growth factor receptor signaling |
0.012331868 |
5 |
NaN |
|
FLT1;KDR |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Vasoactive intestinal peptide receptor signaling |
0.046553835 |
24 |
NaN |
|
VIPR1 |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Versican receptor signaling |
0.046553835 |
24 |
NaN |
|
VCAN |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Versican receptor signaling |
0.049996342 |
12.5 |
NaN |
|
VCAN |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Versican synthesis |
0.023553282 |
15.5 |
NaN |
|
VCAN |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Versican synthesis |
0.025317572 |
8 |
NaN |
|
VCAN |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
WNT-Beta-catenin signaling pathway |
0.000193151 |
1 |
NaN |
|
DKK1;DKK2;FRZB;FZD8;LEF1;SFRP2;WNT2 |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
WNT-Beta-catenin signaling pathway |
0.041836543 |
23 |
NaN |
|
FRZB;FZD8;SFRP2;WNT2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
WNT-Beta-catenin signaling pathway |
0.028856634 |
11 |
NaN |
|
DKK2;FZD8;LEF1;WNT9A |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
WNT-Beta-catenin signaling pathway |
0.042952383 |
23 |
NaN |
|
FRZB;FZD7;FZD8;SFRP2 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
WNT-Beta-catenin signaling pathway |
0.006657852 |
5 |
NaN |
|
DACT1;FRZB;PAX6;SFRP2;WNT3A;WNT5A |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Z-disc organization |
0.035773535 |
16 |
NaN |
|
MYPN;TCAP |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Z-disc organization |
0.048125749 |
24 |
NaN |
|
CSRP3;PDLIM3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Z-disc organization |
0.033360102 |
12 |
NaN |
|
DES;TCAP |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Z-disc organization |
0.02930283 |
15 |
NaN |
|
DYSF;PDLIM3 |
| delavirdine |
Antiviral |
No |
MSN06 |
Down |
Actin filament bundling and crosslinking |
0.030172379 |
18 |
NaN |
|
FSCN2;TAGLN;USH1C |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Actin polymerization |
0.016697884 |
11 |
NaN |
|
ABRA;ACTA1;ENAH;VAV3 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Actin polymerization |
0.027447118 |
12 |
NaN |
|
ABRA;ACTA1;ENAH;INF2 |
| delavirdine |
Antiviral |
No |
MSN09 |
Down |
Adherens junction organization |
0.025363758 |
8 |
NaN |
|
ALCAM;CDH1;L1CAM;TIAM1 |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Aggrecan synthesis |
0.018172195 |
9 |
NaN |
|
ACAN |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Aggrecan synthesis |
0.016937191 |
13 |
NaN |
|
ACAN |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Albumin mediated blood protein transport |
0.018172195 |
9 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Albumin mediated blood protein transport |
0.016937191 |
13 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN01 |
Down |
Albumin mediated blood protein transport |
0.02664079 |
8.5 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN02 |
Down |
Albumin mediated blood protein transport |
0.022406493 |
12.5 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN05 |
Down |
Albumin mediated blood protein transport |
0.023553282 |
15.5 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN08 |
Down |
Albumin mediated blood protein transport |
0.025317572 |
8 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
MSN01 |
Up |
Alternative complement pathway |
0.003416552 |
5 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Alternative complement pathway |
0.004708979 |
7.5 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
MSN05 |
Up |
Alternative complement pathway |
0.004004069 |
3.5 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
MSN06 |
Up |
Alternative complement pathway |
0.003169819 |
4 |
NaN |
|
C3;CFH |
| delavirdine |
Antiviral |
No |
MSN08 |
Up |
Alternative complement pathway |
0.004072101 |
5 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Alternative complement pathway |
0.0027595 |
6 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
MSN09 |
Up |
Amyloid plaque organization |
0.01419473 |
10.5 |
NaN |
|
HSPB6;VSNL1 |
| delavirdine |
Antiviral |
No |
MSN02 |
Up |
Aspartate and arginine metabolism |
0.019690847 |
16 |
NaN |
|
ARG2;DDAH1 |
| delavirdine |
Antiviral |
No |
MSN05 |